Dispiropyrrolidine derivatives

ABSTRACT

A compound that inhibits interaction between, murine double minute 2 (Mdm2) protein and p53 protein and exhibits anti-tumor activity is provided. The present invention provides a dispiropyrrolidine derivative represented by the following formula (1), which has various substituents, inhibits interaction between Mdm2 protein and p53 protein and exhibits anti-tumor activity, wherein R 1 , R 2 , R 3 , ring A, and ring B in formula (1) respectively have the same meanings as defined in the specification.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to a dispiropyrrolidine compound havinganti-tumor activity by inhibition of murine double minute 2 (Mdm2) or asalt thereof.

2. Description of the Related Art

p53 is known as an important factor for inhibiting canceration of cells.p53 is a transcription factor that induces the expression of genesinvolved in the cell cycle and cellular apoptosis in response to variousstresses. p53 is thought to inhibit canceration of cells by atranscription regulating function thereof. In fact, deletion or mutationof the p53 gene is observed in about half of human cancer cases.

Meanwhile, over expression of murine double minute 2 (Mdm2), a type ofE3 ubiquitin ligase, is known as a factor for canceration of cells thatare cancerated in spice of the presence of normal p53. Mdm2 is a proteinthe expression of which is induced by p53. Mdm2 negatively regulates p53by mediating degradation of p53 by binding to the transcription activitydomain of p53 to decrease the transcription activity of p53, exportingp53 out of the nucleus, and further acting as a ubiquitination ligaseagainst p53. Therefore, it is thought that reactivation of functions ofand degradation of p53 are promoted in cells in which Mdm2 isoverexpressed, resulting in canceration (J. Am. Chem. Soc., 2005, 127,10130-10131).

Paying attention to such functions of Mdm2, many approaches have beenattempted using substances that inhibit the suppression of p53 functionsby Mdm2 as candidate anti-tumor agents. Examples of the Mdm2 inhibitorstargeting the Mdm2-p53 binding site have been reported, which includespirooxindole derivatives (WO2006/091646, WO2006/136606, WO2007/104664,WO2007/104714, WO2008/034736, WO2008/036168, WO2008/055812,WO2008/141917 , WO2008/141375, WO2009/077357, WO2009/080488, WO2010/084097, WO2010/091979, WO2010/094622, WO2010/121995; J. Am. Chem. Soc.,2005, 12, 10130-10131; J. Med. Chem., 2006, 49, 3432-3435; and J. Med.Chem., 2009, 52, 7970-7973), indole derivatives (WO2008/119741),pyrrolidine-2-carboxamide derivatives (WO2010/031713), pyrrolidinonederivatives (WO2010/028862), and isoindolinone derivatives(WO2006/024837; and J. Med. Chem., 2006, 49, 6209-6221).

The present invention provides a novel Mdm2 inhibiting compound.Furthermore, the present invention provides an anti-tumor agentcontaining the Mdm2 inhibiting compound.

SUMMARY OF THE INVENTION

As a result of extensive studies, the present inventors have found thata compound having a structure represented by the following generalformula (1) or a salt thereof has potent Mdm2 inhibiting activity andthey accomplished the present invention.

More specifically, the present invention provides:

[1] A compound represented by general formula (1) or a salt thereof:

wherein ring A represents a spiro-linked 4- to 6-membered saturatedhydrocarbon ring which may have one or more substituents selected fromGroup 1, or a spiro-linked 6-membered saturated heterocyclic ring whichmay have one or more substituents selected from Group 1;

ring B represents a benzene ring which may have one or more substituentsselected from Group 2, a pyridine ring which may have one or moresubstituents selected from Group 2, or a pyrimidine ring which may haveone or more substituents selected from Group 2;

R¹ represents an aryl group which may have one or more or moresubstituents selected from Group 3, a heteroaryl group which may haveone or more substituents selected from Group 3, a C₃-C₆ cycloalkyl groupwhich may have one or more substituents selected from Group 3, or aC₃-C₆ cycloalkenyl group which may have one or more substituentsselected from Group 3;

R² represents a C₁-C₆ alkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, or a hydrogen atom;and

R³ represents a group represented by the following general formula (2),(3), or (4):

wherein in formula (2), R⁴ and R⁵ each independently represent a hydroxygroup, a C₁-C₆ alkyl group, or a C₁-C₆ alkoxy group, or R⁴ and R⁵together with the carbon atoms to which the R⁴ and R⁵ groups arerespectively bonded may together form a 4- to 6-membered saturatedhydrocarbon ring;

In formula (3),

The broken line in the ring structure indicates that the bond may be adouble bond,

R⁶ represents a C₁-C₆ alkyl group which may have one or moresubstituents selected from Group 4, a carbamoyl group which may have oneor more substituents selected from Group 5, a 5- of 6-anti-memberednitrogen-containing heteroaryl group which may be substituted with anoxo group or one or more C₁-C₆ alkyl groups which may be substitutedwith an oxo group or one hydroxy group, a hydroxy group, or —NR′R″,wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group which may be substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group,

R⁷ represents a C₁-C₆ alkyl group which may be substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or

R⁶ and R⁷ may together form a spiro-linked 4- to 6-membered hydrocarbonring or a spiro-linked 4- to 6-membered nitrogen-containing heterocyclicring,

R⁸ represents one or more substituents selected from a hydroxy group, aC₁-C₆ alkyl group, and a C₁-C₆ alkoxy group, and

Z represents CH₂, NH, or an oxygen atom; and

In formula (4),

R⁹ represents a C₁-C₆ alkyl group which may have one or moresubstituents selected from Group 4, a carbamoyl group which may have oneor more substituents selected from Group 5, a 5- or 6-memberednitrogen-containing heteroaryl group which may be substituted with anoxo group or one or more C₁-C₆ alkyl groups which may be substitutedwith an oxo group or one hydroxy group, a hydroxy group, or —NR′R″,wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group which may be substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-membered,nitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group,

R¹⁰ represents a C₁-C₆ alkyl group which may be substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or

R⁹ and R¹⁰ may together form a spiro-linked 4- to 6-membered hydrocarbonring or a spiro-linked 4- to 6-membered nitrogen-containing heterocyclicring, and

R¹¹ represents one or more substituents selected from a hydroxy group, aC₁-C₆ alkyl group, and a C₁-C₆ alkoxy group,

wherein Group 1 represents a halogen atom, a C₁-C₆ alkyl group which maybe substituted with one to three halogen atoms, a C₁-C₆ alkoxy group, ora cyano group,

Group 2 represents a halogen atom; a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, a C₃-C₄ cycloalkyl groupwhich may be substituted with one to three halogen atoms, a vinyl group,an ethinyl group, a cyano group, or a C₁-C₆ alkoxy group,

Group 3 represents a halogen atom, a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms or one to three hydroxygroups, a C₃-C₄ cycloalkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, a vinyl group, anethinyl group, a cyano group, —OR′, —NR′R″, —COOR′, or —CONHR′, wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms or one to three hydroxygroups, a C₃-C₄ cycloalkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, or a hydrogen atom,or R′ and R″ together with the nitrogen atom to which R′ and R″ arebonded may together form a 4- to 7-membered nitrogen-containingheterocyclic group which may have one of more substituents selected froma C₁-C₆ alkyl group and a hydroxy group,

Group 4 represents a halogen atom, a hydroxy group, a carbamoyl group, amorpholino group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylsulfonyl group, or—NR′R″, wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, one to three hydroxygroups, or an oxo group, a C₃-C₄ cycloalkyl group which may besubstituted with one to three halogen atoms or one to three hydroxygroups, or a hydrogen atom, or R′ and R″ together with the nitrogen atomto which R′ and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group, and

Group 5 represents a C₁-C₆ alkyl group which may be substituted with oneto three halogen atoms, one to three hydroxy groups, or a C₁-C₆ alkoxygroup, a C₃-C₆ cycloalkyl group, a C₁-C₆ alkoxy group, or atetrahydropyranyl group.

[2] A compound according to [1] represented by general formula (5) or asalt thereof:

wherein in formula (5),

ring A, R², and R³ have the sane meanings as ring A, R², and R³,respectively, in [1];

R¹² and R¹³ represent a group selected from a halogen atom, a C₁-C₆alkyl group which may be substituted with one to three halogen atoms orone to three hydroxy groups, and a cyano group;

R¹⁴ represents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group; and

R¹⁵ represents one or more substituents selected from Group 3, whereinGroup 3 has the same meaning as Group 3 in [1].

[3] A compound according to [1] represented by general formula (6) or asalt thereof:

wherein in formula (6),

ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in [1];

R¹², R¹³, and R¹⁶ represent a group selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group; and

R¹⁴ represents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogen,atoms or one to three hydroxy groups, and a cyano group.

[4] A compound according to [1] represented by general formula (7) or asalt thereof:

wherein in formula (7),

ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in [1];

R¹², R¹³, and R¹⁶ represent a group selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group; and

R¹⁴ represents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group.

[5] A compound according to [1] represented by general formula (8) or asalt thereof:

wherein in formula (8), ring A, R², and R³ have the same meanings asring A, R², and R³, respectively, in [1];

R¹², R¹³, and R¹⁶ represent a group selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group; and

R¹⁴ represents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group.

[6] A compound selected from the following group or a salt thereof:

[7](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidehydrochloride.

[8](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidesulfate.

[9](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidemethanesulfonate.

[10](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamideethanesulfonate.

[11](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidebenzenesulfonate.

[12](3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidep-toluenesulfonate.

[13](3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidebenzenesulfonate.

[14] An inhibitor of Mdm2 comprising a compound according to any one of[1] to [13] of a salt thereof.

[15] An inhibitor of Mdm2 ubiquitin ligase comprising a compoundaccording to any one of [1] to [13] or a salt thereof.

[16] An inhibitor of p53-Mdm2 binding comprising, a compound accordingto any one of [1] to [13] or a salt thereof.

[17] An inhibitor of suppression of p53 transcription activitycomprising a compound according to any one of [1] to [13] or a saltthereof.

[18] An inhibitor of p53 degradation comprising a compound according toany one of [1] to [13] or a salt thereof.

[19] A medicament comprising a compound according to any one of [1] to[13] or a salt thereof as an active ingredient.

[20] An anticancer agent comprising a compound according to any one of[1] to [13] or a salt thereof as an active ingredient.

[21] An anticancer agent according to [20], wherein the cancer is lungcancer, breast cancer, prostate cancer, colon cancer, acute myeloidleukemia, malignant lymphoma, malignant melanoma, retinoblastoma,neuroblastoma, or sarcoma.

[22] A pharmaceutical composition comprising a compound according to anyone of [1] to [13] or a salt thereof and a pharmaceutically acceptablecarrier.

[23] A method for treating cancer, comprising administering a compoundaccording to any one of [1] to [13] or a salt thereof.

[24] A method for treating cancer according to [23], wherein the canceris lung cancer, breast cancer, prostate cancer, colon cancer, acutemyeloid leukemia, malignant lymphoma, malignant melanoma,retinoblastoma, neuroblastoma, or sarcoma.

[25] A compound according to any one of [1] to [13] or a salt thereoffor the manufacture of a medicament.

[26] Use of a compound according to any one of [1] to [13] or a saltthereof for the manufacture of an anticancer agent.

The present invention provides novel spiroprolinamide derivativesrepresented by the above formula (1), which have Mdm2 inhibitingactivity. Such novel compounds are useful as an anti-tumor agent.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

In the present invention, “Mdm2” means a protein encoded by the murinedouble minute 2 gene. “Mdm2” includes Mdm2 proteins encoded by acomplete length of the Mdm2 gene, Mdm2 proteins encoded by mutated Mdm2genes (including deletion mutants, substitution mutants, and additionmutants), and so forth. In the present invention, “Mdm2” also includeshomologues derived from various animal species such as, for example,human Mdm2 homologue (HDM2).

In the present invention, “p53” means a protein encoded by the p53 gene.“p53” means the p53 protein encoded by a full length p53 gene or a p53protein that has a mutation (including mutations by deletion,substitution, or addition), but functions normally.

In the present invention, “Mdm2 inhibitor” means a factor that restoresp53 functions suppressed by Mdm2 by acting on either Mdm2 or p53, or onboth Mdm2 and p53. The p53 functions are not particularly limited solong as they are functions that p53 normally has. Examples thereofinclude inhibition of canceration of cells by inducing the expression ofgenes involved in the cell cycle or cellular apoptosis. Examples of Mdm2inhibitors include factors that inhibit binding of Mdm2 to p53(hereinafter, referred to as p53-Mdm2 binding inhibitors) or factorsthat inhibit ubiquitination of p53 by Mdm2 (hereinafter, referred to asMdm2 ubiguitin ligase inhibitory).

In the present invention, “inhibitor of suppression of p53 transcriptionactivity” means a factor that restores the functions of p53 as atranscription factor previously suppressed by Mdm2.

In the present invention, “inhibitor of p53 degradation” means a factorthat inhibits degradation of p53 in proteasomes by inhibitingubiquitination of p53 by Mdm2.

In the present invention, the terms “tumor” and “cancer” are usedinterchangeably. Furthermore, in the present invention, tumor, malignanttumor, cancer, malignant neoplasm, carcinoma, sarcoma, and the like maybe collectively referred to as a “tumor” or “cancer.”

In the present invention, “C₁-C₆ alkyl group” means a straight orbranched alkyl group having 1 to 6 carbon atoms. Examples of a “C₁-C₆alkyl group” include a methyl group, an ethyl group, a propyl group, anisopropyl group, a butyl group, and a tert-butyl group.

“C₁-C₆ alkoxy group” means an alkoxy group having a straight or branchedalkyl group having 1 to 6 carbon atoms. Examples of a “C₁-C₆ alkoxygroup” include a methoxy group, an ethoxy group, a propoxy group, anisopropoxry groups and a butoxy group.

Examples of “halogen atom” include a fluorine atom, a chlorine atom, abromine atom, and an iodine atom.

“Oxo group” means a group represented by “═O” unless otherwisespecified.

“Carbamoyl group” also includes a cyclic carbamoyl group.

Hereafter, each substituent in formula (1) will be explained.

In the following general formula (1),

ring A represents a spiro-linked 4- to 6-membered saturated hydrocarbonring which may have one or more substituents selected from Group 1 aboveor a spiro-linked 6-membered saturated heterocyclic ring which may haveone or more substituents selected from Group 1 above. Here,“spiro-linked” means that ring A and the pyrrolidine ring to which ringA is bonded form a spiro ring, as illustrated in, for example, thecompounds of the Examples.

A substituent bonded to ring A may be positioned at any position. Aplurality of substituents may be the same or different and two identicalsubstituents are preferably bonded at the 2- to 6-positions.

The substituent(s) is preferably a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, more preferably a C₁-C₆alkyl group which may be substituted with one fluorine atom, yet morepreferably two methyl groups, ethyl groups, or fluoromethyl groupsbonded at the 2-position for a 4-membered ring A, bonded at the 3- and4-positions for a 5-membered ring A, or bonded at the 4-position for a6-membered ring A.

The 6-membered saturated heterocyclic ring represented by ring A ispreferably dioxane or hexahydropyrimidine. The 5-position in these ringsis preferably bonded to the pyrrolidine ring in a compound of formula(1).

Ring A is more preferably a 4- of 6-membered saturated hydrocarbon ring.

Ring B represents a benzene ring which may have one or more substituentsselected from Group 2 above, a pyridine ring which may have one or moresubstituents selected from Group 2 above, or a pyrimidine ring which mayhave one or more substituents selected from Group 2 above.

A substituent bonded to ring B may be positioned at any position. Aplurality of substituents may be the same or different. For the benzenering, one or two substituents are preferably bonded at the 5- or6-position. For the pyridine ring, one substituent is preferably bondedat the 6-position. For the pyrimidine ring, one substituent ispreferably bonded at the 2-position.

The substituent(s) is preferably a halogen atom, a C₁-C₆ alkyl groupwhich may be substituted with one to three halogen atoms, a cyano group,or a C₁-C₆ alkoxy group, more preferably a halogen atom of a cyanogroup, yet more preferably a halogen atom. The halogen atom ispreferably a fluorine atom or a chlorine atom.

R¹ represents an aryl group which may have one or more substituentsselected from Group 3 above, a heteroaryl group which may have one ormore substituents selected from Group 3 above, a C₃-C₆ cycloalkyl groupwhich may have one or more substituents selected from Group 3 above, ora C₃-C₆ cycloalkenyl group which may have one or more substituentsselected from Group 3 above.

Here, examples of the aryl group include a phenyl group, a benzyl group,an indenyl group, a naphthyl group, a fluorenyl group, an anthranilgroup, and a phenanthrenyl group. A phenyl group is particularlypreferred.

Here, examples of the heteroaryl group include a pyrrolyl group, apyrazolyl group, a triazolyl group, an oxazolyl group, an oxadiazolylgroup, a thiophenyl group, a thiazolyl group, a thiadiazolyl group, apyridyl group, a pyrimidyl group, a pyridazinyl group, a pyrazinylgroup, a benzimidazolyl group, a benzotriazolyl group, a benzofuranylgroup, a benzothiophenyl group, a quinolyl group, a carbazolyl group,and a dibenzofuranyl group. A pyridyl group and a benzimidazolyl groupare particularly preferred. The position of binding of the heteroarylgroup to the pyrrolidine ring is not particularly limited and a pyridylgroup, for example, is more preferably bonded at the 4-position.

Here, examples of the C₃-C₆ cycloalkyl group include a cyclopropylgroup, a cyclobutanyl group, a cyclopentanyl group, and a cyclohexylgroup. The C₃-C₆ cycloalkyl group is preferably a cyclopentanyl group ora cyclohexyl group, more preferably a cyclohexyl group.

Here, examples of the C₃-C₆ cycloalkenyl group include a cyclopropenylgroup, a cyclobutenyl group, a cyclopentenyl group, and a cyclohexenylgroup. The C₃-C₆ cycloalkenyl group is preferably a cyclopentenyl groupor a cyclohexenyl group, more preferably a cyclohexenyl group.

The number and position of the substituent(s) bonded to the aryl group,the heteroaryl group, the C₃-C₆ cycloalkyl group, and the C₃-C₆cycloalkenyl group are not limited and a plurality of substituents maybe the same or different.

Examples of the types of substituents include a halogen atom, a C₁-C₆alkyl group which may be substituted with one to three halogen atoms orone to three hydroxy groups, a C₃-C₄ cycloalkyl group which may besubstituted with one to three halogen, atoms or one to three hydroxygroups, a vinyl group, an ethinyl group, a cyano group, —OR′, —NR′R″,—COOR′, and —CONHR′, wherein R′ and R″ each independently represent aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, a C₃-C₄ cycloalkyl group which maybe substituted with one to three halogen atoms or one to three hydroxygroups, or a hydrogen atom, or R′ and R″ together with the nitrogen atomto which R′ and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group.

Here, examples ox the “4- to 7-membered nitrogen-containing heterocyclicgroup” in the phrase “R′ and R″ together with the nitrogen atom to whichR′ and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group, a hydroxy group, and anoxo group” include an azetidinyl group, a pyrrolidinyl group, apiperidinyl group a piperazinyl group, a morpholinyl group, ahexamethyleneiminyl group, a homopiperazinyl group, and ahomomorpholinyl group. Examples of preferable substitutes include ahalogen atom, a C₁-C₆ alkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, —NR′R″, —CONHR′, anda cyano group. A halogen atom, a hydroxy-C₁-C₃ alkyl group, an aminogroup, —CONHR′ wherein R′ is a C₁-C₃ alkyl group, or a cyano group ismore preferred.

The position of a substituent on the R′ group when R′ represents a ringis not particularly limited. For the phenyl group and cyclohexyl group,particularly preferably, one chlorine atom is bonded at the 3-position,or a chlorine atom and a fluorine atom are bonded at the 3- and2-positions, respectively. For the cyclohexenyl group, the position ofthe double bond is not particularly limited. Particularly preferably,one chlorine atom is bonded at the 3-position with respect to theposition of binding to the pyrrolidine ring, or a chlorine atom and afluorine atom are bonded at the 3- and 2-positions, respectively. Forthe pyridyl group, particularly preferably, one chlorine atom is bondedat the 2-position, or a chlorine atom and a fluorine atom are bonded atthe 2- and 3-positions, respectively.

R² represents a C₁-C₆ alkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, or a hydrogen atom.The substituent bonded to the C₁-C₆ alkyl group is preferably a fluorineatom or a hydroxy group. R² is preferably a hydrogen atom, a methylgroup, or an ethyl group, particularly preferably a hydrogen a atom.

R³ represents a group represented by the following general formula (2),(3), or (4):

In formula (2), R⁴ and R⁵ each independently represent a hydroxy group,a C₁-C₆ alkyl group, or a C₁-C₆ alkoxy group, or R⁴ and R⁵ together withthe carbon atoms to which the R⁴ and R⁵ groups are respectively bondedmay form a 4- to 6-membered saturated hydrocarbon ring.

Preferably, both of R⁴ and R⁵ are a hydroxy group, or R⁴ and R⁵ togetherwith the carbon atoms to which the R⁴ and R⁵ groups are respectivelybonded form a 4- to 6-membered saturated hydrocarbon ring. Morepreferably, both R⁴ and R⁵ are a hydroxy group.

In formula (3), the broken line in the ring structure indicates that thebond may be a double bond;

R⁶ represents a C₁-C₆ alkyl group which may have one or moresubstituents selected from Group 4 above, a carbamoyl group which mayhave one or more substituents selected from Group 5 above, a 5- or6-membered nitrogen-containing heteroaryl group which may be substitutedwith an oxo group or one or more C₁-C₆ alkyl groups which may besubstituted with an oxo group or one hydroxy group, a hydroxy group, or—NR′R″, wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group which may be substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may form a 4- to 7-membered nitrogen-containingheterocyclic group which may have one or more substituents selected froma C₁-C₆ alkyl group and a hydroxy group;

R⁷ represents a C₁-C₆ alkyl group which may be substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or

R⁶ and R⁷ may together form a spiro-linked 4- to 6-membered hydrocarbonring or a spiro-linked 4- to 6-membered nitrogen-containing heterocyclicring (wherein “spiro-linked” means that a ring formed by R⁶ and R⁷together and the Z-containing 6-membered ring form a spiro ring);

R⁸ represents one or more substituents selected from a hydroxy group, aC₁-C₆ alkyl group, and a C₁-C₆ alkoxy group; and

Z represents CH₂, NH, or an oxygen atom.

When R⁶ is a “C₁-C₆ alkyl group which may have one or moresubstituents”, examples of the substituent(s) include a halogen atom, ahydroxy group, a carbamoyl group, a morpholino group, a C₁-C₆ alkoxygroup, a C₁-C₆ alkylsulfonyl group, and —NR′R″. Here, R′ and R″ eachindependently represent, a C₁-C₆ alkyl group which may be substitutedwith one to three halogen atoms, one to three hydroxy groups, or an oxogroups a C₃-C₄ cycloalkyl group which may be substituted with one tothree halogen atoms or one to three hydroxy groups, or a hydrogen atom,or R′ and R″ together with the nitrogen atom to which R′ and R″ arebonded may form a 4- to 7-membered nitrogen-containing heterocyclicgroup which may have one or more substituents selected from a C₁-C₆alkyl group and a hydroxy group. Here, examples of the “4- to 7-memberednitrogen-containing heterocyclic group” when “R′ and R″ together withthe nitrogen atom to which R′ and R″ are bonded form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group”include an azetidinyl group, a pyrrolidinyl group, and a piperidinylgroup.

The “C₁-C₆ alkyl group which may have one or more substituents”,represented by R⁶, is preferably a hydroxymethyl group, a 1-hydroxyethylgroup, a 2-hydroxypropyl group, a hydroxyethyl group, a1-hydroxy-1-methylethyl group, a 3,4-dihydroxybutyl group, amethoxymethyl group, a methylsulfonylmethyl group, an aminomethyl group,a di-C₁-C₃ alkylaminomethyl group, a (hydroxyethyl) aminomethyl group, aC₁-C₃ alkyloxy(hydroxyethyl)aminomethyl group, an aminooxoethyl group,or a di-C₁-C₃ alkylaminooxoethyl group.

When R⁶ is a “carbamoyl group which may have one or more substituents”,examples of the substituent(s) include a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, one to three hydroxygroups, or a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₁-C₆alkoxy group, and a tetrahydropyranyl group.

The “carbamoyl group which may have one or more substituents”,represented by R⁶, is preferably an unsubstituted carbamoyl group, amethylcarbamoyl group, a dimethylcarbamoyl group, an ethylcarbamoylgroup, a diethylcarbamoyl group, a methylethylcarbamoyl group, anisopropylcarbamoyl group, a cyclopropylcarbamoyl group, a2-hydroxyethylcarbamoyl group, a 2-methoxyethylcarbamoyl group, a2-methoxyethyl-C₁-C₃ alkylcarbamoyl group, or a 2-fluoroethylcarbamoylgroup.

When R⁶ is a “5- or 6-membered nitrogen-containing heteroaryl groupwhich may be substituted with an oxo group or one or more C₁-C₆ alkylgroups which may be substituted with an oxo group or one hydroxy group”,examples of the “5- or 6-membered nitrogen-containing heteroaryl group”include an oxadiazolyl group, a triazolyl group, an imidazolyl group, athiazolyl group, a thiadiazolyl group, a pyrrolyl group, a pyridylgroup, a pyrimidyl group, a pyridazinyl group, and a triazinyl group. Anoxadiazolyl group or a triazolyl group is preferred. An oxadiazolylgroup, for example, is preferably bonded at the 2-position. The positionof the substituent bonded to the “5- or 6-membered nitrogen-containingheteroaryl group” is not particularly limited. For the 6-memberednitrogen-containing heteroaryl group, the substituent is positioned atany position. For the 5-membered nitrogen-containing heteroaryl group,the substituent is preferably substituted at the 5-position.

“5- or 6-membered nitrogen-containing heteroaryl group which may besubstituted with an oxo group or one or more C₁-C₆ alkyl groups whichmay be substituted with an oxo group or one hydroxy group”, representedby R⁶, is preferably an unsubstituted oxadiazolyl group, a triazolylgroup, or a pyridyl group, particularly preferably an oxadiazolyl group.

Furthermore, R⁶ may be a hydroxy group or —NR′R″.

When R⁶ is “—NR′R″”, R′ and R″ each independently represent a C₁-C₆alkyl group which may be substituted with one to three halogen atoms, anoxo group, or one to three hydroxy groups, a C₃-C₄ cycloalkyl groupwhich may be substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom, or R′ and R″ together with thenitrogen atom to which R′ and R″ are bonded may form a 4- to 7-memberednitrogen-containing heterocyclic group which may have one or moresubstituents selected from a C₁-C₆ alkyl group and a hydroxy group.Here, examples of the “4- to 7-membered nitrogen-containing heterocyclicgroup” when “R′ and R″ together with the nitrogen atom to which R′ andR″ are bonded form a 4- to 7-membered nitrogen-containing heterocyclicgroup which may have one or more substituents selected from a C₁-C₆alkyl group and a hydroxy group” include an azetidinyl group, apyrrolidinyl group, a piperidinyl group, a piperazinyl group, a2-oxopiperazinyl group, a morpholinyl group, a homopiperidinyl group, ahomopiperazinyl group, and a 1,4-oxazepanyl group.

“—NR′R″” represented by R⁶ preferably forms an azetidinyl group, apiperazinyl group, or a morpholinyl group.

R⁶ is preferably a hydroxymethyl group, a 1-hydroxyethyl group, a2-hydroxypropyl group, a hydroxyethyl group, a 1-hydroxy-1-methylethylgroup, an oxazolyl group, an oxadiazolyl group, an oxathiazolyl group,or a carbamoyl group which may have an alkyl group having 1 to 6 carbon,atoms as a substituent, more preferably a 1-hydroxyethyl group, anoxadiazolyl group, or an unsubstituted carbamoyl group.

R⁷ represents a C₁-C₆ alkyl group which may be substituted with onehydroxy group, a hydroxy group, or a hydrogen atom.

R⁷ is more preferably a methyl group, an ethyl group, a hydroxymethylgroup, a hydroxyethyl group, a hydroxy group, or a hydrogen atom, yetmore preferably a hydroxy group or a hydrogen atom.

Furthermore, R⁶ and R⁷ may together form a 4- to 6-membered spiro-linkedhydrocarbon ring or a 4- to 6-membered spiro-linked nitrogen-containingheterocyclic ring. Examples of the ring formed include a cyclobutanering, a cyclopentane ring, a cyclohexane ring, an azetidine ring, apyrrolidine ring, and a tetrahydropyran ring. A cyclobutane ring or anazetidine ring is more preferred.

R⁸ is a substituent on the 6-membered ring in formula (3) and representsone or more substituents selected from a hydroxy group, a C₁-C₆ alkylgroup, and a C₁-C₆ alkoxy group.

The position of R⁸ bonded to the 6-membered ring in formula (3) is notparticularly limited so long as it is other than the position to whichR⁶ and R⁷ are bonded. The number of the substituent is not limited.Furthermore, R⁸ is not required to be present. R⁸ is preferably ahydroxy group, a methoxy group, or a methyl group. More preferably, R⁸is absent, or one R⁸ group is present. Yet more preferably, R⁸ isabsent, or a methoxy group is bonded in the same positionalconfiguration as in R⁶ on the carbon atom adjacent to the carbon to atomwhich R⁶ is bonded.

In formula (4),

R⁹ represents a C₁-C₆ alkyl group which may have one or moresubstituents selected from Group 4 above, a carbamoyl group which mayhave one or more substituents selected from Group 5 above, a 5- or6-membered nitrogen-containing heteroaryl group which may be substitutedwith an oxo group or one or more C₁-C₆ alkyl groups which may besubstituted with an oxo group or one hydroxy group, a hydroxy group, or—NR′R″, wherein

R′ and R″ each independently represent a C₁-C₆ alkyl group which may besubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group which may be substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may form a 4- to 7-membered nitrogen-containingheterocyclic group which may have one or more substituents selected froma C₁-C₆ alkyl group and a hydroxy group.

R¹⁰ represents a C₁-C₆ alkyl group which may be substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or R⁹ and R¹⁰ maytogether form a spiro-linked 4- to 6-membered hydrocarbon ring or aspiro-linked 4- to 6-membered nitrogen-containing heterocyclic ring, and

R¹¹ represents one or more substituents selected from a hydroxy group, aC₁-C₆ alkyl group, and a C₁-C₆ alkoxy group.

R⁹ has the same meaning as defined above in R⁶ in formula (3) and alsohas the same preferred examples.

R¹⁰ has the same meaning as defined above in R⁷ in formula (3) and alsohas the same preferred examples.

R¹¹ has the same meaning as defined, above in R⁸ in formula (3) and alsohas the same preferred examples. The phrase “R⁹ and R¹⁰ may togetherform a spiro-linked 4- to 6-membered hydrocarbon ring or a spiro-linked4- to 6-membered nitrogen-containing heterocyclic ring” means that R⁹and R¹⁰ together form a ring structure and this ring and the cyclobutanering to which R⁹ and R¹⁰ are bonded form a spiro ring.

A compound represented by general formula (1) of the present inventionis more preferably a compound represented by any of the followinggeneral formulas (5) to (8) (in formulas (5) to (8), ring A, R², and R³have the same meanings as defined above and also have the same preferredexamples):

R¹², R¹³, and R¹⁶ represent a group selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group and arepreferably a halogen atom or a cyano group, more preferably a halogenatom, yet more preferably a chlorine atom or a fluorine atom.

R¹⁴ represents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group which may be substituted with one to three halogenatoms or one to three hydroxy groups, and a cyano group and is notrequired to be present. Preferably, R¹⁴ is absent or R¹⁴, if present, isa fluorine atom. The position of the substituent bonded to the ring isnot limited.

R¹⁵ represents one or more substituents selected from Group 3 above andis not required to be present. More preferably, R¹⁵ is absent or R¹⁵, ifpresent, is a halogen atom, a hydroxy-C₁-C₃ alkyl group, an amino group,—CONHR′ wherein R′ is a C₁-C₃ alkyl group, or a cyano group.

A compound represented by general formula (1) of the present inventionis more preferably a compound selected from the following group:

A compound represented by formula (1) of the present invention may havestereoisomers or optical isomers due to asymmetric carbon atoms, and allthese stereoisomers, optical isomers, and mixtures thereof are includedin the present invention.

In one embodiment of the present invention, a compound having anabsolute configuration represented by the following formula ispreferred:

From previous studies, it is known that in a compound having a6-oxo-2,7-diazaspiro[4.4]nonane-3-carboxamide structure, the centralskeleton of general formula (9), which is unsubstituted ormonosubstituted at the 2-position in the pyrrolidine ring, cleavage andrecyclization at the C2-C3 carbon bond of the pyrrolidine ring occur ina polar solvent to facilitate isomerization of the spiro ring structureat the 3-position (Helv. Chim. Acta, 1996, 79, 151-168, etc). Thepresent inventors have found that introduction of the spiro ringstructure A to the 2-position at the pyrrolidine ring can prevent theprogression of this isomerization. The present inventors have also foundthat the compound group having an absolute configuration represented bygeneral formula (9) is far superior in the ability to inhibit Mdm2-p53binding to that reported in the previous studies. Furthermore, thepresent inventors have obtained co-crystals with Mdm2 protein fromcompounds of Examples 18, 38, and 70 of the present application, whichare described later, and consequently found that these compounds bind toMdm2 protein in a manner different from that predicted in silico in J.Am. Chem. Soc., 2005, 127, 10130-10131 and J. Med. Chem., 2006, 49,3432-3435.

A compound represented by general formula (1) of the present inventioncan form a pharmaceutically acceptable salt, if desired, when having abasic group such as an amino group. Examples of such salts can includethe following: hydrohalides such as hydrochloride and hydroiodide;inorganic acid salts such as nitrate, perchlorate, sulfate, andphosphate; lower alkanesulfonates such as methanesulfonate,trifluoromethanesulfonate, and ethanesulfonate; arylsulfonates such asbenzenesulfonate and p-toluenesulfonate; organic acid salts such asformic acid, acetic acid, malic acid, fumarate, succinate, citrate,tartrate, oxalate, and maleate; and amino acid salts such as ornithinesalt, glutamate, and aspartate. Hydrohalides and organic acid salts arepreferred.

A compound represented by general formula (1) of the present inventionmay generally form a base addition salt when having an acidic group suchas a carboxy group. Examples of pharmaceutically acceptable salts caninclude the following: alkali metal salts such as sodium salt, potassiumsalt, and lithium salt; alkaline earth metal salts, such as calcium saltand magnesium salt; inorganic salts such as ammonium salt; and organicamine salts such as dibenzylamine salt, morpholine salt, phenylglycinealkyl ester salt, ethylenediamine salt, N-methylglucamine salt, diethylamine salt, triethylamine salt, cyclohexylamine salt, dicyclohexylaminesalt, N,N′-dibenzylethylenediamine salt, diethanolamine salt,N-benzyl-N-(2-phenylethoxy)amine salt, piperazine salt,tetramethylammonium salt, and tris(hydroxymethyl)aminomethane salt.

A compound represented by general formula (1) of the present inventionor the salt thereof may be present in a free or solvate form. A compoundrepresented by general formula (1) of the present invention or a saltthereof may be present in a hydrate form, for example, by absorbingmoisture in the air. The solvate is not particularly limited so long asit is pharmaceutically acceptable. Specifically, the solvate ispreferably a hydrate, an ethanol solvate, a 2-propanol solvate, or thelike. Moreover, a compound represented by general formula (1) of thepresent invention may be in an N-oxide form when containing a nitrogenatom. These solvate and N-oxide forms are also included in the presentinvention.

A compound represented by general formula (1) of the present inventionmay have various isomers such as geometrical isomers (e.g., cis andtrans forms), tautomers, and optical isomers (e.g., d and l forms),depending on the types or combinations of substituents. The compounds ofthe present invention also encompasses all of these isomers,stereoisomers, and mixtures of these isomers and stereoisomers in anyratio, unless otherwise specified.

A compound represented by general formula (1) of the present inventionmay contain an isotope in a non-natural proportion as one or moreconstituent atoms. Examples of an isotope include deuterium (²H),tritium (³H), iodine-125 (¹²⁵I), and carbon-14 (¹⁴C). These compoundsare useful as a therapeutic or preventive agent, a research reagent(e.g., an assay reagent), and a diagnostic agent (e.g., an in vivodiagnostic imaging agent). All isotonic variants of the compoundsrepresented by general formula (1) are included in the scope of thepresent invention, regardless of one presence or absence ofradioactivity.

Moreover, the present invention also encompasses compounds that areconverted to the compounds represented by general formula (1) as anactive ingredient in the pharmaceutical composition of the presentinvention due to a reaction induced by an enzyme, gastric acid, or thelike under physiological conditions in vivo, i.e., a compound that isconverted to a compound represented by general formula (1) throughenzymatic oxidation, reduction, hydrolysis, or the like or apharmaceutically acceptable prodrug compound that is converted to acompound represented by general formula (1) through hydrolysis or thelike induced by gastric acid or the like.

Examples of a prodrug can include the following: compounds in which anamino group in a compound represented by general formula (1) isacylated, alkylated, or phosphorylated (e.g., compounds in which theamino group is eicosanoylated, alanylated, pentylaminocarbonylated,(5-methyl-2-oxo-1,3-dioxolen-4-yl) methoxycarbonylated,tetrahydrofuranylated, pyrrolidylmethylated, pivaloyloxymethylated, ortert-butylated); compounds in which a hydroxy group in a compoundrepresented by general formula (1) is acylated, alkylated,phosphorylated, or borated (e.g., compounds in which the hydroxy groupis acetylated, palmitoylated, propanoylated, pivaloylated, succinylated,fumarylated, alanylated, or dimethylaminomethylcarbonylated); andcompounds in which a carboxy group in a compound represented by generalformula (1) is esterified or amidated (e.g., compounds in which thecarboxy group is ethyl esterified, phenyl esterified, carboxymethylesterified, dimethylaminomethyl esterified, pivaloyloxymethylesterified, dimethylaminomethyl esterified, esterified, amidated, ormethylamidated).

A prodrug of a compound of the present invention can be produced from acompound represented by general formula (1) according to any methodknown in the art. Moreover, a prodrug of a compound of the presentinvention also includes those converted to a compound represented bygeneral formula (1) under physiological conditions as described in“Development of Pharmaceutical Products”, vol. 7, Molecule Design, p.163-198, Hirokawa-Shoten Ltd, (1990).

Next, a representative method for producing a compound represented bygeneral formula (1) will be explained. A compound of the presentinvention can be produced by various production methods and thefollowing production methods are illustrative and should not beconstrued in any limitive way. Reactions shown below can be performed byprotecting substituents with appropriate protective groups, ifnecessary, and the types of protective groups are not particularlylimited.

[Production Method1]

wherein ring A ring B, R¹, R², and R³ have the same meanings as definedabove.

Synthesis at Compound (3)

A compound (3) can be obtained by subjecting an oxindole compound (1)and an aldehyde compound (2) to a dehydration reaction through treatmentwith an organic base such as pyrrolidine, piperidine, ordiisobutylethylamine as a catalyst. Here, the solvent used in thereaction is not particularly limited and examples thereof include loweralcohols such as methanol and ethanol, and mixed solvents in which anyof these solvents are mixed with water in an arbitrary ratio. Thereaction temperature is not particularly limited and examples thereofinclude room temperature to 120° C. Moreover, the compound can also beobtained by a cyclodehydration reaction using an organic acid such asp-toluenesulfonic acid or camphorsulfonic acid as a catalyst. Here, thesolvent used in the reaction is not particularly limited and examplesthereof include benzene, toluene, and xylene. The reaction temperatureis preferably in the range from 80° C. to 100° C. or the boiling pointof the solvent.

Synthesis of Compound (6)

A compound (6) can be obtained by reacting compound (3) with amorpholinone compound (4) as a chiral auxiliary compound and a ketonecompound (5) using a dehydrating agent such as a molecular sieve and aLewis acid such as copper sulfate, zinc bromide, or a borontrifluoride-diethyl ether complex as a catalyst. Here, the solvent usedin the reaction is not particularly limited and examples thereof includetetrahydrofuran, dioxans, chloroform, benzene, toluene, and mixed,solvents thereof. However, dried solvents are preferred. The reactiontemperature is usually preferably in the range from room temperature to100° C. or the boiling point of the solvent (J. Am. Chem. Soc., 2000,122, 5666-5667; and Tetrahedron Lett. 2005, 5949-5951).

Synthesis of Compound (8)

A compound (8) can be obtained by reacting compound (6) with an aminecompound (7). In this reaction, an organic base such as triethylamine,diisopropylethylamine, 4-dimethylaminopyridine, N-methylmorpholine,pyridine, 2,6-lutidine, or diazabicyclo[5.4.0]undec-7-ene, or aninorganic base such as potassium carbonate, sodium carbonate, potassiumbicarbonate, or sodium bicarbonate can also be added. Here, examples ofthe solvent used in the reaction can include dichloromethane,chloroform, diethyl ether, tetrahydrofuran, toluene, methanol, ethanol,isopropyl alcohol, and mixed solvents thereof. The reaction temperatureis usually preferably in the range from 0° C. to 100° C. or the boilingpoint of the solvent.

Synthesis of Compound (9)

A compound (9) can be obtained by hydrolyzing compound (6) with a basesuch as sodium hydroxide, potassium hydroxide, lithium hydroxide,potassium tert-butoxide, potassium carbonate, or sodium carbonate, thenneutralizing the hydrolysate with an acid such as hydrochloric acid,sulfuric acid, or methanesulfonic acid, then reacting the reactionmixture with lead (IV) acetate or cerium (II) diammonium nitrate, andneutralizing the reaction product with, for example, an inorganic basesuch as sodium hydroxide, potassium hydroxide, potassium carbonate,sodium carbonate, potassium bicarbonate, or sodium bicarbonate.Alternatively, the compound can also be obtained by reacting compound(6) under the hydrolysis conditions above, then reacting the hydrolysatewith lead (IV) acetate or cerium (IV) diammonium nitrate withoutneutralizing it, and then neutralizing the reaction product under theconditions above. Here, examples of the solvent used in the reactioninclude methanol, ethanol, tetrahydrofuran, dioxane, acetonitrile,dichloromethane, water, and mixed solvents thereof. However, organicsolvents that can be mixed with water in an arbitrary ratio arepreferred. The reaction temperature is usually preferably in the rangefrom −20°C. to room temperature.

Synthesis of Compound (10) [via Compound (8)]

A compound (10) can be obtained by reacting compound (8) with lead (IV)acetate or cerium (IV) diammonium nitrate. Here, examples of the solventused in the reaction include methanol, ethanol, tetrahydrofuran,dioxane, acetonitrile, dichloromethane, water, and mixed solventsthereof. However, organic solvents that can be mixed with water in anarbitrary ratio are preferred. The reaction temperature is usuallypreferably in the range from −20° C. to room temperature. Subsequently,the reaction mixture is preferably treated with an inorganic base suchas potassium carbonate or sodium carbonate. The treatment temperature isusually preferably in the range from −20° C. to room temperature.

The product obtained by the production method above is more preferablyconverted to a compound that is thermodynamically stable and has thedesired positional configuration by heating, usually in the range fromroom temperature to 80° C. or the boiling point of the solvent, usingmethanol, ethanol, tetrahydrofuran, dioxane, water, acetonitrile, or thelike or a mixed solvent thereof, or an organic solvent that can be mixedwith water in an arbitrary ratio.

Synthesis of Compound (10) [via Compound (9)]

A compound (10) can be obtained by reacting compound (9) with an aminecompound (7) in the presence of a condensing agent. Here, examples ofthe condensing agent used can include N,N-dicyclohexylcarbodiimide(DCC), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI),carbonyldiimidazole (CDI),2-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol (BOP),1H-benzotriazol-1-yloxytripyrrolidinophosphoniumhexafluorophosphate(PyBOP), and O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluroniumhexafluorophosphate (HATU). The solvent used in the reaction is notparticularly limited and examples thereof include dichloromethane,dimethylformamide, tetrahydrofuran, ethyl acetate, and mixed solventsthereof. The reaction temperature is usually in the range from −20° C.to 100° C. or the boiling point of the solvent, preferably in the rangefrom −5° C. to 50° C. Moreover, an organic base such as triethylamine,diisopropylethylamine, N-methylmorphonine, or 4-dimethylaminopyridine,or an inorganic base such as potassium carbonate, sodium carbonate,potassium bicarbonate, or sodium bicarbonate can be added, if necessary.Furthermore, 1-hydroxybenzotriazole, N-hydroxysuccinimide, or the likecan be added as a reaction accelerator.

The product obtained by the production method above is more preferablyconverted to a compound that is thermodynamically stable and has thedesired positional configuration by heating, usually in the range fromroom temperature to 80° C. or the boiling point of the solvent, usingmethanol, ethanol, tetrahydrofuran, dioxane, water, acetonitrile, or thelike or a mixed solvent thereof, or an organic solvent that can be mixedwith water in an arbitrary ratio.

[Production Method 2]

wherein ring A, ring B, R¹, R², and R³ have the same meanings as definedabove, and W means a protective group for the carboxy group. Examples ofthe protective group for the carboxy group include substituted orunsubstituted alkyl groups or aralkyl groups such as a methyl group, anethyl group, a tert-butyl group, and a benzyl group.

Synthesis of Compound (12)

A compound (12) can be obtained by reacting a compound (3), a ketonecompound (5), and a compound (11) such as a glycine ester orhydrochloride thereof with a dehydrating agent such as a molecular sieveor magnesium sulfate. Here, the solvent used in the reaction is notparticularly limited and examples thereof include tetrahydrofuran,dioxane, chloroform, 1,2-dichloroethane, benzene, toluene, and mixedsolvents thereof. However, dried solvents are preferred. The reactiontemperature is usually preferably in the range from room temperature to100° C. or the boiling point of the solvent (Tetrahedron, 2001, 57,1129-1137). Moreover, silver acetate, silver fluoride, or the like canalso be added as a catalyst in the reaction (Tetrahedron, 2003, 59,335-340; and WO2010/031713).

Synthesis of Compound (9)

Because the compound synthesized by the production method above is aracemate, the compound of interest can be obtained by optical resolutionusing a chiral column or a crystallization method involving formation ofan optically active salt or the like of tartaric acid,bromocamphorsulfonic acid, chlorocamphorsulfonic acid, camphorsulfonicacid, or the like, followed by deprotection of the ester (W). Althoughreaction conditions differ depending on the type of W, this reaction maybe hydrolysis. When W is a methyl group, an ethyl group, a benzyl group, or the like, the compound can be obtained by treating compound (12)with a base such as sodium hydroxide, potassium hydroxide, lithiumhydroxide, or potassium tert-butoxide, or an acid such as hydrochloricacid or p-toluenesulfonic acid. Here, examples of the solvent used inthe reaction include methanol, ethanol, water, tetrahydrofuran, dioxane,and mixed solvents thereof. However, organic solvents that can be mixedwith water in an arbitrary ratio are preferred. The reaction temperatureis usually preferably in the range from −20° C. to 100° C. or theboiling point of the solvent. When W is a tert-butyl group or the like,the compound can be obtained by treating compound (12) with, forexample, trifluoroacetic acid or hydrochloric acid. Here, the solventused in the reaction is not particularly limited and examples thereofinclude dichloromethane, chloroform, 1,2-dichloroethane, and mixedsolvents thereof. The reaction temperature is usually in the range from−20° C. to 80° C. or the boiling point of the solvent, preferably in therange from 0° C. to around room temperature.

Synthesis of Compound (10)

A compound (10) can be obtained according to the method for producingcompound (10) with compound (9) as a starting material described in[Production Method 1] above.

The starting material compounds (1), (2), (3), (4), (5), (7), (11), and(12) are commercially available products or can be synthesized accordingto methods described in the Reference Examples section.

In one embodiment of the present invention, a compound of the presentinvention can be used as a p53-Mdm2binding inhibitor and/or an Mdm2ubiquitin ligase inhibitor because it inhibits the binding of p53 withMdm2 and the ubiquitination of p53 by Mdm2.

The condition of the p53-Mdm2 binding can be examined by a mattedconventionally used by those skilled in the art to examine bindingconditions between proteins (for example, immunological techniques,surface plasmon resonance techniques, etc.), Examples of methods forexamining the condition of the Mdm2-p53 binding using an immunologicaltechnique include an immuno-sedimentation method, andenzyme-linked-immunosorbent assay (ELISA). An antibody used in suchimmunological techniques may be an anti-Mdm2 antibody and/or an anti-p53antibody that can directly detect Mdm2 and/or p53. When Mdm2 and/or p53is labeled with a tag (for example, a GST tag or a histidine tag) or thelike, an antibody suitable for labeling (for example, an anti-GSTantibody or an anti-histidine antibody) can be used. Methods forexamining the condition of the Mdm2-p53 binding using an immunologicaltechnique are described in, for example, WO2003/51359, WO2003/51360,U.S. Patent Application Publication No. 2004/259867 or 2004/259884, andWO2005/110996. Methods for examining the condition of the Mdm2-p53binding using a surface plasmon resonance technique are described in,for example, Science, vol. 303, p. 844-848, 2004.

Ubiquitin ligase activity of Mdm2 against p53 can be examined by aubiquitin ligase assay conventionally used by those skilled in the art.The ubiquitin ligase activity can be detected by, for example, comparingubiquitination of p53 by ubiquitin activation enzyme (E1), ubiquitinbinding enzyme (E2), and ubiquitin ligase (E3) (Mdm2) in the presenceand absence of a test compound (for example, refer to WO2001/75145 andWO2003/76608).

In another embodiment, a compound of the present invention can be usedas an inhibitor of suppression of the p53 transcription activity becauseit restores functions of p53 as a transcription factor that issuppressed by Mdm2 by inhibiting the binding of Mdm2 to the p53transcription activation domain. The inhibitor of suppression of the p53transcription activity can be obtained by, for example, measuring themRNA level or the protein level of a protein whose transcription isregulated by p53 (for example, p21^(Waf1/Cip1)) in the presence orabsence of a test compound by an mRNA measuring method (for example,Northern blot) or a protein measuring method (for example, Western blot)conventionally used by those skilled in the art, and selecting the testcompound as an inhibitor of suppression of the p53 transcription,activity when the mRNA level or the protein level is increased in thepresence of the test compound as compared with that in the absence ofthe test compound. Furthermore, the inhibitor of suppression of the p53transcription activity can also be identified by a reporter assay usingthe reporter activity of a reporter gene that includes a p53 responsiveelement as an indicator.

In another embodiment, a compound of the present invention can be usedas a p53 degradation inhibitor because it inhibits ubiquitination of p53by Mdm2 and thereby prevents the degradation of p53 in proteasomes. Thep53 degradation inhibitor can be obtained by, for example, measuring theprotein level of p53 in the presence or absence of a test compound by aprotein measuring method (for example, Western blot) conventionally usedby those skilled in the art and selecting the test compound as a p53degradation inhibitor when the protein level is increased in thepresence of the test compound as compared with that in the absence ofthe test compound.

In another embodiment, a compound of the present invention can be usedas an anti-tumor agent because it normalizes functions of p53 as acancer-restraining gene by inhibition of the Mdm2-p53 binding and/orubiquitination of p53 by Mdm2.

Cellular growth inhibiting activity can be examined by methods fortesting growth inhibition conventionally used by those skilled in theart. The cell growth inhibition activity can be determined by, forexample, comparing the levels of cellular growth (for example, tumorcells) in the presence and absence of a test compound as described inthe following Test Example 2. The levels of cellular growth can beexamined by using, for example, a test system, for measuring livingcells. Examples of methods for measuring living cells include the[³H]-thymidine uptake test, the BrdO method, the MTT assay, and soforth.

Moreover, in vivo anti-tumor activity can be examined by methods fortesting anti-tumor activity conventionally used by those skilled in theart. The in vivo anti-tumor activity of a compound of the presentinvention cab be confirmed by, for example, transplanting various tumorcells into mice, rats, or the like; after confirming the engraftment ofthe transplanted cells, orally or intravenously administering a compoundof the present invention to the animals; a few days or a few weekslater, comparing tumor growth in the non-compound-administered groupwith that in the compound-administered group.

A compound of the present invention can be used for the treatment oftumors or cancers, for example, lung cancer, digestive system cancer,ovary cancer, uterine cancer, breast cancer, prostate cancer, livercancer, head/neck region cancer, blood cancer, renal cancer, skin cancer(malignant melanoma, etc.), retinoblastoma, testicular tumors, andsarcoma, more preferably lung cancer, breast cancer, prostate cancer,colon cancer, acute myeloid leukemia, malignant lymphoma, malignantmelanoma, retinoblastoma. neuroblastoma, and sarcoma. However, thepresent invention is not limited to these cancers.

A pharmaceutical composition of the present invention can contain acompound of the present invention and a pharmaceutically acceptablecarrier and can be administered as various injections such asintravenous injection, intramuscular injection, and subcutaneousinjection or by various methods such as oral administration orpercutaneous administration. “Pharmaceutically acceptable carrier” meansa pharmacologically acceptable material that is involved in transport ofa compound of the present invention or a composition containing acompound of present invention (for example, an excipient, a diluent, anadditive, a solvent, etc.) from a given organ to another organ.

A formulation can be prepared by selecting a suitable formulation form(for example, oral formulation or injection) depending on theadministration method and using various conventionally used methods forpreparing a formulation. Examples of oral formulations include tablets,powders, granules, capsules, pills, lozenges, solutions, syrups,elixirs, emulsions, oily or aqueous suspensions, and so forth. In oraladministration, the free compound or a salt form may be used. An aqueousformulation can be prepared by forming an acid adduce with apharmacologically acceptable acid or by forming an alkali metal saltsuch as sodium. As an injection, a stabilizer, a preservative, adissolving aid, and the like can be used in the formulation. Afterfilling a solution that may contain these aids and the like in a vessel,a formulation for use may be prepared as a solid formulation bylyophilization or the like. Furthermore, one dose may be filled in onevessel, or two or more doses may be filled in a vessel.

Examples of solid formulations include tablets, powders, granules,capsules, pills, and lozenges. These solid formulations may containpharmaceutically acceptable additives together with a compound of thepresent invention. Examples of additives include fillers, extenders,binders, disintegrating agents, dissolution promoting agents, skinwetting agents, and lubricants, and these can be selected and mixed asrequired to prepare a formulation.

Examples of liquid formulations include solutions, syrups, elixirs,emulsions, and suspensions. These liquid formulations may containpharmaceutically acceptable additives together with a compound of thepresent invention. Examples of additives include suspending agents andemulsifiers, and these are selected and mixed as required to prepare aformulation.

The compound of the present invention can be used in cancer treatment ofmammals, in particular, humans. The dose and the administration intervalcan be suitably selected depending on the site of the disease, thepatient's height, body weight, sex, or medical history, according to aphysician's judgment. When the compound of the present invention isadministered to a human, the dose range is approx. 0.01 to 500 mg/kgbody weight per day, preferably, approx. 0.1 to 100 mg/kg body weight.Preferably, the compound of the present invention is administered to ahuman once a day, or the dose is divided two to four times, andadministration is repeated at an appropriate interval. Furthermore, thedaily dose may exceed the above-mentioned dose at a physician'sdiscretion, if necessary.

The compound of the present invention may be used in combination with anadditional anti-tumor agent. Examples thereof include anti-tumorantibiotics, anti-tumor plant constituents, BRMs (biological responsemodifiers), hormones, vitamins, anti-tumor antibodies, molecular targetdrugs, and other anti-tumor agents.

More specifically, examples of alkylating agents include the following:alkylating agents such as nitrogen mustard, nitrogen mustard H-oxide,and chlorambucil; aziridine alkylating agents such as carboquone andthiotepa; epoxide alkylating agents such as dibromomannitol anddibromodulcitol; nitrosourea alkylating agents such as carmustine,lomustine, semustine, nimustine hydrochloride, streptozocin,chlorozotocin, and ranimustine; and busulfan, improsulfan tosylate, anddacarbazine.

Examples of various metabolic antagonists include the following: purinemetabolic antagonists such as 6-mercaptopurine, 6-thioguanine, andthioinosine; pyrimidine metabolic antagonists such as fluorouracil,tegafur, tegafur-uracil, carmofur, doxifluridine, broxuridine,cytarabine, and enocitabine; and folic acid metabolic antagonists suchas methotrexate and trimetrexate.

Examples of anti-tumor antibiotics include the following: anti-tumoranthracycline antibiotics such as mitomycin C, bleomycin, peplomycin,daunornbicin, aclarubicin, doxorubicin, pirarubicin, THP-adriamycin,4′-epidoxorubicin, and epirubicin; and chromomycin A3 and actinomycin D.

Examples of anti-tumor plant constituents include the following: vincaalkaloids such as vindesine, vincristine, and vinblastine; taxanes suchas paclitaxel and docetaxel; and epipodophyllotoxins such as etoposideand teniposide.

Examples of BRMs include tumor necrosis factors and indomethacin.

Examples of hormones include hydrocortisone, dexamethasone,methylprednisolone, prednisolone, prasterone, betamethasone,triamcinolone, oxymetholone, nandrolone, metenolone, fosfestrol,ethinylestradiol, chlormadinone, and medroxyprogesterone.

Examples of vitamins include vitamin C and vitamin A.

Examples of anti-tumor antibodies and molecular target drugs includetrastuzumab, rituximab, cetuximab, nimotuzumab, denosumab, bevacizumab,infliximab, imatinib mesilate, gefitinib, erlotinib, sunitinib,lapatinib, and sorafenib.

Examples of other anti-tumor agents include cisplatin, carboplatin,oxaliplatin, tamoxifen, camptothecin, ifosfamide, cyclophosphamide,melphalan, L-asparaginase, aceglatone, sizofiran, picifoanil,procarbazine, pipobroman, neocarzinostatin, hydroxyurea, ubenimex, andkrestin.

The present invention also includes a method for preventing and/ortreating cancer comprising administering a compound of the presentinvention or a salt thereof.

The present invention further includes use of a compound of the presentinvention, a salt, or a solvate thereof for the manufacture of themedicament.

Hereinafter, the present invention will be specifically explained withreference to the Examples. However, the present invention is not limitedto these examples, and they should not be construed in any limitive way.Furthermore, reagents, solvents, and starting materials in thespecification can be readily obtained from commercially available supplysources unless otherwise specified.

Hereinafter, the present invention will be specifically explained withreference to the Examples. However, the present invention is not limitedto these examples, and they should not be construed in any limitativeway. Furthermore, reagents, solvents, and starting materials in thespecification can be readily obtained from commercially available supplysources unless otherwise specified.

EXAMPLES Example 1

[Step1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

(5R,6S)-5,6-diphenylmorpholin-2-one (506 mg, 2.00 mmol),4,4-dimethylcyclohexanone (252 mg, 2.00 mmol), and molecular sieves 4A(powder) (2 g) were added to a toluene (20 ml) solution of (3E/Z)-6-chloro-3-(3-chloro-2-fluorobenzylidene)-1,3-dihydro-2H-indol-2-one(WO2006/091646) (616 mg, 2.00 mmol) under nitrogen atmosphere and theresulting mixture was stirred under heating at 70° C. for 5 days. Aftercooling, insoluble matter was removed by filtration through celite andthe filtrate was concentrated under reduced pressure. The residue wasdissolved in ethyl acetate and the organic layer was washed with 1Nhydrochloric acid and brine and then dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure and theresidue was purified by silica gel column chromatography [n-hexane:ethylacetate=9:1→6:1 (v/v)] to give 194 mg (14%) of the title compound as ayellow amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.19 (3H, s), 0.52 (3H, s), 0.94-1.00 (3H,m), 1.29-1.41 (3H, m), 1.80 (1H, d, J=11.0 Hz), 2.27 (1H, d, J=14.2 Hz),4.61 (1H, d, J=11.0 Hz), 4.86 (1H, d, J=2.7 Hz), 5.35 (1H, d, J=11.4Hz), 6.23 (1H, d, J=8.2 Hz), 6.60 (1H, dd, J=8.2, 1.8 Hz), 6.72-6.78(2H, m), 6.88 (1H, d, J=1.8 Hz), 7.07-7.26 (11H, m), 7.67 (1H, s), 7.77(1H, t, J=6.4 Hz).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

Trans-4-aminocyclohexanol (167 mg, 1.45 mmol) was added to atetrahydrofuran (10 ml) solution of the compound (194 mg, 0.29 mmol)obtained in Step 1 above and the resulting mixture was heated to refluxfor 6 days. After cooling, saturated ammonium chloride solution wasadded, followed by extraction with ethyl acetate. The organic layer waswashed with brine and then dried over anhydrous sodium sulfate. Thesolvent was evaporated under reduced pressure and the residue waspurified by silica gel column chromatography[chloroform:methanol=100:0→30:1 (v/v)] to give 230 mg (100%) of thetitle compound as a pale yellow amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.51-0.57 (1H, m), 0.85-0.89 (5H, m), 1.05(3H, s), 1.29-1.35 (6H, m), 1.69-1.71 (3H, m), 1.82-1.97 (2H, m),2.26-2.42 (2H, m), 2.90 (1H, d, J=12.8 Hz), 3.43-3.46 (2H, m), 3.73-3.74(1H, m), 4.15 (1H, d, J=7.8 Hz), 4.64 (1H, d, J=11.0 Hz), 4.90 (1H, d,J=2.7 Hz), 5.55 (1H, s), 6.13 (1H, s), 6.43 (1H, t, J=6.4 Hz), 6.64 (1H,t, J=7.8 Hz), 6.75 (1H, d, J=1.8 Hz), 7.00-7.03 (2H, m), 7.09-7.11 (4H,m), 7.19-7.20 (5H, m), 7.36 (1H, s), 7.42 (2H, s).

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-trans--hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (230 mg, 0.29 mmol) obtained in Step 2 above was dissolvedin acetonitrile (10 ml) and water (3 ml), cerium (IV) diammonium nitrate(318 mg, 0.58 mmol) was added under ice cooling and the resultingmixture was stirred for 10 minutes. Potassium carbonate (160 mg, 1.16mmol) was added to the reaction mixture, the resulting mixture wasstirred and then insoluble matter was removed by filtration throughcelite. The filtrate was diluted with ethyl acetate, washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure: and the residue was purified by silica gelcolumn chromatography [chloroform:methanol=100:0→30:1→20:1 (v/v] to give90 mg (53%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.06-1.23 (2H,m), 1.25-1.44 (5H, m), 1.48-1.63 (2H, m), 1.71-2.06 (7H, m), 3.50-3.65(2H, m), 4.48 (1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz), 6.73 (1H, d,J=2.3 Hz), 7.00-7.06 (2H, m), 7.16-7.24 (1H, m), 7.39-7.45 (1H, m),7.57-7.64 (1H, m).

MS (ESI) m/z: 588 (M+H)⁺.

Example 2

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[2,3-b]pyridine]-1′,2″(1″H)-dione

(5R,6S)-5,6-diphenylmorpholin-2-one (2.62 g, 10.3 mmol),4,4-dimethylcyclohexanone (1.30 g, 10.3 mmol), and anhydrous coppersulfate (16.4 g, 103 mmol) were added to a toluene (80 ml) solution ofthe compound (2.67 g, 8.60 mmol) obtained in Reference Example 1 and theresulting mixture was heated to reflux for 24 hours under nitrogenatmosphere. After cooling, insoluble matter was removed by filtrationthrough celite and the filtrate was concentrated under reduced pressure.The residue was dissolved in ethyl acetate and the organic layer waswashed with 1N hydrochloric acid solution and brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=9:1→6:1 (v/v)] to give 5.1 g(90%) of the title compound as a yellow amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.20 (3H, s), 0.55 (3H, s), 0.90-1.08 (3H,m), 1.21-1.32 (1H, m), 1.33-1.47 (2H, m), 1.76-1.86 (1H, m), 2.26-2.36(1H, m), 4.65 (1H, d, J=11.2 Hz), 4.88 (1H, d, J=3.2 Hz), 5.36 (1H, d,J=11.2 Hz), 6.52 (1H, d, J=7.8 Hz), 6.64 (1H, d, J=8.2 Hz), 6.71-6.78(2H, m), 7.06-7.24 (10H, m), 7.25-7.32 (1H, m), 7.74-7.83 (1H, m), 9.00(1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[trans040(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (260 mg, 0.39 mmol) obtained in Step 1 above and(trans-4-aminocyclohexyl)methanol (100 mg, 0.77 mmol) were used asstarting materials and treated in the same way as in Step 2 of Example 1to give 260 mg (83%) of the title compound as a pale yellow oil.

MS (ESI) m/z: 799 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[trans-4-(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (260 mg, 0.33 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 63 mg (33%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.95 (3H, s), 1.04-1.10 (2H,m), 1.20-1.32 (5H, m), 1.45-1.46 (1H, m), 1.56-1.59 (2H, m), 1.71-1.78(2H, m), 1.85-2.01 (5H, m), 3.37 (2H, d, J=6.0 Hz), 3.55-3.57 (1H, m),4.52 (1H, d, J=9.6 Hz), 4.68 (1H, d, J=9.6 Hz), 7.04-7.07 (2H, m), 7.24(1H, t, J=7.1 Hz), 7.59 (1H, t, J=6.9 Hz), 7.83 (1H, dd, J=7.8, 2.3 Hz).

MS (ESI) m/z: 603 (M+H)⁺.

Example 3

[Step 1]

(4′S,5′R)-6″-chloro-4″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (670 mg, 1.00 mmol) obtained in Step 1 of Example 2 and thecompound (262 mg, 2.0 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 2of Example 1 to give 200 mg (25%) of the title compound as a light brownamorphous solid.

MS (ESI) m/z: 801 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (200 mg, 0.25 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 77 mg (51%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.95 (3H, s), 1.16-1.20 (2H,m), 1.36-1.45 (2H, m), 1.58-1.61 (3H, m), 1.71-1.84 (4H, m), 2.01-2.11(1H, m), 3.15 (1H, t, J=10.5 Hz), 3.36-3.39 (1H, m), 3.49 (2H, d, J=5.0Hz), 3.73-3.81 (1H, m), 3.88-3.96 (1H, m), 4.53 (1H, d, J=9.2 Hz), 4.70(1H, d, J=9.2 Hz), 7.03-7.08 (2H, m), 7.21-7.27 (1H, m), 7.57 (1H, t,J=6.9 Hz), 7.83 (1H, dd, J=7.8, 2.3 Hz).

MS (ESI) m/z: 605 (M+H)⁺.

Example 4

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorophenyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

Cyclohexanone (0.25 ml, 2.40 mmol) was used as a starting material andtreated in the same way as in Step 1 of Example 1 to give 900 mg (70%)of the title compound as a yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.15-1.32 (8H, m), 2.01 (1H, d, J=12.9 Hz),2.45 (1H, d, J=13.4 Hz), 4.61 (1H, d, J=11.0 Hz), 4.88 (1H, d, J=2.9Hz), 5.36 (1H, d, J=11.5 Hz), 6.23 (1H, d, J=8.3 Hz), 6.60 (1H, dd,J=8.2, 1.8 Hz), 6.76 (2H, d, J=6.8 Hz), 6.87 (1H, d, J=1.7 Hz),7.05-7.23 (11H, m), 7.42 (1H, s), 7.75 (1H, t, J=6.6 Hz).

[Step 2]

(4′S,5′R)-6″chloro-4′-(3-chloro-2-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (320 mg, 0.50 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of Example 1to give 228 mg (60%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.49-0.53 (1H, m), 0.82-0.90 (3H, m),1.28-1.30 (4H, m), 1.58-1.62 (2H, m), 1.80-1.90 (6H, m), 2.09 (1H, t,J=11.4 Hz), 2.16-2.23 (1H, m), 3.03 (1H, d, J=14.7 Hz), 3.43-3.45 (2H,m), 3.72-3.73 (1H, m), 4.12 (1H, d, J=8.2 Hz), 4.65 (1H, d, J=10.5 Hz),4.90 (1H, d, J=3.2 Hz), 5.53 (1H, d, J=2.7 Hz), 6.18 (1H, s), 6.41 (1H,t, J=6.6 Hz), 6.64 (1H, t, J=8.0 Hz), 6.75 (1H, d, J=1.8 Hz), 7.00-7.03(2H, m), 7.10 (4H, 1, J=7.6 Hz), 7.17 (3H, t, J=3.0 Hz), 7.21 (2H, d,J=7.3 Hz), 7.34 (1H, s), 7.43 (2H, br s).

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (228 mg, 0.30 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 76 mg (45%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.88-0.97 (2H, m), 1.05-1.08 (1H, m),1.29-1.43 (5H, m), 1.54-1.59 (2H, m), 1.64-1.79 (3H, m), 1.87-1.99 (5H,m), 3.56-3.58 (2H, m), 4.50 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.6 Hz),6.71 (1H, d, J=2.3 Hz), 7.00-7.04 (2H, m), 7.18-7.22 (1H, m), 7.39 (1H,dd, J=8.2, 2.3 Hz), 7.61 (1H, t, J=6.6 Hz).

MS (ESI) m/z: 560 (M+H)⁺.

Example 5

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

A methanol (18 ml) solution of the compound (3.61 g, 21.0 mmol) obtainedin Step 3 of Reference Example 3 was added to a methanol (6 ml) solutionof the compound (3.42 g, 4.82 mmol) obtained in Step 1 of Example 2under nitrogen atmosphere and the resulting mixture was stirred underheating at 60° C. for 2 days. After cooling, dichloromethane was addedand the organic layer was washed with saturated ammonium chloridesolution. The organic layer was dried over anhydrous sodium sulfate, thesolvent was concentrated under reduced pressure and the residue obtainedwas purified by silica gel column chromatography[dichloromethane:methanol=99:1→49:1 (v/v)] to give 3.26 g of the titlecompound as a mixture of isomers.

MS (ESI) m/z: 837 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (3.26 g, 3.89 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 1.00 g (31%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.71 (3H, s), 0.97 3H, s), 1.14-1.28 (2H, m),1.30-1.44 (3H, m), 1.46-1.61 (2H, m), 1.62-1.81 (5H, m), 2.09-2.29 (4H,m), 2.91-2.99 (1H, m), 3.17-3.30 (1H, m), 3.74-3.84 (1H, m), 4.48 (1H,d, J=9.2 Hz), 4.70 (1H, d, J=9.2 Hz), 6.97 (1H, t, J=7.7 Hz), 7.06 (1H,d, J=8.0 Hz), 7.14-7.19 (1H, m), 7.46-7.51 (1H, m), 7.56 (1H, d, J=8.6Hz), 7.64 (1H, dd, J=7.5, 2.3 Hz), 7.85 (1H, s), 8.33 (1H, s).

MS (ESI) m/z: 641 (M+H)⁺.

Example6

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (335 mg, 0.50 mmol) obtained in Step 1 of Example 2 wasused as a starting material and treated in the same way as in Step 2 ofExample 1 to give 160 mg (40%) of the title compound as a pale yellowamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.55-0.59 (1H, m), 0.87 (3H, s), 0.95-1.01(1H, m), 1.05 (3H, s), 1.25-1.44 (6H, m), 1.63-1.69 (2H, m), 1.85-1.97(2H, m), 2.29-2.33 (2H, m), 2.82 (1H, d, J=15.9 Hz), 3.45 (1H, s),3.70-3.73 (3H, m), 4.42 (1H, d, J=7.8 Hz), 4.54 (1H, d, J=10.5 Hz), 4.85(1H, d, J=3.4 Hz), 5.56 (1H, s), 5.67 (1H, s), 6.58 (1H, s), 6.77 (1H,t, J=7.8 Hz), 6.95 (1H, d, J=7.8 Hz), 7.03-7.05 (2H, m), 7.14-7.24 (9H,m), 7.38-7.46 (2H, m), 7.48 (1H, s).

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (160 mg, 0.20 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 30 mg (25%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.95 (3H, s), 1.09-1.25 (2H,m), 1.26-1.43 (5H, m), 1.51-1.63 (2H, m), 1.64-2.02 (7H, m), 3.49-3.64(2H, m), 4.52 (1H, d, J=9.3 Hz), 4.68 (1H, d, J=9.3 Hz), 7.01-7.09 (2H,m), 7.20-7.28 (1H, m), 7.54-7.62 (1H, m), 7.83 (1H, dd, J=7.9 2.6 Hz).

MS (ESI) m/z: 589 (M+H)⁺.

Example 7

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3S)-3,4-dihydroxybutyl]-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (1.01 g, 1.51 mmol) obtained in Step 1 of Example 1 and(2S) -4-aminobutane-1,2-diol (WO2007/0111162) (475 mg, 4.53 mmol) wereused as starting materials and treated in the same way as in Step 2 ofExample 1 to give 644 mg (55%) of the title compound as a colorlessamorphous solid.

MS (ESI) m/z: 774 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3S)-3,4-dihydroxybutyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (644 mg, 0.83 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 330 mg (67%) of the title compound as a colorless amorphoussolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.58 (3H, s), 0.88 (3H, s), 0.94 (1H, td,J=13.9, 4.3 Hz), 1.09 (1H, d, J=13.3 Hz), 1.18 (1H, d, J=13.4 Hz),1.30-1.63 (5H, m), 1.71-1.81 (2H, m), 3.05-3.08 (1H, m), 3.19-3.32 (3H,m), 3.40-3.47 (2H, m), 4.38 (1H, t, J=9.8 Hz), 4.49 (2H, dd, J=12.1, 5.3Hz), 4.55 (1H, d, J=9.2 Hz), 6.66 (1H, d, J=1.8 Hz), 7.02 (1H, dd,J=8.2, 1.8 Hz), 7.09 (1H, t, J=8.0 Hz), 7.30 (1H, td, J=7.6, 1.4 Hz),7.42 (1H, dd, J=8.0, 2.1 Hz), 7.56 (1H, t, J=6.6 Hz), 7.98 (1H, t, J=6.2Hz), 10.50 (1H, br s).

MS (ESI) m/z: 578 (M+H)⁺.

Example 8

[Step1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (164 mg, 0.24 mmol) obtained in Step 1 of Example 1 and thecompound (79.0 mg, 0.49 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 5 to give 92.5 mg of the title compound as a mature ofisomers.

MS (ESI) m/z: 800 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (92.5 mg, 0.12 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 28.1 mg (19%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.27 (3H,m), 1.32-1.39 (1H, m), 1.41-1.79 (6H, m), 1.97-2.06 (1H, m), 2.08-2.14(1H, m), 3.12 (1H, t, J=10.6 Hz), 3.40-3.46 (1H, m), 3.51-3.57 (1H, m),3.58-3.65 (1H, m), 3.84-3.95 (1H, m), 4.06-4.11 (1H, m), 4.45 (1H, d,J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.69 (1H, d, J=2.0 Hz), 6.88-6.93(1H, m), 7.05 (1H, dd, J=8.3, 2.0 Hz), 7.10-7.14 (1H, m), 7.31-7.35 (1H,m), 7.41 (1H, s), 7.47-7.55 (2H, m).

MS (ESI) m/z: 604 (M+H)⁺.

Example 9

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(2-chloropyridin-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-1′2″(1′H)-dione

A boron trifluoride-diethyl ether complex (0.038 ml, 0.30 mmol) andmolecular sieves 4A (powder) (3g) were added to a tetrahydrofuran (30ml) solution of the compound (873 mg, 3.00 mmol) obtained in ReferenceExample 4, (5R,6S)-5,6-diphenylmorpholin-2-one (760 mg, 3.00 mmol), and4,4-dimethylcyclohexanone (379 mg, 3.00 mmol) under nitrogen atmosphereand the resulting mixture was stirred under heating at 70° C. for 7days. After cooling, insoluble matter was removed by filtration throughcelite and the filtrate was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=4:1→1:1 (v/v)] to give 1.18 g(60%) of the title compound as a pale yellow amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.54 (3H, s), 0.67 (3H, s), 0.80-0.92 (1H,m), 1.15-1.41 (4H, m), 1.71-1.82 (1H, m), 1.82-1.94 (1H, m), 2.15-2.26(1H, m), 4.42 (1H, d, J=10.7 Hz), 4.81 (1H, d, J=3.7 Hz), 5.03 (1H, d,J=10.7 Hz), 6.60-6.68 (2H, m), 6.78-6.84 (2H, m), 6.85-6.89 (1H, m),6.91-6.98 (2H, m), 7.06-7.31 (9H, m), 7.47 (1H, s), 8.14 (1H, d, J=5.1Hz).

[Step 2]

(4′R,5′R)-6″-chloro-4′-(2-chloropyridine-4-yl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (195 mg, 0.30 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of Example 1to give 184 mg (80%) of the title compound as a yellow amorphous solid.

MS (ESI) m/z: 767 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (184 mg, 0.24 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 81 mg (59%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.13-1.19 (2H,m), 1.33-1.41 (5H, m), 1.50-1.60 (2H, m), 1.76-1.78 (3H, m), 1.95-1.99(4H, m), 3.58-3.60 (2H, m), 4.21 (1H, d, J=9.2 Hz), 4.60 (1H, d, J=9.2Hz), 6.79 (1H, d, J=1.8 Hz), 7.06 (1H, dd, J=5.3, 1.6 Hz), 7.10 (2H, dd,J=8.2, 1.8 Hz), 7.23 (1H, s), 7.52 (1H, d, J=8.2 Hz), 8.06 (1H, d, J=5.5Hz).

MS (ESI) m/z: 575 (M+H)⁺.

Example 10

[Step 1]

(4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (159 mg, 1.00 mmol) obtained in Step 2 of Reference Example5 and triethylamine (0.14 ml, 1.00 mmol) were added to a 2-propanol (4ml) solution of the compound (195 mg, 0.30 mmol) obtained in Step 1 ofExample 9 and the resulting mixture was stirred under heating at 70° C.for 4 days. After cooling, the reaction mixture was diluted with ethylacetate, washed with saturated ammonium chloride solution and brine andthen dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue was purified by silica gel columnchromatography [chloroform:methanol=100:0→40:1 (v/v)] to give 98 mg(40%) of the title compound as a pale yellow amorphous solid.

MS (ESI) m/z: 811 (M+H)⁺.

[Step 2]

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

Cerium (IV) diammonium nitrate (132 mg, 0.24 mmol)

was added to an acetonitrile (10 ml)/water (3 ml) solution of thecompound (98 mg, 0.12 mmol) obtained in Step 1 above under ice coolingand the resulting mixture was stirred for 10minutes. Potassium carbonate(65 mg, 0.48 mmol) was added to the reaction mixture and insolublematter was removed by filtration through celite. The filtrate wasdiluted with ethyl acetate, washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure, the residue was dissolved in chloroform (9 ml) and methanol (1ml), silica gel (980 mg) was added and the resulting mixture was stirredovernight at room temperature. Insoluble matter was removed byfiltration and the residue was purified by NH-silica gel columnchromatography (chloroform) to give 39 mg (53%) of the title compound asa colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.14-1.16 (9H,m), 1.31-1.34 (1H, m), 1.48-1.58 (3H, m), 1.77-1.79 (3H, m), 1.83-1.86(1H, m), 2.06-2.08 (1H, m), 3.11-3.16 (2H, m), 3.74-3.75 (1H, m),3.98-4.01 (1H, m), 4.23 (1H, d, J=9.2 Hz), 4.61 (1H, d, J=8.7 Hz), 6.79(1H, d, J=1.8 Hz), 7.06 (1H, dd, J=5.3, 1.6 Hz), 7.11 (1H, dd, J=8.0,2.1 Hz), 7.22-7.30 (1H, m), 7.52 (1H, d, J=8.2 Hz), 8.06 (1H, d, J=5.5Hz).

MS (ESI) m/z: 615 (M+H)⁺.

Example 11

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluoropyridin-1′-[(1R,2S)-2-hydroxy1,2-diphenylethyl]-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

Trimethylaluminum (2.0 mol/l, n-hexane solution, 0.5 ml, 1.00 mmol) wasadded to a tetrahydrofuran (6.0 ml) solution of the compound (201 mg,0.30 mmol) obtained in Step 1 of Example 2 under ice cooling undernitrogen atmosphere and the resulting mixture was stirred for 30minutes. A tetrahydrofuran (4 ml) solution of the compound (159 mg, 1.00mmol) obtained in Step 2 of Reference Example 5 was added to thereaction mixture and the resulting mixture was warmed to 50° C. andstirred overnight. After cooling, 1N hydrochloric acid was added,followed by extraction with ethyl acetate. The organic layer was washedwith brine and then dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure and the residue was purified by silicagel column chromatography [chloroform:methanol=50:0→30:1 (v/v)] to give56 mg (2.2%) of the title compound as a purple amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.86 (3H, s), 1.05 (3H, s), 1.08-1.14 (6H,m), 1.23-1.34 (2H, m), 1.38-1.70 (5H, m), 1.98-2.07 (1H, m), 2.20-2.41(4H, m), 2.75-2.84 (1H, m), 2.85-2.91 (1H, m), 3.61-3.69 (1H, m),3.71-3.78 (1H, m), 3.80-3.92 (1H, m), 4.37-4.44 (1H, m), 4.45-4.52 (1H,m), 4.82-4.87 (1H, m), 5.37 (1H, s), 5.52-5.57 (1H, m), 6.56-6.64 (1H,m), 6.78 (1H, t, J=7.8 Hz), 6.94 (1H, d, J=7.8 Hz), 7.02-7.08 (1H, m),7.09-7.15 (2H, m), 7.16-7.25 (8H, m), 7.38-7.46 (2H, m), 7.64 (1H, s).

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (56 mg, 0.067 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 30 mg (70%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.95 (3H, s), 1.09-1.39 (9H,m), 1.43-1.90 (8H, m), 2.04-2.13 (1H, m), 3.04-3.17 (2H, m), 3.69-3.80(1H, m), 3.91-3.99 (1H, m), 4.52 (1H, d, J=9.2 Hz), 4.70 (1H, d, J=9.2Hz), 7.02-7.10 (2H, m), 7.20-7.28 (1H, m), 7.54-7.61 (1H, m), 7.83 (1H,dd, J=7.8, 2.3 Hz).

MS (ESI) m/z: 633 (M+H)⁺.

Example 12

[Step1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylicacid

1N sodium hydroxide solution (50 ml, 50 mmol) was added to a methanol(250 ml) solution of the compound (15.7 g, 23.4 mmol) obtained in Step 1of Example 1 and the resulting mixture was heated to reflux overnight.After cooling, methanol (500 ml) and water (200 ml), were added to thereaction mixture and then the resulting mixture was neutralized byaddition of 1N hydrochloric acid (50 ml) under ice cooling. Cerium (IV)diammonium nitrate (26.9 g, 49.1 mmol) was added under ice pooling, theresulting mixture was stirred for 20 minutes, then potassium, carbonate(13.6 g, 98.3 mmol) was added and the resulting mixture was furtherstirred for 30 minutes. Insoluble matter was removed by filtrationthrough celite and the filtrate was concentrated under reduced pressure.The residue was diluted with water, followed by extraction with ethylacetate. The aqueous layer was further subjected to extraction withchloroform:methanol [5:1 (v/v)], the organic layers were combined anddried over anhydrous sodium sulfate, then the solvent was evaporatedunder reduced pressure and the residue was dried to give 6.54 g (57%) ofthe title compound as a pale yellow solid.

¹H-NMR (400 MHz, CD₃₀D) δ: 0.75 (3H, s), 1.02 (3H, s), 1.26-1.36 (1H,m), 1.39-1.45 (1H, m), 1.46-1.54 (1H, m), 1.60-1.67 (1H, m), 1.74-1.83(1H, m), 1.94-2.00 (1H, m), 2.06-2.14 (1H, m), 2.34-2.43 (1H, m),4.50-4.98 (2H, m), 6.76 (1H, d, J=2.3 Hz), 7.08-7.14 (2H, m), 7.28-7.32(1H, m), 7.56 (1H, dd, J=8.0, 2.3 Hz), 7.60-7.65 (1H, m).

MS (ESI) m/z: 491 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[trans-4-(3-hydroxyazetidin-1-yl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (146 mg, 0.60 mmol) obtained in Step 2 of Reference Example13, triethylamine (0.14 ml, 1.00 mmol), 1-hydroxybenzotriazole (74 mg,0.55 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (105 mg, 0.55 mmol) were added to an N,N-dimethylformamide(5 ml) solution of the compound (246 mg, 0.50 mmol) obtained in Step 1above and the resulting mixture was stirred at room, temperature for 18hours. The reaction mixture was diluted with ethyl acetate, washed withwater, saturated sodium bicarbonate solution, and brine in that orderand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure, then the residue was purified by silica gelcolumn chromatography [chloroform:methanol=70:1 (v/v)] and the purifiedproduct obtained was dissolved in methanol (10 ml) and stirred at 60° C.for 24 hours. The solvent was evaporated under reduced pressure to give150 mg (47%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.96 (3H, s), 1.06-1.39 (7H,m), 1.53-1.63 (1H, m), 1.75-2.03 (7H, m), 2.10-2.18 (1H, m), 2.88-2.96(2H, m), 3.26-3.32 (1H, m), 3.53-3.62 (1H, m), 3.62-3.71 (2H, m),4.30-4.36 (1H, m), 4.50 (1H, d, J=9.2 Hz), 4.68 (1H, d, J=9.7 Hz), 6.75(1H, d, J=2.3 Hz), 7.02-7.07 (2H, m), 7.22 (1H, t, J=8.0 Hz), 7.44 (1H,dd, J=8.0, 2.3 Hz), 7.63 (1H, t, J=6.6 Hz).

MS (ESI) m/z: 643 (M+H)⁺.

Example 13

[Step1]

(4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (195 mg, 0.30 mmol) obtained in Step 1 of Example 9 and thecompound (131 mg, 1.00 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 10 to give 233 mg (99%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.87 (3H, s), 1.05 (3H, s), 1.07-1.19 (1H,m), 1.21-1.32 (1H, m), 1.35-1.54 (2H, m), 1.58-1.76 (3H, m), 1.89-1.98(1H, m), 2.00-2.08 (1H, m), 2.20-2.37 (2H, m), 2.51 (1H, t, J=10.5 Hz),2.75-2.85 (1H, m), 3.19-3.28 (1H, m), 3.43-3.61 (3H, m), 3.68-3.76 (1H,m), 3.84-3.97 (1H, m), 4.12 (1H, d, J=11.0 Hz), 4.66-4.78 (1H, m),4.84-4.91 (1H, m), 5.20-5.30 (1H, m), 5.50-5.57 (1H, m), 6.51-6.55 (1H,m), 6.71-6.76 (2H, m), 6.92 (1H, d, J=8.2 Hz), 6.99 (1H, dd, J=8.2, 1.8Hz), 7.01-7.08 (1H, m), 7.08-7.18 (4H, m), 7.21-7.28 (4H, m), 7.35 (1H,s), 7.33-7.47 (2H, m), 8.00 (1H, d, J=5.0 Hz).

[Step 2]

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (233 mg, 0.30 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of Example 10to give 90 mg (52%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.17-1.19 (2H,m), 1.31-1.33 (1H, m), 1.41-1.62 (4H, m), 1.75-1.79 (4H, m), 2.05 (1H,d, J=11.0 Hz), 3.18 (1H, t, J=10.5 Hz), 3.37-3.41 (1H, m), 3.50 (2H, d,J=5.0 Hz), 3.77-3.81 (1H, m), 3.95-3.98 (1H, m), 4.23 (1H, d, J=8.7 Hz),4.61 (1H, d, J=9.2 Hz), 6.79 (1H, d, J=1.8 Hz), 7.06 (1H, dd, J=5.3, 1.6Hz), 7.11 (1H, dd, J=8.2, 1.8 Hz), 7.22 (1H, s), 7.52 (1H, d, J=8.2 Hz),8.06 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 587 (M+H)⁺.

Example 14

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(3-chloro-5-fluorophenyl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (1.55 g, 5.00 mmol) obtained in Reference Example 6 wasused and treated in the same way as in Step 1 of Example 9 to give 2.03g (61%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.48 (3H, s), 0.64 (3H, s), 0.83-0.92 (1H,m), 1.11-1.29 (3H, m), 1.33-1.41 (1H, m), 1.71-1.83 (2H, m), 2.15-2.24(1H, m), 4.43 (1H, d, J=11.0 Hz), 4.80 (1H, d, J=3.7 Hz), 5.02 (1H, d,J=11.0 Hz), 6.64 (1H, d, J=8.7 Hz), 6.73 (2H, dd, J=6.9, 2.8 Hz), 6.79(2H, dt, J=8.4, 2.9 Hz), 6.85-6.93 (4H, m), 7.09-7.18 (5H, m), 7.21-7.28(3H, m), 7.44 (1H, br s).

MS APCI) m/z: 669 (M+H)⁺.

[Step 2]

(4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (1.01 g, 1.51 mmol) obtained in Step 1 above was used andtreated in the same way as in Step 2 of Example 1 to give 0.75 g (63%)of the title compound as a colorless amorphous solid.

MS (APCI) m/z: 784 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (0.72 g, 0.92 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 213 mg (40%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.93 (3H, s), 1.08-1.41 (8H,m), 1.49-1.62 (2H, m), 1.70-1.82 (3H, m), 1.87-2.02 (4H, m), 3.51-3.65(2H, m), 4.17 (1H, d, J=9.2 Hz), 4.52 (1H, d, J=9.2 Hz), 6.77 (1H, d,J=1.8 Hz), 6.84-6.89 (1H, m), 6.90-6.95 (1H, m), 6.97 (1H, s), 7.09 (1H,dd, J=8.0, 2.1 Hz), 7.49 (1H, d, J=8.3 Hz). MS (ESI) m/z: 588 (M+H)⁺.

Example 15

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-8′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-1′,2″-dioxo-3′,4′-diphenyl-1″,2″,3′,4′,8′,8a′-hexahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-6″-carbonitrile

The compound (869 mg, 3.00 mmol) obtained in Reference Example 7 wasused as a starting material and treated in the same way as in Step 1 ofexample 9 to give 49 mg (2%) of the title compound as a blackish brownsolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.22 (3H, s), 0.53 (3H, s), 0.91-1.09 (3H,m), 1.21-1.28 (1H, m) 1.32-1.45 (2H, m) 1.83-1.89 (1H, m), 2.29-2.35(1H, m), 4.67 (1H, d, J=11.5 Hz), 4.89 (1H, d, J=3.4 Hz), 5.40 (1H, d,J=11.5 Hs), 6.44 (1H, d, J=8.0 Hz), 6.77 (2H, m), 6.97 (1H, dd, J=8.0,1.1 Hz), 7.09-7.28 (12H, m), 7.68 (1H, s, 7.84 (1H, t, J=6.6 Hz).

[Step 2]

(4′S,5′R)-4′-(3-chloro-2-fluorophenyl)-6″-cyano-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (49 mg, 0.074 mmol) obtained in Step 1 above was used as astarting material and treated: in the same way as in Step 2 of Example 1to give 46 mg (80%) of the title compound as a blackish brown oil.

MS (APCI) m/z: 775 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-4′-(3-chloro-2-fluorophenyl)-6″-cyano-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (46 mg, 0.06 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 21 mg (62%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.96 (3H, s), 1.09-1.17 (1H,m), 1.18-1.24 (1H, m), 1.30-1.44 (5H, m), 1.55-1.64 (2H, m), 1.74-1.85(2H, m), 1.87-2.02 (5H, m), 3.55-3.66 (2H, m), 4.55 (1H, d, J=9.2 Hz),4.77 (1H, d, J=9.2 Hz), 7.02 (1H, br s), 7.04 (1H, t, J=8.0 Hz), 7.22(1H, t, J=7.7 Hz), 7.44 (1H, d, J=7.7 Hz), 7.64 (1H, t, J=7.2 Hz), 7.69(1H, d, J=8.0 Hz).

MS (ESI) m/z: 579 (M+H)⁺.

Example 16

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (1.86 g, 6.00 mmol) obtained in Reference Example 8 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 3.39 g (84%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.21 (3H, s), 0.53 (3H, s), 0.89-1.08 (3H,m), 1.28-1.43 (3H, m), 1.73-1.81 (1H, m), 2.23-2.33 (1H, m), 4.58 (1H,d, J=11.0 Hz), 4.86 (1H, d, J=3.2 Hz), 5.31 (1H, d, J=11.0 Hz), 6.25(1H, d, J=8.3 Hz), 6.67 (1H, dd, J=8.3, 1.8 Hz), 6.72-6.77 (2H, m), 6.93(1H, d, J=1.8 Hz), 7.04-7.17 (6H, m), 7.18-7.25 (3H, m), 7.79 (1H, t,J=4.6 Hz), 7.99 (1H, s), 8.29 (1H, d, J=5.0 Hz).

MS (APCI) m/z: 670 (M+H)⁺.

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-(trans-4-hydroxycyclohexyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (671 mg, 100 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of Example 1to give 730 mg (93%) of the title compound as a pale yellow solid.

MS (ESI) m/z: 785 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (710 mg, 0.90 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 14to give 357 mg (67%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.09-1.24 (2H,m), 1.28-1.42 (5H, m), 1.50-1.63 (2H, m), 1.74-1.82 (3H, m), 1.85-2.02(4H, m), 3.51-3.65 (2H, m), 4.53 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.2Hz), 6.76 (1H, d, J=1.8 Hz), 7.06 (1H, dd, J=3.0, 2.1 Hz), 7.45 (1H, dd,J=8.3, 2.3 Hz), 7.66 (1H, t, J=5.0 Hz), 8.06 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 589 (M+H)⁺.

Example 17

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyrirdin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylicacid

The compound (630 mg, 0.94 mmol) obtained in Step 1 of Example 16 wasdissolved in acetonitrile (10 ml) and water (4 ml), potassium carbonate(130 mg, 0.94 mmol) was added and the resulting mixture was heated toreflux at 85° C. for 16 hours. After cooling, anhydrous magnesiumsulfate (113 mg, 0.94 mmol) was added and the resulting mixture wasstirred at room temperature for 15 minutes. After extraction with ethylacetate, the organic layer was washed with brine and dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure to give(4′S,5′R)-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylicacid (650 mg, 100%) as a pale orange amorphous solid [MS (ESI) m/z: 688(M+H)⁺.]. The carboxylic acid (650 mg, 0.94 mmol) obtained was dissolvedin methanol (30 ml) and water (8 ml), cerium (IV) diammonium nitrate(1.55 g, 2.82 mmol) was added under ice cooling and the resultingmixture was stirred at she same temperature for 30 minuses. Potassiumcarbonate (780 mg, 5.64 mmol) was added under ice cooling and theresulting mixture was stirred at the same temperature for 1 hour.Insoluble matter was removed by filtration through celite, then thefiltrate was concentrated under reduced pressure and water was added tothe residue obtained, followed by extraction with ethyl acetate. Theorganic layer was washed with brine and dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure and theresidue obtained was purified by silica gel column chromatography[chloroform:methanol=20:1→4:1 (v/v)] to give 1.52 mg (33%) of the titlecompound as a colorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.74 (3H, s), 0.9 (3H, s), 1.29-1.44 (2H, m),1.48-1.58 (2H, m), 1.64-1.76 (1H, m), 1.94-2.02 (1H, m), 2.11 (1H, ddd,J=14.0, 14.0, 4.0 Hz), 2.43-2.53 (1H, m), 5.07 (1H, d, J=10.3 Hz), 5.32(1H, d, J=10.3 Hz), 6.84 (1H, d, J=1.7 Hz), 7.16 (1H, dd, J=8.3, 2.0Hz), 7.63 (1H, dd, J=8.0, 2.3 Hz), 7.75 (1H, t, J=5.2 Hz), 8.15 (1H, d,J=5.2 Hz).

¹H-NMR 492 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 above and thecompound (34 mg, 0.21 mmol) obtained in Step 2 of Reference Example 5were used as starting materials and treated in the same way as in Step 2of Example 12 to give 38 mg (42%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.24 (8H,m), 1.29-1.39 (1H, m), 1.44-1.63 (4H, m), 1.74-1.88 (4H, m), 2.05-2.13(1H, m), 3.07-3.19 (2H, m), 3.71-3.81 (1H, m), 3.93-4.00 (1H, m), 4.54(1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.75-6.78 (1H, m), 7.07 (1H,dd, J=8.2, 1.8 Hz), 7.43-7.48 (1H, m), 7.65 (1H, t, J=5.0 Hz), 8.05 (1H,d, J=5.0 Hz).

MS (ESI) m/z: 633 (M+H)⁺.

Example 18

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (180 mg, 0.27 mmol) obtained in Step 1 of Example 16 andthe compound (154 mg, 0.92 mmol) obtained in Step 3 of Reference Example3 were used as starting materials and treated in the same way as in Step1 of Example 5 to give 134 mg of the title compound as a pale yellowamorphous solid.

MS (ESI) m/z: 837 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (134 mg, 0.16 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 73 mg (44%) of the title compound as a pale yellow solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.31-1.44 (3H, m), 1.45-1.54 (2H, m), 1.58-1.82 (5H, m), 2.10-2.29(4H, m), 2.92-3.00 (1H, m), 3.18-3.44 (1H, m), 3.74-3.84 (1H, m), 4.45(1H, d, J=8.9 Hz), 4.66 (1H, d, J=8.9 Hz), 6.73 (1H, d, J=1.7 Hz), 7.06(1H, dd, J=8.0, 1.7 Hz), 7.32 (1H, dd, J=8.3, 2.0 Hz), 7.51 (1H, t,J=5.2 Hz), 7.61 (1H, d, J=8.3 Hz), 7.74 (1H, s), 8.04 (1H, d, J=5.2 Hz),8.34 (1H, s).

MS (ESI) m/z: 641 (M+H)⁺.

Example 19

(3′R4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(hydroxymethyl)-3,6-dihydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (60 mg, 0.12 mmol) obtained in Step 1 of Example 12 and thecompound obtained in Step 2 of Reference Example 9 were used as startingmaterials and treated in the same way as in Step 2 of Example 12 to give52 mg (81%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.92 (3H, s), 1.13-1.21 (2H,m), 1.29-1.35 (1H, m), 1.47-1.67 (3H, m), 1.73-1.78 (2H, m), 2.00 (1H,t, J=6.1 Hz), 3.26 (1H, br s), 3.48 (1H, dd, J=11.2, 6.3 Hz), 3.65 (2H,t, J=5.9 Hz), 4.10 (1H, dd, J=11.4, 4.8 Hz), 4.25-4.29 (1H, m),4.45-4.52 (2H, m), 4.70 (1H, d, J=9.0 Hz), 5.84 (1H, dt, J=10.3, 1.7Hz), 5.90 (1H, dt, J=10.0, 2.6 Hz), 6.69 (1H, d, J=1.7 Hz), 6.92 (1H, t,J=8.1 Hz), 7.05 (1H, dd, J=8.2, 1.8 Hz), 7.11-7.15 (1H, m), 7.33-7.36(2H, m), 7.51 (1H, t, J=6.6 Hz), 7.79 (1H, d, J=9.0 Hz).

MS (ESI) m/z: 602 (M+H)⁺.

Example 20

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (131 mg, 1.00 mmol) obtained in Step 3 of Reference Example2 and triethylamine (0.14 ml, 1.00 mmol) were added to a methanol (4 ml)solution of the compound (268 mg, 0.40 mmol) obtained in Step 1 ofExample 16 and the resulting mixture was stirred at 50° C. for 5 days.After cooling, saturated ammonium chloride solution was added, followedby extraction with ethyl acetate. The organic layer was washed withbrine and then dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure and the residue was purified bysilica: gel column chromatography [chloroform:methanol=100:0→30:1 (v/v)]to give 288 mg (89%) of the title compound as a colorless amorphoussolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.86 (3H, s), 1.05 (3H, s), 1.12-1.18 (1H,m), 1.26-1.29 (1H, m), 1.41-1.48 (2H, m), 1.58-1.68 (5H, m), 2.05 (1H,d, J=9.6 Hz), 2.22-2.32 (2H, m), 2.61 (1H, t, J=10.5 Hz), 2.83 (1H, d,J=14.2 Hz), 3.26 (1H, s), 3.48-3.51 (1H, m), 3.56-3.58 (1H, m), 3.63(1H, d, J=10.5 Hz), 3.82-3.84 (1H, m), 3.89-3.91 (1H, m), 4.58 (1H, d,J=10.5 Hz), 4.86 (1H, s), 4.97-5.01 (2H, m), 5.53 (1H, s), 6.40 (1H, t,J=4.6 Hz), 6.79 (1H, s), 6.93 (1H, d, J=7.8 Hz), 6.98 (1H, d, J=8.2 Hz),7.04-7.07 (1H, m), 7.12-7.13 (4H, m), 7.21-7.23 (3H, m), 7.42 (2H, s),7.67 (1H, s), 7.75 (1H, d, J=5.0 Hz).

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (288 mg, 0.36 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 140 mg (65%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.15-1.21 (2H,m), 1.33-1.35 (1H, m), 1.43-1.48 (1H, m), 1.56-1.59 (3H, m), 1.76-1.79(4H, m), 2.06 (1H, d, J=11.9 Hz), 3.17 (1H, t, J=10.8 Hz), 3.37-3.40(1H, m), 3.49 (2H, d, J=5.5 Hz), 3.77-3.80 (1H, m), 3.93 (1H, dd, J=9.8,3.9 Hz), 4.54 (1H, d, J=8.7 Hz), 4.67 (1H, d, J=9.2 Hz), 6.77 (1H, d,J=1.8 Hz), 7.05-7.07 (1H, m), 7.46 (1H, dd, J=8.2, 2.3 Hz), 7.65 (1H, t,J=5.0 Hz), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 605 (M+H)⁺.

Example 21

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-8′-(3-bromo-5-chlorophenyl)-6″-chloro-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (4.25 g, 11.5 mmol) obtained in Reference Example 10 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 3.44 g (41%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.49 (3H, s), 0.65 (3H, s), 0.83-0.93 (1H,m), 1.12-1.29 (3H, m), 1.34-1.44 (1H, m), 1.74-1.84 (2H, m), 2.14-2.25(1H, m), 4.39 (1H, d, J=11.0 Hz), 4.80 (1H, d, J=3.7 Hz), 5.00 (1H, d,J=11.0 Hz), 6.62-6.68 (1H, m), 6.70-6.74 (1H, m), 6.79-6.85 (2H, m),6.88-6.94 (2H, m), 6.99-7.03 (1H, m), 7.07-7.19 (6H, m), 7.20-7.25 (3H,m), 7.28-7.30 (1H, m), 7.48 (1H, s).

MS (FAB) m/z: 729 (M+H)⁺.

[Step 2]

Methyl3-chloro-5-[(3′S,4′R,8′R,8a′R)-6″-chloro-4,4-dimethyl-1′,2″2-dioxo-3′,4′-diphenyl-1″,2″,3′,4′,8′,8a′-hexahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-8′-yl]benzoate

The compound (3.14 g, 4.30 mmol) obtained in Stop 1 above was dissolvedin dimethyl sulfoxide (40 ml) and methanol (40 ml), triethylamine (0.71ml, 5.16 mmol) and a 1,1′-bis(diphenylphosphino)ferrocene-palladium (II)dichloride dichloromethane complex (351 mg, 0.43 mmol) were added andthe resulting mixture was stirred under heating at 90° C. for 2 daysunder carbon monoxide atmosphere. Saturated sodium bicarbonate solutionwas added to the reaction mixture, followed by extraction with ethylacetate. The organic layer was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=1:1 (v/v)] to give 0.40 g (13%)of the title compound as a yellow solid.

MS (FAB) m/z: 709 (M+H)⁺.

[Step 3]

Methyl3-chloro-5-{(4′R,5′R)-6″-chloro-5′-[(trans-4-hydroxycyclohexyl)carbamoyl]-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-4′-yl}benzoate

The compound (312 mg, 0.44 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 2 of Example 1to give 302 mg (83%) of the title compound as a pale yellow solid.

MS (FAB) m/z: 824 (M+H)⁺.

[Step 4]

Methyl3-chloro-5-{(3′R,4′R,5′R)-6″-chloro-5′-[(trans-4-hydroxycyclohexyl)carbamoyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-4′-yl}benzoate

The compound (301 mg, 0.37 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 3 of Example 1under ice cooling to give 104 mg (45%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.94 (3H, s), 1.11-1.55 (10H,m), 1.59-1.80 (2H, m), 1.93-2.06 (4H, m), 3.26 (1H, s), 3.60-3.75 (2H,m), 3.82 (3H, s), 4.17 (1H, d, J=8.6 Hz), 4.52 (1H, d, J=8.6 Hz), 6.73(1H, d, J=2.3 Hz), 7.10 (1H, dd, J=8.0, 1.7 Hz), 7.20-7.26 (1H, m),7.28-7.33 (2H, m), 7.53-7.58 (1H, m), 7.63 (1H, br s), 7.72-7.77 (1H,m).

MS (ESI) m/z: 628 (M+H)⁺.

[Step 5]

(3′R,4′R,5′R)-6″-chloro-4′-[3-chloro-5-(methylcarbamoyl)phenyl]-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3,3″-indole]-5′-carboxamide

1N sodium hydroxide solution (0.19 ml, 0.19 mmol) was added to amethanol (4 ml) solution of the compound (81 mg, 0.13 mmol) obtained inStep 4 above and the resulting mixture was stirred at 50° C. for 4hours. The reaction mixture was neutralized by addition of 1Nhydrochloric acid and then the resulting mixture was concentrated underreduced pressure. Dichloromethane (4 ml) was added to the residue, thenmethylamine hydrochloride (26 mg, 0.39 mmol), triethylamine (0.11 ml,0.77 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (74 mg, 0.39 mmol) were added and the resulting mixturewas stirred at room temperature for 24 hours. Saturated sodiumbicarbonate solution was added to the reaction mixture, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and then the residue was purified by NH-silicagel column chromatography [methanol:ethyl acetate=5.95 (v/v)] to give 42mg (52%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.69 (3H, s), 0.94 (3H, s), 1.08-1.24 (2H,m), 1.27-1.45 (5H, m), 1.48-1.63 (2H, m), 1.72-1.85 (3H, m), 1.87-2.02(4H, m), 2.85 (3H, s), 3.51-3.67 (2H, m), 4.21 (1H, d, J=9.2 Hz), 4.62(1H, d, J=9.2 Hz), 6.74 (1H, d, J=1.7 Hz), 7.09 (1H, dd, J=8.0, 2.3 Hz),7.23-7.26 (1H, m), 7.51 (1H, d, J=8.0 Hz), 7.53-7.56 (2H, m)..

MS (ESI) m/z: 627 (M+H)⁺.

Example 22

[Step 1]

1,5-Anhydro-2-[({(4′R,5′R)-6″-chloro-4′-[3-chloro-5-(methoxycarbonyl)phenyl]-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indol]-5′-yl}carbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol

The compound (253 mg, 2.20 mmol) obtained in Step 3 of Reference Example2 was added to a sulfolane (9 ml) solution of the compound (1.27 g, 1.79mmol) obtained in Step 2 of Example 21 and the resulting mixture wasstirred under heating at 70° C. for 28 hours. Saturated sodiumbicarbonate solution was added to the reaction mixture, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=1:1 (v/v)] to give 511 mg (34%)of the title compound as a pale yellow solid.

MS (FAB) m/z: 840 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-[({(3′R,4′R,5′R)-6″-chloro-4′-[3-chloro-5-(methoxycarbonyl)phenyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl}carbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol

The compound (498 mg, 0.592 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 252 mg (66%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.95 (3H, s), 1.11-1.23 (2H,m), 1.26-1.49 (2H, m), 1.50-1.68 (3H, m), 1.71-1.87 (4H, m), 2.01-2.11(1H, m), 3.10-3.24 (1H, m), 3.34-3.43 (1H, m), 3.44-3.54 (2H, m),3.72-3.80 (1H, m), 3.83 (3H, s), 3.92-4.00 (1H, m), 4.26 (1H, d, J=9.2Hz), 4.59 (1H, d, J=8.7 Hz), 6.75 (1H, d, J=1.8 Hz), 7.10 (1H, dd,J=8.0, 2.1 Hz), 7.38-7.43 (1H, m), 7.53 (1H, d, J=8.3 Hz), 7.64-7.69(1H, m), 7.70-7.74 (1H, m).

MS (ESI) m/z: 644 (M+H)⁺.

Example 23

[Step1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-5″-fluoro-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-1′,2″(1″H)-dione

The compound (981 mg, 3.0 mmol) obtained in Reference Example 11 wasused as a starting material and treated in the same: way as in Step 1 ofExample 9 to give 1.20 g (58%) of the title compound as a pale pinksolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.22 (3H, s), 0.55 (3H, s), 0.97-1.00 (3H,m), 1.29-1.38 (3H, m), 1.74 (1H, d, J=11.4 Hz), 2.27 (1H, d, J=11.4 Hz),4.58 (1H, d, J=11.4 Hz), 4.83 (1H, d, J=2.7 Hz), 5.26 (1H, d, J=11.4Hz), 6.20 (1H, d, J=8.7 Hz), 6.74 (2H, d, J=7.3 Hz), 6.93 (1H, d, J=6.0Hz), 7.05-7.07 (3H, m), 7.11-7.16 (3H, m), 7.21-7.22 (3H, m), 7.42 (1H,s), 7.76 (1H, t, J=4.8 Hz), 8.32 (1H, d, J=5.0 Hz).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-5″-fluoro-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (275 mg, 0.40 mmol) obtained in Step 1 above and thecompound (131 mg, 1.00 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 22 to give 205 mg (62%) of the title compound as a paleyellow amorphous solid.

MS (ESI) m/z: 819 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-5″-fluoro-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (205 mg, 0.25 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 73 mg (57%) or the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.70 (3H, s), 0.95 (3H, s), 1.12-1.22 (2H,m), 1.38-1.46 (2H, m), 1.57-1.63 (3H, m), 1.71-1.84 (4H, m), 2.07 (1H,d, J=11.4 Hz), 3.17 (1H, t, J=10.5 Hz), 3.39 (1H, dd, J=11.0, 5.0 Hz),3.50 (2H, d, J=5.0 Hz), 3.74-3.82 (1H, m), 3.93 (1H, dd, J=11.0, 4.6Hz), 4.55 (1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.83 (1H, d, J=6.4Hz), 7.48 (1H, dd, J=9.2, 1.8 Hz), 7.65 (1H, t, J=5.0 Hz), 8.06 (1H, d,J=5.0 Hz).

MS (ESI) m/z: 623 (M+H)⁺.

Example 24

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{trans-4-[(hydroxyacetyl)amino]cyclohexyl}-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.22 mmol) obtained in Step 1 of Example 1 andN-(trans-4-aminocyclohexyl)-2-hydroxyacetamide hydrochloride (331 mg,1.23 mmol) were used as starting materials and treated in the same wayas in Step 1 of Example 20 to give 58 mg (31%) of the title compound asa colorless solid.

MS (ESI) m/z: 841 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{trans-4-[(hydroxyacetyl)amino]cyclohexyl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (58 mg, 0.07 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 18 mg (40%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.07-1.65 (10H,m), 1.74-2.03 (6H, m) 3.55-3.81 (2H, m), 3.94 (2H, s), 4.49 (1H, d,J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 6.99-7.07(2H, m), 7.16-7.23 (1H, m), 7.39-7.46 (1H, m), 7.57-7.65 (1H, m).

MS (ESI) m/z: 645 (M+H)⁺.

Example 25

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-3,40,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-pyrrolo[2,3-b]pyridine]-1′,2″(1″H)-dione

The compound (1.46 g 4.71 mmol) obtained in Reference Example 12 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 1.90 g (60%) of the title compound as a pale redsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.21 (3H, s), 0.55 (3H, s), 0.93-1.07 (3H,m), 1.22-1.30 (1H, m), 1.33-1.42 (2H, m), 1.72-1.79 (1H, m), 2.24-2.31(1H, m), 1.33-1.42 (2H, m), 1.72-1.79 (1H, m), 2.24-2.31 (1H, m), 4.58(1H, d, J=11.5 Hz), 4.84 (1H, d, J=3.4 Hz), 5.29 (1H, d, J=11.5 Hz),6.53 (1H, d, J=8.0 Hz), 6.69 (1H, d, J=7.5 Hz), 6.71-6.75 (2H, m),7.04-7.08 (3H, m), 7.09-7.18 (3H, m), 7.19-7.25 (3H, m), 7.76-7.82 (1H,m), 8.16 (1H, s), 8.32 (1H, d, J=4.6 Hz).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (204 mg, 0.30 mmol) obtained in Step 1 above and thecompound (120 mg, 0.91 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 5 to give 136 mg of the title compound as a brownish redamorphous solid of a mixture of isomers.

MS (ESI) m/z: 802 (M+H)⁺.

[Step3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (136 mg, 0.17 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 59 mg (32%) of the title compound as a pale yellow solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.13-1.28 (2H,m), 1.33-1.76 (8H, m), 1.99-2.13 (2H, m), 3.13 (1H, t, J=10.9 Hz),3.39-3.47 (1H, m), 3.51-3.58 (1H, m), 3.59-3.66 (1H, m), 3.84-3.94 (1H,m), 4.04-4.11 (1H, m), 4.45 (1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz),7.07 (1H, d, J=7.5 Hz), 7.40 (1H, d, J=8.6 Hz), 7.45 (1H, t, J=4.9 Hz),7.61 (1H, dd, J=7.5, 2.3 Hz), 7.97 (1H, br s), 8.09 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 606 (M+H)⁺.

Example 26

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (202 mg, 0.30 mmol) obtained in Step 1 of Example 25 andthe compound (176 mg, 1.05 mmol) obtained in Step 3 of Reference Example3 were used as starting materials and treated in the same way as in Step1 of Example 5 to give 142 mg of the title compound as a brown amorphoussolid.

MS (ESI) m/z: 838 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamideThe compound (142 mg, 0.17 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 72 mg (37%) of the title compound as a pale yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.97 (3H, s), 1.14-1.29 (2H,m), 1.31-1.44 (3H, m), 1.46-1.55 (2H, m), 1.57-1.82 (5H, m), 2.09-2.29(4H, m), 2.92-3.00 (1H, m), 3.17-3.40 (1H, m), 3.74-3.83 (1H, m), 4.47(1H, d, J=8.9 Hz), 4.68 (1H, d, J=8.9 Hz), 7.07 (1H, d, J=7.5 Hz), 7.48(1H, t, J=4.9 Hz), 7.53 (1H, d, J=8.6 Hz), 7.63 (1H, dd, J=8.0, 2.3 Hz),8.08 (1H, d, J=5.2 Hz), 8.30-8.38 (2H, m).

MS (ESI) m/z: 642 (M+H)⁺.

Example 27

1,5-Anhydro-2-[({(3′R,4′R,5′R)-6″-chloro-4′-[3-chloro-5-(methylcarbamoyl)phenyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl}carbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol

The compound (82 mg, 0.13 mmol) obtained in Step 22 of Example 2 wasused as a starting material and treated in the same way as in Step 5 ofExample 21 to give 31 mg (37%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.69 (3H, s), 0.95 (3H, s), 1.09-1.24 (2H,m), 1.26-1.38 (1H, m), 1.38-1.49 (1H, m), 1.49-1.66 (3H, m), 1.70-1.86(4H, m), 1.99-2.11 (1H, m), 2.85 (3H, s), 3.12-3.21 (1H, m), 3.35-3.42(1H, m), 3.49 (2H, d, J=5.2 Hz), 3.73-3.83 (1H, m), 3.91-3.98 (1H, m),4.23 (1H, d, J=9.2 Hz), 4.63 (1H, d, J=9.2 Hz), 6.74 (1H, d, J=2.3 Hz),7.09 (1H, dd, J=8.0, 1.7 Hz), 7.23-7.26 (1H, m), 7.51 (1H, d, J=8.0 Hz),7.52-7.57 (2H, m).

MS (ESI) m/z: 643 (M+H)⁺.

Example 28

(3′R,4′R,5′R)-6″-chloro-4′-[3-chloro-5-(hydroxymethyl)phenyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

Lithium borohydride (26 mg, 1.25 mmol) was gradually added to atetrahydrofuran (4 ml) solution of the compound (107 mg, 0.17 mmol)obtained in Step 2 of Example 22 at room temperature and the resultingmixture was stirred at the same temperature for 18 hours. Water wasadded to the reaction mixture, followed by extraction with ethylacetate. The organic layer was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and then the residue was purified by silica gel columnchromatography [methanol:ethyl acetate=1:9 (v/v) ] to give 69 mg (68%)of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.04-1.24 (2H,m), 1.26-1.49 (2H, m), 1.50-1.65 (3H, m), 1.68-1.87 (4H, m), 2.00-2.12(1H, m), 3.06-3.20 (1H, m), 3.34-3.43 (1H, m), 3.46-3.51 (2H, m),3.71-3.83 (1H, m), 3.89-3.99 (1H, m), 4.18 (1H, d, J=9.2 Hz), 4.40 (2H,s), 4.56 (1H, d, J=9.2 Hz), 6.74 (1H, d, J=1.8 Hz), 6.97-7.02 (1H, m),7.03-7.15 (3H, m), 7.49 (1H, d, J=7.8 Hz).

MS (ESI) m/z: 616 (M+H)⁺.

Example 29

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,5S,6R)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 17 and thecompound (39 mg, 0.27 mmol) obtained in Step 4 of Reference Example 14were used as starting materials and treated in the same way as in Step 2of Example 12 to give 68 mg (67%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.10-1.27 (4H,m), 1.36-1.79 (5H, m), 2.32-2.42 (1H, m), 2.55 (1H, br s), 3.04-3.13(1H, m), 3.14-3.21 (1H, m), 3.68-3.90 (3H, m), 3.95-4.07 (2H, m), 4.45(1H, d, J=9.0 Hz), 4.63 (1H, d, J=9.0 Hz), 6.73 (1H, d, J=1.8 Hz),7.05-7.10 (1H, m), 7.29-7.34 (1H, m), 7.47-7.60 (3H, m), 8.05 (1H, d,J=5.5 Hz).

MS (ESI) m/z: 621 (M+H)⁺.

Example 30

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,5S,6R)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (170 mg, 0.25 mmol) obtained in Step 1 of Example 2 and thecompound (145 mg, 0.98 mmol) obtained in Step 4 of Reference Example 14were used as starting materials and treated in the same way as in Step 1of Example 5 to give 100 mg (50%) of the title compound as a colorlesssolid.

MS (ESI) m/z: 815 (M−H)⁻.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,5S,6R)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (99 mg, 0.12 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 44 mg (58%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.12-1.28 (3H,m), 1.35-1.81 (6H, m), 2.31-2.56 (2H, m), 3.03-3.12 (1H, m), 3.13-3.21(1H, m), 3.68-3.90 (3H, m), 3.94-4.08 (2H, m), 4.48 (1H, d, J=9.2 Hz),4.67 (1H, d, J=9.2 Hz), 6.94-7.01 (1H, m), 7.06 (1H, d, J=7.8 Hz),7.14-7.21 (1H, m), 7.43-7.56 (2H, m), 7.63 (1H, dd, J=8.0 2.5 Hz), 7.88(1H, br s).

MS (ESI) m/z: 621 (M+H)⁺.

Example 31

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

Triethylamine (0.22 ml, 1.58 mmol) was added to a methanol (2 ml)solution of the compound (201 mg, 0.30 mmol) obtained in Step 1 ofExample 1 and the compound (278 mg, 1.53 mmol) obtained in ReferenceExample 15, and the resulting mixture was stirred under heatingovernight at 60° C. The reaction mixture was diluted with ethyl acetate,washed with water and brine in that order and then dried over anhydrousmagnesium sulfate. The solvent was concentrated under reduced pressureand the residue obtained was purified by silica gel columnchromatography [methanol:chloroform=5.95 (v/v)]. the solid obtained wasdissolved in acetonitrile (1.8 ml) and water (0.6 ml), cerium (IV)diammonium nitrate (136 mg, 0.25 mmol) was added under ice cooling andthe resulting mixture was stirred for 30 minutes. Subsequently,potassium carbonate (69 mg, 0.50 mmol) was added and the resultingmixture was stirred for 30 minutes. Water was added, followed byextraction with chloroform. The organic layer was dried over anhydroussodium sulfate. The solvent was concentrated under reduced pressure,chloroform (9 ml), methanol (1 ml), and silica gel (1 g) were added tothe residue obtained and the resulting mixture was stirred at roomtemperature for 2 hours. Insoluble matter was removed by filtrationthrough celite and the filtrate was concentrated under reduced pressure.The residue obtained was purified by silica gel column chromatography[methanol:chloroform=5:95 (v/v)] to give 32 mg (17%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.96 (1H, td,J=14.1, 4.1 Hz), 1.10-1.14 (1H, m), 1.22-1.26 (1H, m), 1.35-1.59 (11H,m), 1.67-1.79 (2H, m), 3.14 (2H, d, J=5.5 Hz), 3.37-3.43 (1H, m), 3.49(1H, d, J=10.1 Hz), 3.94 (1H, s), 4.36 (1H, t, J=9.2 Hz), 4.49 (1H, t,J=5.7 Hz), 4.55 (1H, d, J=9.6 Hz), 6.67 (1H, d, J=2.3 Hz), 7.04 (1H, dd,J=8.3, 1.8 Hz), 7.11 (1H, t, J=8.0 Hz), 7.30-7.34 (1H, m), 7.44 (1H, dd,J=8.0, 2.1 Hz), 7.56-7.60 (1H, m), 7.72 (1H, d, J=8.7 Hz), 10.52 (1H,s).

MS (ESI) m/z: 618 (M+H)⁺.

Example 32

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-N-[trans-4-(4H-1,2,4-triazol-3-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (154 mg, 0.23 mmol) obtained in Step 1 of Example 16 andthe compound (115 mg, 0.69 mmol) obtained in Step 4 of Reference Example16 were used as starting materials and treated in the same way as inStep 1 of Example 5 to give 130 mg (68%) of the title compound as acolorless solid.

MS (ESI) m/z: 835 (M−H)⁻.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(4H-1,2,4-triazol-3-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (130 mg, 0.16 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 77 mg (77%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.10-1.89 (12H,m), 2.08-2.25 (4H, m), 2.79-2.90 (1H, m), 3.72-3.87 (2H, m), 4.46 (1H,d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.74 (1H, d, J=2.3 Hz), 7.05-7.10(1H, m), 7.30-7.38 (2H, m), 7.49-7.54 (1H, m), 7.56-7.65 (1H, m), 8.01(1H, s), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 640 (M+H)⁺.

Example 33

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (108 mg, 0.22 mmol) obtained in Step 1 of Example 12 andthe compound (0.27 mmol) obtained in Step 3 of Reference Example 17 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 93 mg (68%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.88 (3H, s), 0.92-1.00 (1H,m), 1.10-1.14 (1H, m), 1.24-1.63 (10H, m), 1.69-1.77 (4H, m), 3.26 (2H,d, J=6.0 Hz), 3.51 (1H, d, J=9.6 Hz), 3.68 (1H, s), 4.02 (1H, s),4.38-4.45 (2H, m), 4.52 (1H, d, J=9.2 Hz), 6.67 (1H, d, J=1.8 Hz), 7.03(1H, dd, J=8.3, 2.3 Hz), 7.11 (1H, t, J=8.0 Hz), 7.30-7.34 (1H, m), 7.44(1H, dd, J=8.3, 1.8 Hz), 7.56-7.60 (1H, m), 7.85 (1H, d, J=8.3 Hz),10.53 (1H, s).

MS (ESI) m/z: 618 (M+H)⁺.

Example 34

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (81 mg, 0.16 mmol) obtained in Step 1 of Example 17 and thecompound (34 mg, 0.20 mmol) obtained in Step 6 of Reference Example 18were used as starting materials and treated in the same way as in Step 2of Example 12 to give 72 mg (68%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.36-1.43 (1H, m), 1.45-1.55 (2H, m), 1.61-1.82 (4H, m), 2.11-2.29(3H, m), 3.21-3.43 (2H, m), 3.99-4.08 (1H, m), 4.09-4.15 (1H, m), 4.47(1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.2 Hz), 4.78 (1H, dd, J=9.7, 2.9 Hz),6.73 (1H, d, J=1.7 Hz), 7.60 (1H, dd, J=8.3, 2.0 Hz), 7.31 (1H, dd,J=8.3, 2.0 Hz), 7.51 (1H, t, J=4.9 Hz), 7.70 (1H, d, J=8.6 Hz), 7.92(1H, s)8.05 (1H, d, J=5.2 Hz), 8.43 (1H, s).

MS (ESI) m/z: 643 (M+H)⁺.

Example 35

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 17 and thecompound (31 mg, 0.17 mmol) obtained in Step 2 of Reference Example 19were used as starting materials and treated in the same way as in Step 2of Example 12 to give 53 mg (57%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.10-1.80 (12H,m), 2.06-2.19 (4H, m), 2.52-2.61 (1H, m), 3.19-3.40 (1H, m), 3.69-3.80(1H, m), 4.44 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.2 Hz), 6.73 (1H, d,J=2.3 Hz), 7.07 (1H, dd, J=8.0, 1.7 Hz), 7.32 (1H, dd, J=8.0, 2.3 Hz),7.41 (1H, s), 7.50 (1H, t, J=4.9 Hz), 7.59 (1H, d, J=8.6 Hz), 8.05 (1H,d, J=5.2 Hz), 8.76 (1H, s).

MS (ESI) m/z: 657 (M+H)⁺.

Example 36

[Step 1]

Tert-butyl{3-chloro-5-[(3′S,4′R,8′R,8a′R)-6″-chloro-4,4-dimethyl-1′,2″-dioxo-3′,4′-diphenyl-1″,2″,3′,4′,8′,8a′-hexahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-8′-yl]phenyl}carbamate

The compound (2.41 g, 6.16 mmol) obtained in Step 3 of Reference Example20 was used as a starting material and treated in the same way as inStep 1 of Example 3 to give 859 mg (18%) of the title compound as ayellow solid.

MS (FAB) m/z: 766 (M+H)⁺.

[Step 2]

Tert-butyl(3-chloro-5-{(4′R,5′R)-6″-chloro-5′-[(trans-4-hydroxycyclohexyl)carbamoyl]-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-4′-yl}phenyl)carbamate

The compound (842 mg, 1.10 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of Example 1to give 621 mg (64%) of the title compound as a colorless solid.

MS (FAB) m/z: 881 (M+H)⁺.

[Step 3]

Tert-butyl(3-chloro-5-{(3′R,4′R,5′R)-6″-chloro-5′-[(trans-4-hydroxycyclohexyl)carbamoyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-4′-yl}phenyl)carbamate

The compound (610 mg, 0.69 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 338 mg (71%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.93 (3H, s), 1.08-1.64 (18H,m), 1.68-1.84 (3H, m), 1.87-2.02 (4H, m), 3.48-3.68 (2H, m), 4.10 (1H,d, J=9.2 Hz), 4.51 (1H, d, J=8.7 Hz), 6.74-6.79 (2H, m), 6.97-7.02 (1H,m), 7.08 (1H, dd, J=8.0, 2.1 Hz), 7.30-7.35 (1H, m), 7.45 (1H, d, J=8.3Hz).

MS (FAB) m/z: 685 (M+H)⁺.

[Step 4]

(3′R,4′R,5′R)-4′-(3-amino-5-chlorophenyl)-6″-chloro-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

4N hydrochloric acid/1,4-dioxane solution (1.16 ml, 4.64 mmol) was addedto a 1,4-dioxane (6 ml) solution of the compound (321 mg, 0.47 mmol)obtained in Step 3 above and the resulting mixture was stirred at roomtemperature for 24 hours. Saturated sodium bicarbonate solution wasadded to the reaction mixture, followed by extraction with ethylacetate. The organic layer was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and then the residue was purified by silica gel columnchromatography [methanol:ethyl acetate=1:4 (v/v)] to give 248 mg (91%)of the title compound as a colorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.68 (3H, s), 0.93 (3H, s), 1.05-1.22 (2H,m), 1.24-1.42 95H, m), 1.48-1.61 (2H, m), 1.69-1.82 (3H, m), 1.86-2.01(4H, m), 3.51-3.64 (2H, m), 4.02 (1H, d, J=9.2 Hz), 4.46 (1H, d, J=9.2Hz), 6.34-6.37 (1H, m), 6.41-6.46 (2H, m), 6.76 (1H, d, J=1.7 Hz), 7.06(1H, dd, J=8.3, 2.0 Hz), 7.43 (1H, d, J=8.0 Hz).

MS (ESI) m/z: 585 (M+H)⁺.

Example 37

(3′R,4′R,5′R)-4′-(3-acetamide-5-chlorophenyl)-6″-chloro-N-(trans-4-hydroxycyclohexyl)-4,4-dimethyl-2″-oxo-1,41,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (101 mg, 0.172 mmol) obtained in Step 4 of Example 36 andacetic acid (0.015 ml, 0.26 mmol) were used as starting materials andtreated in the same way as in Step 2 of Example 12 to give 53 mg (49%)of the title compound as a colorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.68 (3H, s), 0.93 (3H, s), 1.08-1.22 (2H,m), 1.27-1.42 (5H, m), 1.49-1.61 (2H, m), 1.71-1.82 (3H, m), 1.86-2.02(4H, m), 2.04 (3H, s), 3.51-3.66 (2H, m), 4.11 (1H, d, J=9.2 Hz), 4.51(1H, d, J=9.2 Hz), 6.76 (1H, d, J=1.7 Hz), 6.86-6.88 (1H, m), 7.06-7.10(2H, m), 7.46 (1H, d, J=8.0 Hz), 7.57-7.59 (1H, m).

MS (ESI) m/z: 627 (M+H)⁺.

Example 38

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-1′,2″(1″H)-dione

The compound (WO2006/091646) (5.44 g, 21.5 mmol) used as a startingmaterial in Step 1 of Example 1 and the compound (2.88 g, 21.5 mmol)obtained in Step 2 of Reference Example 21 were used as startingmaterials and treated in the same way as in Step 1 of Example 9 to give10.2 g (87%) of the title compound as a pale yellow amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.95 (1H, d, J=14.2 Hz), 2.26 (1H, d, J=14.2Hz), 2.79 (1H, d, J=14.2 Hz), 2.88 (1H, d, J=14.2 Hz), 3.82-4.02 (2H,m), 4.14-4.34 (2H, m), 4.55 (1H, d, J=9.6 Hz), 4.73 (1H, d, J=9.6 Hz),5.19-5.23 (1H, m) 6.38 (1H, d, J=4.1 Hz), 6.65 (1H, d, J=7.8 Hz),6.85-6.92 (3H, m), 6.95-7.01 (1H, m), 7.10-7.16 (2H, m), 7.18-7.25 (9H,m), 7.56 (1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (300 mg, 0.44 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 20to give 233 mg (65%) of the title compound as a pale yellow amorphoussolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.12-1.27 (1H, m), 1.42-1.69 (3H, m),2.04-2.13 (1H, m), 2.53-2.66 (2H, m), 2.85 (1H, d, J=14.7 Hz), 3.23-3.31(1H, m), 3.36 (1H, d, J=14.2 Hz), 3.45-3.53 (1H, m), 3.57 (1H, dd,J=11.7, 3.0 Hz), 3.79-3.86 (2H, m), 3.91-4.02 (1H, m), 4.06-4.26 (3H,m), 4.43-4.62 (3H, m), 4.85 (1H, d, J=3.7 Hz), 5.01 (1H, d, J=8.2 Hz),5.59-5.64 (1H, m), 6.49-6.55 (1H, m), 6.74 (1H, t, J=8.0 Hz), 6.79-6.83(2H, m), 6.89 (1H, dd, J=8.2, 1.8 Hz), 7.06-7.30 (10H, m), 7.33-7.40(2H, m), 7.72 (1H, s).

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (200 mg, 0.25 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 66 mg (44%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.37-1.49 (1H, m), 1.52-1.64 (1H, m),1.64-1.78 (2H, m), 1.88 (1H, d, J=13.3 Hz), 2.03-2.13 (2H, m), 2.48 (1H,d, J=12.8 Hz), 3.10 (1H, t, J=10.5 Hz), 3.32-3.40 (1H, m), 3.49 (2H, d,J=5.0 Hz), 3.74-3.94 (4H, m), 4.38 (1H, d, J=9.4 Hz), 4.45 (1H, d, J=9.4Hz), 4.58-4.78 (2H, m), 6.81 (1H, d, J=1.8 Hz), 7.02 (1H, t, J=8.0 Hz),7.10 (1H, dd, J=8.0, 2.1 Hz), 7.19-7.26 (1H, m), 7.50 (1H, dd, J=8.2,2.3 Hz), 7.52-7.57 (1H, m).

MS (ESI) m/z: 612 (M+H)⁺.

Example 39

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 17 and thecompound (0.33 mmol) obtained in Reference Example 15 were used asstarting materials and treated in the same way as in Step 2 of Example12 to give 63 mg (62%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.93-1.00 (1H,m), 1.11-1.15 (1H, m), 1.23-1.25 (1H, m), 1.36-1.60 (11H, m), 1.67-1.77(2H, m), 3.14 (2H, d, J=6.0 Hz), 3.38-3.47 (1H, m), 3.54-3.57 (1H, m),3.96 (1H, s), 4.43 (1H, t, J=9.6 Hz), 4.49 (1H, t, J=5.7 Hz), 4.54 (1H,d, J=9.1 Hz), 6.71 (1H, d, J=1.8 Hz), 7.05 (1H, dd, J=8.0, 2.1 Hz), 7.50(1H, dd, J=8.3, 1.8 Hz), 7.63 (1H, t, J=5.0 Hz), 7.72 (1H, d, J=8.3 Hz),8.18 (1H, d, J=5.0 Hz), 10.61 (1H, s).

MS (ESI) m/z: 619 (M+H)⁺.

Example 40

(3′R,4′S,5′R)-6″-chloro-′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 17 and thecompound (0.24 mmol) obtained in Step 3 of Reference Example 17 wereused as starting materials and treated in the same way as in step 2 ofExample 12 to give 67 mg (66%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.97 (1H, dt,J=5.5, 13.3 Hz), 1.11-1.15 (1H, m), 1.24-1.75 (14H, m), 3.27 (2H, d,J=6.0 Hz), 3.56-3.59 (1H, m), 3.69 (1H, s), 4.03 (1H, s), 4.43-4.53 (3H,m), 6.71 (1H, dd, J=8.3, 1.8 Hz), 7.63 (1H, t, J=5.3 Hz), 7.85 (1H, d,J=8.3 Hz), 8.18 (1H, d, J=5.5 Hz), 10.62 (1H, s).

MS (ESI) m/z: 619 (M+H)⁺.

Example 41

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (84 mg, 0.17 mmol) obtained in Step 1 of Example 17 and thecompound (46 mg, 0.20 mmol) obtained in Step 7 of Reference Example 22were used as starting materials and treated in the same way as in Step 2of Example 12 to give 87 mg (78%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.10-1.24 (2H,m), 1.32-1.67 (7H, m), 1.75-1.84 (3H, m), 1.98-2.12 (4H, m), 2.57-2.66(1, m), 3.62-3.71 (1H, m), 4.55 (1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2Hz), 6.77 (1H, d, J=2.3 Hz), 7.06 (1H, dd, J=8.0, 2.3 Hz), 7.46 (1H, dd,J=8.0, 2.3 Hz), 7.65-7.69 (1H, m), 8.06 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 657 (M+H)⁺.

Example 42

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,5S,6R)-5-hydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.15 mmol) obtained, in Step 1 of Example 12 andthe compound (34 mg, 0.23 mmol) obtained in Step 4 of Reference Example12 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 67 mg (66%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.94 (3H, s), 1.07-1.88 (9H,m), 2.24-2.34 (1H, m), 3.04-3.15 (2H, m), 3.45-3.65 (2H, m), 3.80-3.95(3H, m), 4.50 (1H, d, J=9.4 Hz), 4.69 (1H, d, J=9.4 Hz), 6.73 (1H, d,J=1.8 Hz), 6.98-7.08 (2H, m), 7.17-7.24 (1H, m), 7.39-7.46 (1H, m),7.55-7.65 (1H, m).

MS (ESI) m/z: 620 (M+H)⁺.

Example 43

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,5S,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 12 and thecompound (34 mg, 0.21 mmol) obtained in Step 4 of Reference Example 23were used as starting materials and treated in the same way as in Step 2of Example 12 to give 69 mg (67%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.95 (3H, s), 1.07-1.91 (9H,m), 2.46-2.56 (1H, m), 3.08-3.27 (3H, m), 3.39 (3H, s), 3.61 (1H, dd,J=11.7, 5.7 Hz), 3.74-3.93 (3H, m), 4.50 (1H, d, J=9.2 Hz), 4.70 (1H, d,J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 6.98-7.08 (2H, m), 7.17-7.24 (1H, m),7.40-7.47 (1H, m), 7.56-7.64 (1H, m).

MS (ESI) m/z: 634 (M+H)⁺.

Example 44

(3′R,4′S,5′R)-N-[(3R,6S)-6-{[acetyl(2-hydroxyethyl)amino]methyl}tetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chlorodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (237 mg, 0.48 mmol) obtained in Step 1 of Example 17 andthe compound (142 mg) obtained in Step 6 of Reference Example 24 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 171 mg (47%) of the title compound as a pale yellowamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.24 (2H,m), 1.32-1.84 (9H, m), 2.08-2.13 (4H, m), 2.14 (3H, s), 2.82 (1H, dd,J=14.2, 9.3 Hz), 3.09 (1H, t, J=11.1 Hz), 3.18-3.31 (2H, m), 3.38-3.53(2H, m), 3.62-3.76 (3H, m), 3.82-3.92 (2H, m), 4.02 (1H, dd, J=10.7, 2.9Hz), 4.40-4.46 (1H, m), 4.63 (1H, dd, J=9.2, 4.3 Hz), 6.73 (1H, t, J=1.8Hz), 7.06 (1H, dd, J=8.2, 1.8 Hz), 7.30 (1H, dd, J=8.3, 2.2 Hz),7.43-7.52 (3H, m), 8.05 (1H, dd, J=5.1, 2.2 Hz).

MS (ESI) m/z: 690 (M+H)⁺.

Example 45

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,5S,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (140 mg, 0.21 mmol) obtained in Step 1 of Example 16 andthe compound (101 mg, 0.63 mmol) obtained in Step 4 of Reference Example23 were used as starting materials and treated in the same way as inStep 1 of Example 5 to give 48 mg (27%) of the title compound as acolorless solid.

MS (ESI) m/z: 833 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,5S,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (48 mg, 0.06 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 26 mg (71%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.83 (9H,m), 2.09-2.24 (1H, m), 2.48-2.58 (1H, m), 3.08-3.38 (4H, m), 3.40 (3H,s), 3.66-4.06 (4H, m), 4.45 (1H, d, J=9.0 Hz), 4.64 (1H, d, J=9.0 Hz),6.72 (1H, d, J=1.8 Hz), 7.03-7.09 (1H, m), 7.28-7.35 (1H, m), 7.47-7.52(1H, m), 7.60 (1H, d, J=8.3 Hz), 7.74 (1H, s), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Example 46

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (40 mg, 0.08 mmol) obtained in Step 1 of Example 12 and thecompound (16 mg, 0.10 mmol) obtained in Step 2 of Reference Example 5were used as starting materials and treated in the same way as in Step 2of Example 12 to give 15 mg (28%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.23 (8H,m), 1.32-1.56 (5H, m), 1.57-1.66 (1H, m), 1.69-1.80 (3H, m), 2.08-2.15(1H, m), 3.07-3.13 (2H, m), 3.82-3.92 (1H, m), 4.06-4.12 (1H, m), 4.45(1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.69 (1H, d, J=2.3 Hz),6.87-6.91 (1H, m), 7.05 (1H, dd, J=8.0, 1.7 Hz), 7.10-7.14 (1H, m), 7.33(1H, dd, J=8.0, 2.3 Hz), 7.46-7.54 (2H, m), 7.72 (1H, s).

MS (ESI) m/z: 632 (M+H)⁺.

Example 47

[Step 1]

(4′S5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxylicacid

The compound (406 mg, 0.60 mmol) obtained in Step 25 of Example 1 wasused as a starting material and treated in the same way as in Step 1 ofExample 12 to give 134 mg (45%) of the title compound as a brown solid.

MS (ESI) m/z: 493 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1,41,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (65 mg, 0.13 mmol) obtained in Step 1 above and thecompound (25 mg, 0.16 mmol) obtained in Step 2 of Reference Example 5were used as starting materials and treated in the same way as in Step 2of Example 12 to give 20 mg (24%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.07-1.82 (16H,m), 2.05-2.16 (1H, m), 2.37-2.49 (1H, m), 3.05-3.14 (2H, m), 3.17-3.41(1H, m), 3.80-3.92 (1H, m), 4.04-4.12 (1H, m), 4.45 (1H, d, J=9.0 Hz),4.66 (1H, d, J=9.0 Hz), 7.07 (1H, d, J=8.0 Hz), 7.34-7.40 (1H, m),7.43-7.48 (1H, m), 7.62 (1H, dd, J=8.0, 2.3 Hz), 7.92 (1H, s), 8.09 (1H,d, J=5.2 Hz).

MS (ESI) m/z: 634 (M+H)⁺.

Example 48

(3′R,4′S,5′R0-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (87 mg, 0.18 mmol) obtained in Step 1 of Example 12 and thecompound (48 mg, 0.21 mmol) obtained in Step 7 of Reference Example 22were used as starting materials and treated in the same way as in Step 2of Example 12 to give 75 mg (64%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.69 (3H, s), 0.94 (3H, s), 1.09-1.23 (2H,m), 1.27-1.50 (4H, m), 1.52-1.66 (4H, m), 1.76-1.88 (2H, m), 1.95-2.12(4H, m), 2.57-2.65 (1H, m), 3.61-3.70 (1H, m), 4.48-4.53 (1H, m),4.54-4.60 (1H, m), 4.68 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=2.3 Hz),7.00-7.06 (2H, m), 7.18-7.23 (1H, m), 7.43 (1H, dd, J=8.0, 2.3 Hz),7.59-7.64 (1H, m).

MS (ESI) m/z: 656 (M+H)⁺.

Example 49

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexanone-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxylicacid

The compound (10.6 g, 15.7 mmol) obtained in Step 2 of Example 1 wasused as a starting material and treated in the same way as in Step 1 ofExample 12 to give 1.79 g (23%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.61-0.69 (3H, m), 0.84-0.92 (3H, m),0.99-1.29 (3H, m), 1.33-1.67 (3H, m), 1.73-1.83 (1H, m), 1.96-2.05 (1H,m), 4.51-4.58 (1H, m), 4.68-4.74 (1H, m), 6.86-7.30 (3H, m), 7.37-7.43(1H, m), 7.49-7.56 (1H, m), 7.92-7.99 (1H, m), 11.30-11.38 (1H, m).

MS (ESI) m/z: 492 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′-,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (121 mg, 0.25 mmol) obtained in Step 1 above and thecompound (66 mg, 0.29 mmol) obtained in Step 7 of Reference Example 22were used as starting materials and treated in the same way as in Step 2of Example 12 to give 56 mg (35%) of the title compound as a light brownsolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.71 (3H, s), 0.95 (3H, s), 1.11-1.50 (6H,m), 1.52-1.91 (6H, m), 4.51-4.60 (2H, m), 4.70 (1H, d, J=9.2 Hz),7.03-7.10 (1H, m), 7.17-7.29 (2H, m), 7.56-7.62 (1H, m), 7.80-7.86 (1H,m).

MS (ESI) m/z: 657 (M+H)⁺.

Example 50

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (69 mg, 0.14 mmol) obtained in Step 1 of Example 47 and thecompound (28 mg, 0.17 mmol) obtained in Step 6 of Reference Example 18were used as starting materials and treated in the same way as in Step 2of Example 12 to give 12 mg (14%) of the title compound as a light brownsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.71 (3H, s), 0.98 (3H, s), 1.15-1.79 (8H,m), 2.10-2.29 (4H, m), 3.39 (1H, dd, J=10.9, 9.2 Hz), 3.98-4.07 (1H, m),4.09-4.14 (1H, m), 4.48 (1H, d, J=9.2 Hz), 4.67 (1H, d, J=8.0 Hz),7.44-7.47 (1H, m), 7.58-7.65 (2H, m), 7.67-7.72 (1H, m), 8.10 (1H, d,J=5.2 Hz), 8.42 (1H, s).

MS (ESI) m/z: 644 (M+H)⁺.

Example 51

[Step 1]

(4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylicacid

The compound (192 g, 294 mmol) obtained in Step 9 of Example 1 was usedas a starting material and treated in the same way as in Step 1 ofExample 12 to give 53.6 g (38%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.76 (3H, s), 1.01 (3H, s), 1.33 (1H, td,J=14.1, 4.3 Hz), 1.41 (1H, dd, J=14.0, 2.3 Hz), 1.52 (1H, td, J=14.1,3.7 Hz), 1.61 (1H, dd, J=14.0, 2.3 Hz), 1.80 (1H, td, J=14.1, 3.4 Hz),1.95 (1H, dd, J=14.1, 2.7 Hz), 2.06 (1H, td, J=14.0, 4.1 Hz), 2.35 (1H,dd, J=14.2, 3.2 Hz), 4.43 (1H, d, J=10.1 Hz), 5.03 (1H, d, J=10.1 Hz),6.82 (1H, d, J=1.8 Hz), 7.12 (1H, dd, J=5.5, 1.4 Hz), 7.18 (1H, dd,J=8.2, 2.3 Hz), 7.28 (1H, s), 7.66 (1H, d, J=8.2 Hz), 8.14 (1H, d, J=5.5Hz).

[Step 2]

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.17 mmol) obtained in Step 1 above and thecompound (37 mg, 0.20 mmol) obtained in Step 2 of Reference Example 19were used as starting materials and treated in the same way as in Step 2of Example 12 to give 28 mg (26%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.10-1.82 (12H,m), 1.99-2.19 (4H, m), 2.62-2.67 (1H, m), 3.64-3.68 (1H, m), 4.22 (1H,d, J=9.2 Hz), 4.62 (1H, d, J=9.2 Hz), 6.79 (1H, d, J=2.3 Hz), 7.05-7.09(1H, m), 7.11 (1H, dd, J=8.3, 2.0 Hz), 7.21-7.25 (1H, m), 7.52 (1H, d,J=8.0 Hz), 8.06 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 639 (M+H)⁺.

Example 52

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyyl-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (84 mg, 0.17 mmol) obtained in Step 1 of Example 49 and thecompound (35 mg, 0.20 mmol) obtained in Step 6 of Reference Example 18were used as starting materials and treated in the same way as in Step 2of Example 12 to give 97 mg (89%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.71 (3H, s), 0.97 (3H, s), 1.14-1.27 (2H,m), 1.33-1.44 (1H, m), 1.46-1.58 (2H, m), 1.61-1.86 (4H, m), 2.09-2.29(3H, m), 3.38 (1H, dd, J=11.2, 9.5 Hz), 3.99-4.08 (1H, m), 4.09-4.15(1H, m), 4.51 (1H, d, J=9.2 Hz), 4.70 (1H, d, J=9.2 Hz), 4.78 (1H, dd,J=10.0, 2.6 Hz), 6.94 (1H, t, J=8.0 Hz), 7.05 (1H, d, J=8.0 Hz),7.13-7.18 (1H, m), 7.45-7.51 (1H, m), 7.62-7.68 (2H, m), 8.43 (1H, s),8.72 (1H, s).

MS (ESI) m/z: 643 (M+H)⁺.

Example 53

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (61 mg, 0.17 mmol) obtained in Step 1 of Example 51 and thecompound (35 mg, 0.20 mmol) obtained in Step 6 of Reference Example 18were used as starting materials and treated in the same way as in Step 2of Example 12 to give 74 mg (69%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.33-1.41 (1H, m), 1.43-1.81 (6H, m), 2.10-2.28 (3H, m), 3.22-3.36(1H, m)3.41 (1H, dd, J=10.9, 9.2 Hz), 3.98-4.08 (1H, m), 4.09-4.18 (2H,m), 4.53 (1H, d, J=9.2 Hz), 4.78 (1H, dd, J=9.2, 2.9 Hz), 6.78 (1H, d,J=1.7 Hz), 6.90 (1H, dd, J=5.2, 1.7 Hz), 7.07-7.09 (1H, m), 7.12 (1H,dd, J=8.3, 2.0 Hz), 7.29 (1H, d, J=8.0 Hz), 7.44 (1H, s), 7.72 (1H, d,J=8.6 Hz), 8.11 (1H, d, J=5.2 Hz), 8.43 (1H, s).

MS (ESI) m/z: 625 (M+H)⁺.

Example 54

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (86 mg, 0.18 mmol) obtained in Step 1 of Example 51 and thecompound (36 mg, 0.22 mmol) obtained in Step 3 of Reference Example 3were used as starting materials and treated in the same way as in Step 2of Example 12 to give 81 mg (72%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.69 (3H, s), 0.96 (3H, s),1.12-1.24 (2H, m), 1.32-1.44 (3H, m), 1.45-1.54 (2H, m), 1.56-1.83 (5H,m), 2.06-2.29 (4H, m), 2.92-3.00 (1H, m) 3.14-3.46 (1H, m), 3.75-3.85(1H, m), 4.12 (1H, d, J=8.6 Hz), 4.51 (1H, d, J=8.6 Hz), 6.78 (1H, d,J=1.7 Hz), 6.91 (1H, dd, J=5.15, 1.7 Hz), 7.08-7.12 (2H, m), 7.29 (1H,d, J=8.0 Hz), 7.66 (1H, d, J=8.0 Hz), 7.73 (1H, s), 8.09 (1H, d, J=5.2Hz), 8.34 (1H, s).

MS (ESI) m/z: 623 (M+H)⁺.

Example 55

(3′R,4′R,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-N-[(3R,6S)-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrospiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (76 mg, 0.15 mmol) obtained in Step 1 of Example 49 and thecompound (41 mg, 0.18 mmol) obtained in Step 3 of Reference Example 25were used as starting materials and treated in the same way as in Step 2of Example 12 to give 67 mg (66%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.71 (3H, s), 0.97 (3H, s),1.14-1.81 (9H, m), 1.95-2.12 (2H, m), 2.16-2.23 (1H, m), 3.19-3.28 (1H,m), 3.28-3.35 (1H, m), 3.9404.04 (1H, m), 4.08-4.15 (1H, m), 4.37 (1H,dd, J=10.0, 3.2 Hz), 4.46-4.52 (1H, m), 4.69 (1H, d, J=9.7 Hz),6.95-7.01 (1H, m), 7.06 (1H, d, J=8.02 Hz), 7.15-7.20 (1H, m), 7.44-7.50(1H, m), 7.60-7.66 (2H, m), 7.75-7.92 (1H, m).

MS (ESI) m/z: 659 (M+H)⁺.

Example 56

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[(3R,6S)-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (85 mg, 0.18 mmol) obtained in Step 1 of Example 51 and thecompound (48 mg, 0.21 mmol) obtained in Step 3 of Reference Example 25were used as starting materials and treated in the same way as in Step 2of Example 12 to give 34 mg (29%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.95 (3H, s), 1.11-1.81 (9H,m), 1.94-2.21 (3H, m), 3.30-3.38 (1H, m), 3.93-4.04 (1H, m), 4.08-4.17(2H, m), 4.38 (1H, dd, J=9.6, 3.2 Hz), 4.52 (1H, d, J=8.7 Hz), 6.78 (1H,d, J=1.8 Hz), 6.90 (1H, dd, J=5.3, 1.6 Hz), 7.06-7.09 (1H, m), 7.11 (1H,dd, J=8.3, 1.8 Hz), 7.29 (1H, d, J=8.3 Hz), 7.70-7.75 (2H, m), 8.10 (1H,d, J=5.5 Hz).

MS (ESI) m/z: 641 (M+H)⁺.

Example 57

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[(3R,6S)-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (81 mg, 0.17 mmol) obtained in Step 1 of Example 17 and thecompound (44 mg, 0.20 mmol) obtained in Step 3 of Reference Example 25were used as starting materials and treated in the same way as in Step 2of Example 12 to give 57 mg (52%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.82 (9H,m), 1.95-2.14 (2H, m), 2.15-2.25 (1H, m), 3.21-3.39 (2H, m), 3.94-4.05(1H, m), 4.07-4.14 (1H, m), 4.38 (1H, dd, J=9.9, 3.4 Hz), 4.47 (1H, d,J=8.7 Hz), 4.65 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=2.3 Hz), 7.07 (1H, dd,J=8.3, 1.8 Hz), 7.32 (1H, dd, J=8.0, 2.1 Hz), 7.50 (1H, t, J=5.0 Hz),7.62 (1H, s), 7.68 (1H, d, J=8.3 Hz), 8.05 (1H, d, J=5.0 Hz), 9.23 (1H,s).

MS (ESI) m/z: 659 (M+H)⁺.

Example 58

(3′R,4′R,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,5S,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 49 and thecompound (30 mg, 0.18 mmol) obtained in Step 4 of Reference Example 23were used as starting materials and treated in the same way as in Step 2of Example 12 to give 48 mg (47%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.71 (3H, s), 0.96 (3H, s), 1.16-1.77 (9H,m), 1.98-2.04 (1H, m), 2.48-2.58 (1H, m), 3.07-3.30 (4H, m), 3.40 (3H,s), 3.67-3.74 (1H, m), 3.81-3.89 (1H, m), 3.94-4.05 (2H, m), 4.44-4.53(1H, m), 4.68 (1H, d, J=9.2 Hz), 6.96-7.03 (1H, m), 7.06 (1H, d, J=7.8Hz), 7.15-7.22 (1H, m), 7.44-7.66 (4H, m).

MS (ESI) m/z: 635 (M+H)⁺.

Example 59

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-N-[(3R,5S,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.17 mmol) obtained in Step 1 of Example 51 and thecompound (36 mg, 0.22 mmol) obtained in Step 4 of Reference Example 23were used as starting materials and treated in the same way as in Step 2of Example 12 to give 48 mg (46%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.95 (3H, s), 1.13-1.78 (9H,m), 1.99-2.05 (1H, m), 2.47-2.57 (1H, m), 3.10-3.32 (4H, m), 3.40 (3H,s), 3.67-3.76 (1H, m), 3.82-4.06 (3H, m), 4.10 (1H, d, J=8.7 Hz), 4.51(1H, d, J=8.7 Hz), 6.78 (1H, d, J=2.3 Hz), 6.87-6.91 (1H, m), 7.06-7.13(2H, m), 7.25-7.29 (2H, m), 7.62 (1H, d, J=8.3 Hz), 8.11 (1H, d, J=5.0Hz).

MS (ESI) m/z: 617 (M+H)⁺.

Example 60

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (96 mg, 0.19 mmol) obtained in Step 1 of Example 47 and thecompound (43 mg, 0.23 mmol) obtained in Step 2 of Reference Example 19were used as starting materials and treated in the same way as in Step 2of Example 12 to give 51 mg (40%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.71 (3H, s), 0.96 (3H, s), 1.15-1.84 (12H,m), 1.95-2.18 (4H, m), 2.59-2.68 (1H, m), 3.61-3.70 (1H, m), 4.58 (1H,d, J=9.2 Hz), 4.69 (1H, d, J=9.2 Hz), 7.09 (1H, d, J=8.0 Hz), 7.62-7.67(1H, m), 7.87 (1H, dd, J=7.7, 2.0 Hz), 8.09 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 658 (M+H)⁺.

Example 61

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[cis-4-hydroxy-4-(methoxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (100 mg, 0.20 mmol) obtained in Step 1 of Example 17 andthe compound (0.31 mmol) obtained in Step 2 of Reference Example 31 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 80 mg (62%) of the title compound as a colorlesssolid.

¹H-NMR (DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.93-1.00 (1H, m),1.11-1.14 (1H, m), 1.22-1.30 (1H, m), 1.33-1.65 (11H, m), 1.67-1.77 (2H,m), 3.10 (2H, s), 3.26 (3H, s), 3.39-3.44 (1H, m), 3.54-3.56 (1H, m),4.21 (1H, s), 4.43 (1H, t, J=9.2 Hz), 4.54 (1H, d, J=9.2 Hz), 6.71 (1H,d, J=1.8 Hz), 7.05 (1H, dd, J=8.0, 2.1 Hz), 7.50 (1H, dd, J=8.3, 1.8Hz), 7.63 (1H, t, J=5.0 Hz), 7.72 (1H, d, J=8.3 Hz), 8.18 (1H, d, J=5.0Hz), 10.61 (1H, s).

MS (ESI) m/z: 633 (M+H)⁺.

Example 62

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-N-[(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (87 mg, 0.18 mmol) obtained in Step 1 of Example 49 and thecompound (44 mg, 0.21 mmol) obtained in Step 4 of Reference Example 26were used as starting materials and treated in the same way as in Step 2of Example 12 to give 91 mg (80%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.71 (3H, s), 0.97 (3H, s), 1.13-1.28 (2H,m), 1.32-1.85 (7H, m), 2.01-2.12 (1H, m), 2.15-2.27 (2H, m), 3.33-3.42(1H, m), 4.01-4.10 (1H, m), 4.16-4.23 (1H, m), 4.50 (1H, d, J=9.2 Hz),4.68-4.74 (2H, m), 6.95 (1H, t, J=8.0 Hz), 7.06 (1H, d, J=8.0 Hz),7.13-7.18 (1H, m), 7.45-7.50 (1H, m), 7.59-7.66 (2H, m), 8.36 (1H, s),8.72 (1H, s).

MS (ESI) m/z: 643 (M+H)⁺.

Example 63

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (86 mg, 0.18 mmol) obtained in Step 1 of Example 51 and thecompound (45 mg, 0.22 mmol) obtained in Step 4 of Reference Example 26were used as starting materials and treated in the same way as in Step 2of Example 12 to give 71 mg (63%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.32-1.40 (1H, m), 1.45-1.80 (6H, m), 2.02-2.13 (1H, m), 2.15-2.24(2H, m), 3.36-3.43 (1H, m), 4.01-4.10 (1H, m), 4.12 (1H, d, J=8.6 Hz),4.19-4.25 (1H, m), 4.52 (1H, d, J=8.6 Hz), 4.72 (1E, dd, J=10.3, 2.3Hz), 6.77 (1H, d, J=2.3 Hz), 6.88-6.92 (1H, m), 7.06-7.09 (1H, m), 7.11(1H, dd, J=8.0, 1.7 Hz), 7.29 (1H, d, J=8.0 Hz), 7.56 (1H, s), 7.69 (1H,d, J=8.6 Hz), 8.10 (1H, d, J=5.2 Hz), 8.73 (1H, s).

MS (ESI) m/z: 625 (M+H)⁺.

Example 64

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (84 mg, 0.17 mmol) obtained in Step 1 of Example 17 and thecompound (42 mg, 0.20 mmol) obtained in Step 4 of Reference Example 26were used as starting materials and treated in the same way as in Step 2of Example 12 to give 92 mg (82%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.35-1.42 (1H, m), 1.45-1.55 (2H, m), 1.57-1.83 (4H, m), 2.03-2.13(1H, m), 2.15-2.28 (2H, m), 3.22-3.45 (2H, m), 4.00-4.11 (1H, m),4.15-4.22 (1H, m), 4.47 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.2 Hz), 4.72(1H, dd, J=1.03, 2.3 Hz), 6.72 (1H, d, J=1.7 Hz), 7.06 (1H, dd, J=8.3,2.0 Hz), 7.29-7.34 (1H, m), 7.50 (1H, t, J=5.2 Hz), 7.66 (1H, d, J=8.6Hz), 7.82 (1H, s), 8.04 (1H, d, J=5.2 Hz), 8.73 (1H, s).

MS (ESI) m/z: 643 (M+H)⁺.

Example 65

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[(3R,6S)-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (87 mg, 0.18 mmol) obtained in Step 1 of Example 47 and thecompound (47 mg, 0.21 mmol) obtained in Step 3 of Reference Example 25were used as starting materials and treated in the same way as in Step 2of Example 12 to give 54 mg (46%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.96 (3H, s), 1.08-2.20 (12H,m), 3.34-3.41 (1H, m), 3.82-3.91 (1H, m), 3.93-4.00 (1H, m), 4.42 (1H,dd, J=10.1, 3.2 Hz), 4.60 (1H, d, J=9.2 Hz), 4.71 (1H, d, J=9.2 Hz),7.10 (1H, d, J=8.0 Hz), 7.61-7.66 (1H, m), 7.87 (1H, dd, J=8.0, 2.3 Hz),8.09 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 660 (M+H)⁺.

Example 66

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (88 mg, 0.18 mmol) obtained in Step 1 of Example 47 and thecompound (44 mg, 0.21 mmol) obtained in Step 4 of Reference Example 26were used as starting materials and treated in the same way as in Step 2of Example 12 to give 81 mg (71%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.71 (3H, s), 0.97 (3H, s), 1.15-1.29 (2H,m), 1.35-1.43 (1H, m), 1.145-1.79 (6H, m), 2.02-2.13 (1H, m), 2.16-2.26(2H, m), 3.20-3.47 (2H, m), 4.00-4.11 (1H, m), 4.16-4.22 (1H, m), 4.48(1H, d, J=9.2 Hz), 4.65-4.74 (2H, m), 7.08 (1H, d, J=8.0 Hz), 7.46 (1H,t, J=4.9 Hz), 7.57 (1H, d, J=8.0 Hz), 7.63 (1H, dd, J=7.5, 2.3 Hz), 8.09(1H, d, J=5.2 Hz), 8.28 (1H, br s), 8.73 (1H, s).

MS (ESI) m/z: 644 (M+H)⁺.

Example 67

(3′R,4′S,5′R)-N-(trans-4-carbamoylcyclohexyl)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (200 mg, 0.41 mmol) obtained in Step 1 of Example 17 andtrans-4-aminocyclohexanecarboxamide hydrochloride (WO2005/058892) (87mg, 0.49 mmol) were used as starting materials and treated in the sameway as in Step 2 of Example 12 to give 53 mg (21%) of the title compoundas a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.67 (3H, s), 0.93 (3H, s), 1.09-1.22 (2H,m), 1.26-1.41 (3H, m), 1.49-1.64 (4H, m), 1.76-1.81 (3H, m), 1.86-2.07(4H, m), 2.18-2.27 (1H, m), 3.57-3.66 (1H, m), 4.52 (1H, d, J=9.2 Hz),4.65 (1H, d, J=9.2 Hz), 6.76 (1H, d, J=1.8 Hz), 7.05 (1H, dd, J=8.0, 2.1Hz), 7.45 (1H, dd, J=8.2, 2.3 Hz), 7.65 (1H, t, J=5.0 Hz), 8.04 (1H, d,J=5.0 Hz).

MS (ESI) m/z: 616 (M+H)⁺.

Example 68

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,5R,6R)-6-(hydroxymethyl-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 49 and thecompound (25 mg, 0.16 mmol) obtained in Step 5 of Reference Example 27were used as starting materials and treated in the same way as in Step 2of Example 12 to give 78 mg (86%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.10-1.82 (9H,m), 2.20-2.49 (2H, m), 3.18-3.28 (1H, m), 3.40 (3H, s), 3.45-3.55 (2H,m), 3.63-3.77 (1H, m), 3.84-3.94 (1H, m), 4.05-4.28 (2H, m), 4.47 (1H,d, J=9.2 Hz), 4.70 (1H, d, J=9.2 Hz), 6.91-6.99 (1H, m), 7.05 (1H, d,J=7.8 Hz), 7.11-7.19 (1H, m), 7.42-7.69 (3H, m), 8.22-8.32 (1H, m).

MS (ESI) m/z: 635 (M+H)⁺.

Example 69

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,5R,6R)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 17 and thecompound (25 mg, 0.16 mmol) obtained in Step 5 of Reference Example 27were used as starting materials and treated in the same way as in Step 2of Example 12 to give 66 mg (73%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.95 (3H, s), 1.10-1.82 (9H,m), 2.16-2.23 (1H, m), 2.38-2.49 (1H, m), 3.20-3.28 (1H, m), 3.41 (3H,s), 3.46-3.55 (2H, m), 3.66-3.76 (1H, m), 3.85-3.94 (1H, m), 4.06-4.28(2H, m), 4.44 (1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz), 6.74 (1H, d,J=1.8 Hz), 7.07 (1H, dd, J=8.3, 1.8 Hz), 7.31-7.54 (4H, m), 8.05 (1H, d,J=5.5 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Example 70

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (100 mg, 0.20 mmol) obtained in Step 1 of Example 17 andthe compound (35 mg, 0.24 mmol) obtained in Step 3 of Reference Example28 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 94 mg (76%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.27 (2H,m), 1.35-1.81 (8H, m), 2.10-2.17 (1H, m), 2.25-2.32 (1H, m), 3.15 (1H,t, J=10.5 Hz), 3.27 (1H, br s), 3.80 (1H, dd, J=11.0, 2.3 Hz), 3.85-3.95(1H, m), 4.13 (1H, ddd, J=10.8, 4.5, 1.3 Hz), 4.44 (1H, d, J=9.2 Hz),4.64 (1H, d, J=9.2 Hz), 5.46 (1H, d, J=3.7 Hz), 6.49 (1H, d, J=3.7 Hz),6.74 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd,J=8.2, 2.3 Hz), 7.48-7.52 (2H, m), 7.62 (1H, s), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 618 (M+H)⁺.

Example 71

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (100 mg, 0.20 mmol) obtained in Step 1 of Example 47 andthe compound (35 mg, 0.24 mmol) obtained in Step 3 of Reference Example28 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 41 mg (33%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.15-1.27 (2H,m), 1.34-1.40 (1H, m), 1.45-1.73 (7H, m), 2.10-2.16 (1H, m), 2.26-2.32(1H, m), 3.15 (1H, t, J=10.8 Hz), 3.26 (1H, br s), 3.81 (1H, dd, J=11.2,2.5 Hz), 3.87-3.93 (1H, m), 4.12 (1H, dd, J=11.0, 2.7 Hz), 4.45 (1H, d,J=8.7 Hz), 4.65 (1H, d, J=9.2 Hz), 5.52 (1H, d, J=3.2 Hz), 6.49 (1H, d,J=3.2 Hz), 7.07 (1H, d, J=7.8 Hz), 7.42-7.47 (2H, m), 7.61 (1H, dd,J=7.8, 2.3 Hz), 8.09 (1H, d, J=5.0 Hz), 8.20 (1H, br s).

MS (ESI) m/z: 619 (M+H)⁺.

Example 72

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[trans-4-(3-hydroxyazetidine-1-yl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (197 mg, 0.40 mmol) obtained in Step 1 of Example 17 andthe compound (117 mg, 0.48 mmol) obtained in Step 2 of Reference Example13 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 107 mg (40%) of the title compound as apale yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.97 (3H, s), 1.07-1.41 (7H,m), 1.53-1.64 (2H, m), 1.75-1.83 (2H, m), 1.86-2.02 (4H, m), 2.10-2.18(1H, m), 2.90-2.96 (2H, m), 3.56-3.64 (2H, m), 3.64-3.69 (2H, m),4.30-4.36 (1H, m), 4.55 (1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 6.79(1H, d, J=2.3 Hz), 7.08 (1H, dd, J=8.3, 2.0 Hz), 7.47 (1H, dd, J=8.3,2.0 Hz), 7.68 (1H, t, J=4.9 Hz), 8.07 (1H, d, J=5.7 Hz).

MS (ESI) m/z: 644 (M+H)⁺.

Example 73

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[cis-4-(hydroxymethyl)-4-methoxycyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (68 mg, 0.14 mmol) obtained in Step 1 of Example 12 and thecompound (0.12 mmol) obtained in Step 6 of Reference Example 29 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 35 mg (48%) of the title compound as a colorlessamorphous solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.93-0.98 (1H,m), 1.10-1.13 (1H, m), 1.19-1.59 (10H, m), 1.67-1.78 (4H, m), 2.09 (2H,s), 3.11 (3H, s), 3.28-3.49 (4H, m), 4.33-4.37 (1H, m), 4.45-4.47 (1H,m), 4.56 (1H, d, J=9.7 Hz), 6.68 (1H, d, J=1.7 Hz), 7.04 (1H, d, J=9.7Hz), 7.11 (1H, t, J=7.7 Hz), 7.32 (1H, t, J=7.2 Hz), 7.44 (1H, d, J=8.0Hz), 7.57 (1H, t, J=6.6 Hz), 7.75 (1H, d, J=8.6 Hz), 10.52 (1H, s).

MS (ESI) m/z: 632 (M+H)⁺.

Example 74

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorphenyl)-N-[trans-4-(hydroxymethyl)-4-methoxycyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (79 mg, 0.16 mmol) obtained in Step 1 of Example 12 and thecompound (0.18 mmol) obtained in Step 4 of Reference Example 29 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 50 mg (51%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.88 (3H, s), 0.92-1.00 (1H,m), 1.10-1.14 (1H, m), 1.23-1.26 (1H, m), 1.30-1.37 (1H, m), 1.44-1.79(12H, m), 3.11 (3H, s), 3.39 (2H, d, J=5.5 Hz), 3.50 (1H, d, J=10.1 Hz),3.65-3.72 (1H, m), 4.38-4.47 (2H, m), 4.53 (1H, d, J=9.6 Hz), 6.67 (1H,d, J=1.8 Hz), 7.03 (1H, dd, J=8.0 2.1 Hz), 7.11 (1H, t, J=8.0 Hz),7.30-7.34 (1H, m), 7.44 (1H, dd, J=8.3, 2.3 Hz), 7.56-7.60 (1H, m), 7.88(1H, d, J=7.8 Hz), 10.53 (1H, s).

MS (ESI) m/z: 632 (M+H)⁺.

Example 75 (Isomer A) and 76 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (200 mg, 0.41 mmol) obtained in Step 1 of Example 47 andthe compound (89 mg, 0.49 mmol) obtained in Step 3 of Reference Example30 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give a mixture of diastereomers. The mixture ofdiastereomers obtained was resolved and purified by chiral column liquidchromatography [fractionation conditions: CHIRALPAK IC,n-hexane:ethanol=3:2 (v/v)] to separately give 12 mg (5%: isomer A) and82 mg (32%: isomer B) of the title compounds as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.15 (3H, d,J=6.9 Hz), 1.16-1.27 (3H, m), 1.37-1.63 (6H, m), 1.70-1.77 (2H, m),2.05-2.15 (2H, m), 3.12 (1H, t, J=10.5 Hz), 3.20-3.28 (2H, m), 3.81-3.90(2H, m), 4.06 (1H, dd, J=10.3, 4.4 Hz), 4.45 (1H, d, J=8.7 Hz), 4.66(1H, d, J=9.2 Hz), 7.07 (1H, d, J=7.8 Hz), 7.38 (1H, d, J=8.2 Hz), 7.45(1H, t, J=4.8 Hz), 7.61 (1H, d, J=8.2 Hz), 8.02 (1H, br s), 8.08 (1H, d,J=5.0 Hz).

MS (ESI) m/z: 620 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.16 (3H, d,J=6.0 Hz), 1.17-1.29 (3H, m), 1.34-1.63 (6H, m), 1.71-1.77 (2H, m),2.07-2.12 (1H, m), 2.64 (1H, br s), 3.03-3.09 (1H, m), 3.10 (1H, t,J=10.8 Hz), 3.26 (1H, br s), 3.63 (1H, t, J=6.2 Hz), 3.83-3.92 (1H, m),4.04-4.10 (1H, m), 4.45 (1H, d, J≦8.7 Hz), 4.66 (1H, d, J=8.7 Hz), 7.07(1H, d, J=8.2 Hz), 7.39 (1H, d, J=8.7 Hz), 7.45 (1H, t, J=4.8 Hz), 7.61(1H, dd, J=7.6, 2.1 Hz), 8.01 (1H, br s), 8.09 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 620 (M+H)⁺.

Example 77 (Isomer A) and 78 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(2-chlorpyridin-4-yl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (300 mg, 0.63 mmol) obtained in Step 1 of Example 51 andthe compound (137 mg, 0.76 mmol) obtained in Step 3 of Reference Example30 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give a mixture of diastereomers. The mixture ofdiastereomers obtained was resolved and purified by chiral column liquidchromatography [fractionation conditions: CHIRALCEL OD-H,n-hexane:ethanol=4:1 (v/v)] to separately give 45 mg (12%: isomer A) and249 mg (66%: isomer B) of the title compounds as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.94 (3H, s), 1.14-1.23 (5H,m), 1.31-1.37 (1H, m), 1.40-1.53 (3H, m), 1.55-1.65 (3H, m), 1.69-1.77(2H, m), 2.06-2.14 (2H, m), 3.14 (1H, t, J=10.8 Hz), 3.21-3.26 (1H, m),3.29 (1H, br s), 3.83-3.90 (2H, m), 4.09 (1H, m), 4.10 (1H, d, J=8.7Hz), 4.49 (1H, d, J=8.2 Hz), 6.76 (1H, d, J=1.4 Hz), 6.90 (1H, d, J=5.5Hz), 7.08 (1H, s), 7.10 (1H, dd, J=8.2, 1.4 Hz), 7.28 (1H, d, J=9.2 Hz),7.52 (1H, d, J=8.7 Hz), 7.57 (1H, s), 8.10 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 601 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.15-1.27 (5H,m), 1.30-1.36 (1H, m), 1.41-1.53 (4H, m), 1.56-1.63 (2H, m), 1.69-1.77(2H, m), 2.03-2.11 (1H, m), 2.68 (1H, s), 3.03-3.08 (1H, m), 3.11 (1H,t, J=10.8 Hz), 3.30 (1H, br s), 3.59-3.67 (1H, m), 3.84-3.93 (1H, m),4.09 (1H, m), 4.10 (1H, d, J=8.7 Hz), 4.49 (1H, d, J=8.7 Hz), 6.77 (1H,d, J=1.8 Hz), 6.90 (1H, dd, J=5.5, 1.4 Hz), 7.08 (1H, s), 7.10 (1H, dd,J=8.2, 1.8 Hz), 7.28 (1H, d, J=8.7 Hz), 7.53 (1H, d, J=8.7 Hz, 7.66 (1H,s), 8.09 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 601 (M+H)⁺.

Example 79

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorphenyl)-3,3-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H,dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[2,3-b]pyridine]-1′,2″(1″H)-dione

The compound (0.93 g, 3.00 mmol) obtained in Reference Example 1 and3,3-dimethylcyclobutanone (Tetrahedron, 1968, 6017-6028) (0.30 g, 3.00mmol) were used and treated in the same way as in Step 1 of Example 9 togive 1.10 g (51%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.71 (3H, s), 0.92 (3H, s), 1.66 (1H, d,J=13.2 Hz), 1.85 (1H, d, J=13.2 Hz), 2.45 (1H, d, J=14.2 Hz), 2.62 (1H,d, J=14.2 Hz), 4.60 (1H, d, J=9.3 Hz), 4.83 (1H, d, J=9.3 Hz), 5.04 (1H,,d, J=4.4 Hz), 6.39 (1H, d, J=4.4 Hz), 6.86 (1H, d, J=7.8 Hz), 6.99 (1H,t, J=7.8 Hz), 7.04 (1H, d, J=7.8 Hz), 7.10-7.25 (12H, m), 7.77 (1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyll]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-3,3-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (430 mg, 0.67 mmol) obtained in Step 1 above and thecompound (263 mg, 2.00 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 20 to give 390 mg (76%) of the title compound as a brownamorphous solid.

MS (ESI) m/z: 773 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-3,3-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (390 mg, 0.50 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 150 mg (52%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 1.33 (3H, s), 1.38-1.64 (3H,m), 1.71-1.79 (1H, m), 1.83 (1H, dd, J=12.8, 3.2 Hz), 2.00 (1H, dd,J=12.4, 3.2 Hz), 2.10 (1H, d, J=12.4 Hz), 2.24 (1H, d, J=12.4 Hz), 3.11(1H, t, J=10.8 Hz), 3.33-3.41 (1H, m), 3.49 (2H, d, J=5.0 Hz), 3.73-3.83(1H, m), 3.88-3.94 (1H, m), 4.34 (1H, d, J=9.2 Hz), 4.45 (1H, d, J=9.2Hz), 7.05 (1H, t, J=8.0 Hz), 7.11 (1H, d, J=7.8 Hz), 7.23-7.27 (1H, m),7.52 (1H, t, J=7.1 Hz), 7.88 (1H, dd, J=7.8, 2.3 Hz).

MS (ESI) m/z:577 (M+H)⁺.

Example 80

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[cis-4-hydroxy-4-(methoxymethyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (79 mg, 0.16 mmol) obtained in Step 1 of Example 47 and thecompound (40 mg, 0.20 mmol) obtained in Step 2 of Reference Example 31were used as starting materials and treated in the same way as in Step 2of Example 12 to give 63 mg (62%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.80-1.17 (16H,m), 2.19 (1H, s), 3.21 (3H, s), 3.39 (3H, s), 3.68-3.74 (1H, m),4.45-4.47 (1H, m), 4.67 (1H, d, J=8.7 Hz), 7.06 (1H, d, J=8.3 Hz),7.46-7.51 (2H, m), 7.60-7.63 (1H, m), 8.07 (1H, d, J=5.0 Hz), 8.17 (1H,s).

MS (ESI) m/z: 634 (M+H)⁺.

Example 81

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorphenyl)-N-[trans-4-(hydroxymethyl)-4-methoxycyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (71 mg, 0.15 mmol) obtained in Step 1 of Example 49 and thecompound (42 mg, 0.21 mmol) obtained in Step 4 of Reference Example 29were used as starting materials and treated in the same way as in Step 2of Example 12 to give 65 mg (71%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.95 (3H, s), 1.14-1.24 (2H,m), 1.34-1.70 (11H, m), 1.76-1.79 (1H, m), 1.87-1.92 (3H, m), 3.18-3.22(4H, m), 3.60 (2H, d, J=5.7 Hz), 3.83-3.89 (1H, m), 4.48 (1H, d, J=9.2Hz), 4.68 (1H, d, J=9.7 Hz), 6.96 (1H, t, J=8.0 Hz), 7.05 (1H, d, J=8.0Hz), 7.14-7.18 (1H, m), 7.48 (1H, t, J=6.3 Hz), 7.63 (2H, dd, J=8.0, 2.3Hz), 7.87 (1H, s).

MS (ESI) m/z: 633 (M+H)⁺.

Example 82

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[trans-4-(hydroxymethyl)-4-methoxycyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (96 mg, 0.20 mmol) obtained in Step 1 of Example 47 and thecompound (42 mg, 0.22 mmol) obtained in Step 4 of Reference Example 29were used as starting materials and treated in the same way as in Step 2of Example 12 to give 26 mg (21%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.95 (3H, s), 1.14-1.26 (2H,m), 1.35-1.74 (12H, m), 1.88-1.94 (3H, m), 3.21-3.25 (4H, m), 3.60 (2H,d, J=5.5 Hz), 3.82-3.90 (1H, m), 4.47 (1H, d, J=8.7 Hz), 4.65 (1H, d,J=9.2 Hz), 7.07 (1H, d, J=7.8 Hz), 7.47 (1H, t, J=5.0 Hz), 7.59-7.63(2H, m), 8.02 (1H, s), 8.08 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 634 (M+H)⁺.

Example 83

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[cis-4-(hydroxymethyl)-4-methoxycyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]-pyridine]-5′-carboxamide

The compound (67 mg, 0.14 mmol) obtained in Step 1 of Example 47 and thecompound (0.11 mmol) obtained in Step 6 of Reference Example 29 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 36 mg (53%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.14-1.83 (15H,m), 1.90-1.99 (2H, m), 3.21-3.26 (4H, m), 3.41-3.53 (2H, m), 3.66-3.76(1H, m), 4.45 (1H, d, J=8.7 Hz), 4.68 (1H, d, J=9.2 Hz), 7.07 (1H, d,J=7.8 Hz), 7.46-7.50 (2H, m), 7.61-7.63 (1H, m), 8.08 (2H, d, J=5.0 Hz).

MS (ESI) m/z: 634 (M+H)⁺.

Example 84

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorphenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[2,3-b]pyridine]-1′,2″(1″H)-dione

The compound (4.60 g, 15.0 mmol) obtained in Reference Example 1 aboveand the compound (2.21 g, 16.5 mmol) obtained in Step 2 of ReferenceExample 21 were used as starting materials and treated in the same wayas in Step 1 of Example 9 to give 1.77 g (11%) of the title compound asa pale yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.87 (1H, d, J=14.2 Hz), 2.23 (1H, d, J=14.2Hz), 2.76 (1H, d, J=14.2 Hz), 2.88 (1H, d, J=14.2 Hz), 3.90-3.96 (1H,m), 4.02-4.08 (1H, m), 4.15 (1H, dd, J=15.3, 9.8 Hz), 4.27 (1H, dd,J=15.3, 9.8 Hz), 4.57 (1H, d, J=9.6 Hz), 4.80 (1H, d, J=9.6 Hz), 5.20(1H, dd, J=4.1, 1.8 Hz), 6.39 (1H, d, J=4.1 Hz), 6.87 (1H, d, J=7.8 Hz),6.96 (2H, t, J=8.0 Hz), 7.05-7.09 (1H, m), 7.10-7.13 (2H, m), 7.14-7.25(10H, m), 7.92 (1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorphenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (339 mg, 0.50 mmol) obtained in Step 1 above and thecompound (197 mg, 1.50 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 20 to give 198 mg (49%) of the title compound as a brownamorphous solid.

MS (ESI) m/z: 809 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorphenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (198 mg, 0.24 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 2 of Example 10to give 80 mg (53%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.36-1.48 (1H, m), 1.53-1.64 (1H, m),1.71-1.81 (2H, m), 1.87-1.93 (1H, m), 2.03-2.13 (2H, m), 2.42 (1H, d,J=12.8 Hz), 3.11 (1H, t, J=10.5 Hz), 3.32-3.40 (1H, m), 3.49 (2H, d,J=5.0 Hz), 3.74-3.85 (1H, m), 3.86-4.06 (3H, m), 4.41 (1H, d, J=9.6 Hz),4.48 (1H, d, J=9.2 Hz), 4.61-4.80 (2H, m), 7.06 (1H, t, J=8.0 Hz), 7.11(1H, d, J=7.8 Hz), 7.24-7.28 (1H, m), 7.52 (1H, t, J=6.6 Hz), 7.92 (1H,dd, J=8.0, 2.1 Hz).

MS (ESI) m/z: 613 (M+H)⁺.

Example 85 (Isomer A) and 86 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorpyridin-4-yl)-N-[(3R,6R)-5-hydroxy-6-(hydroxymethyl)-5-methyltetrahydro-2H-pyran-3-yl]4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (60 mg, 0.12 mmol) obtained in Step 1 of Example 17 and thecompound (21 mg, 0.13 mmol) obtained in Step 3 of Reference Example 32were used as starting materials and treated in the same way as in Step 2of Example 12 to separately give 35 mg (46%: isomerA) and 15 mg (20%:isomerB) of the title compound as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.28 (3H,m), 1.32 (3H, s), 1.36-1.76 (5H, m), 1.98-2.11 (2H, m), 2.33 (1H, s),3.04-3.27 (2H, m), 3.30-3.38 (1H, m), 3.70-4.10 (4H, m), 4.40-4.50 (1H,m), 4.64 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 7.04-7.12 (1H, m),7.29-7.35 (2H, m), 7.46-7.57 (2H, m), 8.06 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.94 (3H, s), 1.11-1.76 (11H,m), 2.00-2.07 (1H, m), 2.37-2.44 (1H, m), 3.08-3.30 (4H, m), 3.82-3.96(2H, m), 4.11-4.20 (1H, m), 4.21-4.33 (1H, m), 4.43 (1H, d, J=9.0 Hz),4.62 (1H, d, J=9.0 Hz), 6.69 (1H, d, J=1.8 Hz), 7.05-7.10 (1H, m),7.29-7.34 (1H, m), 7.46-7.62 (3H, m), 8.06 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Example 87

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{cis-4-hydroxy-4-[(methylsulfonyl)methyl]cyclohexyl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (89 mg, 0.18 mmol) obtained in Step 1 of Example 17 and thecompound (0.20 mmol) obtained in Step 3 of Reference Example 33 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 84 mg (67%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.90 (3H, s), 0.93-1.00 (1H,m), 1.11-1.14 (1H, m), 1.22-1.25 (1H, m), 1.41-1.64 (9H, m), 1.67-1.76(2H, m), 1.84-1.91 (2H, m), 3.00 (3H, s), 3.22 (2H, s), 3.44-3.49 (1H,m), 3.56 (1H, d, J=11.5 Hz), 4.44 (1H, t, J=9.7 Hz), 4.55 (1H, d, J=9.2Hz), 4.86 (1H, s), 6.71 (1H, d, J=2.3 Hz), 7.06 (1H, dd, J=8.3, 2.0 Hz),7.50 (1H, dd, J=8.3, 2.0 Hz), 7.63 (1H, t, J=5.2 Hz), 7.74 (1H, d, J=8.0Hz), 8.18 (1H, d, J=5.2 Hz), 10.61 (1H, s).

MS (ESI) m/z: 681 (M+H)⁺.

Example 88

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(ethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (160 mg, 0.33 mmol) obtained in Step 1 of Example 17 andthe compound (87 mg, 0.40 mmol) obtained in Step 2 of Reference Example34 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 143 mg (67%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.15 (3H, t,J=7.2 Hz), 1.16-1.24 (2H, m), 1.35-1.41 (1H, m), 1.43-1.62 (5H, m),1.70-1.77 (2H, m), 2.09-2.15 (1H, m), 2.28-2.34 (1H, m), 3.13 (1H, t,J=10.7 Hz), 3.25-3.36 (2H, m), 3.74-3.79 (1H, m), 3.85-3.94 (1H, m),4.11 (1H, dd, J=11.7, 3.9 Hz), 4.44 (1H, d, J=8.8 Hz), 4.64 (1H, d,J=9.0 Hz), 6.52 (1H, t, J=5.5 Hz), 6.73 (1H, d, J=1.7 Hz), 7.07 (1H, dd,J=8.1, 2.0 Hz), 7.31 (1H, dd, J=8.2, 2.1 Hz), 7.48-7.52 (2H, m), 7.62(1H, s), 8.05 (1H, d, J=5.1 Hz).

MS (ESI) m/z: 646 (M+H)⁺.

Example 89 (Isomer A) and 90 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(1,2-dihydroxyethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (332 mg, 0.67 mmol) obtained in Step 1 of Example 17 andthe compound (160 mg, 0.80 mmol) obtained in Step 3 of Reference Example35 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give a mixture of diastereomers. The mixture ofdiastereomers obtained was resolved and purified by chiral column liquidchromatography [fractionation conditions: CHIRALPAK IA,n-hexane:ethanol=1:1 (v/v)] to separately give 100 mg (23%: isomer A)and 174 mg (40%: isomer B) of the title compounds as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.26 (2H,m), 1.33-1.39 (1H, m), 1.42-1.63 (5H, m), 1.70-1.76 (2H, m), 1.82-1.89(1H, m), 2.10-2.16 (2H, m), 2.56 (1H, d, J=6.4 Hz), 3.09 (1H, t, J=10.5Hz), 3.27 (1H, br s), 3.40-3.45 (1H, m), 3.61-3.66 (1H, m), 3.69-3.75(2H, m), 3.84-3.93 (1H, m), 4.03-4.08 (1H, m), 4.43 (1H, d, J=9.2 Hz),4.64 (1H, d, J=9.2 Hz), 6.72 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.0, 2.1Hz), 7.31 (1H, dd, J=8.0, 2.1 Hz), 7.43-7.51 (3H, m), 8.05 (1H, d, J=5.0Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.10-1.24 (2H,m), 1.33-1.38 (1H, m), 1.43-1.54 (3H, m), 1.57-1.79 (5H, m), 2.09-2.14(1H, m), 2.20-2.25 (1H, m), 2.277 (1H, d, J=4.1 Hz), 3.12 (1H, t, J=10.5Hz), 3.31 (1H, br s), 3.37-3.43 (1H, m), 3.53-3.59 (1H, m), 3.62-3.67(1H, m), 3.71-3.78 (1H, m), 3.86-3.94 (1H, m), 4.06-4.11 (1H, m), 4.43(1H, d, J=9.2 Hz), 4.64 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07(1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd, J=8.0, 2.1 Hz), 7.46-7.51 (3H,m), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Example 91

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-4′-8′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (5.0 g, 17.2 mmol) obtained in Reference Example 8 and thecompound (2.88 g, 21.5 mmol) obtained in Step 2 of Reference Example 21were used as starting materials and treated in the same way as in Step 1of Example 9 to give 10.2 g (87%) of the title compound as a pale yellowamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.82 (1H, d, J=14.7 Hz), 2.35 (1H, d, J=14.7Hz), 2.84 (1H, d, J=14.2 Hz), 3.07 (1H, d, J=14.2 Hz), 3.90-3.98 (1H,m), 4.02-4.10 (1H, m), 4.23-4.30 (1H, m), 4.35-4.42 (1H, m), 4.52 (1H,d, J=9.6 Hz), 4.69 (1H, d, J=9.6 Hz), 5.22-5.25 (1H, m), 6.30 (1H, d,J=4.1 Hz), 6.78 (1H, d, J=8.3 Hz), 6.84 (1H, t, J=4.8 Hz), 6.89 (1H, d,J=1.8 Hz), 6.94 (1H, dd, J=8.3, 1.8 Hz), 7.14-7.27 (10H, m), 7.97 (1H,d, J=5.0 Hz), 8.00 (1H, s).

MS (ESI) m/z: 678 (M+H)⁺.

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (203 mg, 0.30 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 20to give 153 mg (63%) of the title compound as a pale yellow amorphoussolid.

MS (ESI) m/z: 809 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (153 mg, 0.19 mmol) obtained in Step 2 above was dissolvedin acetonitrile (10 ml) and water (3 ml), cerium (IV) diammonium nitrate(207 mg, 0.38 mmol) was added under ice cooling and the resultingmixture was stirred for 10 minutes. Potassium carbonate (104 mg, 0.76mmol) was added to the reaction mixture and the precipitated insolublematter was removed by filtration through celite. The filtrate wasdiluted with ethyl acetate, washed with brine and dried over anhydroussodium sulfate. the solvent was evaporated, the residue was purified byNH-silica gel column chromatography (chloroform:methanol=100:0→40:1) andthen the residue was dissolved in 2-propanol (10 ml) and stirred at 50°C. for 2 days. The solvent was evaporated under reduced pressure andthen the residue was purified by chiral column liquid chromatography[fractionation conditions: CHIRALPAK IC, n-hexane:ethanol=2:3 (v/v)] togive 67 mg (57%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.37-1.49 (1H, m), 1.55-1.78 (2H, m),1.85-1.91 (1H, m), 2.00-2.20 (2H, m), 2.48 (1H, d, J=12.8 Hz), 3.16 (1H,t. J=10.5 Hz), 3.33-3.41 (1H, m), 3.45-3.51 (2H, m), 3.74-3.94 (4H, m),4.39 (1H, d, J=9.2 Hz), 4.50 (1H, d, J=9.2 Hz), 4.60-4.77 (2H, m), 6.84(1H, d, J=1.8 Hz), 7.13 (1H, dd, J=8.0, 2.1 Hz), 7.54 (1H, dd, J=8.0,2.1 Hz), 7.60 (1H, t, J=5.0 Hz), 8.06 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 613 (M+H)⁺.

Example 92

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(5-chloropyridin-3-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (1.35 g, 4.65 mmol) obtained in Reference Example 36 wasused as a starting material and treated in the same was as in Step 1 ofExample 9 to give 2.35 g (77%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.56 (3H, s), 0.67 (3H, s), 0.81-1.01 (1H,m), 1.16-1.44 (4H, m), 1.74-1.83 (1H, m), 1.86-1.97 (1H, m), 2.16-2.27(1H, m), 4.48 (1H, d, J=11.0 Hz), 4.82 (1H, d, J=3.7 Hz), 5.03 (1H, d,J=11.0 Hz), 6.61-6.68 (2H, m), 6.77-6.84 (2H, m), 6.92-6.98 (2H, m),7.10-7.29 (9H, m), 7.47-7.50 (1H, m), 8.14 (1H, d, J=1.4 Hz), 8.34 (1H,d, J=2.3 Hz).

MS (APCI) m/z: 652 (M+H)⁺.

[Step 2]

(4′R,5′R)-6″-chloro-4′-(5-chloropyridin-3-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (2.29 g, 3.52 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 12to give 827 mg (50%) of the title compound as a light brown solid.

MS (APCI) m/z: 474 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(5-chloropyridin-3-yl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (200 mg, 0.42 mmol) obtained in Step 2 above and thecompound (83 mg, 0.63 mmol) obtained in Step 3 of Reference Example 2were used as starting materials and treated in the same way as in Step 2of Example 12 to give 23 mg (9%) of the title compound as a pale yellowsolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.67-0.71 (3H, m), 0.93-0.96 (3H, m),1.15-1.24 (2H, m), 1.27-1.66 (5H, m), 1.69-1.86 (4H, m), 2.02-2.10 (1H,m), 3.11-3.53 (4H, m), 3.73-3.82 (1H, m), 3.94-3.98 (1H, m), 4.26 (1H,d, J=9.2 Hz), 4.61 (1H, d, J=9.2 Hz), 6.76 (1H, d, J=1.8 Hz), 7.10 (1H,dd, J=8.0, 2.1 Hz), 7.54 (1H, d, J=8.3 Hz), 7.78 (1H, t, J=2.1 Hz), 8.07(1H, d, J=1.8 Hz), 8.28 (1H, d, J=2.3 Hz).

MS (ESI) m/z: 587 (M+H)⁺.

Example 93 (Isomer A) and 94 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (300 mg, 0.61 mmol) obtained in Step 1 of Example 17 andthe compound (133 mg, 0.73 mmol) obtained in Step 3 of Reference Example30 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give a mixture of diastereomers. The mixture ofdiastereomers obtained was resolved and purified by chiral column liquidchromatography [fractionation conditions: CHIRALCEL OD-H,n-hexane:ethanol=7:3 (v/v)] to separately give 42 mg (11%: isomer A) and233 mg (61%: isomer B) of the title compounds as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.09-1.25 (5H,m), 1.34-1.65 (5H, m), 1.69-1.79 (3H, m), 2.07 (1H, d, J=4.4 Hz),2.10-2.15 (1H, m), 3.13 (1H, t, J=10.6 Hz), 3.20-3.25 (1H, m), 3.27 (1H,br s), 3.82-3.91 (2H, m), 4.04-4.09 (1H, m), 4.43 (1H, d, J=9.0 Hz),4.65 (1H, d, J=9.0 Hz), 6.72 (1H, d, J=2.0 Hz), 7.07 (1H, dd, J=8.1, 2.0Hz), 7.31 (1H, dd, J=8.1, 2.2 Hz), 7.40 (1H, s), 7.46 (1H, d, J=8.8 Hz),7.49 (1H, t, J=5.0 Hz), 8.05 (1H, d, J=5.1 Hz),

MS (ESI) m/z: 619 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.16 (3H, d,J=6.3 Hz), 1.17-1.24 (3H, m), 1.32-1.39 (1H, m), 1.42-1.64 (4H, m),1.67-1.79 (3H, m), 2.08-2.14 (1H, m), 2.64 (1H, d, J=2.4 Hz), 3.02-3.08(1H, m), 3.10 (1H, t, J=10.6 Hz), 3.27 (1H, br s), 3.60-3.65 (1H, m),3.85-3.91 (1H, m), 4.05-4.10 (1H, m), 4.44 (1H, d, J=9.0 Hz), 4.65 (1H,d, J=9.0 Hz), 6.73 (1H, d, J=2.0 Hz), 7.07 (1H, dd, J=8.1, 2.0 Hz), 7.31(1H, dd, J=8.1, 2.0 Hz), 7.36 (1H, s), 7.46 (1H, d, J=8.5 Hz), 7.49 (1H,t, J=5.0 Hz), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 95

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (203 mg, 0.30 mmol) obtained in Step 91 of Example 1 wasused as a starting material and treated in the same way as in Step 1 ofExample 5 to give 60 mg (23%) of the title compound as a colorlessamorphous solid. MS (ESI) m/z: 845 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (60 mg, 0.07 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 23 mg (58%) of the title compound as a colorless solid[fractionation conditions: CHIRALPAK IC, n-hexane:ethanol=1:4 (v/v)].

¹H-NMR (400 MHz, CD₃OD) δ: 1.49-1.57 (2H, m), 1.67-1.75 (3H, m), 1.91(1H, d, J=12.8 Hz), 2.03-2.11 (3H, m), 2.22 (2H, t, J=15.6 Hz), 2.49(1H, d, J=12.4 Hz), 2.99-3.04 (1H, m), 3.70-3.76 (1H, m), 3.81 (1H, s),3.92 (1H, s), 4.39 (1H, d, J=9.2 Hz), 4.52 (1H, d, J=9.2 Hz), 4.64 (1H,dd, J=15.6, 9.2 Hz), 4.76 (1H, dd, J=14.7, 8.7 Hz), 6.85 (1H, d, J=1.8Hz), 7.13 (1H, dd, J=8.2, 1.8 Hz), 7.55 (1H, dd, J=8.2, 1.8 Hz), 7.62(1H, t, J=5.0 Hz), 8.07 (1H, d, J=5.0 Hz), 8.84 (1H, s),

MS (ESI) m/z: 649 (M+H)⁺.

Example 96

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(isopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (80 mg, 0.36 mmol) obtained in Step 2 of Reference Example37 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 182 mg (92%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.16 (6H, d,J=6.4 Hz), 1.17-1.22 (2H, m), 1.34-1.39 (1H, m), 1.44-1.77 (7H, m),2.08-2.16 (1H, m), 2.27-2.34 (1H, m), 3.13 (1H, t, J=10.8 Hz), 3.28 (1H,br s), 3.71-3.76 (1H, m), 3.84-3.93 (1H, m), 4.01-4.14 (2H, m), 4.44(1H, d, J=8.7 Hz), 4.64 (1H, d, J=9.2 Hz), 6.36 (1H, d, J=8.2 Hz), 6.73(1H, d, J=1.8 Hz), 7.07 (1H, dd, J=7.8, 1.8 Hz), 7.31 (1H, dd, J=8.2,2.3 Hz), 7.48-7.52 (2H, m), 7.61 (1H, s), 8.05 (1H, d, J=5.0 Hz). MS(ESI) m/z: 662 (M+H)⁺.

Example 97

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(cyclopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (79 mg, 0.36 mmol) obtained in Step 2 of Reference Example38 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 163 mg (82%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.50-0.55 (2H, m), 0.68 (3H, s), 0.71-0.80(2H, m), 0.95 (3H, s), 1.09-1.25 (2H, m), 1.33-1.1.80 (8H, m), 2.09-2.15(1H, m), 2.27-2.33 (1H, m), 2.69-2.75 (1H, m), 3.11 (1H, t, J=10.8 Hz),3.27 (1H, br s), 3.73-3.78 (1H, m), 3.85-3.91 (1H, m), 4.06-4.12 (1H,m), 4.43 (1H, d, J=9.2 Hz), 4.63 (1H, d, J=9.2 Hz), 6.57 (1H, d, J=3.7Hz), 6.74 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.0, 2.1 Hz), 7.30 (1H, dd,J=8.2, 2.3 Hz), 7.47-7.52 (2H, m), 7.68 (1H, s), 8.04 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 658 (M+H)⁺.

Example 98

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-{(3R,6S)-6-[(methylsulfonyl)methyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (94 mg, 0.19 mmol) obtained in Step 1 of Example 17 and thecompound (0.21 mmol) obtained in Step 2 of Reference Example 39 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 86 mg (68%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.59 (3H, s), 0.90 (3H, s), 0.92-1.00 (1H,m), 1.10-1.13 (1H, m), 1.19-1.22 (1H, m), 1.38-1.88 (9H, m), 2.96 (3H,s), 3.15-3.22 (2H, m), 3.41 (1H, dd, J=14.9, 8.9 Hz), 3.50-3.52 (1H, m),3.60-3.77 (3H, m), 4.46 (1H, t, J=9.4 Hz), 4.57 (1H, d, J=8.7 Hz), 6.71(1H, d, J=2.3 Hz), 7.06 (1H, dd, J=8.3, 1.8 Hz), 6.71 (1H, d, J=2.3 Hz),7.06 (1H, dd, J=8.3, 1.8 Hz), 7.50 (1H, dd, J=8.3, 1.8 Hz), 7.63 (1H, t,J=5.0 Hz), 7.82 (1H, d, J=8.3 Hz), 8.18 (1H, d, J=5.0 Hz), 10.61 (1H,s).

MS (ESI) m/z: 667 (M+H)⁺.

Example 99

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(isopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (70 mg, 0.36 mmol) obtained in Step 2 of Reference Example40 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 157 mg (83%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.27 (2H,m), 1.34-1.39 (1H, m), 1.44-1.60 (5H, m), 1.69-1.78 (2H, m), 2.09-2.15(1H, m), 2.28-2.34 (1H, m), 2.82 (3H, d, J=5.0 Hz), 3.13 (1H, t, J=10.5Hz), 3.27 (1H, br s), 3.76-3.81 (1H, m), 3.85-3.93 (1H, m), 4.12 (1H,dd, J=10.8, 3.0 Hz), 4.43 (1H, d, J=8.7 Hz), 4.64 (1H, d, J=9.2 Hz),6.52-6.58 (1H, m), 6.73 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.0, 2.1 Hz),7.31 (1H, dd, J=8.2, 2.3 Hz), 7.50 (2H, t, J=5.0 Hz), 7.62 (1H, s), 8.05(1H, d, J=5.0 Hz).

MS (ESI) m/z: 632 (M+H)⁺.

Example 100

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (75 mg, 0.36 mmol) obtained in Step 2 of Reference Example41 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 136 mg (70%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.13-1.27 (2H,m), 1.35-1.40 (1H, m), 1.44-1.59 (4H, m), 1.71-1.78 (2H, m), 1.87-2.02(2H, m), 2.16-2.22 (1H, m), 2.95 (3H, s), 3.09 (3H, s), 3.25 (1H, t,J=10.1 Hz), 3.27 (1H, br s), 3.89-3.99 (1H, m), 4.06 (1H, dd, J=10.8,3.4 Hz), 4.12 (1H, dd, J=9.4, 3.0 Hz), 4.45 (1H, d, J=9.2 Hz), 4.65 (1H,d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 7.06 (1H, dd, J=8.2, 1.8 Hz), 7.32(1H, dd, J=8.2, 1.8 Hz), 7.50 (1H, t, J=5.0 Hz), 7.61 (1H, d, J=8.7 Hz),7.69 (1H, s), 8.04 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 646 (M+H)⁺.

Example 101

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-4,4-dimethyl-N-[(3R,6S)-6-(methylcarbamoyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 47 andthe compound (59 mg, 0.36 mmol) obtained in Step 2 of Reference Example40 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 94 mg (49%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.13-1.27 (2H,m), 1.34-1.40 (1H, m), 1.45-1.74 (7H, m), 2.08-2.14 (1H, m), 2.29-2.34(1H, m), 2.83 (3H, d, J=5.0 Hz), 3.13 (1H, t, J=10.8 Hz), 3.21-3.27 (1H,m), 3.77-3.81 (1H, m), 3.84-3.91 (1H, m), 4.08-4.13 (1H, m), 4.41-4.48(1H, m), 4.65 (1H, d, J=9.2 Hz), 6.52-6.57 (1H, m), 7.08 (1H, d, J=8.2Hz), 7.41-7.47 (2H, m), 7.61 (1H, dd, J=7.8, 2.3 Hz), 8.08 (2H, d, J=5.0Hz).

MS (ESI) m/z: 633 (M+H)⁺.

Example 102

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(cyclopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 47 andthe compound (60 mg, 0.27 mmol) obtained in Step 2 of Reference Example38 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 106 mg (54%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.51-0.54 (2H, m), 0.70 (3H, s), 0.75-0.80(2H, m), 0.96 (3H, s), 1.13-1.19 (1H, m), 1.20-1.28 (1H, m), 1.34-1.39(1H, m), 1.43-1.76 (7H, m), 2.07-2.13 (1H, m), 2.27-2.33 (1H, m),2.70-2.75 (1H, m), 3.11 (1H, t, J=10.8 Hz), 3.24 (1H, br s), 3.76 (1H,dd, J=11.0, 2.3 Hz), 3.85-3.90 (1H, m), 4.08 (1H, dd, J=10.8, 3.0 Hz),4.45 (1H, d, J=8.7 Hz), 4.65 (1H, d, J=9.2 Hz), 6.56 (1H, d, J=3.7 Hz),7.07 (1H, d, J=8.2 Hz), 7.42 (1H, d, J=8.7 Hz), 7.45 (1H, t, J=5.0 Hz),7.61 (1H, dd, J=7.8, 2.3 Hz), 8.08 (1H, d, J=5.0 Hz), 8.26 (1H, br s).

MS (ESI) m/z: 659 (M+H)⁺.

Example 103

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[(2-hydroxyethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (81 mg, 0.36 mmol) obtained in Step 2 of Reference Example42 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 86 mg (43%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.13-1.28 (2H,m), 1.33-1.40 (1H, m), 1.45-1.65 (5H, m), 1.68-1.81 (2H, m), 2.10-2.17(1H, m), 2.27-2.36 (2H, m), 3.14 (1H, t, J=10.6 Hz), 3.27 (1H, br s),3.40-3.48 (2H, m), 3.70-3.75 (2H, m), 3.80 (1H, dd, J=11.1, 2.3 Hz),3.86-3.95 (1H, m), 4.11-4.16 (1H, m), 4.44 (1H, d, J=9.0 Hz), 4.64 (1H,d, J=9.0 Hz), 6.71 (1H, d, J=2.0 Hz), 6.85-6.89 (1H, m), 7.07 (1H, dd,J=8.2, 1.8 Hz), 7.24-7.26 (1H, m), 7.31 (1H, dd, J=7.9, 2.3 Hz), 7.44(1H, d, J=8.1 Hz), 7.47 (1H, t, J=5.0 Hz), 8.04 (1H, d, J=5.1 Hz).

MS (ESI) m/z: 662 (M+H)⁺.

Example 104

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 47 andthe compound (75 mg, 0.36 mmol) obtained in Step 2 of Reference Example41 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 105 mg (54%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.13-1.29 (2H,m), 1.36-1.41 (1H, m), 1.46-1.66 (5H, m), 1.72-1.77 (1H, m), 1.88-2.05(2H, m), 2.15-2.23 (1H, m), 2.96 (3H, s), 3.09 (3H, s), 3.23-3.29 (2H,m), 3.90-3.97 (1H, m), 4.03-4.07 (1H, m), 4.13 (1H, dd, J=9.6, 3.2 Hz),4.46 (1H, d, J=9.2 Hz), 4.67 (1H, d, J=9.2 Hz), 7.08 (1H, d, J=7.8 Hz),7.45 (1H, t, J=5.0 Hz), 7.54 (1H, d, J=8.7 Hz), 7.62 (1H, dd, J=8.0, 2.5Hz), 8.08 (1H, d, J=5.0 Hz), 8.12 (1H, br s).

MS (ESI) m/z: 647 (M+H)⁺.

Example 105

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(hydroxymethyl)-2-methyltetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (85 mg, 0.17 mmol) obtained in Step 1 of Example 17 and thecompound (38 mg, 0.21 mmol) obtained in Step 7 of Reference Example 43were used as starting materials and treated in the same way as in Step 2of Example 12 to give 43 mg (40%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.95 (3H, s), 1.12-1.26 (6H,m), 1.35-1.94 (10H, m), 3.28 (1H, br s), 3.47-3.58 (1H, m), 3.68-4.17(4H, m), 4.49 (1H, d, J=9.17 Hz), 4.65 (1H, d, J=9.17 Hz), 6.74 (1H, d,J=1.83 Hz), 7.07 (1H, dd, J=8.25, 1.83 Hz), 7.20-7.25 (1H, m), 7.30-7.35(1H, m), 7.49-7.53 (1H, m), 7.78 (1H, d, J=8.71 Hz), 8.06 (1H, d, J=5.04Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 106

(3′R,4′S,5′R)-N-[(3R,6S)-6-(azetidin-1-ylcarbonyl)tetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (99 mg, 0.45 mmol) obtained in Step 2 of Reference Example44 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 26 mg (13%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.12-1.23 (2H,m), 1.33-1.40 (1H, m), 1.45-1.65 (5H, m), 1.68-1.84 (3H, m), 2.05-2.15(2H, m), 2.23-2.31 (2H, m), 3.13 (1H, t, J=10.3 Hz), 3.26 (1H, s),3.86-3.92 (1H, m), 3.93 (1H, dd, J=10.5, 2.3 Hz), 4.04 (2H, t, J=7.6Hz), 4.05-4.08 (1H, m), 4.32 (2H, t, J=7.8 Hz), 4.43 (1H, d, J=9.6 Hz),4.64 (1H, d, J=9.2 Hz), 6.74 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.2, 1.8Hz), 7.29-7.33 (1H, m), 7.49 (1H, t, J=4.8 Hz), 7.54 (1H, d, J=8.2 Hz),8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 660 (M+H)⁺.

Example 107

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[(3-hydroxyazetidin-1-yl)carbonyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (106 mg, 0.45 mmol) obtained in Step 2 of Reference Example45 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 60 mg (30%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.23 (2H,m), 1.33-1.40 (1H, m), 1.45-1.65 (4H, m), 1.67-1.83 (3H, m), 2.06-2.17(2H, m), 2.42-2.58 (1H, m), 3.12 (1H, t, J=10.3 Hz), 3.25 (1H, br s),3.83-3.91 (2H, m), 3.94 (1H, dd, J=10.5, 1.8 Hz), 4.01-4.07 (1H, m),4.14 (1H, dd, J=10.5, 4.1 Hz), 4.23-4.28 (1H, m), 4.44 (1H, d, J=8.7Hz), 4.50-4.56 (1H, m), 4.59-4.66 (2H, m), 6.72 (1H, d, J=1.8 Hz), 7.07(1H, dd, J=8.0, 2.1 Hz), 7.31 (1H, dd, J=8.0, 2.1 Hz), 7.50 (1H, t,J=4.8 Hz), 7.54-7.58 (2H, m), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 674 (M+H)⁺.

Example 108

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[3,2-c]pyridine]-1′,2″(1″H)-dione

The compound (3.94 g, 12.7 mmol) obtained in Reference Example 46 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 6.51 g (76%) of the title compound as a yellowamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.20 (3H, s), 0.54 (3H, s), 0.94-1.01 (3H,m), 1.29-1.42 (4H, m), 1.83-1.85 (1H, m), 2.22-2.26 (1H, m), 4.60 (1H,d, J=11.2 Hz), 4.84 (1H, d, J=3.2 Hz), 5.36 (1H, d, J=11.2 Hz), 6.74(2H, d, J=6.6 Hz), 6.87 (1H, s), 7.05-7.32 (10H, m), 7.79 (1H, t, J=6.7Hz), 8.22 (1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (1.38 g, 2.06 mmol) obtained in Step 1 above the comound(1.03 g, 6.17 mmol) obtained in Step 3 of Reference Example 3 were usedas starting materials and treated in the same way as in Step 1 ofExample 5 to give 0.95 g (55%) of the title compound as a pale yellowamorphous solid.

MS (ESI) m/z: 837 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (950 mg, 1.18 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 350 mg (46%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) 0.73 (3H, s), 0.97 (3H, s), 1.12-1.24 (2H, m),1.38-2.26 (14H, m), 3.01-3.04 (1H, m), 3.68-3.72 (1H, m), 4.57 (1H, d,J=9.3 Hz), 4.75 (1H, d, J=9.3 Hz), 6.79 (1H, s), 7.05 (1H, t, J=8.1 Hz),7.22-7.26 (1H, m), 7.55-7.61 (1H, m), 8.31 (1H, d, J=2.4 Hz), 8.85 (1H,s).

MS (ESI) m/z: 641 (M+H)⁺.

Example 109

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[(3R,6S)-6-(tetrahydro-2H-pyran-4-ylcarbamoyl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (95 mg, 0.36 mmol) obtained in Step 2 of Reference Example47 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 121 mg (57%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.25 (2H,m), 1.37 (1H, d, J=12.8 Hz), 1.47-1.77 (9H, m), 1.83-1.91 (2H, m),2.10-2.16 (1H, m), 2.28-2.34 (1H, m), 3.14 (1H, t, J=10.5 Hz), 3.29 (1H,br s), 3.43-3.51 (2H, m), 3.76 (1H, d, J=8.7 Hz), 3.86-4.02 (4H, m),4.12 (1H, dd, J=10.8, 3.4 Hz), 4.44 (1H, d, J=8.7 Hz), 4.64 (1H, d,J=9.2 Hz), 6.46 (1H, d, J=8.2 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07 (1H, dd,J=8.2, 1.8 Hz), 7.31 (1H, dd, J=8.0, 2.1 Hz), 7.49-7.52 (2H, m), 7.65(1H, s),8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 702 (M+H)⁺.

Example 110

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(morpholin-4-ylcarbonyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (112 mg, 0.45 mmol) obtained in Step 2 of Reference Example45 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 98 mg (47%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.25 (2H,m), 1.37 (1H, d, J=12.8 Hz), 1.45-1.65 (4H, m), 1.71-1.81 (2H, m),1.93-2.01 (2H, m), 2.16-2.23 (1H, m), 3.24 (1H, dd, J=11.0, 9.2 Hz),3.26 (1H, br s), 3.52-3.59 (2H, m), 3.63-3.73 (6H, m), 3.90-3.97 (1H,m), 4.03 (1H, dd, J=10.1, 3.7 Hz), 4.10 (1H, dd, J=8.0, 3.4 Hz), 4.45(1H, d, J=9.2 Hz), 4.64 (1H, d, J=8.7 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07(1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd, J=8.0, 2.1 Hz), 7.48-7.52 (2H,m), 7.62 (1H, d, J=8.7 Hz), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 688 (M+H)⁺.

Example 111

(3′R,4′S,5′R)-N-[(3R,6S)-6-(2-amino-2-oxoethyl)tetrahydro-2H-pyran-3-yl]6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (89 mg, 0.18 mmol) obtained in Step 1 of Example 17 and thecompound (0.15 mmol) obtained in Step 3 of Reference Example 49 wereused as starting materials and treated in the same way as in Step 2 ofExample 12 to give 31 mg (32%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.67 (3H, s), 0.94 (3H, s), 1.11-1.26 (2H,m), 1.36 (1H, dd, J=12.9, 2.0 Hz), 1.45-1.82 (8H, m), 2.07-2.10 (1H, dd,J=12.9, 2.0 Hz), 1.45-1.82 (8H, m), 2.07-2.10 (1H, m), 2.37-2.46 (2H,m), 3.14 (1H, t, J=10.6 Hz), 3.29 (1H, s), 3.65-3.71 (1H, m), 3.85-3.93(1H, m), 4.03-4.06 (1H, m), 4.44 (1H, d, J=9.2 Hz), 4.62 (1H, d, J=9.2Hz), 5.68 (1H, s), 6.29 (1H, s), 6.71 (1H, d, J=1.7 Hz), 7.05 (1H, dd,J=8.3, 2.0 Hz), 7.27-7.30 (2H, m), 7.49-7.53 (2H, m), 8.04 (1H, d, J=5.2Hz), 8.42 (1H, s).

MS (ESI) m/z: 654 (M+H)⁺.

Example 112

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)--4,4-dimethyl-N-[trans-3-(1,3,4-oxadiazol-2-yl)cyclobutyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (1.00 g, 2.03 mmol) obtained in Step 1 of Example 17 andthe compound (391 mg, 2.81 mmol) obtained in Step 3 of Reference Example50 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 753 mg (60%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.98 (3H, s), 1.12-1.24 (2H,m), 1.33-1.40 (1H, m), 1.52-1.69 (2H, m), 1.77-1.92 (3H, m), 2.60-2.80(4H, m), 3.76-3.82 (1H, m), 4.56 (1H, d, J=9.2 Hz), 4.57-4.65 (1H, m),4.70 (1H, d, J=9.2 Hz), 6.77 (1H, d, J=2.3 Hz), 7.07 (1H, dd, J=8.0, 2.1Hz), 7.47 (1H, dd, J=8.2, 2.3 Hz), 7.66 (1H, t, J=5.0 Hz), 7.90 (1H, s),8.06 (1H, d, J=5.0 Hz), 8.89 (1H, s).

MS (ESI) m/z: 613 (M+H)⁺.

Example 113

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-4-(dimethylcarbamoyl)cyclohexyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (29 mg, 0.06 mmol) obtained in Step 1 of Example 17 andtrans-4-amino-N,N-dimethylcyclohexanecarboxamide hydrochloride(WO2008/068171) (17 mg, 0.08 mmol) were used as starting materials andtreated in the same way as in Step 2 of Example 12 to give 36 mg (100%)of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.67 (3H, s), 0.95 (3H, s), 1.08-1.40 (6H,m), 1.42-1.55 (2H, m), 1.56-1.91 (6H, m), 2.00-2.13 (2H, m), 2.44-2.55(1H, m), 2.93 (3H, s), 3.06 (3H, s), 3.66-3.79 (1H, m), 4.44 (1H, d,J=8.7 Hz), 4.65 (1H, d, J=8.7 Hz), 6.71 (1H, d, J=1.8 Hz), 7.05 (1H, dd,J=8.3, 1.8 Hz), 7.31 (1H, dd, J=8.3, 2.3 Hz), 7.49-7.57 (2H, m), 8.03(1H, d, J=5.0 Hz), 8.09 (1H, s).

MS (ESI) m/z: 644 (M+H)⁺.

Example 114

(3′R,4′S,5′R)-(trans-3-carbamoylcyclobutyl)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (90 mg, 0.18 mmol) obtained in Step 1 of Example 17 and thecompound (21 mg, 0.18 mmol) obtained in Step 2 of Reference Example 51were used as starting materials and treated in the same way as in Step 2of Example 12 to give 66 mg (61%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.79 (8H,m), 2.24-2.41 (2H, m), 2.61-2.75 (2H, m), 2.99-3.09 (1H, m), 3.73 (1H,br s), 4.40-4.52 (2H, m), 4.65 (1H, d, J=9.17 Hz), 5.39 (2H, br s), 6.73(1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.25, 1.8 Hz), 7.30-7.35 (1H, m),7.41 (1H, s), 7.46-7.51 (1H, m), 7.85 (1H, d, J=7.8 Hz), 8.05 (1H, d,J=5.0 Hz).

MS (ESI) m/z: 588 (M+H)⁺.

Example 115

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-3-(dimethylcarbamoyl)cyclobutyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (90 mg, 0.18 mmol) obtained in Step 1 of Example 17 and thecompound (106 mg, 0.45 mmol) obtained in Step 2 of Reference Example 52were used as starting materials and treated in the same way as in Step 2of Example 12 to give 35 mg (31%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.95 (3H, s), 1.11-1.78 (8H,m), 2.19-2.38 (2H, m), 2.66-2.81 (2H, m), 2.90 (3H, s), 2.96 (3H, s),3.23-3.37 (2H, m), 4.25-4.36 (1H, m), 4.43 (1H, d, J=9.0 Hz), 4.66 (1H,d, J=9.0 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=7.8, 1.83 Hz),7.31-7.41 (2H, m), 7.47-7.51 (1H, m), 7.87 (1H, d, J=7.3 Hz), 8.04 (1H,d, J=5.0 Hz).

MS (ESI) m/z: 616 (M+H)⁺.

Example 116

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(diethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (73 mg, 0.36 mmol) obtained in Step 2 of Reference Example53 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 124 mg (61%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.12 (3H, t,J=7.1 Hz), 1.19 (3H, t, J=7.1 Hz), 1.20-1.23 (2H, m), 1.37 (1H, d,J=11.0 Hz), 1.46-1.67 (4H, m), 1.71-1.80 (2H, m), 1.86-1.93 (1H, m),1.97-2.06 (1H, m), 2.17-2.25 (1H, m), 3.23-3.51 (6H, m), 3.90-3.99 (1H,m), 4.05 (1H, dd, J=12.4, 4.6 Hz), 4.09 (1H, dd, J=9.4, 3.0 Hz),4.42-4.47 (1H, m), 4.65 (1H, d, J=9.2 Hz), 6.74 (1H, d, J=1.8 Hz), 7.07(1H, dd, J=8.0, 2.1 Hz), 7.32 (1H, dd, J=8.2, 2.3 Hz), 7.42 (1H, s),7.49 (1H, t, J=5.0 Hz), 7.62 (1H, d, J=8.2 Hz), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 674 (M+H)⁺.

Example 117

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(diethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 47 andthe compound (72 mg, 0.36 mmol) obtained in Step 2 of Reference Example53 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 129 mg (68%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.13 (3H, t,J=7.1 Hz), 1.18 (3H, t, J=7.1 Hz), 1.20-1.27 (2H, m), 1.38 (1H, d, J=9.2Hz), 1.46-1.66 (5H, m), 1.73-1.77 (1H, m), 1.86-1.92 (1H, m), 1.97-2.07(1H, m), 2.16-2.23 (1H, m), 3.22-3.48 (6H, m), 3.90-3.98 (1H, m), 4.04(1H, dd, J=10.8, 3.0 Hz), 4.09 (1H, dd, J=9.2, 3.2 Hz), 4.46 (1H, d,J=8.7 Hz), 4.67 (1H, d, J=9.2 Hz), 7.07 (1H, d, J=7.8 Hz), 7.45 (1H, t,J=5.0 Hz), 7.56 (1H, d, J=8.2 Hz), 7.63 (1H, dd, J=7.8, 2.3 Hz), 8.08(1H, d, J=5.5 Hz), 8.28 (1H, s).

MS (ESI) m/z: 675 (M+H)⁺.

Example 118

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-3-(ethylcarbamoyl)cyclobutyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (110 mg, 0.22 mmol) obtained in Step 1 of Example 17 andthe compound (41 mg, 0.29 mmol) obtained in Step 2 of Reference Example54 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 42 mg (31%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.96 (3H, s), 1.07-1.40 (7H,m), 1.51-1.91 (4H, m), 2.22-2.35 (2H, m), 2.47-2.61 (2H, m), 2.96-3.06(1H, m), 3.20 (2H, q, J=7.3 Hz), 4.41-4.56 (2H, m), 4.67 (1H, d, J=9.2Hz), 6.77 (1H, d, J=2.1 Hz), 7.06 (1H, dd, J=8.0, 2.1 Hz), 7.43-7.50(1H, m), 7.62-7.68 (1H, m), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 616 (M+H)⁺.

Example 119

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-3-(hydroxymethyl)cyclobutyl]-4,4-dimethyl-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (55 mg, 0.11 mmol) obtained in Step 1 of Example 17 and thecompound (11 mg, 0.11 mmol) obtained in Step 2 of Reference Example 55were used as starting materials and treated in the same way as in Step 2of Example 12 to give 55 mg (86%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.96 (3H, s), 1.08-1.42 (4H,m), 1.51-1.92 (4H, m), 2.05-2.49 (5H, m), 3.60 (2H, d, J=6.9 Hz),4.26-4.37 (1H, m), 4.53 (1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz), 6.77(1H, d, J=1.8 Hz), 7.06 (1H, dd, J=8.3, 1.83 Hz), 7.43-7.50 (1H, m),7.63-7.69 (1H, m), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 575 (M+H)⁺.

Example 120

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-4,4-dimethyl-2″-oxo-N-[trans-3-(tetrahydro-2H-pyran-4-ylcarbamoyl)cyclobutyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (95 mg, 0.19 mmol) obtained in Step 1 of Example 17 and thecompound (46 mg, 0.23 mmol) obtained in Step 2 of Reference Example 56were used as starting materials and treated in the same way as in Step 2of Example 12 to give 66 mg (51%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.69 (3H, s), 0.96 (3H, s), 1.09-1.91 (12H,m), 2.22-2.36 (2H, m), 2.47-2.61 (2H, m), 2.96-3.06 (1H, m), 3.41-3.52(2H, m), 3.81-3.97 (3H, m), 4.48 (1H, t, J=7.8 Hz), 4.54 (1H, d, J=9.2Hz), 4.67 (1H, d, J=9.2 Hz), 6.77 (1H, d, J=2.1 Hz), 7.06 (1H, dd,J=8.1, 2.1 Hz), 7.46 (1H, dd, J=8.1, 2.1 Hz), 7.62-7.68 (1H, m), 8.05(1H, d, J=5.0 Hz).

MS (ESI) m/z: 672 (M+H)⁺.

Example 121

[Step 1]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylicacid

The compound (1.95 g, 3.70 mmol) obtained in Step 2 of Reference Example57 was dissolved in ethanol (37 ml), 1N sodium hydroxide solution (7.4ml, 7.40 mmol) was added and the resulting mixture was stirred underheating at 50°0 C. for 1 hour. After cooling, the reaction mixture wasneutralized by addition of 1N hydrochloric acid (7.4 ml, 7.40 mmol) at0° C. and the solvent was evaporated under reduced pressure. The residueobtained was collected by filtration and dried to give 2.02 g (100% ofthe title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.92 (1H, d, J=14.2 Hz), 2.44 (1H, d, J=14.2Hz), 2.69 (1H, d, J=14.7 Hz), 2.91 (1H, d, J=14.7 Hz), 3.75 (1H, dd,J=15.1, 10.5 Hz), 3.87 (1H, dd, J=14.4, 9.4 Hz), 4.48 (1H, d, J=10.5Hz), 4.54 (1H, dd, J=15.8, 9.4 Hz), 4.66 (1H, dd, J=15.8, 9.4 Hz), 4.78(1H, d, J=10.5 Hz), 6.84 (1H, d, J=1.8 Hz), 7.07-7.12 (1H, m), 7.17 (1H,dd, J=8.2, 1.8 Hz), 7.27-7.33 (1H, m), 7.54-7.59 (1H, m), 7.67 (1H, dd,J=8.2, 2.3 Hz).

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorophenyl)-3,3-bis(fluoromethyl)-N-(trans-4-hydroxycyclohexyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 above andtrans-4-aminocyclohexanol (19.4 mg, 0.17 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Example 12 to give56 mg (67%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.25-1.42 (5H, m), 1.68 (1H, dd, J=13.7, 2.3Hz), 1.81-2.00 (5H, m), 2.07 (1H, d, J=12.8 Hz), 2.47 (1H, d, J=12.8Hz), 3.50-3.64 (2H, m), 3.76-3.93 (2H, m), 4.36 (1H, d, J=9.2 Hz), 4.44(1H, d, J=9.2 Hz), 4.58-4.76 (2H, m), 6.80 (1H, d, J=2.3 Hz), 7.00-7.05(1H, m), 7.10 (1H, dd, J=8.2, 1.8 Hz), 7.20-7.25 (1H, m), 7.50 (1H, dd,J=8.2, 2.3 Hz), 7.53-7.58 (1H, m).

MS (ESI) m/z: 596 (M+H)⁺.

Example 122

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 121 andthe compound (26.8 mg, 0.17 mmol) obtained in Step 3 of ReferenceExample 28 were used as starting materials and treated in the same wayas in Step 2 of Example 12 to give 72 mg (86%) of the title compound asa colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.52-1.71 (3H, m), 1.89 (1H, d, J=13.3 Hz),2.04-2.19 (3H, m), 2.48 (1H, d, J=13.3 Hz), 3.17 (1H, t, J=10.5 Hz),3.74-3.92 (4H, m), 3.94-4.00 (1H, m), 4.39 (1H, d, J=9.2 Hz), 4.46 (1H,d, J=9.2 Hz), 4.59-4.77 (2H, m), 6.81 (1H, d, J=1.8 Hz), 7.00-7.06 (1H,m), 7.11 (1H, dd, J=8.2, 1.8 Hz), 7.20-7.25 (1H, m), 7.50 (1H, dd,J=8.2, 2.3 H), 7.52-7.57 (1H, m).

MS (ESI) m/z: 625 (M+H)⁺.

Example 123

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorophenyl)-3,3-bis(fluoromethyl)-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (32 mg, 0.10 mmol) obtained in Step 3 of Reference Example3 were used as starting materials and treated in the same way as in Step2 of Example 12 to give 91 mg (87%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.37-1.58 (2H, m), 1.64-1.80 (3H, m), 1.90(1H, d, J=13.3 Hz), 1.99 (1H, d, J=12.4 Hz), 2.07-2.27 (4H, m), 2.49(1H, d, J=13.3 Hz), 2.96-3.04 (1H, m), 3.67-3.75 (1H, m), 3.79-3.91 (2H,m), 4.39 (1H, d, J=9.2 Hz), 4.47 (1H, d, J=9.2 Hz), 4.59-4.78 (2H, m),6.81 (1H, d, J=2.3 Hz), 7.01-7.06 (1H, m), 7.11 (1H, dd, J=8.2, 1.8 Hz),7.20-7.26 (1H, m), 7.51 (1H, dd, J=8.2, 2.3 Hz), 7.54-7.59 (1H, m), 8.85(1H, d, J=1.4 Hz).

MS (ESI) m/z: 648 (M+H)⁺.

Example 124

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluorophenyl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (33.1 mg, 0.19 mmol) obtained in Step 2 of ReferenceExample 41 were used as starting materials and treated in the same wayas in Step 2 of Example 12 to give 79 mg (75%) of the title compound asa colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.62-1.73 (2H, m), 1.77-1.92 (3H, m), 2.07(1H, d, J=13.3 Hz), 2.11-2.18 (1H, m), 2.49 (1H, d, J=13.3 Hz), 2.92(3H, s), 3.09 (3H, s), 3.23 (1H, t, J=10.1 Hz), 3.77-3.95 (4H, m), 4.22(1H, dd, J=9.8, 3.4 Hz), 4.38 (1H, d, J=9.2 Hz), 4.46 (1H, d, J=9.2 Hz),4.60-4.77 (2H, m), 6.81 (1H, d, J=1.8 Hz), 7.00-7.06 (1H, m), 7.11 (1H,dd, J=8.0, 2.1 Hz), 7.20-7.25 (1H, m), 7.51 (1H, dd, J=8.0, 2.1 Hz),7.52-7.57 (1H, m).

MS (ESI) m/z: 653 (M+H)⁺.

Example 125

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[ethyl(methyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (67 mg, 0.36 mmol) obtained in Step 2 of Reference Example58 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 122 mg (62%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.26 (5H,m), 1.37 (1H, d, J=11.0 Hz), 1.45-1.66 (4H, m), 1.70-1.78 (2H, m),1.88-2.02 (2H, m), 2.15-2.23 (1H, m), 2.91-3.05 (3H, m), 3.25 (1H, t,J=9.8 Hz), 3.28 (1H, br s), 3.34-3.51 (2H, m), 3.92-3.98 (1H, m),4.03-4.07 (1H, m), 4.08-4.13 (1H, m), 4.45 (1H, d, J=9.2 Hz), 4.65 (1H,d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 7.06 (1H, dd, J=8.2, 1.8 Hz), 7.31(1H, dd, J=8.0, 2.1 Hz), 7.50 (1H, t, J=5.0 Hz), 7.63 (1H, d, J=8.2 Hz),7.80 (1H, s), 8.04 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 660 (M+H)⁺.

Example 126

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[(2-fluoroethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (68 mg, 0.36 mmol) obtained in Step 2 of Reference Example59 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 97 mg (49%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.25 (2H,m), 1.32-1.83 (8H, m), 2.11-2.18 (1H, m), 2.27-2.33 (1H, m), 3.15 (1H,t, J=10.8 Hz), 3.28 (1H, br s), 3.49-3.69 (2H, m), 3.81 (1H, dd, J=11.0,2.3 Hz), 3.86-3.95 (1H, m), 4.07-4.15 (1H, m), 4.40-4.50 (2H, m),4.52-4.57 (1H, m), 4.64 (1H, d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 6.91(1H, t, J=6.0 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd, J=8.0,2.1 Hz), 7.48-7.53 (2H, m), 7.60 (1H, s), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 664 (M+H)⁺.

Example 127

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[(2-methoxyethyl)(methyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (78 mg, 0.36 mmol) obtained in Step 2 of Reference Example60 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 143 mg (69%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.10-1.25 (2H,m), 1.34-1.41 (1H, m), 1.45-1.67 (4H, m), 1.71-1.78 (2H, m), 1.88-2.03(2H, m), 2.16-2.23 (1H, m), 2.96-3.14 (3H, m), 3.18-3.28 (1H, m), 3.33(3H, s), 3.38-3.80 (5H, m), 3.91-3.97 (1H, m), 4.02-4.07 (1H, m),4.14-4.21 (1H, m), 4.45 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=8.7 Hz), 6.73(1H, d, J=2.3 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.32 (1H, dd, J=8.0,2.1 Hz), 7.50 (1H, t, J=5.0 Hz), 7.59-7.64 (2H, m), 8.04 (1H, d, J=5.0Hz).

MS (ESI) m/z: 690 (M+H)⁺.

Example 128

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[(2-methoxyethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (73 mg, 0.36 mmol) obtained in Step 2 of Reference Example61 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 121 mg (60%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.11-1.81 (10H,m), 2.10-2.16 (1H, m), 2.26-2.33 (1H, m), 3.14 (1H, t, J=10.5 Hz), 3.27(1H, br s), 3.36 (3H, s), 3.40-3.53 (4H, m), 3.79 (1H, dd, J=11.2, 2.5Hz), 3.86-3.96 (1H, m), 4.12 (1H, m), 4.44 (1H, d, J=8.7 Hz), 4.64 (1H,d, J=9.2 Hz), 6.73 (1H, d, J=1.8 Hz), 6.84-6.88 (1H, m), 7.07 (1H, dd,J=8.0, 2.1 Hz), 7.31 (1H, dd, J=8.2, 2.3 Hz), 7.48-7.52 (2H, m), 7.61(1H, s), 8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 676 (M+H)⁺.

Example 129

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)-5-methoxytetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (100 mg, 0.20 mmol) obtained in Step 1 of Example 121 andthe compound (65 mg, 0.40 mmol) obtained in Step 5 of Reference Example27 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 95 mg (74%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.41-1.50 (1H, m), 1.65-1.86 (2H, m),2.03-2.17 (2H, m), 2.36-2.52 (2H, m), 3.14-3.22 (1H, m), 3.41 (3H, s),3.45-3.55 (2H, m), 3.66-4.32 (7H, m), 4.40 (2H, br s), 4.54-4.82 (2H,m), 6.79 (1H, d, J=2.3 Hz), 6.93-6.99 (1H, m), 7.11-7.23 (3H, m),7.36-7.48 (3H, m).

MS (ESI) m/z: 642 MS (ESI) m/z:

Example 130

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{trans-4-[5-(hydroxymethyl-1,3,4-oxadiazol-2-yl]cyclohexyl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (64 mg, 0.12 mmol) obtained in Step 1 of Example 17 and thecompound (27 mg, 0.13 mmol) obtained in Step 3 of Reference Example 62were used as starting materials and treated in the same way as in Step 2of Example 12 to give 55 mg (67%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.96 (3H, s), 1.11-1.28 (2H,m), 1.31-1.43 (3H, m), 1.45-1.81 (7H, m), 2.10-2.28 (4H, m), 2.72-2.86(1H, m), 2.87-2.97 (1H, m), 3.18-3.43 (1H, m), 3.72-3.82 (1H, m), 4.45(1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz), 4.83 (2H, s), 6.74 (1H, d,J=2.3 Hz), 7.07 (1H, dd, J=8.3, 2.0 Hz), 7.30-7.34 (1H, m), 7.49-7.53(1H, m), 7.57-7.65 (2H, m), 8.05 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 671 (M+H)⁺.

Example 131

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-n-{trans-4-[5-(hydroxymethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (60 mg, 0.12 mmol) obtained in Step 1 of Example 121 andthe compound (26 mg, 0.13 mmol) obtained in Step 3 of Reference Example62 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 46 mg (57%) of the title compound as acolorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 1.37-1.47 (1H, m), 1.47-1.57 (1H, m),1.63-1.78 (3H, m), 1.86-1.93 (1H, m), 1.94-2.02 (1H, m), 2.06-2.13 (2H,m), 2.14-2.27 (2H, m), 2.45-2.53 (1H, m), 2.97 (1H, tt, J=12.0, 3.7 Hz),3.71 (1H, tt, J=11.5, 4.0 Hz), 3.77-3.93 (2H, m), 4.39 (1H, d, J=9.2Hz), 4.47 (1H, d, J=9.2 hz0, 4.61-4.77 (4H, m), 6.81 (1H, d, J=1.7 Hz),7.00-7.06 (1H, m), 7.11 (1H, dd, J=8.0, 1.7 Hz), 7.20-7.25 (1H, m),7.48-7.53 (1H, m), 7.54-7.59 (1H, m).

MS (ESI) m/z: 678 (M+H)⁺.

Example 132

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-(trans-4-{5-[(1R)-1-hydroxyethyl]-1,3,4-oxadiazol-2-yl}cyclohexyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (74 mg, 0.14 mmol) obtained in Step 1 of Example 17 and thecompound (33 mg, 0.16 mmol) obtained in Step 3 of Reference Example 63were used as starting materials and treated in the same way as in Step 2of Example 12 to give 71 mg (73%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.96 (3H, s), 1.12-1.27 (2H,m), 1.29-1.43 (3H, m), 1.44-1.55 (2H, m), 1.56-1.81 (8H, m), 2.09-2.28(4H, m), 2.86-2.99 (2H, m), 3.20-3.40 (1H, m), 3.71-3.82 (1H, m), 4.45(1H, d, J=9.2 Hz), 4.66 (1H, d, J=9.2 Hz), 5.01-5.11 (1H, m), 6.74 (1H,d, J=1.72 Hz), 7.05-7.08 (1H, m), 7.30-7.34 (1H, m), 7.50-7.53 (1H, m),7.60 (1H, d, J=8.6 Hz), 7.79 (1H, s), 8.04 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 685 (M+H)⁺.

Example 133

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-(methoxymethyl)tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (70 mg, 0.36 mmol) obtained in Step 2 of Reference Example64 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 156 mg (84%) of the title compound as apale orange solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.67 (3H, s), 0.95 (3H, s), 1.08-1.65 (8H,m), 1.68-1.77 (3H, m), 2.08-2.14 (1H, m), 3.13 (1H, t, J=10.8 Hz), 3.27(1H, br s), 3.33-3.45 (5H, m), 3.48-3.55 (1H, m), 3.87-3.96 (1H, m),4.04-4.10 (1H, m), 4.43 (1H, d, J=9.2 Hz), 4.65 (1H, d, J=8.7 Hz), 7.31(1H, dd, J=1.8 Hz), 7.06 (1, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd, J=8.0,2.1 Hz), 7.46-7.51 (3H, m), 8.04 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 134

(3′R,4′S,5′R)-N-(trans-3-carbamoylcyclobutyl)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (75 mg, 0.15 mmol) obtained in Step 1 of Example 121 andthe compound (19 mg, 0.17 mmol) obtained in Step 2 of Reference Example51 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 66 mg (74%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.67 1H, d, J=13.3 Hz), 1.89 (1H, d, J=13.3Hz), 2.08 (1H, d, J=11.5 Hz), 2.19-2.37 (2H, m), 2.44-2.63 (3H, m),3.00-3.09 (1H, m), 3.78-3.90 (2H, m), 4.34-4.50 (4H, m), 4.59-4.81 (2H,m), 6.81 (1H, d, J=2.3 Hz), 7.00-7.13 (1H, m), 7.19-7.26 (1H, m),7.48-7.59 (2H, m).

MS (ESI) m/z: 595 (M+H)⁺.

Example 135

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (200 mg, 0.30 mmol) obtained in Step 1 of Example 38 andthe compound (159 mg, 1.00 mmol) obtained in Step 2 of Reference Example5 were used as starting materials and treated in the same way as in Step1 of Example 20 to give 118 mg (47%) of the title compound as a brownamorphous solid.

MS (ESI) m/z: 836 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophen6l)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (118 mg, 0.14 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 40 mg (44%) of the title compound as a colorless solid[fractionation conditions: CHIRALPAK IC, n-hexane:ethanol=7:3 (v/v)].

¹H-NMR (400 MHz, CD₃OD) δ: 1.14 (3H, s), 1.16 (3H, s), 1.44-1.60 (2H,m), 1.68 (1H, d, J=13.7 Hz), 1.83 (1H, d, J=10.5 Hz), 1.89 (1H, d,J=12.8 Hz), 2.02-2.12 (2H, m), 2.48 (1H, d, J=12.8 Hz), 3.05-3.10 (2H,m), 3.71-3.95 (4H, m), 4.38 (1H, d, J=9.2 Hz), 4.45 (1H, d, J=9.2 Hz),4.59-4.76 (2H, m), 6.81 (1H, d, J=1.8 Hz), 7.03 (1H, t, J=8.5 Hz), 7.11(1H, dd, J=8.2, 1.8 Hz), 7.21-7.25 (1H, m), 7.50 (1H, dd, J=8.2, 2.3Hz), 7.52-7.56 (1H, m).

MS (ESI) m/z: 640 (M+H)⁺.

Example 136

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (33 mg, 0.19 mmol) obtained in Step 6 of Reference Example18 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 79 mg (75%) of the title compound as acolorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.66-1.76 (2H, m), 1.85 (1H, dd, J=13.3, 2.7Hz), 2.04-2.35 (4H, m), 2.40 (1H, d, J=13.3 Hz), 3.33-3.40 (1H, m),3.78-4.13 (5H, m), 4.36-4.44 (2H, m), 4.56-4.82 (3H, m), 6.75 (1H, d,J=1.8 Hz), 6.86-6.91 (1H, m), 7.11-7.16 (2H, m), 7.38 (1H, dd, J=8.1,2.2 Hz), 7.41-7.45 (1H, m), 7.66 (1H, d, J=8.1 Hz), 7.85 (1H, s), 8.43(1H, s).

MS (ESI) m/z: 650 (M+H)⁺.

Example 137

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-N-[(3R,6S)-6-tetrahydro-2H-pyran-4-ylcarbamoyl)tetrahydro-2H-pyran-3-yl]-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 121 andthe compound (45 mg, 0.17 mmol) obtained in Step 2 of Reference Example47 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 79 mg (79%) of the title compound as acolorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.44-1.71 (5H, m), 1.81-1.91 (3H, m), 2.03(1H, d, J=13.3 Hz), 2.14-2.21 (1H, m), 2.27-2.33 (1H, m), 2.39 (1H, d,J=12.8 Hz), 3.10 (1H, t, J=10.8 Hz), 3.43-3.51 (2H, m), 3.74-4.03 (8H,m), 4.09-4.15 (1H, m), 4.33-4.41 (2H, m), 4.55-4.76 (2H, m), 6.46 (1H,d, J=8.2 Hz), 6.77 (1H, d, J=1.8 Hz), 6.87-6.92 (1H, m), 7.11-7.17 (2H,m), 7.37 (1H, dd, J=8.0, 2.1 Hz), 7.41-7.47 (2H, m), 7.92 (1H, s).

MS (ESI) m/z: 709 (M+H)⁺.

Example 138

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{(3R,6S)-6-[(2-fluoroethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 121 andthe compound (32 mg, 0.17 mmol) obtained in Step 2 of Reference Example59 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 64 mg (68%) of the title compound as acolorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.47-1.71 (3H, m), 1.84 (1H, dd, J=13.7, 2.8Hz), 2.01-2.07 (1H, m), 2.16-2.22 (1H, m), 2.27-2.33 (1H, m), 2.39 (1H,d, J=12.8 Hz), 3.12 (1H, t, J=10.8 Hz), 3.47-3.70 (2H, m), 3.78-4.02(5H, m), 4.10-4.16 (1H, m), 4.35-4.40 (2H, m), 4.44 (1H, t, J=4.8 Hz),4.54-4.77 (3H, m), 6.78 (1H, d, J=1.8 Hz), 6.89 (1H, t, J=6.0 Hz), 6.93(1H, t, J=8.0 Hz), 7.12-7.18 (2H, m), 7.37 (1H, dd, J=8.0, 2.2 Hz),7.41-7.47 (3H, m).

MS (ESI) m/z: 671 (M+H)⁺.

Example 139

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[(2-methoxyethyl)(methyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 121 andthe compound (36 mg, 0.17 mmol) obtained in Step 2 of Reference Example60 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 49 mg (52%) of the title compound as acolorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.39-1.61 (3H, m), 1.70 (1H, dd, J=13.4, 2.4Hz), 1.81-2.11 (4H, m), 2.21-2.30 (1H, m), 2.41 (1H, d, J=12.7 Hz),2.91-3.17 (2H, m), 3.23 (1H, t, J=9.8 Hz), 3.32 (3H, s), 3.49-3.63 (3H,br s), 3.78-4.23 (6H, m), 4.38 (2H, s), 4.54-4.75 (2H, m), 6.75 (1H, d,J=1.8 Hz), 6.88-6.93 (1H, m), 7.10-7.16 (2H, m), 7.25-7.30 (1H, m),7.35-7.47 (3H, m).

MS (ESI) m/z: 697 (M+H)⁺.

Example 140

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(2-chloropyrimidin-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (3.80 g, 13.0 mmol) obtained in Reference Example 65 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 4.48 g (53%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CD₃OD) δ: 0.33 (3H, s), 0.59 (3H, s), 0.93-1.55 (6H,m), 2.07-2.16 (1H, m), 2.23-2.32 (1H, m), 4.57 (1H, d, J=9.7 Hz), 4.93(1H, d, J=3.4 Hz), 5.60 (1H, d, J=9.7 Hz), 6.73-6.76 (1H, m), 6.80-6.93(4H, m), 6.97-7.10 (3H, m), 7.10-7.37 (7H, m), 8.43 (1H, d, J=5.2 Hz).

MS (FAB) m/z: 653 (M+H)⁺.

[Step 2]

(4′R,5′R)-6″-chloro-4′-(2-chloropyrimidin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxlicacid

The compound (952 mg, 1.46 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 12to give 314 mg (45%) of the title compound as a brown solid.

MS (FAB) m/z: 475 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloropyrimidin-4-yl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (120 mg, 0.25 mmol) obtained in Step 2 above and thecompound (51 mg, 0.30 mmol) obtained in Step 2 of Reference Example 41were used as starting materials and treated in the same way as in Step 2of Example 12 to give 62 mg (68%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.66 (3H, s), 0.93 (3H, s), 1.13-1.73 (9H,m), 1.90-2.08 (2H, m), 2.17-2.25 (1H, m), 2.97 (3H, s), 3.11 (3H, s),3.26-3.35 (1H, m), 3.98-4.08 (1H, m), 4.11-4.17 (2H, m), 4.33-4.42 (2H,m), 6.94 (1H, d, J=1.7 Hz), 7.01 (1H, dd, J=8.1, 2.0 Hz), 7.13 (1H, d,J=8.1 Hz), 7.67 (1H, d, J=5.4 Hz), 7.72 (1H, d, J=8.3 Hz), 7.85 (1H, s),8.39 (1H, d, J=5.1 Hz).

MS (ESI) m/z: 629 (M+H)⁺.

Example 141

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N[(3R,6S)-6-(ethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 121 andthe compound (62 mg, 0.36 mmol) obtained in Step 2 of Reference Example34 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 94 mg (48%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.15 (3H, t, J=7.3 Hz), 1.48-1.60 (2H, m),1.68 (1H, dd, J=13.5, 2.5 Hz), 1.83-1.86 (1H, m), 2.03 (1H, d, J=11.4Hz), 2.13-2.20 (1H, m), 2.25-2.35 (1H, m), 2.39 (1H, d, J=13.3 Hz), 3.10(1H, t, J=10.8 Hz), 3.24-3.36 (2H, m), 3.71-3.98 (5H, m), 4.12 (1H, ddd,J=10.9, 4.8, 1.3 Hz), 4.37 (2H, s), 4.54-4.75 (2H, m), 6.51 (1H, t,J=5.7 Hz), 6.77 (1H, d, J=1.8 Hz), 6.92 (1H, t, J=8.0 Hz), 7.10-7.18(2H, m), 7.37 (1H, dd, J=8.0, 2.1 Hz), 7.40-7.47 (2H, m), 7.68 (1H, s).

MS (ESI) m/z: 653 (M+H)⁺.

Example 142

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[(2-methoxyethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 121 andthe compound (73 mg, 0.36 mmol) obtained in Step 2 of Reference Example61 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 116 mg (57%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.47-1.63 (2H, m), 1.68 (1H, dd, J=13.3, 2.7Hz), 1.84 (1H, dd, J=13.3, 2.7 Hz), 2.03 (1H, d, J=12.4 Hz), 2.13-2.21(1H, m), 2.27-2.31 (1H, m), 2.38 (1H, d, J=12.8 Hz), 3.10 (1H, t, J=10.8Hz), 3.36 (3H, s), 3.44-3.47 (4H, m), 3.77-4.01 (5H, m), 4.12 (1H, ddd,J=10.9, 4.3, 1.4 Hz), 4.37 (2H, s), 4.54-4.75 (2H, m), 6.77 (1H, d,J=1.8 Hz), 6.82-6.87 (1H, m), 6.92 (1H, t, J=8.0 Hz), 7.12-7.17 (2H, m),7.37 (1H, dd, J=8.0, 2.1 Hz), 7.41-7.46 (2H, m), 7.60 (1H, s).

MS (ESI) m/z: 683 (M+H)⁺.

Example 143

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(methoxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.30 mmol) obtained in Step 1 of Example 121 andthe compound (70 mg, 0.36 mmol) obtained in Step 2 of Reference Example64 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 121 mg (64%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.40-1.55 (2H, m), 1.63-1.76 (2H, m), 1.83(1H, dd, J=13.5, 3.0 Hz), 2.04 (1H, dd, J=12.4, 2.7 Hz), 2.12-2.19 (1H,m), 2.37 (1H, d, J=12.4 Hz), 3.09 (1H, t, J=10.8 Hz), 3.34-3.45 (5H, m),3.48-3.55 (1H, m), 3.78-4.02 (4H, m), 4.07 (1H, ddd, J=10.6, 4.3, 1.5Hz), 4.38 (2H, s), 4.55-4.76 (2H, m), 6.76 (1H, d, J=1.8 Hz), 6.88-6.92(1H, m), 7.11-7.16 (2H, m), 7.35-7.40 (2H, m), 7.41-7.45 (1H, m), 7.53(1H, s).

MS (ESI) m/z: 626 (M+H)⁺.

Example 144

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-imidazo[1,2-a]pyridin-3-yl-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (550 mg, 1.86 mmol) obtained in Reference Example 66 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 344 mg (28%) of the title compound as a yellowamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.26 (3H, s), 0.54 (3H, s), 0.96-1.00 (2H,m), 1.07-1.10 (2H, m), 1.31-1.39 (4H, m), 1.69-1.71 (4H, m), 1.96-1.99(1H, m), 2.25j-2.28 (1H, m), 4.64 (1H, d, J=10.7 Hz), 4.91 (1H, d, J=2.9Hz), 5.45 (1H, d, J=10.5 Hz), 6.31 (1H, d, J=8.3 Hz), 6.46 (1H, dd,J=8.3, 1.7 Hz), 6.52 (1H, t, J=6.8 Hz), 6.78 (1H, d, J=1.7 Hz),6.82-6.84 (2H, m), 7.01-7.28 (16H, m), 7.52 (1H, d, J=9.0 Hz), 8.02-8.05(1H, m), 8.21 (1H, br s).

MS (ESI) m/z: 658 (M+H)⁺.

[Step 2]

(4′4,5′R)-6″-chloro-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4′-(imidazo[1,2-1]pyridin-3-yl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]92″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (344 mg, 0.52 mmol) obtained in Step 1 above and thecompound (265 mg, 1.57 mmol) obtained in Step 3 of Reference Example 3were used as starting materials and treated in the same way as in Step 1of Example 5 to give 239 mg (55%) of the title compound as a pale yellowamorphous solid.

MS (ESI) m/z: 824 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-imidazo[1,2-a]pyridin-3-yl-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (239 mg, 0.29 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 81 mg (44%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.70 (3H, s), 0.95 (3H, s), 1.13-1.22 (2H,m), 1.27-1.88 (10H, m), 1.94-2.02 (2H, m), 2.06-2.27 (3H, m), 3.01 (1H,tt, J=12.1, 4.1 Hz), 3.69 (1H, tt, J=12.1, 4.1 Hz), 4.49 (1H, d, J=8.7Hz), 6.68 (1H, d, J=1.8 Hz), 6.72 (1H, td, J=6.9, 0.9 Hz), 6.98 (1H, dd,J=8.2, 1.8 Hz), 7.13 (1H, td, J=8.0, 1.4 Hz), 7.36 (1H, d, J=9.2 Hz),7.62 (1H, s), 7.66 (1H, d, J=7.8 Hz), 7.89 (1Hz, s), 8.23 (1H, d, J=7.3Hz), 8.84 (1H, s).

MS (ESI) m/z: 628 (M+H)⁺.

Example 145

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[trans-3-(dimethylcarbamoyl)cyclobutyl]-3,3-bis(fluoromethyl-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (80 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (39 mg, 0.16 mmol) obtained in Step 2 of Reference Example52 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 72 mg (72%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.69 (1H, dd, J=13.5, 3.0 Hz), 1.86 (1H, dd,J=13.5, 3.0 Hz), 2.10 (1H, dd, J=12.8, 2.8 Hz), 2.21-2.31 (2H, m), 2.40(1H, d, J=12.8 Hz), 2.70-2.81 (2H, m), 2.90 (3H, s), 2.96 (3H, s), 2.97(1H, dd, J=6.2, 1.6 Hz), 3.28-3.36 (1H, m), 3.79-4.00 (2H, m), 4.30-4.38(1H, m), 4.39 (2H, s), 4.59-4.82 (2H, m), 6.78 (1H, d, J=1.8 Hz), 6.93(1H, t, J=8.0 Hz), 7.12-7.17 (2H, m), 7.40 (1H, dd, J=7.8, 2.3 Hz),7.43-7.48 (1H, m), 7.50 (2H, s), 7.77 (1H, d, J=7.3 Hz),

MS (ESI) m/z: 623 (M+H)⁺.

Example 146 (Isomer A) and 147 (Isomer B)

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (300 mg, 0.6 mmol) obtained in Step 1 of Example 121 andthe compound (131 mg, 0.72 mmol) obtained in Step 3 of Reference Example30 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give a mixture of diastereomers. The mixture ofdiastereomers obtained was resolved and purified by chiral column liquidchromatography [fractionation conditions: CHIRALPAK IC,n-hexane:ethanol=3:2 (v/v)] to separately give 161 mg (42%: isomer A)and 86 mg (23%: isomer B) of the title compound as colorless solids.

Isomer A:

¹H-NMR (400 MHz, CDCl₃) δ: 1.15 (3H, d, J=6.4 Hz), 1.44 (1H, ddd,J=24.5, 12.1, 4.1 Hz), 1.61-1.75 (3H, m), 1.84 (1H, dd, J=13.3, 2.7 Hz),2.01-2.09 (2H, m), 2.13-2.22 (1H, m), 2.38 (1H, d, J=13.3 Hz), 3.09 (1H,t, J=10.5 Hz), 3.23 (1H, dt, J=11.3, 2.9 Hz), 3.79-3.99 (5H, m), 4.07(1H, dq, J=10.5, 2.3 Hz), 4.38 (2H, s), 4.55-4.76 (2H, m), 6.92 (1H, t,J=8.0 Hz), 7.12-7.16 (2H, m), 7.36-7.40 (2H, m), 7.43-7.45 (1H, m), 7.52(1H, s).

MS (ESI) m/z: 626 (M+H)⁺.

Isomer B:

¹H-NMR (400 MHz, CDCl₃) δ: 1.16 (3H, d, J=6.4 Hz), 1.39-1.50 (2H, m),1.67 (1H, dd, J=13.3, 2.7 Hz), 1.72-1.78 (1H, m), 1.83 (1H, dd, J=13.7,3.2 Hz), 2.04 (1H, d, J=12.8 Hz), 2.12-2.18 (1H, m), 2.38 (1H, d, J=12.4Hz), 2.64 (1H, s), 3.03-3.09 (2H, m), 3.58-3.67 (1H, m), 3.83 (1H, dd,J=23.8, 9.2 Hz), 3.88-4.03 (3H, m), 4.08 (1H, ddd, J=11.0, 4.2, 1.4 Hz),4.38 (2H, s), 4.55-4.76 (2H, m), 6.77 (1H, d, J=1.8 Hz), 6.91 (1H, t,J=8.0 Hz), 7.12-7.17 (2H, m), 7.35-7.41 (2H, m), 7.44 (1H, t, J=6.6 Hz),7.50 (1H, s).

MS (ESI) m/z: 626 (M+H)⁺.

Example 148

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-[trans-4-(dimethylcarbamoyl)cyclohexyl]-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (70 mg, 0.14 mmol) obtained in Step 1 of Example 121 andtrans-4-amino-N,N-dimethylcyclohexanecarboxamide hydrochloride(WO2008/068171) (29 mg, 0.17 mmol) were used as starting materials andtreated in the same way as in Step 2 of Example 12 to give 62 mg (68%)of the title compound as a colorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.15-1.34 (2H, m), 1.61-1.87 (6H, m),2.01-2.15 (3H, m), 2.36 (1H, d, J=12.9 Hz), 2.45-2.54 (1H, m), 2.93 (3H,s), 3.06 (3H, s), 3.70-4.03 (4H, m), 4.34-4.40 (2H, m), 4.56-4.79 (2H,m), 6.72 (1H, d, J=2.0 Hz), 6.85-6.91 (1H, m), 7.08-7.14 (2H, m), 7.36(1H, dd, J=8.2, 2.1 Hz), 7.41-7.47 (2H, m), 8.19 (1H, s).

MS (ESI) m/z: 651 (M+H)⁺.

Example 149

(3′R,4′S,5′R)-N-[(3R,6S)-6-(2-amino-2-oxoethyl)tetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (60 mg, 0.12 mmol) obtained in Step 1 of Example 121 andthe compound (28 mg, 0.14 mmol) obtained in Step 3 of Reference Example49 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 29 mg (38%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.46-1.57 (2H, m), 1.66-1.69 (1H, m),1.79-1.85 (2H, m), 2.02-2.05 (1H, m), 2.13-2.15 (1H, m), 2.37-2.46 (3H,m), 3.10 (1H, t, J=10.9 Hz), 3.66-3.70 (1H, m), 3.80-4.08 (5H, m),4.35-4.40 (2H, m), 4.56-4.75 (2H, m), 5.35 (1H, s), 6.21 (1H, s), 6.78(1H, d, J=1.7 Hz), 6.94 (1H, t, J=7.7 Hz), 7.12-7.17 (2H, m), 7.36-7.40(2H, m), 7.46-7.43 (1H, m), 7.52 (1H, s).

MS (ESI) m/z: 639 (M+H)⁺.

Example 150

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-{(3R,6S)-6-[2-methylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (99 mg, 0.20 mmol) obtained in Step 1 of Example 17 and thecompound (180 mg, 0.22 mmol) obtained in Step 3 of Reference Example 67were used as starting materials and treated in the same way as in Step 2of Example 12 to give 35 mg (27%) of the title compound as a solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.59 (3H, s), 0.90-0.99 (4H, m), 1.10-1.13(1H, m), 1.19-1.33 (2H, m), 1.40-1.43 (1H, m), 1.48-1.60 (3H, m),1.70-1.76 (3H, m), 1.82-1.86 (1H, m), 2.14 (1H, dd, J=14.3, 5.2 Hz),2.23 (1H, dd, J=14.0, 7.7 Hz), 2.54 (3H, d, J=4.6 Hz), 3.08 (1H, t,J=10.3 Hz), 3.52-3.50 (1H, m), 3.58-3.67 (3H, m), 4.45 (1H, t, J=9.5Hz), 4.56 (1H, d, J=9.2 Hz), 6.71 (1H, d, J=2.3 Hz), 7.06 (1H, dd,J=8.3, 2.0 Hz), 7.50 (1H, dd, J=8.3, 2.0 Hz), 7.63 (1H, t, J=4.9 Hz),7.79-7.74 (2H, m), 8.17 (1H, d, J=5.2 Hz), 10.62 (1H, s),

MS (ESI) m/z: 646 (M+H)⁺.

Example 151

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[2-(methylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (81 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (197 mg, 0.24 mmol) obtained in Step 3 of Reference Example67 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 28 mg (26%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.46-1.52 (2H, m), 1.66-1.69 (1H, m),1.75-1.85 (2H, m), 2.01-2.04 (1H, m), 2.11-2.13 (1H, m), 2.36-2.39 (3H,m), 2.79 (3H, d, J=4.6 Hz), 3.09 (1H, t, J=10.9 Hz), 3.67-3.69 (1H, m),3.80-4.05 (5H, m), 4.35-4.39 (2H, m), 4.56-4.74 (2H, m), 6.15-6.16 (1H,m), 6.78 (1H, s), 6.93 (1H, t, J=7.7 Hz), 7.16-7.12 (2H, m), 7.36-7.46(3H, m), 7.56 (1H, s).

MS (ESI) m/z: 653 (M+H)⁺.

Example 152

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[2-(methylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl})-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (98 mg, 0.20 mmol) obtained in Step 1 of Example 17 and thecompound (53 mg, 0.24 mmol) obtained in Step 2 of Reference Example 68were used as starting materials and treated in the same way as in Step 2of Example 12 to give 82 mg (62%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.67 (3H, s), 0.95 (3H, s), 1.11-1.26 (2H,m), 1.34-1.62 (5H, m), 1.71-1.77 (2H, m), 1.91-1.93 (1H, m), 2.07-2.09(1H, m), 2.34 (1H, dd, J=15.2, 5.4 Hz), 2.67 (1H, dd, J=15.2, 6.6 Hz),2.95 (3H, s), 3.01 (3H, s), 3.13 (1H, t, J=10.6 Hz), 3.27 (1H, br s),3.82-4.00 (3H, m), 4.43 (1H, d, J=9.2 Hz), 4.64 (1H, d, J=9.2 Hz), 6.73(1H, s), 7.06 (1H, d, J=6.9 Hz), 7.31 (1H, d, J=8.0 Hz), 7.51-7.44 (3H,m), 8.05 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 660 (M+H)⁺.

Example 153

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{(3R,6S)-6-[2-(methylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (81 mg, 0.16 mmol) obtained in Step 1 of Example 121 andthe compound (53 mg, 0.24 mmol) obtained in Step 2 of Reference Example68 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 58 mg (54%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.44-1.50 (2H, m), 1.66-1.68 (1H, m),1.82-1.92 (2H, m), 2.01-2.12 (2H, m), 2.31 -2.39 (2H, m), 2.67 (1H, dd,J=15.5, 6.9 Hz), 2.95 (3H, s), 3.01 (3H, s), 3.09 (1H, t, J=10.6 Hz),3.83-3.99 (6H, m), 4.37 (2H, s), 4.57-4.74 (2H, m), 6.77 (1H, s), 6.92(1H, t, J=7.7 Hz), 7.12-7.15 (2H, m), 7.36-7.37 (2H, m), 7.43-7.46 (1H,m), 7.57-7.54 (1H, m).

MS (ESI) m/z: 667 (M+H)⁺.

Example 154

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[trans-3-(hyddroxypropan-2-yl)cyclobutyl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (45 mg, 0.09 mmol) obtained in Step 1 of Example 17 and thecompound (13 mg, 0.10 mmol) obtained in Step 2 of Reference Example 69were used as starting materials and treated in the same way as in Step 2of Example 12 to give 38 mg (69%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.05-2.10 (16H,m), 2.31-2.46 (3H, m), 3.34 (1H, br s), 4.22-4.34 (1H, m), 4.43 (1H, d,J=8.90 Hz), 4.66 (1H, d, J=8.90 Hz), 6.72 (1H, d, J=1.83 Hz), 7.07 (1H,dd, J=8.25, 1.83 Hz), 7.27-7.35 (2H, m), 7.47-7.53 (1H, m), 7.82-7.89(1H, m), 8.05 (1H, d, J=5.04 Hz).

MS (ESI) m/z: 603 (M+H)⁺.

Example 155

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[trans-4-(1,3,4-thiadiazol-2-yl)cyclohexyl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (84 mg, 0.16 mmol) obtained in Step 1 of Example 17 and thecompound (45 mg, 0.18 mmol) obtained in Step 3 of Reference Example 70were used as starting materials and treated in the same way as in Step 2of Example 12 to give 76 mg (72%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.96 (3H, s), 1.12-1.26 (2H,m), 1.34-1.55 (5H, m), 1.60-1.81 (5H, m), 2.10-2.20 (2H, m), 2.25-2.35(2H, m), 3.18-3.43 (2H, m), 3.76-3.87 (1H, m), 4.46 (1H, d, J=8.88 Hz),4.66 (1H, d, J=8.88 Hz), 6.73 (1H, d, J=1.72 Hz), 7.06 (1H, dd, J=8.31,2.00 Hz), 7.29-7.34 (1H, m), 7.50-7.55 (1H, m), 7.63 (1H, d, J=8.59 Hz),7.98 (1H, s), 8.04 (1H, d, J=5.15 Hz), 9.05 (1H, s).

MS (ESI) m/z: 657 (M+H)⁺.

Example 156

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(5-methyl-1,3,4-oxadiazol-2-yl)-tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (204 mg, 0.39 mmol) obtained in Step 1 of Example 17 andthe compound (79 mg, 0.43 mmol) obtained in Step 2 of Reference Example71 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 165 mg (64%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.11-1.27 (2H,m), 1.35-1.43 (1H, m), 1.44-1.55 (2H, m), 1.60-1.83 (4H, m), 2.07-2.28(3H, m), 2.55 (3H, s), 3.14-3.43 (2H, m), 3.98-4.07 (1H, m), 4.08-4.15(1H, m), 4.47 (1H, d, J=9.16 Hz), 4.65 (1H, d, J=9.16 Hz), 4.69 (1H, dd,J=9.74, 2.86 Hz), 6.73 (1H, d, J=1.72 Hz), 7.06 (1H, dd, J=8.02, 1.72Hz), 7.29-7.33 (1H, m), 7.47-7.53 (1H, m), 7.69 (1H, d, J=8.59 Hz), 8.04(1H, d, J=5.15 Hz), 8.08 (1H, s).

MS (ESI) m/z: 657 (M+H)⁺.

Example 157

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (267 mg, 1.55 mmol) obtained in Step 2 of Reference Example5 and triethylamine (0.23 ml, 2.06 mmol) were added to a tetrahydrofuransolution (5.5 ml) of the compound (350 mg, 0.52 mmol) obtained in Step 1of Example 91 and the resulting mixture was stirred at 60° C. for 36hours. After cooling, saturated ammonium chloride solution was added,followed by extraction with ethyl acetate. The organic layer was washedwith brine and then dried over anhydrous magnesium sulfate. The solventwas evaporated and the residue was purified by silica gel columnchromatography [chloroform:methanol=100:0→11.1 (v/v)] to give 232 mg(53%) of the title compound as a solid.

MS (ESI) m/z: 837 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)N-[(3R,6S)-6-(1-hydroxy-1-methylethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (162 mg, 0.38 mmol) obtained in Step 1 above was used as astartign material and treated in the same way as in Step 3 of Example 91to give 58 mg (51%) of the title compound as a solid [fractionationconditions: CHIRALPAK IC, n-hexane:ethanol=1:1 (v/v)].

¹H-NMR (400 MHz, CDCl₃) δ: 1.15 (3H, s), 1.19 (3H, s), 1.39-1.59 (2H,m), 1.62-1.88 (3H, m), 2.03 (1H, d, J=11.9 Hz), 2.16 (1H, d, J=12.4 Hz),2.38 (1H, d, J=12.8 Hz), 2.48 (1H, s), 3.04-3.13 (2H, m), 3.78-4.11 (5H,m), 4.32-4.41 (2H, m), 4.53-4.79 (2H, m), 6.80 (1H, s), 7.14 (1H, d,J=7.8 Hz), 7.36 (2H, d, J=7.8 Hz), 7.44 (1H, t, J=4.6 Hz, 7.88 (1H, s),8.04 (1H, d, J=5.0 Hz),

MS (ESI) m/z: 641 (M+H)⁺.

Example 158

[Step 1]

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro4′-(2-chloro-3-fluropyridin-4-yl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (300 mg, 0.44 mmol) obtained in Step 1 of Example 91 andthe compound (240 mg, 1.33 mmol) obtained in Step 3 of Reference Example28 were used as starting materials and treated in the same way as inStep 1 of Example 20 to give 180 mg (50%) of the title compound as asolid.

MS (ESI) m/z: 822 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.18 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 76 mg (59%) of the title compound as a solid [fractionationconditions: CHIRALPAK IC, n-hexane:ethanol=3:2 (v/v)].

¹H-NMR (400 MHz, CDCl₃) δ: 1.47-1.74 (3H, m), 1.85 (1H, d, J=13.3 Hz),2.03 (1H, d, J=12.8 Hz), 2.16-2.43 (3H, m), 3.14 (1H, t, J=10.5 Hz),3.76-4.16 (6H, m), 4.29-4.43 (2H, m), 4.53-4.76 (2H, m), 5.70 (1H, s),6.51 (1H, s), 6.83 (1H, s), 7.14 (1H, d, J=7.3 Hz), 7.35 (1H, d, J=7.8Hz), 7.41-7.47 (2H, m), 8.05 (1H, d, J=5.0 Hz), 8.30 (1H, s).

MS (ESI) m/z: 626 (M+H)⁺.

Example 159

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{trans-4-[5-(methoxymethyl)-1,3,4-oxadiazol-2-yl]cyclohexyl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (174 mg, 0.34 mmol) obtained in Step 1 of Example 17 andthe compound (78 mg, 0.37 mmol) obtained in Step 3 of Reference Example72 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 168 mg (73%) of the title compound as asolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.96 (3H, s), 1.10-1.26 (2H,m), 1.30-1.55 (5H, m), 1.58-1.82 (5H, m), 2.08-2.29 (4H, m), 2.87-2.97(1H, m), 3.19-3.39 (1H, m), 3.45 (3H, s), 3.71-3.85 (1H, m), 4.46 (1H,d, J=8.7 Hz), 4.62 (2H, s), 4.65 (1H, d, J=8.7 Hz), 6.70 (1H, d, J=1.8Hz), 7.01-7.06 (1H, m), 7.28-7.33 (1H, m), 7.50-7.55 (1H, m), 7.64 (1H,d, J=8.2 Hz), 8.02 (1H, d, J=5.5 Hz), 8.50 (1H, s),

MS (ESI) m/z: 685 (M+H)⁺.

Example 160

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(2-hydroxyethyl)tetrahydro-2H-pyran-3-yl]-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (101 mg, 0.20 mmol) obtained in Step 1 of Example 17 andthe compound (19 mg, 0.10 mmol) obtained in Step 2 of Reference Example73 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 21 mg (33%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.15-1.22 (2H,m), 1.35-1.72 (11H, m), 2.07-2.09 (1H, m), 2.42 (1H, br s), 3.12 (1H, t,J=10.6 Hz), 3.28 (1H, br s), 3.53 (1H, br s), 3.77 (2H, br s), 3.89-3.89(1H, m), 4.02-4.04 (1H, m), 4.43 (1H, d, J=8.6 Hz), 4.64 (1H, d, J=8.6Hz), 6.72 (1H, br s), 7.07 (1H, d, J=7.4 Hz), 7.30-7.32 (1H, m),7.46-7.50 (3H, m), 8.05 (1H, d, J=4.6 Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 161

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-(1,3,4-oxadiazol-2-ylmethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (200 mg, 0.41 mmol) obtained in Step 1 of Example 17 andthe compound (58 mg, 0.26 mmol) obtained in Step 3 of Reference Example74 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 72 mg (42%) of the title compound as asolid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.59 (3H, s), 0.90-0.99 (4H, m), 1.10-1.12(1H, m), 1.19-1.21 (1H, m), 1.41-1.63 (5H, m), 1.71-1.76 (2H, m),1.83-1.88 (2H, m), 3.00-3.15 (3H, m), 3.51 (1H, d, J=9.7 Hz), 3.71-3.65(3H, m), 4.45 (1H, t, J=9.2 Hz), 4.57 (1H, d, J=8.6 Hz), 6.71 (1H, d,J=1.7 Hz), 7.06 (1H, d, J=6.3 Hz), 7.50 (1H, d, J=7.4 Hz), 7.63 (1H, t,J=4.6 Hz), 7.80 (1H, d, J=8.0 Hz), 8.17 (1H, d, J=5.2 Hz), 9.14 (1H, s),10.62 (1H, 2).

MS (ESI) m/z: 657 (M+H)⁺.

Example 162

(3′R,4′S,5′R)-6″-N-[6,6-bis(hydroxymethyl)spiro[3.3]hepta-2-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (98 mg, 0.20 mmol) obtained in Step 1 of Example 17 and thecompound (38 mg, 0.20 mmol) obtained in Step 5 of Reference Example 75were used as starting materials and treated in the same way as in Step 2of Example 12 to give 76 mg (56%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.68 (3H, s), 0.95 (3H, s), 1.13-1.22 (2H,m), 1.33-1.36 (1H, m), 1.55-1.57 (2H, m), 1.72-1.87 (5H, m), 1.97-2.00(4H, m), 2.36-2.47 (2H, m), 3.46-3.54 (4H, m), 4.09-4.17 (1H, m), 4.51(1H, d, J=9.2 Hz), 4.65 (1H, d, J=9.2 Hz), 6.76 (1H, d, J=1.8 Hz), 7.06(1H, dd, J=8.0, 1.8 Hz), 7.45 (1H, dd, J=8.0, 2.1 Hz), 7.65 (1H, m),8.05 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 649 (M+H)⁺.

Example 163

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-5″-fluoro-3,3-bis(fluoromethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (402 mg, 3.0 mmol) obtained in Step 2 of Example 21 and thecompound (981 mg, 3.00 mmol) obtained in Reference Example 11 were usedas starting materials and treated in the same way as in Step 1 ofExample 9 to give 1.20 g (57%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.74 (1H, d, J=14.2 Hz), 2.42 (1H, d, J=14.7Hz), 2.84 (1H, d, J=14.7 Hz), 3.19 (1H, d, J=14.2 Hz), 4.00-4.04 (1H,m), 4.12-4.15 (1H, m), 4.31 (1H, t, J=10.1 Hz), 4.43 (1H, t, J=9.6 Hz),4.53 (1H, d, J=9.6 Hz), 4.65 (1H, d, J=10.1 Hz), 5.26 (1H, t, J=3.2 Hz),6.29 (1H, d, J=4.1 Hz), 6.78-6.79 (2H, m), 6.90 (1H, d, J=6.0 Hz),7.16-7.18 (2H, m), 7.21-7.29 (8H, m), 7.73 (1H, s), 7.98 (1H, d, J=5.0Hz).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-5″-fluoro-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (348 mg, 0.50 mmol) obtained in Step 1 above and thecompound (251 mg, 1.50 mmol) obtained in Step 1 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 20 to give 353 mg (85%) of the title compound as a solid.

MS (ESI) m/z: 827 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluropyridin-4-yl)-5′-fluoro-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (353 mg, 0.43 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 140 mg (52%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.42-1.46 (1H, m), 1.59-1.65 (1H, m),1.71-1.79 (2H, m), 1.84-1.91 (1H, m), 1.99-2.13 (2H, m), 2.46 (1H, d,J=13.3 Hz), 3.16 (1H, t, J=10.5 Hz), 3.37-3.39 (1H, m), 3.50 (2H, d,J=5.0 Hz), 3.76-3.84 (1H, m), 3.88 (1H, s), 3.90-3.93 (1H, m), 4.00 (1H,s), 4.40 (1H, d, J=9.2 Hz), 4.51 (1H, d, J=9.2 Hz), 4.60-4.82 (2H, m),6.90 (1H, d, J=6.0 Hz), 7.60-7.61 (2H, m), 8.08 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 635 (M+H)⁺.

Example 164

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(3-chloro-5-fluorophenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′2″(1″H)-dione

The compound (402 mg, 3.00 mmol) obtained in Step 2 of Reference Example21 and the compound (981 mg, 3.00 mmol) obtained in Reference Example 6were used as starting materials and treated in the same way as in Step 1of Example 9 to give 1.32 g (65%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.68 (1H, d, J=15.1 Hz), 2.45 (1H, d, J=14.2Hz), 2.88 (1H, d, J=14.2 Hz), 3.30 (1H, d, J=14.7 Hz), 4.02 (1H, d,J=12.4 Hz), 4.07 (1H, d, J=10.1 Hz), 4.14-4.19 (1H, m), 4.39 (1H, dd,J=13.1, 9.4 Hz), 4.50 (1H, dd, J=12.8, 9.6 Hz), 4.61 (1H, d, J=9.6 Hz),5.24 (1H, t, J=3.4 Hz), 6.18 (1H, d, J=3.7 Hz), 6.54 (1H, d, J=9.6 Hz),6.75 (1H, s), 6.81 (1H, d, J=1.8 Hz), 6.87-6.90 (2H, m), 6.97 (1H, dd,J=8.2, 1.8 Hz), 7.21-7.30 (10H, m), 7.54 (1H, s).

[Step 2]

(4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (338 mg, 0.50 mmol) obtained in Step 1 above and thecompound (251 mg, 1.50 mmol) obtained in Step 1 of reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 20 to give 335 mg (83%) of the title compound as a solid.

MS (ESI) m/z: 808 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (335 mg, 0.41 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 97 mg (38%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.41-1.45 (1H, m), 1.51-1.78 (3H, m), 1.88(1H, d, J=12.8 Hz), 1.98-2.11 (2H, m), 2.46 (1H, d, J=12.8 Hz), 3.11(1H, t, J=10.8 Hz), 3.33-3.40 (1H, m), 3.49 (2H, d, J=5.0 Hz), 3.74-3.84(2H, m), 3.87-3.94 (3H, m), 4.47 (1H, d, J=9.6 Hz), 4.56-4.78 (2H, m),6.84 (1H, d, J=2.3 Hz), 6.87 (1H, m), 6.93-6.97 (1H, m), 7.00-7.03 (1H,m), 7.14 (1H, dd, J=8.2, 1.8 Hz), 7.57 (1H, d, J=8.2 Hz).

Example 165

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(2-chloropyridin-4-yl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (402 mg, 3.00 mmol) obtained in Step 2 of Reference Example21 and the compound (873 mg, 3.00 mmol) obtained in Reference Example 4were used as starting materials and treated in the same way as in Step 1of Example 9 to give 1.35 g (63%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.65 (1H, d, J=14.9 Hz), 2.46 (1H, d, J=14.9Hz), 2.88 (1H, d, J=14.4 Hz), 3.32 (1H, d, J=13.7 Hz), 4.01-4.10 (2H,m), 4.13-4.21 (1H, m), 4.39 (1H, dd, J=13.2 9.5 Hz), 4.51 (1H, dd,J=12.9, 9.5 Hz), 4.65 (1H, d, J=10.0 Hz), 5.26 (1H, t, J=3.5 Hz), 6.19(1H, d, J=3.9 Hz), 6.76 (1H, dd, J=5.2, 1.6 Hz), 6.80 (1H, d, J=1.7 Hz),6.91-6.95 (3H, m), 7.20-7.27 (10H, m), 7.85 (1H, s), 8.11 (1H, d, J=5.4Hz).

[Step 2]

(3′S,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

A methanol solution (5 mil of the compound (330 mg, 0.50 mmol) obtainedin Step 1 above and the compound (251 mg, 1.50 mmol) obtained in Step 1of Reference Example 2 were used as starting materials and treated inthe same way as in Step 1 of Example 20 to give 222 mg (56%) of thetitle compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.25-1.29 (1H, m), 1.46-1.51 (2H, m),1.61-1.64 (1H, m), 1.99 (1H, dd, J=7.3, 4.6 Hz), 2.11 (1H, d, J=12.2Hz), 2.63 (1H, d, J=16.6 Hz), 2.70 (1H, t, J=10.6 Hz), 2.82 (1H, d,J=14.9 Hz), 3.27-3.31 (1H, m), 3.46-3.60 (3H, m), 3.81-3.84 (2H, m),3.93-3.97 (2H, m), 4.05 (1H, d, J=2.4 Hz), 4.18 (1H, s), 4.30 (1H, s),4.44 (1H, dd, J=12.6, 9.6 Hz), 4.56 (1H, dd, J=12.5, 9.8 Hz), 4.80 (1H,d, J=2.9 Hz), 5.32 (1H, d, J=8.1 Hz), 5.62 (1H, s), 6.61 (1H, dd, J=5.4,1.5 Hz), 6.80-6.83 (3H, m), 6.89 (1H, dd, J=8.1, 2.0 Hz), 7.05-7.19 (6H,m), 7.29-7.32 (4H, m), 7.65 (1H, s), 8.05 (1H, d, J=5.1 Hz).

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(2-chloropyridin-4-yl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (222 mg, 0.28 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 80 mg (56%) of the title compound as a colorless solid[fractionation conditions: CHIRALPAK IC, n-hexane:2-propanol=2:3 (v/v)].

¹H-NMR (400 MHz, CD₃OD) δ: 1.40-1.46 (1H, m), 1.54-1.80 (3H, m), 1.88(1H, d, J=12.4 Hz), 1.98-2.11 (2H, m), 2.47 (1H, d, J=13.3 Hz), 3.15(1H, t, J=10.5 Hz), 3.36-3.39 (1H, m), 3.50 (2H, d, J=5.0 Hz), 3.75-3.85(2H, m), 3.88-4.00 (3H, m), 4.55 (1H, d, J=9.2 Hz), 4.60-4.80 (2H, m),6.86 (1H, d, J=1.8 Hz), 7.09-7.18 (2H, m), 7.20-7.30 (1H, m), 7.60 (1H,d, J=8.2 Hz), 8.10 (1H, d, J=5.5 Hz).

MS (ESI) m/z: 599 (M+H)⁺.

Example 166

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(3R,6S)-6-{[(methylsulfonyl)amino]methyl}tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (199 mg, 0.40 mmol) obtained in Step 1 of Example 17 andthe compound (81 mg, 0.33 mmol) obtained in Step 2 of Reference Example76 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 184 mg (83%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.12-1.22 (2H,m), 1.34-1.37 (1H, m), 1.43-1.62 (5H, m), 1.68-1.78 (3H, m), 2.09-2.11(1H, m), 2.96 (3H, s), 3.02-3.12 (2H, m), 3.26-3.32 (2H, m), 3.45-3.50(1H, m), 3.88-3.88 (1H, m), 4.02-4.05 (1H, m), 4.42-4.45 (1H, m), 4.64(1H, d, J=9.2 Hz), 4.74 (1H, dd, J=8.0 4.0 Hz), 6.73 (1H, d, J=1.7 Hz),7.07 (1H, dd, J=8.3, 2.0 Hz), 7.31 (1H, dd, J=8.3, 2.0 Hz), 7.37 (1H,s), 7.50-7.47 (2H, m), 8.05 (1H, d, J=5.2 Hz).

MS (ESI) m/z: 682 (M+H)⁺.

Example 167

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (350 mg, 0.52 mmol) obtained in Step 1 of Example 91 andthe compound (267 mg, 1.55 mmol) obtained in Step 2 of Reference Example77 were used as starting materials and treated in the same way as inStep 1 of Example 157 to give 232 mg (53%) of the title compound as asolid.

MS (ESI) m/z: 850 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluropyridin-4-yl)-N-[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (320 mg, 0.38 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 138 mg (56%) of the title compound as a solid [fractionationconditions: CHIRALPAK IC, n-hexane:ethanol=2:3 (v/v)].

¹H-NMR (400 MHz, CDCl₃) δ: 1.52-1.63 (2H, m), 1.69 (1H, dd, J=13.5, 2.5Hz), 1.82-2.08 (4H, m), 2.21-2.31 (1H, m), 2.39 (1H, d, J=12.8 Hz), 2.96(3H, s), 3.09 (3H, s), 3.24 (1H, dd, J=10.5, 8.7 Hz), 3.79-4.09 (4H, m),4.16 (1H, dd, J=9.2, 3.2 Hz), 4.34-4.41 (2H, m), 4.54-4.78 (2H, m), 6.83(1H, d, J=1.8 Hz), 7.15 (1H, dd, J=8.3, 1.8 Hz), 7.37 (1H, dd, J=8.0,2.1 Hz), 7.44 (1H, t, J=4.8 Hz), 7.55 (1H, d, J=8.3 Hz), 7.68 (1H, brs), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 654 (M+H)^(+.)

Example 168

[Step 1]

(4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-N-[trans-4-(dimethylcarbamoyl)cyclohexyl]-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (339 mg, 0.50 mmol) obtained in Step 1 of Example 164 andtrans-4-amino-N,N-dimethylcyclohexanecarboxamide (144 mg, 0.85 mmol)were used as starting materials and treated in the same way as in Step 1of Example 20 to give 178 mg (42%) of the title compound as a colorlesssolid.

MS (ESI) m/z: 847 (M+H)⁺.

[Step 2]

(3′R,4′R,5′R)-6″-chloro-4′-(3-chloro-5-fluorophenyl)-N-[trans-4-(dimethylcarbamoyl)cyclohexyl]-3,3-bis(fluoromethyl-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (178 mg, 0.21 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 60 mg (44%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.26-1.71 (5H, m), 1.75-2.09 (6H, m), 2.46(1H, d, J=12.8 Hz), 2.60-2.72 (1H, m), 2.91 (3H, s), 3.11 (3H, s),3.59-3.71 (1H, m), 3.79 (1H, s), 3.88-3.94 (2H, m), 4.46 (1H, d, J=9.6Hz), 4.56-4.76 (2H, m), 6.84 (1H, d, J=1.8 Hz), 6.87-6.99 (2H, m), 7.02(1H, br s), 7.14 (1H, dd, J=8.0, 1.6 Hz), 7.57 (1H, d, J=8.2 Hz).

MS (ESI) m/z: 653 (M+H)⁺.

Example 169

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(3,5-dichlorophenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3,40,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (402 mg, 3.00 mmol) obtained in Step 2 of Reference Example21 and the compound (974 mg, 3.00 mmol) obtained in Reference Example 78were used as starting materials and treated in the same way as in Step 1of Example 9 to give 1.27 g (61%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.70 (1H, d, J=15.1 Hz), 2.46 (1H, d, J=14.7Hz), 2.89 (1H, d, J=13.3 Hz), 3.30 (1H, d, J=14.7 Hz), 3.99-410 (2H, m),4.11-4.22 (1H, m), 4.39 (1H, dd, J=12.8, 9.6 Hz)4.51 (1H, dd, J=12.8,9.6 Hz), 4.60 (1H, d, J=10.1 Hz), 5.24 (1H, t, J=3.4 Hz), 6.17 (1H, d,J=4.1 Hz), 6.78-6.84 (3H, m), 6.91 (1H, d, J=8.2 Hz), 6.98 (1H, dd,J=8.2 1.8 Hz), 7.15 (1H, t, J=1.8 Hz), 7.16-7.34 (10H, m), 7.52 (1H, s).

[Step 2]

(4′R,5′R)-6″-chloro-4′-(3,5-dichlorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (347 mg, 0.50 mmol) obtained in Step 1 above and thecompound (197 mg, 1.50 mmol) obtained in Step 1 of Reference Example 2were used as starting materials and treated in the same way as in Step 1of Example 20 to give 285 mg (69%) of the title compound as a solid.

MS (ESI) m/z: 825 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6″-chloro-4′-(3,5-dichlorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (285 mg, 0.35 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 99 mg (46%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.38-1.48 (1H, m), 1.53-1.65 (1H, m), 1.68(1H, dd, J=13.7, 2.3 Hz), 1.75-1.78 (1H, m), 1.88 (1H, d, J=13.7 Hz),2.01-2.12 (2H, m), 2.46 (1H, d, J=13.3 Hz), 3.12 (1H, t, J=10.8 Hz),3.34-3.40 (1H, m), 3.49 (2H, d, J=5.5 Hz), 3.76-3.84 (2H, m), 3.88-3.95(3H, m), 4.47 (1H, d, J=9.2 Hz), 4.57-4.76 (2H, m), 6.85 (1H, d, J=1.8Hz), 7.12-7.17 (3H, m), 7.18-7.20 (1H, m), 7.57 (1H, d, J=8.2 Hz).

Example 170

[Step 1]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (500 mg, 0.74 mmol) obtained in Step 1 of Example 91 andthe compound (321 mg, 2.21 mmol) obtained in Step 4 of Reference Example79 were used as starting materials and treated in the same way as inStep 1 of Example 157 to give 378 mg (62%) of the title compound as asolid.

MS (ESI) m/z: 823 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (360 mg, 0.44 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 186 mg (68%) of the title compound as a solid [fractionationconditions: CHIRALPAK IC, n-hexane:ethanol=3:2 (v/v)].

¹H-NMR (CDCl₃) δ: 1.15 (3H, d, J=6.4 Hz), 1.38-1.89 (5H, m), 2.00-2.23(3H, m), 2.38 (1H, d, J=12.4 Hz), 3.10 (1H, t, J=10.5 Hz), 3.23 (1H, d,J=11.0 Hz), 3.77-4.10 (6H, m), 4.32-4.41 (2H, m), 4.53-4.77 (2H, m),6.81 (1H, s), 7.15 (1H, d, J=8.3 Hz), 7.33-7.39 (2H, m), 7.44 (1H, t,J=4.6 Hz), 7.65 (1H, s), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 627 (M+H)⁺.

Example 171

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[(1-methyl-1H-imidazol-5-yl)methyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (400 mg, 0.81 mmol) obtained in Step 1 of Example 17 and1-(1-methyl-1H-imidazole-5-yl)methanamine (95 mg, 0.98 mmol) were usedas starting materials and treated in the same way as in Step 2 ofExample 12 to give 188 mg (41%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.64 (3H, s), 0.88 (3H, s), 1.09-1.26 (3H,m), 1.37-1.52 (2H, m), 1.59-1.82 (3H, m), 3.21-3.28 (1H, m), 3.62 (3H,s), 4.40-4.53 (3H, m), 4.64 (1H, d, J=9.2 Hz), 6.72 (1H, s), 7.00-7.08(2H, m), 7.29 (1H, d, J=8.7 Hz), 7.45 (1H, s), 7.52 (1H, t, J=5.0 Hz),7.83 (1H, t, J=5.0 Hz), 8.05 (1H, d, J=5.0 Hz), 8.45 (1H, s).

MS (ESI) m/z: 585 (M+H)⁺.

Example 172

[Step 1]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(3-chloro-2,4-difluorophenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3,40,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′,2″(1″H)-dione

The compound (402 mg, 3.00 mmol) obtained in Step 2 of Reference Example21 and the compound (978 mg, 3.00 mmol) obtained in Reference Example 80were used as starting materials and treated in the same say as in Step 1of Example 9 to give 1.20 g (58%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.87 (1H, d, J=13.8 Hz), 2.32 (1H, d, J=14.2Hz), 2.83 (1H, d, J=14.2 Hz), 3.01 (1H, d, J=14.7 Hz), 3.89-3.95 (1H,m), 4.01-4.07 (1H, m), 4.24 (1H, dd, J=14.2, 9.6 Hz), 4.36 (1H, dd,J=14.0, 9.4 Hz), 4.48 (1H, d, J=10.1 Hz), 4.68 (1H, d, J=10.1 Hz), 5.22(1H, t, J=3.2 Hz), 6.32 (1H, d, J=3.7 Hz), 6.72-6.80 (2H, m), 6.84-6.89(2H, m), 6.92 (1H, dd, J=8.3, 1.8 Hz), 7.09-7.16 (2H, m), 7.20-7.25 98H,m), 7.62 (1H, s).

[Step 2]

(3′S,4′S,5′R)-6″-chloro-4′-(3-chloro-2,4-difluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (348 mg, 0.50 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 20to give 400 mg (96%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.17-1.30 (1H, m), 1.42-1.56 (2H, m), 1.62(2H, d, J=11.5 Hz), 2.10 (1H, d, J=11.0 Hz), 2.58 (1H, d, J=15.6 Hz),2.70 (1H, t, J=10.5 Hz), 2.85 (1H, d, J=15.1 Hz), 3.25-3.34 (1H, m),3.40 (1H, d, J=14.7 Hz), 3.50 (1H, dd, J=11.5, 6.9 Hz), 3.58 (1H, dd,J=11.7, 3.0 Hz), 3.82 (1H, d, J=9.6 Hz), 3.88 (1H, dd, J=10.5, 2.8 Hz),3.91-4.03 (1H, m), 4.09 (1H, s), 4.20 (2H, d, J=9.6 Hz), 4.35 (1H, s),4.45 (1H, t, J=10.1 Hz), 4.57 (1H, t, J=10.1 Hz), 4.83 (1H, d, J=3.2Hz), 5.22 (1H, d, J=7.8 Hz), 5.61 (1H, s), 6.47-6.52 (1H, m), 6.63 (1H,dd, J=8.9, 6.2 Hz), 6.77-6.85 (2H, m), 6.89 (1H, dd, J=8.0, 1.6 Hz),7.08-7.16 (4H, m), 7.20-7.31 (4H, m), 7.36 (2H, d, J=6.9 Hz), 8.07 (1H,s).

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2,4-difluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (400 mg, 0.48 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 120 mg (40%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.37-1.50 (1H, m), 1.53-1.79 (3H, m), 1.88(1H, d, J=13.6 Hz), 2.02-2.12 (2H, m), 2.47 (1H, d, J=13.6 Hz), 3.12(1H, t, J=10.4 Hz), 3.35-3.41 (1H, m), 3.49 (2H, d, J=5.4 Hz), 3.74-3.84(2H, m), 3.86-3.92 (2H, m), 4.33 (1H, d, J=9.5 Hz), 4.44 (1H, d, J=9.5Hz), 4.57-4.78 (2H, m), 6.82 (1H, br s), 6.98-7.02 (1H, m), 7.08-7.14(1H, m), 7.47-7.53 (1H, m), 7.55-7.63 (1H, m).

MS (ESI) m/z: 632 (M+H)⁺.

Example 173

Methyl(2S,5R)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)tetrahydro-2H-pyran-2-carboxylate

The compound (34.0 g, 69.1 mmol) obtained in Step 1 of Example 17 and:the compound (12.6 g, 64.3 mmol) obtained in Step 1 of Reference Example18 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 31.5 g (76%) of the title compound as asolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.68 (3H, s), 0.95 (3H, s), 1.15-1.26 (2H,m), 1.33-1.40 (1H, m), 1.42-2.03 (7H, m), 2.08-2.17 (2H, m), 3.22-3.31(2H, m), 3.79 (3H, s), 3.91-4.07 (2H, m), 4.15 (1H, dd, J=11.3, 4.1 Hz),4.40-4.49 (1H, m), 4.64 (1H, d, J=9.1 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07(1H, dd, J=8.2, 2.0 Hz), 7.31 (1H, dd, J=8.2, 2.0 Hz), 7.49 (2H, t,J=4.8 Hz), 7.61 (1H, d, J=8.6 Hz), 8.05 (1H, d, J=5.4 Hz).

MS (ESI) m/z: 633 (M+H)⁺.

Example 174

(2S,5R)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)tetrahydro-2H-pyran-2-carboxylicacid

1N sodium hydroxide solution (3 ml) was added to a methanol (10 ml)solution of the compound (1.00 g, 1.58 mmol) obtained in Example 173 andthe resulting mixture was stirred at room temperature for 18 hours. 1Nhydrochloric acid was added to the reaction mixture to adjust its pH toapproximately 6 to 7, followed by extraction with ethyl acetate. Theorganic layer was washed with brine and dried over anhydrous magnesiumsulfate. The solvent was evaporated under reduced pressure to give 577mg (60%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.58 (3H, s), 0.89 (3H, s), 0.91-0.99 (1H,m), 1.07-1.13 (1H, m), 1.17-1.23 (1H, m), 1.37-1.76 (7H, m), 1.82-1.88(1H, m), 1.92-1.99 (1H, m), 3.15-3.22 (1H, m), 3.56-3.91 (3H, m),4.41-4.57 (2H, m), 6.70 (1H, d, J=2.3 Hz), 7.05 (1H, dd, J=8.2, 1.8 Hz),7.50 (1H, d, J=7.2 Hz), 7.62 (1H, t, J=5.0 Hz), 7.84 (1H, d, J=8.6 Hz),8.16 (1H, d, J=5.0 Hz), 10.62 (1H, br s).

MS (ESI) m/z: 619 (M+H)⁺.

Example 175

[Step 1]

(3′S,4′R,7′S,8′R,8a′R)-6″-chloro-8′-(3-chlorophenyl)-3,3-bis(fluoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′3″-indole]-1′,2″(1″H)-dione

The compound (760 mg, 2.6 mmol) obtained in Reference Example 81 and thecompound (402 mg, 3.00 mmol) obtained in Step 2 of Reference Example 21were used as Starting materials and treated in the same way as in Step 1of Example 9 to give 1.20 g (70%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.70 (1H, d, J=14.0 Hz), 2.45 (1H, d, J=14.5Hz), 2.90 (1H, d, J=14.0 Hz), 3.29 (1H, d, J=14.0 Hz), 3.98-4.18 (3H,m), 4.38 (1H, dd, J=14.0, 9.5 Hz), 4.50 (1H, dd, J=14.0, 9.5 Hz), 4.66(1H, d, J=10.0 Hz), 5.24 (1H, t, J=3.2 Hz), 6.18 (1H, d, J=3.6 Hz),6.77-6.82 (2H, m), 6.89 (1H, d, J=8.2 Hz), 6.18 (1H, d, J=8.2 Hz),6.93-6.96 (2H, m), 7.03 (1H, t, J=7.9 Hz), 7.11-7.15 (1H, m), 7.18-7.34(10H, m), 7.65 (1H, s).

[Step 2]

(4′R,5′R)-6″-chloro-4′-(3-chlorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (330 mg, 0.50 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 20to give 343 mg (86%) of the title compound as a solid.

MS (ESI) m/z: 790 (M+H)⁺.

[Step 3]

(3′R,4′R,5′R)-6′-chloro-4′-(3-chlorophenyl)-3,3-bis(fluoromethyl-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (343 mg, 0.43 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 90 mg (35%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.36-1.50 (1H, m), 1.53-1.80 (3H, m), 2.06(2H, d, J=12.4 Hz), 2.47 (1H, d, J=12.4 Hz), 3.09 (1H, t, J=10.5 Hz),3.34-3.38 (1H, m), 3.49 (2H, d, J=5.5 Hz), 3.77-3.83 (2H, m), 3.85-3.95(3H, m), 4.49 (1H, d, J=9.2 Hz), 4.57-4.78 (2H, m), 6.81 (1H, d, J=1.8Hz), 7.03-7.14 (4H, m), 7.19-7.21 (1H, m), 7.56 (1H, d, J=8.2 Hz).

Example 176

[Step 1]

(3′S,4′R,7′S.8′S,8a′R)-6″-chloro-8′-(3-chloro-2,5-difluorophenyl)-3,3-bis(fluuoromethyl)-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclobutane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-indole]-1′2″(1″H)-dione

The compound (978 mg, 3.00 mmol) obtained in Reference Example 82 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 1.50 g (70%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.93 (1H, d, J=14.5 Hz), 2.30 (1H, d, J=14.5Hz), 2.81 (1H, d, J=14.0 Hz), 2.92 (1H, d, J=14.0 Hz), 3.87 (1H, t,J=11.6 Hz), 3.99 (1H, t, J=11.8 Hz), 4.21 (1H, dd, J=14.0, 9.5 Hz), 4.33(1H, dd, J=14.3, 9.7 Hz), 4.50 (1H, d, J=9.5 Hz), 4.61 (1H, d, J=9.1Hz), 5.22 (1H, s), 6.34 (1H, d, J=3.6 Hz), 6.62-6.72 (2H, m), 6.88-7.02(3H, m), 7.10-7.17 (2H, m), 7.19-7.31 (8H, m), 7.81 (1H, s).

[Step 2]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2,5-difluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (348 mg, 0.50 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of Example 20 to give 321 mg (78%) of the title composed as a solid.

MS (ESI) m/z: 826 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6∝1-chloro-4′-(3-chloro-2,5-difluorophenyl)-3,3-bis(fluoromethyl)-N-[(3R,6S)-6-(hydroxymethyl)tetrahydro-2H-pyran-3-yl]-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (321 mg, 0.39 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 91to give 125 mg (51%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.37-1.50 (1H, m), 1.53-1.79 (3H, m), 1.88(1H, d, J=13.7 Hz), 2.02-2.12 (2H, m) 2.47 (1H, d, J=12.8 Hz), 3.12 (1H,t, J=10.5 Hz), 3.33-3.41 (1H, m), 3.49 (2H, d, J=5.0 Hz), 3.75-3.85 (2H,m), 3.88-3.92 (2H, m), 4.36 (1H, d, J=9.6 Hz), 4.41 (1H, d, J=9.2 Hz),4.58-4.78 (2H, m), 6.83 (1H, d, J=1.8 Hz), 7.06-7.14 (2H, m), 7.31-7.35(1H, m), 7.50 (1H, dd, J=8.0, 2.1 Hz).

Example 177

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2,5-difluorophenyl)-3,3-bis(fluoromethyl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (348 mg, 0.50 mmol) obtained in Step 1 of Example 176 andthe compound (272 mg, 1.50 mmol) obtained in Step 4 of Reference Example79 were used as starting materials and treated in the same way as inStep 1 of Example 20 to give 303 mg (72%) of the title compound as asolid.

MS (ESI) m/z: 840 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2,5-difluorophenyl)-3,3-bis(fluoromethyl)-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (303 mg, 0.36 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of Example 31to give 135 mg (58%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.15 (3H, d, J=6.4 Hz), 1.40-1.62 (2H, m),1.68 (1H, d, J=13.3 Hz), 1.88 (2H, d, J=12.8 Hz), 2.02-2.13 (2H, m),2.47 (1H, d, J=12.8 Hz), 3.08-3.13 (2H, m), 3.59-3.65 (1H, m), 3.74-3.82(2H, m), 3.86-3.93 (2H, m), 4.36 (1H, d, J=9.6 Hz), 4.41 (1H, d, J=9.2Hz), 4.56-4.78 (2H, m), 6.83 (1H, d, J=1.8 Hz), 7.06-7.14 (2H, m),7.31-7.35 (1H, m), 7.50 (1H, dd, J=8.0, 2.1 Hz).

Example 178

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-N-[1-(1H-tetrazol-5-yl)piperidin-4-yl]-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (148 mg, 0.30 mmol) obtained in Step 1 of Example 17 andthe compound (72 mg, 0.30 mmol) obtained in Step 3 of Reference Example83 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 170 mg (53%) of the title compound as asolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.67 (3H, s), 0.91 (3H, s), 1.09-1.23 (2H,m), 1.27-1.34 (1H, m), 1.51-1.83 (7H, m), 1.91-2.05 (2H, m), 3.16-3.27(2H, m), 3.80-3.95 (3H, m), 4.56 (1H, d, J=9.2 Hz), 4.69 (1H, d, J=9.2Hz), 6.77 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=7.8, 1.8 Hz), 7.46 (1H, dd,J=8.2, 1.8 Hz), 7.67 (1H, t, J=5.0 Hz), 8.06 (1H, d, J=5.0 Hz).

Example 179

[Step 1]

(4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxylicacid

The compound (18.2 g, 27.0 mmol) obtained in Step 2 of Example 1 wasused as a starting material and treated in the same way as in Step 1 ofExample 17 to give 3.1 g (23%) of the title compound as a solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.65-0.66 (3H, m), 0.86-0.88 (3H, m),1.03-1.63 (6.6H, m), 1.77-1.83 (0.7H, m), 1.98-2.01 (0.7H, m), 4.27(0.3H, d, J=9.2 Hz), 4.52-4.55 (1H, m), 4.72 (0.7 H, d, J=9.7 Hz), 6.88(0.3H, d, J=8.0 Hz), 7.11-7.19 (2H, m), 7.38-7.42 (1H, m), 7.51-7.55(1H, m), 7.95 (0.7H, dd, J=8.0, 2.3 Hz), 11.32-11.31 (1H, m).

[Step 2]

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (248 mg, 0.50 mmol) obtained in Step 1 above and thecompound (104 mg, 0.57 mmol) obtained in Step 2 of Reference Example 84were used as starting materials and treated in the same way as in Step 2of Example 12 to give 258 mg (83%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.16-1.27 (2H,m), 1.36-1.67 (7H, m), 1.76-1.78 (1H, m), 2.11-2.15 (1H, m), 2.26-2.30(1H, m), 3.14 (1H, t, J=10.9 Hz), 3.22 (1H, br s), 3.80 (1H, dd, J=11.5,2.3 Hz), 3.87-3.93 (1H, m), 4.11-4.14 (1H, m), 4.43-4.50 (1H, m), 4.68(1H, d, J=9.7 Hz), 5.50 (1H, d, J=4.0 Hz), 6.49 (1H, d, J=4.6 Hz), 6.97(1H, t, J=8.0 Hz), 7.05 (1H, d, J=7.4 Hz), 7.16-7.19 (1H, m), 7.46-7.49(2H, m), 7.62 (1H, dd, J=8.0, 2.3 Hz), 8.13 (1H, s).

MS (ESI) m/z: 618 (M+H)⁺.

Example 180

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[2,3-b]pyridine]-5′-carboxamide

The compound (250 mg, 0.51 mmol) obtained in Step 1 of Example 179 andthe compound (104 mg, 0.57 mmol) obtained in Step 4 of Reference Example79 were used as starting materials and treated in the same Way as inStep 2 of Example 12 to give 282 mg (90%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.70 (3H, s), 0.96 (3H, s), 1.14-1.24 (5H,m), 1.35-1.64 (7H, m), 1.72-1.79 (2H, m), 2.07-2.13 (2H, m), 3.12 (1H,t, J=10.6 Hz), 3.21-3.24 (2H, m), 3.82-3.90 (2H, m), 4.06-4.09 (1H, m),4.46 (1H, d, J=9.2 Hz), 4.69 (1H, d, J=9.2 Hz), 6.96 (1H, t, J=7.7 Hz),7.05 (1H, d, J=8.0 Hz), 7.16 (1H, t, J=6.9 Hz), 7.43-7.48 (2H, m), 7.63(1H, dd, J=7.4, 2.3 Hz), 8.03 (1H, s).

MS (ESI) m/z: 619 (M+H)⁺.

Example 181

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (250 mg, 0.51 mmol) obtained in Step 1 of Example 12 andthe compound (100 mg, 0.56 mmol) obtained in Step 2 of Reference Example84 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 222 mg (71%) of the title compound as asolid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.90 (3H, s), 0.95 (1H, td,J=13.7, 4.0 Hz), 1.10-1.12 (1H, m), 1.20-1.24 (1H, m), 1.40-1.65 (5H,m), 1.70-1.76 (2H, m), 1.87-1.91 (1H, m), 1.97-2.01 (1H, m), 3.16 (1H,t, J=10.6 Hz), 3.48 (1H, d, J=10.9 Hz), 3.64-3.71 (2H, m), 3.76-3.79(1H, m), 4.38 (1H, t, J=9.7 Hz), 4.58 (1H, d, J=9.2 Hz), 6.68 (1H, d,J=1.7 Hz), 7.04 (1H, dd, J=8.0 , 2.3 Hz), 7.15-7.09 (3H, m), 7.31-7.34(1H, m), 7.45 (1H, dd, J=8.3, 2.0 Hz), 7.57 (1H, t, J=6.6 Hz), 7.83 (1H,d, J=8.0 Hz), 10.53 (1H, s).

MS (ESI) m/z: 617 (M+H)⁺.

Example 182

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (247 mg, 0.50 mmol) obtained in Step 1 of Example 12 andthe compound (104 mg, 0.57 mmol) obtained in Step 4 of Reference Example79 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 261 mg (84%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.68 (3H, s), 0.94 (3H, s), 1.11-1.21 (5H,m), 1.34-1.39 (1H, m), 1.43 (1H, td, J=12.2, 3.6 Hz), 1.48-1.53 (1H, m),1.56-1.64 (3H, m), 1.71-1.76 (3H, m), 2.08 (1H, d, J=4.6 Hz), 2.13 (1H,d, J=12.0 Hz), 3.12 (1H, t, J=10.6 Hz), 3.21-3.25 (2H, m), 3.82-3.92(2H, m), 4.06-4.09 (1H, m), 4.44 (1H, d, J=8.0 Hz), 4.67 (1H, d, J=9.2Hz), 6.68 (1H, d, J=2.3 Hz), 6.91 (1H, t, J=8.0 Hz), 7.05 (1H, dd,J=8.0, 1.7 Hz), 7.11-7.14 (1H, m), 7.33 (1H, dd, J=8.0, 2.3 Hz), 7.40(1H, s), 7.47-7.52 (2H, m).

MS (ESI) m/z: 618 (M+H)⁺.

Example 183

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′3″-indole]-5′-carboxamide

The compound (250 mg, 0.51 mmol) obtained in Step 1 of Example 12 andthe compound (100 mg, 0.60 mmol) obtained in Step 3 of Reference Example3 were used as starting materials and treated in the same way as in Step2 of Example 12 to give 251 mg (77%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.12-1.26 (2H,m), 1.32-1.43 (3H, m), 1.48-1.80 (7H, m), 2.15-2.25 (4H, m), 2.93-2.98(1H, m), 3.24 (1H, br s), 3.76-3.82 (1H, m), 4.46 (1H, d, J=9.2 Hs),4.68 (1H, d, J=9.2 Hz), 6.69 (1H, s), 6.89 (1H, t, J=8.0 Hz), 7.05 (1H,d, J=6.9 Hz), 7.12 (1H, t, J=7.2 Hz), 7.33 (1H, d, J=6.9 Hz), 7.55-7.50(2H, m), 7.64 (1H, d, J=8.6 Hz), 8.34 (1H, s).

MS (ESI) m/z: 640 (M+H)⁺.

Example 184

[Step 1]

(4′S5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxylicacid

1N sodium hydroxide solution (1.8 ml) was added to a methanol (10 ml)solution of the compound (1.00 g, 1.49 mmol) obtained in Step 1 ofExample 108 and the resulting mixture was stirred at 70° C. for 5 hours.65% Aqueous methanol (15 ml) solution of cerium (IV) diammonium nitrate(3.2 g, 5.96 mmol) was added dropwise to the reaction mixture under icecooling and the resulting mixture was stirred at the same temperaturefor 30 minutes. Subsequently, the reaction mixture was rendered weaklyacidic (pH 4 to 5) by addition of 1N sodium hydroxide solution and thenconcentrated under reduced pressure. After extraction with ethylacetate, the organic layer was washed with brine. The organic layer wasdried over anhydrous magnesium sulfate and filtered and then the solventin the filtrate was evaporated under reduced pressure. The residueobtained was solidified by addition of diethyl ether to give 480 mg(65%) of the title compound as a solid.

MS (ESI) m/z: 492 (M+H)⁺.

[Step 2]

(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-N-{(3R,6S)-6-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (300 mg, 0.61 mmol) obtained in Step 1 above and thecompound (111 mg, 0.61 mol) obtained in Step 4 of Reference Example 79were used as starting materials and treated in the same way as in Step 2of Example 12 to give 67 mg (18%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.72 (3H, s), 0.96 (3H, s), 1.15 (3H, d,J=6.3 Hz), 1.17-1.25 (2H, m), 1.28-1.63 (6H, m), 1.73-1.95 (3H, m),2.06-2.11 (1H, m), 3.13 (2H, t, J=10.6 Hz), 3.59-3.65 (1H, m), 3.72-3.80(1H, m), 3.88-3.95 (1H, m), 4.55 (1H, d, J=9.1 Hz), 4.75 (1H, d, J=9.1Hz), 6.79 (1H, s), 7.05 (1H, t, J=8.2 Hz), 7.24 (1H, t, J=6.8 Hz), 7.56(1H, t, J=6.8 Hz), 8.31 (1H, d, J=2.7 Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 185

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(3-chloro-2-fluorophenyl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (300 mg, 0.61 mmol) obtained in Step 1 of Example 185 andthe compound (110 mg, 0.61mol) obtained in Step 3 of Reference Example28 were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 155 mg (41%) of the title compound as asolid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.72 (3H, s), 0.96 (3H, s), 1.11-1.24 (2H,m), 1.36-1.41 (1H, m), 1.51-1.95 (7H, m), 2.09-2.19 (2H, m), 3.23 (1H,t, J=10.6 Hz), 3.77 -3.86 (2H, m), 4.00 (1H, dq, J=10.5, 2.1 Hz), 4.56(1H, d, J=9.1 Hz), 4.76 (1H, d, J=9.1 Hz), 6.79 (1H, s), 7.05 (1H, t,J=8.2 Hz), 7.22-7.27 (1H, m), 7.57 (1H, t, J=6.3 Hz), 8.31 (1H, d, J=2.3Hz).

MS (ESI) m/z: 618 (M+H)⁺.

Example 186

[Step 1]

Methyl(5R)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)-2-methyltetrahydro-2H-pyran-2-carboxylate

The compound (492 mg, 110 mmol) obtained in Step 1 of Example 17 and thecompound (119 mg, 0.70 mmol) obtained in Step 3 of Reference Example 85were used as starting materials and treated in the same way as in Step 2of Example 12 to give 321 mg (71%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.14-1.26 (2H,m), 1.36-1.41 (1H, m), 1.46 (3H, s), 1.49-1.56 (2H, m), 1.63-1.90 (6H,m), 2.19-2.26 (1H, m), 3.19-3.23 (1H, m), 3.72-3.77 (1H, m), 3.80 (3H,s), 3.84 (1H, dd, J=12.7 2.3 Hz), 3.86-3.91 (1H, m), 4.52-4.57 (1H, m),4.64 (1H, d, J=9.5 Hz), 6.73 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.2, 1.8Hz), 7.34 (1H, dd, J=8.4, 2.5 Hz), 7.43 (1H, s), 7.51 (1H, t, J=5.0 Hz),8.05 (1H, d, J=5.4 Hz), 8.14 (1H, d, J=8.2 Hz).

MS (ESI) m/z: 647 (M+H)⁺.

[Step 2]

(5R)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)-2-methyltetrahydro-2H-pyran-2-carboxylicacid

The compound (280 mg, 0.43 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Example 174 to give222 mg (81%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.60 (3H, s), 0.89 (3H, s), 0.95-1.01 (1H,m), 1.10-1.18 (1H, m), 1.28-1.86 912H, m), 1.98-2.04 (1H, m), 3.37-3.39(1H, m), 3.47-3.59 (1H, m), 3.62-3.80 (2H, m), 4.48-4.54 (1H, m), 6.70(1H, s), 7.05 (1H, d, J=8.2 Hz), 7.54 (1H, d, J=7.7 Hz), 7.58-7.65 (1H,m), 8.10 (1H, d, J=7.2 Hz), 8.18 (1H, d, J=4.1 Hz), 10.63 (1H, br s).

MS (ESI) m/z: 633 (M+H)⁺.

Example 187

(3′R,4′S,5′R)-N-[(3R)-6-carbamoyl-6-methyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (150 mg, 0.24 mmol) obtained in Example 187 was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 16 to give 116 mg (76%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.96 (3H, s), 1.16-1.27 (2H,m), 1.38-1.43 (1H, m), 1.47 (3H, s), 1.49-1.56 (2H, m), 1.68-1.80 (5H,m), 1.83-1.91 (1H, m), 2.15-2.21 (1H, m), 3.28 (1H, br s), 3.62 (1H, dd,J=12.0, 4.8 Hz), 3.82-3.93 (2H, m), 4.51 (1H, d, J=9.5 Hz), 4.64 (1H, d,J=9.5 Hz), 5.52 (1H, d, J=3.6 Hz), 6.49 (1H, d, J=3.6 Hz), 6.73 (1H, d,J=1.8 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.34 (1H, dd, J=8.4, 2.0 Hz),7.51 (1H, t, J=5.0 Hz), 7.70 (1H, s), 7.93 (1H, d, J=7.7 Hz), 8.05 (1H,d, J=5.0 Hz).

MS (ESI) m/z: 632 (M+H)⁺.

Example 188

[Step 1]

Methyl(2S)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)-5-methyltetrahydro-2H-pyran-2-carboxylate

1-Chloro-N,N,2-trimethylprop-1-en-1-amine (0.13 ml, 1.00 mmol) was addedto a tetrahydrofuran (8 ml) solution of the compound (492 mg, 1.00 mmol)obtained in Step 1 of Example 17, the resulting mixture was stirred for1 minute, then a tetrahydrofuran (6 ml) solution of the compound (210mg, 1.00 mmol) obtained in Step 2 of Reference Example 85 combined withtriethylamine (0.42 ml, 3.00 mmol) was added dropwise. The resultingmixture was stirred at room temperature for 16 hours. Subsequently,1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (191 mg,1.00 mol) was added to the reaction mixture and the resulting mixturewas stirred at room temperature for 5 hours. The reaction mixture wasdiluted with ethyl acetate, then washed with saturated sodiumbicarbonate solution, and brine in that order, and dried over anhydrousmagnesium sulfate. The solvent was evaporated under reduced pressure andthe residue obtained was purified by silica gel chromatography[chloroform:methanol=50:1 (v/v)] to give 62 mg (10%) of the titlecompound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.67 (3H, s), 0.93-0.98 (1H, m), 0.93 (3H,s), 1.10-1.53 (12H, m), 1.94-1.99 (1H, m), 2.31-2.37 (1H, m), 2.92 (1H,br s), 3.28-3.33 (1H, m), 3.75-3.80 (1H, m), 3.81 (3H, s), 3.91-3.96(1H, m), 4.42 (1H, d, J=9.1 Hz), 4.64 (1H, d, J=9.1 Hz), 6.74 (1H, d,J=2.3 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd, J=7.7, 2.7 Hz),7.41 (1H, s), 7.47-7.53 (2H, m), 8.05 (1H, d, J=5.4 Hz).

MS (ESI) m/z: 647 (M+H)⁺.

[Step 2]

(2S)-5-({[(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-yl]carbonyl}amino)-5-methyltetrahydro-2H-pyran-2-carboxylicacid

The compound (130 mg, 0.20 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Example 174 to give35 mg (20%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.57 (3H, s), 0.86 (3H, s), 0.92-1.23 (4H,m), 1.26 (3H, s), 1.29-1.79 (7H, m), 2.16-2.22 (1H, m), 3.24-3.30 (1H,m), 3.52-3.58 (1H, m), 3.60-3.70 (1H, m), 4.42 (1H, d, J=8.6 Hz), 4.56(1H, d, J=9.1 Hz), 6.70 (1H, d, J=1.8 Hz), 7.04 (1H, dd, J=8.2, 2.3 Hz),7.48 (1H, dd, J=8.2, 1.8 Hz), 7.61 (1H, t, J=5.2 Hz), 7.86 (1H, d, J=8.6Hz), 8.16 (1H, d, J=5.0 Hz), 10.61 (1H, s).

MS (ESI) m/z: 633 (M+H)⁺.

Example 189

(3′R,4′S,5′R)-N-[(6S)-6-carbamoyl-3-methyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamide

The compound (23 mg, 0.04 mmol) obtained in Step 2 Example 189 was usedas a starting material and treated in the same way as in Step 1 ofReference Example 16 to give 11 mg (48%) of the title compound as asolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.66 (3H, s), 0.92 (3H, s), 1.11-1.40 (4H,m), 1.44 (3H, s), 1.46-1.77 (6H, m), 1.92-1.97 (1H, m), 2.24-2.29 (1H,m), 3.40 (1H, dd, J=11.1, 7.0 Hz), 3.85-4.00 (2H, m), 4.47 (1H, d, J=9.1Hz), 4.61 (1H, d, J=9.5 Hz), 5.48 (1H, d, J=4.1 Hz), 6.53 (1H, d, J=4.1Hz), 6.73 (1H, d, J=1.8 Hz), 7.07 (1H, dd, J=8.2, 1.8 Hz), 7.31 (1H, dd,J=8.2, 2.3 Hz), 7.50 (1H, t, J=5.0 Hz), 7.60 (1H, s, 7.70 (1H, d, J=8.2Hz), 8.05 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 632 (M+H)⁺.

Example 190

[Step 1]

(3′S4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluropyridine-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[3,2-c]pyridine]-1′,2″(1″H)-dione

The compound (3.00 g, 9.67 mmol) obtained in Reference Example 86 wasused as a starting material and treated in the same way as in Step 1 ofExample 9 to give 5.00 g (77%) of the title compound as a solid.

¹H-NMR (CDCl₃) δ: 0.22 (3H, s), 0.54 (3H, s), 0.93-1.09 (3H, m),1.24-1.37 (3H, m), 1.75-1.82 (1H, m), 2.20-2.27 (1H, m), 4.56 (1H, d,J=11.0 Hz), 4.82 (1H, d, J=3.2 Hz), 5.29 (1H, d, J=11.0 Hz), 6.73 (1H,d, J=6.9 Hz), 6.90-6.93 (1H, m), 7.03-7.06 (1H, m), 7.09-7.25 (10H, m),7.78 (1H, t, J=4.8 Hz), 7.93 (1H, s), 8.33 (1H, d, J=5.0 Hz).

MS (ESI) m/z: 671 (M+H)⁺.

[Step 2]

(4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-1′-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (300 mg, 0.45 mmol) obtained in Step 1 above and thecompound (242 mg, 1.34 mmol) obtained in Step 3 of Reference Example 3were used as starting materials and treated in the same way as in Step 2of Example 12 to give 177 mg (47%) of the title compound as a solid.

MS (ESI) m/z: 838 (M+H)⁺.

[Step 3]

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-N-[trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (145 mg, 0.17 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of Example 1to give 62 mg (56%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.72 (3H, s), 0.97 (3H, s), 1.09-1.26 (2H,m), 1.37-1.94 (10H, m), 2.01-2.29 (4H, m), 2.98-3.09 (1H, m), 3.67-3.75(1H, m), 4.61 (1H, d, J=9.2 Hz), 4.75 (1H, d, J=9.2 Hz), 6.84 (1H, s),7.64 (1H, t, J=5.0 Hz), 8.09 (1H, d, J=5.0 Hz), 8.36 (1H, s), 8.85 (1H,s).

MS (ESI) m/z: 642 (M+H)⁺.

Example 191

(4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (60 mg, 0.11 mmol) obtained in Step 3 of Reference Example87 and the compound (20.5 mg, 0.11 mmol) obtained in Step 3 of ReferenceExample 28 were used as starting materials and treated in the same wayas in Step 2 of Example 12 to give 26 mg (37%) of the title compound asa solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.71 (3H, s), 0.96 (3H, s), 1.10-1.41 (4H,m), 1.49-1.91 (7H, m), 2.06-2.20 (2H, m), 3.77-3.87 (2H, m), 3.98-4.04(1H, m), 4.60 (1H, d, J=9.2 Hz), 4.76 (1H, d, J=9.2 Hz), 6.83 (1H, s),7.62 (1H, t, J=5.0 Hz), 8.09 (1H, d, J=5.0 Hz), 8.35 (1H, d, J=1.8 Hz).

MS (ESI) m/z: 619 (M+H)⁺.

Example 192

6″-Chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-60-[(1R)-1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3,40,3″-pyrrolo[3,2-c]pyridine]-5′-carboxamide

The compound (40 mg, 0.76 mmol) obtained in Step 3 of Reference Example87 and the compound (14 mg, 0.76 mmol) obtained in Step 4 of ReferenceExample 79 were used as starting materials and treated in the same wayas in Step 2 of Example 12 to give 18 mg (39%) of the title compound asa solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.73 (3H, s), 0.98 (3H, s), 1.13-1.30 (3H,m), 1.18 (3H, d, J=6.4 Hz), 1.39-1.81 (9H, m), 2.12-2.21 (2H, m), 3.15(1H, t, J=10.8 Hz), 3.24-3.29 (1H, m), 3.84-3.93 (2H, m), 4.04-4.09 (1H,m), 4.49 (1H, d, J=9.2 Hz), 4.71 (1H, d, J=9.2 Hz), 6.72 (1H, s),7.45-7.49 (2H, m), 8.09 (1H, d, J=5.0 Hz), 8.31-8.34 (2H, m).

MS (ESI) m/z: 620 (M+H)⁺.

Example 193

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidehydrochloride water/2-propanol (IPA) solvate

Concentrated hydrochloric acid (0.026 ml, 0.31 mmol). was added to a2-propanol (2.0 ml) solution of the compound (192 mg, 0.31 mmol)obtained in Example 70 and the resulting mixture was dissolved byheating. After stirring at room temperature for 18 hours, theprecipitate was collected by filtration to give 173 mg (85%) of thetitle compound as a solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.62 (3H, s), 0.92 (3H, s), 1.09-1.58 (6H,m), 1.65-2.07 (5H, m), 2.53-2.94 (1H, m), 3.29-3.73 (5H, m), 4.56-4.76(1H, m), 4.85-5.23 (1H, m), 6.80 (1H, s), 7.01-7.13 (2H, m), 7.14-7.20(1H, m), 7.49-7.74 (2H, m), 8.19-8.42 (1H, m), 8.61-9.08 (1H, m), 10.41(1H, br s), 11.25 (1H, br s).

Anal. Calcd for C₃₀H₃₄Cl₂FN₅O₄.HCl.0.75H₂O.IPA: C, 54.48: H, 6.03; N,9.63. Found: C, 54.47; H, 6.14; N, 9.65.

Example 194

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidesulfate water/2-propanol (IPA) solvate

Concentrated sulfuric acid (0.005 ml, 0.08 mmol) was added to a2-propanol (0.5 ml) solution of the compound (52 mg, 0.08 mmol) obtainedin Example 70 and the resulting mixture was dissolved by heating. Afterstirring at room, temperature for 2 days, the precipitate was collectedby filtration to give 20 mg (34%) of the title compound as a solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 0.62 (3H, s), 0.92 (3H, s), 1.13-1.61 (6H,m), 1.67-2.09 (5H, m), 2.45-2.88 (1H, m), 3.47-4.01 (5H, m), 4.58-4.77(1H, m), 4.83-5.11 (1H, m), 6.79 (1H, s), 6.98-7.25 (3H, m), 7.51-7.73(2H, m), 8.20-8.41 (1H, m), 8.51-8.73 (1H, m), 8.79-9.05 (1H, m), 10.35(1H, br s), 11.18 (1H, br s).

Anal. Calcd for C₃₀H₃₄Cl₂FN₅O₄.H₂SO₄.0.25H₂O.IPA: C, 49.94; H, 5.71; N,8.82. Found: C, 49.74; H, 5.71; N, 8.85 .

Example 195

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidemethanesulfonate hydrate

Methanesulfonic acid (0.006 ml, 0.09 mmol) was added to a 2-propanol(0.5 ml) solution of the compound (54 mg, 0.09 mmol) obtained in Example70 and the resulting mixture was dissolved by heating. After stirring atroom temperature for 3 days, the precipitate was collected by filtrationto give 27 mg (43%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.74 (3H, s), 1.03 (3H, s), 1.28-1.43 (2H,m), 1.44-1.82 (4H, m), 1.84-2.10 (3H, m), 2.14-2.28 (2H, m), 2.56-2.79(4H, m), 3.09-3.25 (1H, m), 3.72-3.80 (1H, m), 3.81-3.94 (2H, m),4.72-4.85 (1H, m), 5.35-5.54 (1H, m), 5.69-5.88 (1H, m), 6.55-6.68 (1H,m), 6.90 (1H, s), 7.08 (1H, dd, J=7.8, 1.8 Hz), 7.28-7.35 (1H, m),7.81-7.95 (1H, m), 8.14-8.36 (2H, m), 8.44-8.89 (1H, m), 9.83 (1H, brs), 11.03 (1H, br s).

Anal. Calcd for C₃₀H₃₄Cl₂FN₅O₄.CH₃SO₃H.H₂O: C, 50.82; H, 5.50; N, 9.56.Found: C, 50.78; H, 5.51; N, 9.53.

Example 196

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamideethanesulfonate hydrate

Ethanesulfonic acid (0.024 ml, 0.30 mmol) was added to a 2-propanol (2.4ml) solution of the compound (183 mg, 0.30 mmol) obtained in Example 70and the resulting mixture was dissolved by heating. After stirring atroom temperature for 23 hours, the precipitate was collected byfiltration to give 177 mg (82%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.62 (3H, s), 0.92 (3H, s), 1.05 (3H, t,J=7.4 Hz), 1.09-1.59 (6H, m), 1.62-2.06 (5H, m), 2.38 (2H, q, J=7.4 Hz),2.59-3.07 (1H, m), 3.27-3.79 (5H, m), 4.53-4.76 (1H, m), 4.78-5.16 (1H,m), 6.79 (1H, s), 7.00-7.23 (3H, m), 7.51-7.75 (2H, m), 8.21-8.41 (1H,m), 8.48-9.07 (1H, m), 10.35 (1H, br s), 11.19 (1H, br s).

Anal. Calcd For C₃₀H₃₄Cl₂FN₅O₄.C₂H₅SO₃H.H₂O: C, 51.54; H, 5.54; N, 9.39.Found: C, 51.42; H, 5.65; N, 9.35.

Example 197

(3′R,4′-S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidebenzenesulfonate hydrate

Benzenesulfonic acid monohydrate (30 mg, 0.17 mmol) was added to a2-propanol (1.0 ml) solution of the compound (104 mg, 0.17 mmol)obtained in Example 70 and the resulting mixture was dissolved byheating. After stirring at room temperature for 24 hours, theprecipitate was collected by filtration to give 116 mg (89%) of thetitle compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.69 (3H, s), 0.83 (3H, s), 1.09-1.85 (7H,m), 1.88-2.19 (4H, m), 2.53-2.77 (1H, m), 2.95-3.10 (1H, m), 3.53-3.69(1H, m), 3.71-3.89 (2H, m), 4.68-4.85 (1H, m), 5.47-5.80 (2H, m), 6.52(1H, s), 6.77-6.90 (1H, m), 7.03-7.11 (1H, m), 7.24-7.44 (5H, m),7.763-7.98 (4H, m), 8.09-8.43 (1H, m), 10.16 (1H, br s), 10.96 (1H, brs).

Anal. Calcd for C₃₀H₃₄Cl₂FN₅O₄.C₆H₅SO₃H.1.5H₂O: C, 53.80; H, 5.39; N,8.71. Found: C, 53.89; H, 5.40; N, 8.80.

Example 198

(3′R,4′S,5′R)-N-[(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidep-toluenesulfonate hydrate

P-toluenesulfonic acid monohydrate (16 mg, 0.08 mmol) was added to the2-propanol (0.5 ml) solution of the compound (52 mg, 0.08 mmol) obtainedin Example 70 and the resulting mixture was dissolved by heating. Afterstirring at room temperature for 4 hours, the precipitate was collectedby filtration to give 48 mg (72%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.63 (3H, s), 0.92 (3H, s), 1.09-1.59 (6H,m), 1.66-2.03 (5H, m), 2.29 (3H, s), 2.70-2.91 (1H, m), 3.34-3.74 (5H,m), 4.67 (1H, d, J=10.1 Hz), 4.80-5.11 (1H, m), 6.80 (1H, s), 7.02-7.22(5H, m), 7.43-7.52 (2H, m), 7.55-7.70 (2H, m), 8.23-8.39 (1H, m),8.45-8.74 (1H, m), 10.33 (1H, br s), 11.14 (1H, br s).

Anal. Calcd for C₃₀H₃₄Cl₂FN₅O₄.C₆H₄CH₃SO₃H.1.5H₂O: C, 54.34; H, 5.55; N,8.56. Found: C, 54.06; H, 5.45; N, 8.50.

Example 199

(3′R,4′S,5′R)-6″-chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-N-{(3R,6S)-6-[1-hydroxyethyl]tetrahydro-2H-pyran-3-yl}-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxamidebenzenesulfonate hydrate

Benzenesulfonic acid monohydrate (19 mg, 0.11 mmol) was added to anacetonitrile (0.6 ml) solution of the compound (isomer A) (67 mg, 0.11mmol) obtained in Example 93 and the resulting mixture was dissolved byheating. After stirring at room temperature for 26 hours, theprecipitate was collected by filtration to give 62 mg (80%) of the titlecompound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.72 (3H, s), 0.98 (3H, s), 1.04 (3H, d,J=6.4 Hz), 1.21-2.09 (12H, m), 2.59-2.73 (1H, m), 2.86-3.05 (2H, m),3.67-3.87 (3H, m), 4.74 (1H, d, J=10.5 Hz), 5.52-5.70 (1H, m), 6.84 (1H,s), 7.05 (1H, dd, J=8.2, 1.8 Hz), 7.23-7.29 (1H, m), 7.30-7.40 (3H, m),7.69 (2H, d, J=6.4 Hz), 7.83-7.98 (2H, m), 8.04-8.17 (1H, m), 8.44 (1H,br s), 9.88 (1H, br s), 10.93 (1H, br s).

Anal. Calcd for C₃₁H₃₇Cl₂FN₄O₄.C₆H₅SO₃H.1.75H₂O: C, 55.09; H, 5.87; N,8.24. Found: C, 54.68; H, 5.62; N, 8.73

REFERENCE EXAMPLES Reference Example 1

(3E/Z)-6-chloro-3-(3-chloro-2-fluorobenzylidene)-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

N,N-diisopropylethylamine (0.10 ml) was added to a methanol (30 ml)solution of 6-chloro-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one (633 mg,3.75 mmol) and 3-chloro-2-fluorobenzaldehyde (0.45 ml, 3.83 mmol) andthe resulting mixture was heated to reflux for 18 hours. After cooling,the precipitate was collected by filtration, washed with cold methanol,and dried to give 920 mg (79%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.02 (1H, d, J=8.0 Hz), 7.30 (1H, t, J=8.0Hz), 7.53 (1H, d, J=7.8 Hz), 7.66-7.78 (3H, m), 11.4 (1H, s).

Reference Example 2

[Step 1]

2-Amino-1,5-anhydro-2,3,4-trideoxy-D-erythro-hexitol hydrochloride

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-hexitol(Eur. J. Org. Chem., 2003, 2418-2427) (6.00 g, 0.03 mol) was dissolvedin methanol (20 ml), 4N hydrochloric acid/1,4-dioxane solution (60 ml)was added and the resulting mixture was stirred at room temperature for1 hour. The reaction solvent was evaporated under reduced pressure togive 4.5 g (100%) of the title compound as a colorless solid.

¹H NMR (400 MHz, DMSO-d₆) δ: 1.25 (1H, ddd, J=24.3, 13.3, 3.7 Hz), 1.52(1H, ddd, J=24.7, 12.4, 3.9 Hz), 1.66-1.72 (1H, m), 2.03-2.09 (1H, m),2.97-3.06 (1H, m), 3.19-3.37 (4H, m), 3.96-4.00 (1H, m).

MS (ESI) m/z: 132 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-{[(benzyloxy)carbonyl]amino}-2,3,4-trideoxy-D-erythro-hexitol

The compound (3.5 g, 21.0 mmol) obtained an Step 1 above was dissolvedin 5N aqueous sodium hydroxide solution (40 ml) and benzyloxycarbonylchloride (3.3 ml, 23.0 mmol) was added dropwise at 0° C. After stirringat room temperature for 16 hours, the reaction mixture was renderedacidic by addition of 1N hydrochloric acid, followed by extraction withethyl acetate. The organic layer was washed with brine and dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure, diethyl ether and hexane were added to the residue obtainedand then the slurry was filtered and dried to give 2.06 g (37%) of thetitle compound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.33 (1H, ddd, J=24.5, 12.3, 3.9 Hz), 1.48(1H, ddd, J=24.3, 13.2, 3.5 Hz), 1.61-1.67 (1H, m), 1.95-2.00 (1H, m),2.09-2.16 (1H, m), 3.05 (1H, t, J=10.6 Hz), 3.34-3.41 (1H, m), 3.50-3.55(1H, m), 3.57-3.64 (1H, m), 3.65-3.72 (1H, m), 4.11-4.17 (1H, m), 4.48(1H, br s), 5.06-5.13 (2H, m), 7.32-7.38 (5H, m).

MS (ESI) m/z: 266 (M+H)⁺.

[Step 3]

2-Amino-1,5-anhydro-2,3,4-trideoxy-D-erythro-hexitol

The compound (2.00 g, 7.54 mmol) obtained in Step 2 above was dissolvedin methanol (30 ml), 10% palladium carbon (300 mg) was added and theresulting mixture was stirred at room temperature for 4 hours in ahydrogen atmosphere. The catalyst was removed by filtration throughcelite and then the filtrate was concentrated under reduced pressure anddried to give 1.13 g (100%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.07-1.20 (2H, m), 1.54-1.61 (1H, m),1.82-1.88 (1H, m), 2.50-2.56 (1H, m), 2.82 (1H, t, J=10.5 Hz), 3.08-3.14(1H, m), 3.24 (1H, dd, J=11.2, 4.8 Hz), 3.33 (1H, dd, J=11.0, 6.0 Hz),3.73 (1H, dq, J=10.8, 2.2 Hz).

MS (ESI) m/z: 132 (M+H)⁺.

Reference Example 3

[Step 1]

Benzyl [trans-4-(hydrazinocarbonyl)cyclohexyl]carbamate

Hydrazine monohydrate (1.42 ml, 23.4 mmol), 1-hydroxybenzotriazole (2.44g, 18.0 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (4.49 g, 23.4 mmol) were added to an N,N-dimethylformamide(75 ml) solution of trans-4-(carbobenzoxyamino)cyclohexanecarboxylicacid (5.00 g, 18.0 mmol) at room temperature and the resulting mixturewas stirred for 3 days. Water (150 ml) was added to the reaction mixtureand the precipitated solid was collected by filtration and dried underreduced pressure to give 4.52 g (86%) of the title compound as acolorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.09-1.20 (2H, m), 1.56-1.67 (2H, m),1.86-1.94 (2H, m), 1.96-2.05 (1H, m), 2.07-2.17 (2H, m), 3.43-3.57 (1H,m), 3.65-4.05 (2H, m), 4.54-4.63 (1H, m), 5.08 (2H, s), 6.68 (1H, s),7.30-7.39 (5H, m).

[Step 2]

Benzyl [trans-4-(1,3,4-oxadiazol-2-yl)cyclohexyl]carbamate

Trimethyl orthoformate (2 ml) and a boron trifluoride-diethyl ethercomplex (0.02 ml, 0.17 mmol) were added to an N,N-dimethylacetamide (20ml) solution of the compound (1.00 g, 3.43 mmol) obtained in Step 1above at room temperature and the resulting mixture was stirred at 50°C. for 8 hours under nitrogen atmosphere. The reaction mixture wascooled, triethylamine (0.29 ml, 2.06 mmol) was added at roomtemperature, the resulting mixture was stirred overnight, then water wasadded and the precipitated solid was collected by filtration and driedto give 0.91 g (88%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.23-1.34 (2H, m), 1.67-1.80 (2H, m),2.15-2.24 (4H, m), 2.85-2.95 (1H, m), 3.52-3.65 (1H, m), 4.59-4.69 (1H,m), 5.10 (2H, s), 7.30-7.38 (5H, m), 8.33 (1H, s).

[Step 3]

Trans-4-(1,3,4-oxadiazol-2-yl)cyclohexanamine

The compound (2.85 g, 9.45 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 1.55 g (98%) of the title compound as a pale yellowsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.21-1.31 (2H, m), 1.62-1.72 (2H, m),1.74-1.90 (2H, m), 1.98-2.05 (2H, m), 2.14-2.21 (2H, m), 2.73-2.80 (1H,m), 2.85-2.93 (1H, m), 8.38 (1H, s).

Reference Example 4

(3E/Z)-6-chloro-3-[(2-chloropyridin-4-yl)methylene]-1,3-dihydro-2H-indol-2-one

N,N-diisopropylethylamine (22.5 ml, 135 mmol) was added to a methanol(2000 ml) solution of 6-chloro-1,3-dihydro-2H-indol-2-one (141 g, 841mmol) and 2-chloroisonicotinaldehyde (131 g, 925 mmol) and the resultingmixture was heated to reflux for 16 hours. After cooling, theprecipitate was collected by filtration, washed with cold methanol, anddried to give 194 g (79%) of the title compound as an orange solid.

MS (ESI) m/z: 291 (M+H)⁺.

Reference Example 5

[Step 1]

2-[(2S,5R)-5-(dibenzylamino)tetrahydro-2H-pyran-2-yl]propan-2-ol

Methyl 2,6-anhydro-3,4,5-trideoxy-5-(dibenzylamino)-L-erythro-hexonate(16.0 g, 47.0 mmol) was dissolved in tetrahydrofuran (200 ml), undernitrogen atmosphere, methyl magnesium bromide/tetrahydrofuran solution(1.06 mol/l, 300 ml, 0.32 mol) was added dropwise at 0° C. and then theresulting mixture was stirred at room temperature for 16 hours. Afterice cooling again, aqueous ammonium chloride solution (300 ml) wasgradually added to the reaction mixture and the resulting mixture wasstirred for 30 minutes. The reaction mixture was diluted with ethylacetate and the organic layer was washed with brine. The organic layerwas dried over anhydrous magnesium sulfate and the solvent wasevaporated under reduced pressure. The residue obtained was purified bysilica gel column chromatography [n-hexane:ethyl acetate=3:1 (v/v)] togive 15.5 g (97%) of the title compound as a pale yellow oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.08 (3H, s), 1.14 (3H, s), 1.26-1.36 (1H,m), 1.53-1.62 (1H, m), 1.69-1.75 (1H, m), 2.04-2.10 (1H, m), 2.40 (1H,s), 2.69-2.77 (1H, m), 3.00 (1H, dd, J=11.4, 1.8 Hz), 3.41 (1H, t,J=10.8 Hz), 3.61-3.71 (4H, m), 4.03-4.08 (1H, m), 7.20-7.37 (10H, m).

MS (ESI) m/z: 340 (M+H)⁺.

[Step 2]

2-[(2S5R)-5-aminotetrahydro-2H-pyran-2-yl]propan-2-ol

The compound (15.5 g, 46.0 mmol) obtained in Step 1 above was dissolvedin ethanol (300 ml), 20% palladium hydroxide (3.0 g) was added and theresulting mixture was stirred at room temperature for 2 days under ahydrogen atmosphere. The catalyst was removed by filtration throughcelite and then the solvent in the filtrate was evaporated under reducedpressure and dried to give 7.10 g (98%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.00 (3H, s), 1.06 (3H, s), 1.27-1.37 (1H,m), 1.45-1.54 (1H, m), 1.74-1.80 (1H, m), 2.04-2.12 (1H, m), 2.92 (1H,d, J=11.4 Hz), 2.96-3.01 (1H, m), 3.24 (1H, t, J=10.8 Hz), 4.00-4.05(1H, m), 4.28 (1H, br s), 8.16 (2H, br s).

MS (ESI) m/z: 160 (M+H)⁺.

Reference Example 6

(3E/Z)-6-chloro-3-(3-chloro-5-fluorobenzylidene)-1,3-dihydro-2H-indol-2-one

3-Chloro-5-fluorobenzaldehyde (3.00 g, 18.9 mmol) was used as a startingmaterial and treated in the same way as in Reference Example 4 to give3.19 g (56%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 6.89-6.91 (1H, m), 6.93-6.97 (1H, m), 7.34(1H, d, J=8.3 Hz), 7.52-7.58 (2H, m), 7.58-7.62 (2H, m), 10.84 (1H, s).

MS (APCI) m/z: 308 (M+H)⁺.

Reference Example 7

(3E/Z)-3-(3-chloro-2-fluorobenzylidene)-2-oxo-2,3-dihydro-1H-indole-6-carbonitrile

2-Oxo-2,3-dihydro-1H-indole-6-carbonitrile (400 mg, 2.53 mmol) was usedas a starting material and treated in the same way as in ReferenceExample 1 to give 635 mg (31%) of the title compound as a brown solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.24-7.42 (4H, m), 7.72-7.80 (3H, m), 11.07(1H, s).

Reference Example 8

(3E/Z)-6-chloro-3-[(2-chloro-3-fluoropyridin-4-ylmethylene]-1,3-dihydro-2H-indol-2-one

2-Chloro-3-fluoroisonicotinaldehyde (2.20 g, 13.8 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 3.37 g (83%) of the title compound as a yellow solid.

MS (APCI) m/z: 309 (M+H)⁺.

Reference Example 9

[Step 1]

2-Amino-1,5-anhydro-6-O-[tert-butyl(dimethyl)silyl]-2,3,4-trideoxy-D-erythro-hex-3-enitol

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-6-O-[tert-butyl(dimethyl)silyl]-2,3,4-trideoxy-D-erythro-hex-3-enitol(Eur. J. Org. Chem., 2003, 2418-2427) (1.02 g, 2.97 mmol),tert-butyldimethylsilyl trifluoromethanesulfonate (4.10 ml, 17.8 mmol),and 2,6-lutidine (1.73 ml, 14.9 mmol) were mixed with dichloromethane (3ml) and the resulting mixture was stirred at room temperature for 2hours. Saturated ammonium chloride solution (50 ml) was added to thereaction mixture, followed by extraction with dichloromethane. Theorganic layer was washed with brine and dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure and theresidue obtained was purified by silica gel column chromatography[chloroform:methanol=40:1→9:1 (v/v)] to give 295 mg (41%) of the titlecompound as a light brown oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.07 (6H, s), 0.90 (9H, s), 1.43 (2H, br s),3.23 (1H, dd, J=10.9, 7.9 Hz), 3.39-3.44 (1H, m), 3.54 (1H, dd, J=10.3,5.9 Hz), 3.69 (1H, dd, J=10.3, 6.1 Hz), 4.06 (1H, dd, J=11.5, 5.6 Hz),4.08-4.12 (1H, m), 5.78 (1H, dt, J=10.4, 1.8 Hz), 5.83-5.87 (1H, m).

MS (ESI) m/z: 244 (M+H)⁺.

[Step 2]

2-Amino-1,5-anhydro-2,3,4-trideoxy-D-erythro-hex-3-enitol hydrochloride

The compound (1.0 g, 3.0 mmol) obtained in Step 1 above was dissolved in1,4 -dioxane (4 ml), 4N hydrochloric acid/1,4-dioxane solution (10 ml)was added and the resulting mixture was stirred at room temperature for2 hours. The solvent was evaporated under reduced pressure to give 620mg (100%) of the title compound as a light brown solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 3.38 (1H, dd, J=11.2, 4.8 Hz), 3.46 (1H,dd, J=11.4, 6.4 Hz), 3.52-3.59 (1H, m), 3.64-3.70 (1H, m), 4.04 (1H, dd,J=11.4, 4.6 Hz), 4.05-4.09 (1H, m), 5.89 (1H, dt, J=10.5, 2.7 Hz),6.05-6.08 (1H, m), 8.31 (2H, br s).

MS (ESI) m/z: 130 (M+H)⁺.

Reference Example 10

(3E/Z)-3-(3-bromo-5-chlorobenzylidene)-6-chloro-1,3-dihydro-2H-indol-2-one

3-Bromo-5-chlorobenzaldehyde (4.90 g, 22.4 mmol) was used and treated inthe same way as in Reference Example 4 to give 8.11 g (98%) of the titlecompound as a yellow solid.

MS (FAB) m/z: 367 (M+H)⁺.

Reference Example 11

(3E/Z)-6-chloro-3-[(2-chloro-3-fluoropyridin-4-yl)methylene]-5-fluoro-1,3-dihydro-2H-indol-2-one

6-Chloro-5-fluoro-1,3-dihydro-2H-indol-2-one (928 mg, 5.0 mmol) was usedas a starting material and treated in the same way as in ReferenceExample 8 to give 1.6 g (97%) of the title compound as a yellow solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.03 (1H, dd, J=6.3, 0.7 Hz), 7.18 (1H, d,J=9.3 Hz), 7.55 (1H, s), 7.79 (1H, t, J=5.0 Hz), 8.41 (1H, d, J=4.9 Hz),10.94 (1H, s).

Reference Example 12

(3E/Z)-6-chloro-3-[(2-chloro-3-fluoropyridin-4-yl)methylene]-1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one

2-Chloro-3-fluoroisonicotinaldehyde (1.14 g, 7.16 mmol) was used as astarting material and treated in the same way as in Reference Example 1to give 1.46 g (69%) of the title compound as a brown solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 7.02 (0.7H, d, J=8.0 Hz), 7.18 (0.3H, d,J=8.0 Hz), 7.54 (0.7H, d, J=8.0 Hz), 7.63 (0.7H, s), 7,78 (0.7H, t,J=4.9 Hz), 7.89 (0.3H, s), 7.99 (0.3H, d, J=5.2 Hz), 8.18 (0.3H, d,J=3.0 Hz), 8.33 (0.3H, d, J=5.2 Hz), 8.40 (0.7H, d, J=5.2 Hz).

Reference Example 13

[Step 1]

Tert-butyl[trans-4-(3-{[tert-butyl(diphenyl)silyl]oxy}azetidin-1-yl)cyclohexyl]carbamate

1,3-Dibromo-2-propanol (1.70 ml, 16.5 mmol) and sodium carbonate (15.9g, 150 mmol) were added to an ethanol (300 ml) solution oftert-butyl(trans-4-aminocyclohexyl) carbamate (3.21 g, 15.0 mmol) andthe resulting mixture was stirred under heating to reflux overnight.After cooling, insoluble matter was removed by filtration through celiteand then the filtrate was concentrated under reduced pressure. Theresidue was diluted with water, followed by extraction with ethylacetate. Then the organic layer was washed with brine. The organic layerwas dried over anhydrous sodium sulfate and then the solvent wasevaporated under reduced pressure. The residue was dissolved inN,N-dimethylformamide (15 ml) and imidazole (2.45 g, 36.0 mmol) andtert-butyldiphenylchlorosilane (4.29 ml, 16.5 mmol) were added under icecooling. After stirring at room temperature for 1 hour, the reactionmixture was diluted with ethyl acetate and washed with water and brinein that order. The organic layer was dried over anhydrous magnesiumsulfate, then the solvent was evaporated under reduced pressure and theresidue was purified by silica gel column chromatography[chloroform:methanol=10:0→10:1 (v/v)] to give 2.45 g (32%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.01-1.13 (4H, m), 1.06 (9H, s), 1.46 (9H,s), 1.74-1.80 (2H, m), 1.93-2.03 (3H, m), 2.87 (2H, t, J=7.2 Hz),3.35-3.43 (1H, m), 3.51 (2H, t, J=6.9 Hz), 4.42 (1H, t, J=6.3 Hz),7.37-7.41 (4H, m), 7.42-7.47 (2H, m), 7.61-7.65 (4H, m).

[Step 2]

1-(Trans-4-aminocyclohexyl)azetidin-3-ol dihydrochloride

The compound (2.45 g, 4.82 mmol) obtained in Step 1 above was suspendedin methanol (9 ml), 4N hydrochloric acid/1,4-dioxane solution (18 ml)was added and the resulting mixture was stirred at room temperature.After 48 hours, diethyl ether was added to the reaction mixture and theprecipitated solid was collected by filtration and dried to give 1.08 g(92%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.33-1.56 (4H, m), 2.11-2.21 (4H, m),3.13-3.15 (1H, m), 3.22-3.26 (1H, m), 3.92-3.99 (2H, m), 4.36-4.39 (2H,m), 4.56-4.67 (1H, m).

Reference Example 14

[Step 1]

1,5-Anhydro-4,6-O-benzylidene-3-deoxy-2-O-(methylsulfonyl-D-arabino-hexitol

Methanesulfonyl chloride (4.70 ml, 61.0 mmol) was added to adichloromethane (250 ml) solution of1,5-anhydro-4,6O-benzylidene-3-deoxy-D-arabino-hexitol (WO2005/049582)(12.0 g, 50.8 mmol) and triethylamine (8.50 ml, 61.0 mmol) under icecooling. After stirring at the same temperature for 45 minutes, waterwas added and the resulting mixture was subjected to extraction withchloroform. The organic layer was washed with brine and dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure to give the title compound.

[Step 2]

1,5-anhydro-2-azido-4,6-O-benzylidene-2,3-dideoxy-D-ribo-hexitol

An N,N-dimethylformamide (380 ml) solution of the compound (16.0 g, 50.8mmol) obtained in Step 1 above combined with sodium azide (6.60 g, 102mmol) was stirred at 80° C. for 66 hours. N,N-dimethylformamide wasevaporated under reduced pressure, then ether was added and the organiclayer was washed with water and brine and then dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure,n-hexane was added and the precipitated solid was collected byfiltration to give 7.50 g (56%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.68-1.79 (1H, m), 2.49-2.57 (1H, m),3.23-3.35 (2H, m), 3.54-3.72 (3H, m), 4.01-4.09 (1H, m), 4.31 (1H, dd,J=10.6, 4.6 Hz), 5.54 (1H, s), 7.33-7.52 (5H, m).

[Step 3]

1,5-Anhydro-2-azido-2,3-dideoxy-D-ribo-hexitol

The compound (8.00 g, 30.6 mmol) obtained in Step 2 above was dissolvedin acetic acid (160 ml) and water (40 ml) and the resulting solution wasstirred at 90° C. for 1 hour and then concentrated under reducedpressure. The residue was purified by silica gel column chromatography[n-hexane:ethyl acetate=3:1→1:3 v/v)] to give 4.70 g (89%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.47-1.58 (1H, m), 1.95-2.02 (1H, m), 2.26(1H, d, J=5.0 Hz), 2.45-2.53 (1H, m), 3.11-3.21 (2H, m), 3.47-3.57 (1H,m), 3.66-3.75 (1H, m), 3.77-3.91 (2H, m), 3.97-4.04 (1H, m).

[Step 4]

2-Amino-1,5-anhydro-2,3-dideoxy-D-ribo-hexitol

10% Palladium carbon (120 mg) was added to a methanol (14 ml) solutionof the compound (500 mg, 2.89 mmol) obtained in Step 3 above and theresulting mixture was stirred for 6 hours under hydrogen atmosphere. Thecatalyst was removed by filtration through celite and then the solventwas evaporated under reduced pressure to give 341 mg (80%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.00-1.10 (1H, m), 1.38 (2H, br s),2.01-2.10 (1H, m), 2.55-2.65 (1H, m), 2.71-2.78 (1H, m), 2.78-2.85 (1H,m), 3.13-3.24 (1H, m), 3.29-3.39 (1H, m), 3.61-3.72 (2H, m), 4.36-4.44(1H, m), 4.70 (1H, d, J=5.50 Hz).

MS (ESI) m/z: 148 (M+H)⁺.

Reference Example 15

Cis-4-amino-1-hydroxymethyl)cyclohexanol hydrochloride

tert-Butyl[cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]carbamate(WO2010/027500) (376 mg, 1.53 mmol) was used as a starting material andtreated in the same way as in Step 1 of Reference Example 2 to give thetitle compound as a colorless solid.

Reference Example 16

[Step 1]

Benzyl (trans-4-carbamoylcyclohexyl) carbamate

Triethylamine (1.4 ml, 10.1 mmol) was added, to an N,N-dimethylformamide(120 ml) solution oftrans-4-{[(benzyloxy)carbonyl]amino}cyclohexanecarboxylic acid (1.40 g,5.10 mmol), ammonium chloride (0.54 g, 10.1 mmol),1-hydroxybenzotriazole (0.39 g, 2.50 mmol), and1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (1.35 g,7.10 mmol) and the resulting mixture was stirred at room temperature for19 hours. Water was added and the precipitated solid was collected byfiltration to give 1.20 g (86%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.07-1.21 (2H, m), 1.26-1.41 (2H, m),1.68-1.87 (4H, m), 1.92-2.04 (1H, m), 3.15-3.27 (1H, m), 4.99 (2H, s),6.67 (1H, br s), 7.12-7.21 (2H, m), 7.27-7.40 (5H, m).

MS (ESI) m/z: 277 (M+H)⁺.

[Step 2]

Benzyl(trans-4-{[(E)-(dimethylamino)methylidene]carbamoyl}cyclohexyl)carbamate

An N,N-dimethylformamide dimethyl acetal (20 ml) solution of thecompound (1.20 g, 4.34 mmol) obtained in Step 1 above was stirred at120° C. for 3 hours. The solvent was evaporated under reduced pressure,then diethyl ether was added and the precipitated solid was collected byfiltration to give 0.97 g (67%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.09-1.22 (2H, m), 1.51-1.60 (2H, m),1.97-2.14 (4H, m), 2.22-2.34 (1H, m), 3.06 (3H, s), 3.10 (3H, s),3.41-3.58 (1H, m), 4.53-4.64 (1H, m), 5.09 (2H, s), 7.23-7.37 (5H, m),8.39 (1H, s).

MS (ESI) m/z: 332 (M+H)⁺.

[Step 3]

Benzyl [trans-4-(4H-1,2,4-triazol-3-yl)cyclohexyl]carbamate

Hydrazine monohydrate (0.21 ml, 3.51 mmol) was added to an acetic acid(25 ml) solution of the compound (970 mg, 2.93 mmol) obtained in Step 2above and the resulting mixture was stirred at room temperature for 2hours. Water was added and the precipitated solid was collected byfiltration to give 717 mg (82%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.23-1.58 (4H, m), 1.85-2.05 (4H, m),2.47-2.55 (1H, m), 3.29-3.36 (1H, m), 5.01 (2H, s), 7.22-7.40 (6H, m).

MS (ESI) m/z: 301 (M+H)⁺.

[Step 4]

Trans-4-(4H-1,2,4-triazol-3-yl)cyclohexanamine

The compound (360 mg, 1120 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 63 mg (31%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.22-1.38 (2H, m), 1.56-1.70 (2H, m),1.95-2.11 (4H, m), 2.67-2.84 (2H, m), 8.05 (1H, s).

Reference Example 17

[Step 1]

Tert-butyl[trans-4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-4-hydroxycyclohexyl]carbamate(A)

Cis-tert-butyl-1-oxaspiro[2.5]oct-6-ylcarbamate (WO2010/027500) (4.15 g,18.3 mmol) was dissolved in 1,2-dimethoxyethane (50 ml) and water (200ml), potassium hydroxide (5.13 g, 91.5 mmol) was added, and theresulting mixture was heated to reflux for 3 hours. After cooling, theprecipitate was removed by filtration and the filtrate was subjected toextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure to give 2.33 g of a mixture oftert-butyl [cis-4-hydroxy-4-(hydroxymethyl)cyclohexyl]carbamate andtert-butyl [trans-4-hydroxy-4-(hydroxymethyl) cyclohexyl]carbamate as acolorless solid. The mixture above was dissolved inN,N-dimethylformamide (20 ml), tert-butyldiphenylchlorosilane (4.13 g,15.0 mmol) and imidazole (2.74 g, 40.0 mmol) were added and theresulting mixture was stirred at room temperature for 1 hour. Thereaction mixture was diluted with ethyl acetate, washed with water andbrine, and dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [acetonitrile:benzene=1:9 (v/v)] togive 0.81 g (9%) of the title compound as a colorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.07 (9H, s), 1.17-1.27 (2H, m), 1.43 (9H,s), 1.53-1.66 (4H, m), 1.85-1.91 (2H, m), 2.54 (1H, s), 3.53 (2H, s),3.61 (1H, m), 4.38 (1H, m), 7.38-7.47 (6H, m), 7.64-7.66 (4H, m).

MS (APCI) m/z: 482 (M−H)⁻.

[Step 2]

Tert-butyl [trans-4-hydroxy-4-(hydroxymethyl)cyclohexyl]carbamate

Tetrabutylammonium fluoride/tetrahydrofuran solution (1.0 mol/l, 2.0 ml)was added to a tetrahydrofuran (8 ml) solution of the compound (0.80 g,1.65 mmol) obtained in Step 1 above and the resulting mixture wasstirred at room temperature for 1 hour. The solvent was evaporated underreduced pressure and the residue was purified by silica gel columnchromatography [chloroform:methanol=9:1 (v/v)] to give 372 mg (92%) ofthe title compound as a colorless solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.19-1.31 (4H, m), 1.37 (9H, s), 1.61-1.67(4H, m), 3.24 (2H, d, J=5.5 Hz), 3.34 (1H, m), 3.94 (1H, s), 4.33 (1H,t, J=6.0 Hz), 6.63 (1H, d, J=6.9 Hz).

MS (FAB) m/z: 246 (M+H)⁺.

[Step 3]

Trans-4-amino-1-(hydroxymethyl)cyclohexanol hydrochloride

The compound (67 mg, 0.27 mmol obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a colorless solid.

Reference Example 18

[Step 1]

Methyl 5-amino-2,6-anhydro-3,4,5-trideoxy-L-erythro-hexonatehydrochloride

4N hydrochloric acid/1,4-dioxane solution (20 ml) was added to amethanol (5 ml) solution of2,6-anhydro-5-[(tert-butoxycarbonyl)amino]-3,4,5-trideoxy-L-erythro-hexonicacid (Eur. J. Org. Chem., 2003, 2418-2427) (1.00 g, 4.08 mmol) at roomtemperature and the resulting mixture was stirred for 20 hours. Thereaction mixture was concentrated under reduced pressure to give 0.80 g(100%) of the title compound.

MS (ESI) m/z: 160 (M+H)⁺.

[Step 2]

Methyl2,6-anhydro-5-{[(benzyloxy)carbonyl]amino}-3,4,5-trideoxy-L-erythro-hexonate

The compound (0.80 g, 4.08 mmol) obtained in Step 1 above was dissolvedin acetonitrile (10 ml) and water (20 ml), sodium bicarbonate (1.71 g,30.4 mmol) and carbobenzoxy chloride (0.72 ml, 4.89 mmol) were addedunder ice cooling and the resulting mixture was stirred at 5° C. for 21hours. Saturated sodium bicarbonate solution was added to the reactionmixture, followed by extraction with dichloromethane:methanol [10:1(v/v)]. The organic layer was dried over anhydrous sodium sulfate. Thesolvent was concentrated under reduced pressure and the residue obtainedwas purified by silica gel column chromatography [n-hexane:ethylacetate=17:3→3:2 (v/v)] to give 0.97 g (81%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.38-1.54 (1H, m), 1.66-1.85 (1H, m),2.03-2.16 (2H, m), 3.12-3.23 (1H, m), 3.70-3.80 (4H, m), 3.91-4.01 (1H,m), 4.15-4.25 (1H, m), 4.66-4.79 (1H, m), 5.01-5.17 (2H, m), 7.29-7.39(5H, m).

[Step 3]

2,6-anhydro-5-{[(benzyloxy)carbonyl]amino}-3,4,5-trideoxy-L-erythro-hexonicacid

1N sodium hydroxide solution (55.4 ml, 55.4 mmol) was added to atetrahydrofuran (110 ml) solution of the compound (8.12 g, 27.7 mmol)obtained in Step 2 above at room temperature and the resulting mixturewas stirred for 2 hours. 10% Citric acid solution was added under icecooling, followed by extraction with ethyl acetate. Then the organiclayer was washed with brine. The organic layer was dried over anhydroussodium sulfate, then the solvent was concentrated under reduced pressureand the residue was dried under reduced pressure to give 7.78 g (100%)of the title compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.45-1.73 (2H, m), 1.98-2.16 (2H, m),3.10-3.20 (1H, m), 3.51-3.64 (1H, m), 3.85-3.95 (1H, m), 4.08-4.09 (1H,m), 5.06 (2H, s), 6.93-7.08 (1H, m), 7.22-7.44 (5H, m).

[Step 4]

Benzyl [(3R,6S)-6-(hydrazinocarbonyl)tetrahydro-2H-pyran-3-yl]carbamate

Hydrazine monohydrate (0.23 ml, 3.86 mmol), 1-hydroxybenzotriazole (434mg, 3.21 mmol), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (740 mg, 3.86 mmol) were added to an N,N-dimethylformamide(16 ml) solution of the compound (898 mg, 3.21 mmol) obtained in Step 3above at room temperature and the resulting mixture was stirred for 18hours. The reaction mixture was subjected, to extraction withchloroform:methanol [10:1 (v/v)] and the organic layer was washed withsaturated sodium: bicarbonate solution and then dried over anhydroussodium sulfate. The solvent was concentrated under reduced pressure andthe residue obtained was purified by silica gel column chromatography[dichloromethane:methanol=49:1→13:1 (v/v)] to give 811 mg (86%) of thetitle compound as a colorless solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.42-1.60 (2H, m), 2.00-2.16 (2H, m), 3.11(1H, t, J=10.8 Hz), 3.50-3.62 (1H, m), 3.75-3.83 (1H, m), 4.02-4.11 (1H,m), 5.06 (2H, s), 7.26-7.37 (5H, m).

MS (ESI) m/z: 294 (M+H)⁺.

[Step 5]

Benzyl[(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (2.27 g, 7.74 mmol) obtained in Step 4 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 3 at room temperature to give 2.00 g (85%) of the title compoundas a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.49-1.63 (1H, m), 2.04-2.30 (3H, m),3.27-3.37 (1H, m), 3.76-3.90 (1H, m), 4.14-4.22 (1H, m), 4.66-4.77 (2H,m), 5.04-5.19 (2H, m), 7.31-7.40 (5H, m), 8.41 (1H, s).

MS (ESI) m/z: 304 (M+H)⁺.

[Step 6]

(3R,6S)-6-(1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-amino

The compound (749 mg, 2.47 mmol) obtained in Step 5 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 418 mg (100%) of the title compound as a light brownsolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.36-1.48 (1H, m), 1.98-2.10 (1H, m),2.12-2.25 (2H, m), 2.93-3.02 (1H, m), 3.18-3.25 (1H, m), 4.04-4.11 (1H,m), 4.63-4.69 (1H, m), 8.42 (1H, s).

Reference Example 19

[Step 1]

Benzyl[trans-4-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)cyclohexyl]carbamate

Triphosgene (0.36 g, 1.17 mmol) was added to a 1,4-dioxane (15 ml)suspension of the compound (1.00 g, 3.43 mmol) obtained in Step 1 ofReference Example 3 under ice cooling and the resulting mixture wasstirred at room temperature for 20 hours. Water was added to thereaction mixture, the resulting mixture was stirred for 70 minutes andthen the solid was collected by filtration and dried under reducedpressure to give 685 mg (63%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.17-1.28 (2H, m), 1.54-1.65 (2H, m),2.05-2.21 (4H, m), 2.46-2.56 (1H, m), 3.47-3.61 (1H, m), 4.58-4.66 (1H,m), 5.09 (2H, s), 7.29-7.39 (5H, m), 8.12 (1H, s).

[Step 2]

5-(Trans-4-aminocyclohexyl)-1,3,4-oxadiazol-2(3H)-one

The compound (685 mg, 2.16 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 341 mg (86%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 1.21-1.32 (2H, m), 1.40-1.51 (2H, m),1.88-2.05 (4H, m), 2.43-2.51 (1H, m), 2.75-2.83 (1H, m).

Reference Example 20

[Step 1]

Methyl 3-[(tert-butoxycarbonyl)amino]-5-chlorobenzoate

Zinc powder (7.54 g, 116 mmol) and acetic acid (23 ml) were added to amethanol (230 ml) solution of methyl 3-chloro-5-nitrobenzoate (5.00 g,23.0 mmol) under ice cooling and the resulting mixture was heated toreflux for 4 hours. The reaction mixture was filtered through celite andthen saturated sodium bicarbonate solution was added to the filtrate,followed by extraction with ethyl acetate. The organic layer was driedover anhydrous sodium sulfate, then the solvent was concentrated underreduced pressure and the residue obtained was dissolved intetrahydrofuran (250 ml). Di-tert-butyl bicarbonate (7.52 g, 34.5 mmol)and 4-dimethylaminopyridine (141 mg, 1.16 mmol) were added and theresulting mixture was heated at 50° C. for 16 hours. Saturated sodiumbicarbonate solution was added to the reaction mixture, followed byextraction with ethyl acetate. The organic layer was dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue obtained was purified by silica gel columnchromatography [n-hexane:ethyl acetate=2:1 (v/v)] to give 2.77 g (41%)of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.51 (9H, s), 3.91 (3H, s), 6.61 (1H, br s),7.66-7.68 (1H, m), 7.74-7.77 (1H, m), 7.80-7.85 (1H, m).

MS (FAB) m/z: 286 (M+H)⁺.

[Step 2]

Tert-butyl (3-chloro-5-formylphenyl) carbamate

Lithium borohydride (294 mg, 1.40 mmol) was added to a tetrahydrofuran(100 ml) solution of the compound (2.67 g, 9.36 mmol) obtained in Step 1above under ice cooling and the resulting mixture was stirred at roomtemperature for 3 days and then stirred at 50° C. for 2 hours. Water wasadded to the reaction mixture, followed by extraction with ethylacetate. The organic layer was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue was dissolved in dichloromethane (100 ml).Dimethyl sulfoxide (2.00 ml, 28.1 mmol), N,N-diisopropylethylamine (4.81ml, 28.1 mmol), and a sulfur trioxide-pyridine complex (4.38 g, 28.1mmol) were added and the resulting mixture was stirred at roomtemperature for 16 hours. Saturated sodium bicarbonate solution wasadded to the reaction mixture, followed by extraction with ethylacetate. The organic layer was washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue obtained was purified by silica gel columnchromatography [n-hexane:ethyl acetate=4:1 (v/v] to give 2.21 g (92%) ofthe title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.53 (9H, s), 6.65 (1H, br s), 7.50-7.54 (1H,m), 7.71-7.74 (1H, m), 7.75-7.78 (1H, m), 9.92 (1H, s).

MS (FAB) m/z: 256 (M+H)⁺.

[Step 3]

Tert-butyl{3-chloro-5-[(3E/Z)-(6-chloro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]phenyl}carbamate

6-Chloro-1,3-dihydro-2H-indol-2-one (1.31 g, 7.85 mmol) and the compound(2.01 g, 7.85 mmol) obtained in Step 2 above were dissolved in methanol(40 ml) at room temperature and N,N-diisopropylethylamine (0.21 ml, 1.25mmol) was added. After heating to reflux for 24 hours, saturated sodiumbicarbonate solution was added to the reaction mixture, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=4:1 (v/v)] to give 2.53 g (82%)of the title compound as an orange solid.

MS (FAB) m/z: 405 (M+H)⁺.

Reference Example 21

[Step 1]

1,1-Bis(fluoromethyl)-3,3-dimethoxycyclobutane

Tetrabutylammonium fluoride/tetrahydrofuran solution (1.0 mol/l, 74.3ml, 74.3 mmol) was added to a tetrahydrofuran (5 ml) solution of(3,3-dimethoxycyclobutane-1,1-diyl)bis(methylene)bis(4-methylbenzenesulfonate)(390 g, 18.6 mmol) and the resulting mixture was stirred at 50° C. for20 hours. After cooling, tetrabutylammonium fluoride/tetrahydrofuransolution (1.0 mol/l, 37.1 ml, 37.1 mmol) was further added and theresulting mixture was stirred at 50° C. for 12 hours. After cooling,saturated sodium bicarbonate solution was added at 0° C., followed byextraction with diethyl ether. The organic layer was washed withsaturated ammonium chloride solution and brine and then dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure (80 mmHg, 17° C.) and the residue was purified by silica gelcolumn chromatography [n-hexane:ether=9:1→1:1 (v/v)] to give 3.90 g(95%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 2.05 (4H, m), 3.15 (6H, s), 4.39-4.51 (4H,m).

[Step 2]

3,3-Bis(fluoromethyl)cyclobutanone

1N hydrochloric acid (61.7 ml, 61.7 mmol) was added to a tetrahydrofuran(42 ml) solution of the compound (2.8 g, 12.3 mmol) obtained in Step 1above at 0° C. After stirring at room temperature for 13 hours, thereaction mixture was diluted with diethyl ether at 0° C. and saturatedsodium bicarbonate solution was added for extraction. The organic layerwas washed with brine and then dried over anhydrous magnesium sulfate.The solvent was evaporated under reduced pressure (110 mmHg, 17° C.) togive 3.63 g (100%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 2.99-3.04 (4H, m), 4.53-4.66 (4H, m).

Reference Example 22

[Step 1]

Ethyltrans-4-({[2-(trimethylsilyl)ethoxy}carbonyl]amino)cyclohexanecarboxylate

Ethyl trans-4-aminocyclohexanecarboxylate (J. Med. Chem., 1971, 14,600-614) (29.5 g, 143 mmol) was dissolved in 1,4-dioxane (290 ml) andwater (290 ml), triethylamine (30.0 ml, 215 mmol) and1-[2-(trimethylsilyl)ethoxycarbonyloxy]pyrrolidine-2,5-dione (40.8 g,157 mmol) were added under ice cooling and the resulting mixture wasstirred at room temperature for 2 days. The reaction mixture wasconcentrated and then the residue was diluted with ethyl acetate andwashed with 10% aqueous citric acid solution, saturated sodiumbicarbonate solution, and brine in that order. The organic layer wasdried over anhydrous sodium sulfate and the solvent was concentratedunder reduced pressure to give 44.3 g (98%) of the title compound ascolorless needle-like crystals.

¹H-NMR (500 MHz, CDCl₃) δ: 0.03 (9H, s), 0.92-1.01 (2H, m), 1.08-1.18(2H, m), 1.25 (3H, t, J=7.2 Hz), 1.48-1.59 (2H, m), 1.97-2.11 (4H, m),2.21 (1H, tt, J=12.3, 3.7 Hz), 3.38-3.54 (1H, m), 4.07-4.19 (4H, m),4.38-4.49 (1H, m).

[Step 2]

Trans-4-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)cyclohexanecarboxylicacid

The compound (44.3 g, 140 mmol) obtained in Step 1 above was dissolvedin tetrahydrofuran (500 ml) and water (100 ml), lithium hydroxidemonohydrate (11.8 g, 281 mmol) was added at room temperature and theresulting mixture was stirred for 2 days. Lithium hydroxide monohydrate(2.95 g, 70.2 mmol) was further added, the resulting mixture was fartherstirred for 27 hours, then the reaction mixture was concentrated and 10%aqueous citric acid solution was added to the residue, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate and the solvent wasconcentrated under reduced pressure to give 40.0 g (99%) of the titlecompound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.04 (9H, s), 0.92-1.02 (2H, m), 1.10-1.20(2H, m), 1.47-1.63 (2H, m), 2.01-2.13 (4H, m), 2.23-2.31 (1H, m),3.40-3.55 (1H, m), 4.08-4.20 (2H, m), 4.41-4.50 (1H, m).

[Step 3]

2-(trimethylsilyl)ethyl (trans-4-carbamoylcyclohexyl) carbamate

The compound (3.23 g, 11.2 mmol) obtained in Step 2 above and ammoniumchloride (1.20 g, 22.5 mmol) were used as starting materials and treatedin the same way as in Step 1 or Reference Example 16 to give 3.16 g(98%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.04 (9H, s), 0.92-1.01 (2H, m), 1.09-1.20(2H, m), 1.52-1.62 (2H, m), 1.95-2.02 (2H, m), 2.06-2.15 (2H, m),3.40-3.54 (2H, m), 4.08-4.19 (2H, m), 4.38-4.49 (1H, m), 5.17-5.27 (1H,m), 5.35-5.45 (1H, m).

[Step 4]

2-(Trimethylsilyl)ethyl (trans-4-cyanocyclohexyl)carbamate

Anhydrous trifluoroacetic acid (2.30 ml, 16.6 mmol) was added to adichloromethane (60 ml) solution of the compound (3.16 g, 11.0 mmol)obtained in Step 3 above combined with triethylamine (3.10 ml, 22.1mmol) under ice cooling, After stirring at room temperature for 75minutes, saturated sodium bicarbonate solution was added to the reactionmixture. After extraction with dichloromethane, the organic layer wasdried over anhydrous sodium sulfate. The solvent was concentrated underreduced pressure and the residue obtained was purified by silica gelcolumn chromatography [n-hexane:ethyl acetate=19.1→3.2 (v/v)] to give3.06 g (100%) of the title compound as a pale yellow solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.04 (9H, s), 0.92-1.01 (2H, m), 1.14-1.24(2H, m), 1.64-1.75 (2H, m), 2.05-2.15 (4H, m), 2.37-2.45 (1H, m),3.43-3.59 (1H, m), 4.10-4.18 (2H, m), 4.39-4.52 (1H, m).

[Step 5]

2-(Trimethylsilyl)ethyl{trans-4-[(Z)-amino(hydroxyimino)methyl]cyclohexyl}carbamate

Aqueous hydroxylamino solution (50% w/w, 0.68 ml, 11.1 mmol) was addedto an ethanol (40 ml) solution of the compound (1.03 g, 3.71 mmol)obtained in Step 4 above at room temperature and the resulting mixturewas heated to reflux for 21 hours. After cooling, the reaction mixturewas concentrated under reduced pressure to give the title compound as acolorless solid.

[Step 6]

2-(Trimethylsilyl)ethyl[trans-4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)cyclohexyl]carbamate

Carbonyldiimidazole (1.24 g, 7.43 mmol) was added to a tetrahydrofuran(20 ml) solution of the compound (1.12 g, 3.71 mmol) obtained in Step 5above under ice cooling and the resulting mixture was stirred at 50° C.for 24 hours. The reaction mixture was diluted withdichloromethane:methanol [10:1 (v/v)] and washed with 10% aqueous citricacid solution and saturated sodium bicarbonate solution in that orderand then the organic layer was dried over anhydrous sodium sulfate. Thesolvent was concentrated under reduced pressure and the residue obtainedwas purified by silica gel column chromatography [n-hexane:ethylacetate=9:1→13:7→dichloromethane:methanol=49:1→19:1 (v/v)] to give 757mg (62%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 0.05 (9H, s), 0.94-1.02 (2H, m), 1.22-1.33(2H, m), 1.62-1.75 (2H, m), 2.00-2.09 (2H, m), 2.14-2.22 (2H, m),2.55-2.65 (1H, m), 3.44-3.58 (1H, m), 4.18-4.24 (2H, m), 4.61 (1H, d,J=8.0 Hz).

[Step 7]

3-(Trans-4-aminocyclohexyl)-1,2,4-oxadiazol-5(4H)-one hydrochloride

4N hydrochloric acid/1,4-dioxane solution (3.5 ml) was added to thecompound (349 mg, 1.06 mmol) obtained in Step 6 above at roomtemperature and the resulting mixture was stirred for 23 hours. Thereaction mixture was concentrated under reduced pressure to give 234 mg(100%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CD₃OD) δ: 1.45-1.67 (4H, m), 2.11-2.19 (4H, m),2.59-2.68 (1H, m), 3.10-3.19 (1H, m).

Reference Example 23

[Step 1]

1,5-Anhydro-2-azido-6-O-[tert-butyl(dimethyl)silyl]-2,3-dideoxy-D-ribo-hexitol

A dichloromethane (4 ml) solution of tert-butyldimethylchlorosilane (381mg, 2.54 mmol) was added to a dichloromethane (10 ml) solution of1,5-anhydro-2-azido-2,3-dideoxy-D-ribo-hexitol (440 mg, 2.54 mmol) andtriethylamine (0.46 ml, 3.30 mmol) under ice cooling. After stirring atroom temperature for 50 hours, the reaction mixture was diluted withchloroform and the organic layer was washed with water and brine. Theorganic layer was. dried over anhydrous sodium sulfate, then the solventwas evaporated under reduced pressure and the residue was petrified bysilica gel column chromatography [n-hexane:ethyl acetate=10:1→4:1 (v/v)]to give 650 mg (89%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.07-0.10 (6H, m), 0.88 (9H, s), 1.41-1.53(1H, m), 2.39-2.49 (1H, m), 3.06-3.18 (2H, m), 3.41-3.57 (2H, m),3.62-3.71 (2H, m), 3.88-3.96 (2H, m).

MS (ESI) m/z: 310 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-azido-6-O-[tert-butyl(dimethyl)silyl]-2,3-dideoxy-4-O-methyl-D-ribo-hexitol

Sodium hydride (60% oil, 136 mg, 3.39 mmol) was added to a hydrofuran(11 ml) solution of the compound (650 mg, 2.26 mmol) obtained in Step 1above under ice cooling, the resulting mixture was stirred for 5 minutesand then methyl iodide (0.42 ml, 6.78 mmol) was added. After stirring atthe same temperature for 1 hour, saturated ammonium chloride solutionwas added, the resulting mixture was subjected to extraction with ethylacetate and the organic layer was washed with brine. The organic layerwas dried over anhydrous sodium sulfate and then the solvent wasevaporated under reduced pressure to give the title compound.

[Step 3]

1,5-anhydro-2-azido-2,3-dideoxy-4-O-methyl-D-ribo-hexitol

Tetrabutylammonium fluoride/tetrahydrofuran solution (1.0 mol/l, 3.6 ml,3.60 mmol) was added to a tetrahydrofuran (7 ml) solution of thecompound (2.26 mmol) obtained in Step 2 above and the resulting mixturewas stirred at room temperature for 16 hours. The solvent was evaporatedunder reduced pressure and water was added, followed by extraction withethyl acetate. The organic solvent was dried over anhydrous sodiumsulfate, the solvent was evaporated under reduced pressure and theresidue obtained was purified by silica gel column chromatography[n-hexane:ethyl acetate=4:1→1:1 (v/v)] to give 329 mg (78%) of the titlecompound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.34-1.44 (1H, m), 1.90-1.97 (1H, m),2.61-2.69 (1H, m), 3.13-3.29 (3H, m), 3.39 (3H, s), 3.42-3.53 (1H, m),3.65-3.73 (1H, m), 3.81-3.89 (1H, m), 3.97-4.04 (1H, m).

[Step 4]

2-Amino-1,5-anhydro-2,3-dideoxy-4-O-methyl-D-ribo-hexitol

The compound (329 mg, 1.76 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 4 of ReferenceExample 14 to give 283 mg (100%) of the title compound as a colorlessoil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.04-1.15 (1H, m), 2.45-2.54 (1H, m),2.73-2.84 (1H, m), 2.94-3.08 (2H, m), 3.11-3.21 (1H, m), 3.35 (3H, s),3.58 (1H, dd, J=11.69, 5.73 Hz), 3.74-3.81 (1H, m), 3.84-3.92 (1H, m).

MS (ESI) m/z: 162 (M+H)⁺.

Reference Example 24

[Step 1]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-6-O-(methylsulfonyl)-D-erythro-hexitol

The same starting material (2.38 g, 10.30 mmol) as in Step 1 ofReference Example 2 was used and treated in the same way as in Step 1 ofReference Example 14 to give 1.34 g (42%) of the title compound as acolorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.28-1.36 (1H, m), 1.44-1.54 (9H, m), 1.72(1H, dq, J=13.0, 3.1 Hz), 2.12-2.17 (1H, m), 3.02 (1H, t, J=10.6 Hz),3.05 (3H, s), 3.53-3.64 (2H, m), 4.13-4.10 (1H, m), 4.28-4.15 (3H, m).

MS (FAB) m/z: 310 (M+H)⁺.

[Step 2]

1,5-Anhydro-6-azido-2-[(tert-butoxycarbonyl)amino]-2,3,4,6-tetradeoxy-D-erythro-hexitol

The compound obtained in Step 1 above was used as a starting materialand treated in the same way as in Step 2 of Reference Example 14 to givethe title compound.

¹H-NMR (400 MHz, CDCl₃) δ: 1.23-1.34 (1H, m), 1.44 (9H, s), 1.46-1.53(1H, m), 1.66-1.71 (1H, m), 2.09-2.15 (1H, m), 3.02 (1H, t, J=10.8 Hz),3.21 (1H, dd, J=12.6, 3.9 Hz), 3.30 (1H, dd, J=12.8, 6.9 Hz), 3.39-3.45(1H, m), 3.60-3.64 (1H, m), 4.12 (1H, dq, J=10.9, 2.3 Hz), 4.24 (1H, brs).

MS (ESI) m/z: 279 (M+H)⁺.

[Step 3]

6-Amino-1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,6-tetradeoxy-D-erythro-hexitol

The compound obtained in Step 2 above was used as a starting materialand treated in the same way as in Step 4 of Reference Example 14 to givethe title compound.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.13-1.32 (2H, m), 1.35 (9H, s), 1.60-1.65(1H, m), 1.78-1.84 (1H, m), 2.50 (2H, d, J=5.9 Hz), 2.91 (1H, t, J=10.6Hz), 3.01-3.08 (1H, m), 3.25-3.30 (1H, m), 3.74-3.78 (1H, m), 6.72 (1H,d, J=8.1 Hz).

[Step 4]

6-[(2-Acetoxyethyl)amino]-1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,6-tetradeoxy-D-erythro-hexitol

The compound (500 mg, 2.17 mmol) obtained in Step 3 above was dissolvedin dichloromethane (10 ml), 2-oxoethyl acetate (243 mg, 2.39 mmol) wasadded and the resulting mixture was stirred at room temperature for 1hour. Then sodium triacetoxyborohydride (920 mg, 4.34 mmol) was addedand the resulting mixture was stirred at room temperature for 3 hours.After reaction, saturated sodium bicarbonate solution (50 ml) was addedand the resulting mixture was further stirred for 1 hour. The reactionmixture was diluted with dichloromethane and the organic layer waswashed with brine. The organic layer was dried over anhydrous sodiumsulfate and the solvent was evaporated under reduced pressure. Theresidue obtained was purified by silica gel column chromatography[chloroform:methanol=40:1→20:1 (v/v)] to give 544 mg (64%) of the titlecompound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.23-1.33 (1H, m), 1.39-1.49 (10H, m),1.65-1.71 (1H, m), 2.06-2.15 (4H, m), 2.61-2.70 (2H, m), 2.80-2.90 (2H,m), 2.99 (1H, t, J=10.5 Hz), 3.34-3.40 (1H, m), 3.56-3.62 (1H, m),4.05-4.19 (3H, m), 4.24 (1H, br s).

MS (ESI) m/z: 317 (M+H)⁺.

[Step 5]

6-[(2-Acetoxyethyl){acetyl}amino]-1,5-anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,6-tetradeoxy-D-erythro-hexitol

The compound (264 mg, 0.83 mmol) obtained in Step 4 above was dissolvedin dichloromethane (8 ml), acetic anhydride (0.50 ml, 5.30 mmol) wasadded and the resulting mixture was stirred at room temperature for 1hour. Then pyridine (0.10 ml, 1.24 mmol) was added and the resultingmixture was further stirred for 1 hour. Saturated brine (20 ml) wasadded to the reaction mixture and the resulting mixture was stirred for1 hour, followed by extraction with dichloromethane. The organic layerwas washed with saturated sodium bicarbonate solution and brine in thatorder and dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [(chloroform:methanol=40:1 (v/v)] togive 244 mg (82%) of the title compound an a colorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.15-1.40 (3H, m), 1.43 (9H, s), 1.71-1.76(1H, m), 2.05 and 2.06 (total 3H, each s), 2.11 and 2.15 (total 3H, eachs), 2.82-3.02 (2H, m), 3.24-3.78 (5H, m), 4.01-4.30 (4H, m).

MS (ESI) m/z: 359 (M+H)⁺.

[Step 6]

6-[(2-Acetoxyethyl)(acetyl)amino]-2-amino-1,5-anhydro-2,3,4,6-tetradeoxy-D-erythro-hexitolhydrochloride

The compound (240 mg, 0.67 mmol) obtained in Step 5 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound, as a colorless amorphous solid.

Reference Example 25

[Step 1]

Tert-butyl[(3R,6S)-6-(hydrazinocarbonyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (1.52 g, 6.20 mmol) as in Step 1 of ReferenceExample 18 was used and treated in the same way as in Step 4 ofReference Example 18 to give 1.33 g (83%) of the title compound as acolorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.30-1.60 (11H, m), 2.10-2.18 (1H, m),2.20-2.28 (1H, m), 3.03 (1H, t, J=10.9 Hz), 3.55-3.68 (1H, m), 3.81 (1H,dd, J=11.7, 2.6 Hz), 4.12-4.19 (1H, m), 4.27-4.38 (1H, m), 7.63 (1H, s).

MS (ESI) m/z: 260 (M+H)⁺.

[Step 2]

Tert-butyl[(3R,6S)-6-(5-oxo-4,5-dihydro-1,3,4-oxadiazol-2-yl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (1.33 g, 5.13 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 19 to give 1.10 g (75%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 1.38-1.58 (10H, m), 1.84-1.95 (1H, m),1.96-2.03 (1H, m), 2.05-2.13 (1H, m), 3.20 (1H, t, J=10.6 Hz), 3.48-3.59(1H, m), 3.97-4.05 (1H, m), 4.28 (1H, dd, J=10.6, 2,6 Hz), 6.59-6.71(1H, m).

MS (ESI) m/z: 286 (M+H)⁺.

[Step 3]

5-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]-1,3,4-oxadiazol-2(3H)-onehydrochloride

The compound (1.10 g, 3.86 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 688 mg (81%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.70-1.82 (1H, m), 1.94-2.06 (1H, m),2.08-2.17 (1H, m), 2.25-2.34 (1H, m), 3.29-3.38 (1H, m), 3.54 (1H, dd,J=11.5, 9.16 Hz), 4.07-4.15 (1H, m), 4.49 (1H, dd, J=9.6, 3.2 Hz).

MS (ESI) m/z: 186 (M+H)⁺.

Reference Example 26

[Step 1]

Tert-butyl [(3R,6S)-6-cyanotetrahydro-2H-pyran-3-yl]carbamate

Tert-butyl [(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]carbamate(WO2006/125974) (1.54 g, 6.30 mmol) was used as a starting material andtreated in the same way as in Step 4 of Reference Example 22 to give1.39 g (97%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.45 (9H, s), 1.74-1.90 (2H, m), 2.00-2.20(2H, m), 3.52-3.67 (1H, m), 3.70-3.83 (1H, m), 4.05 (1H, dd, J=12.0, 2.9Hz), 4.56-4.67 (1H, m), 4.85-4.98 (1H, m).

[Step 2]

Tert-butyl{(3R,6S)-6-[(Z)-amino(hydroxyimino)methyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound (1.39 g, 6.14 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 5 of ReferenceExample 22 to give 1.59 g 100%) of the title compound as a colorlesssolid.

[Step 3]

Tert-butyl[(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-yl]carbamate

Trimethyl orthoformate (6.0 ml) was added to an N,N-dimethylacetamide(20 ml) solution of the compound (1.59 g, 6.14 mmol) obtained in Step 2above at room temperature under nitrogen atmosphere and then a borontrifluoride-diethyl ether complex (0.08 ml, 0.61 mmol) was added afterstirring at 50° C. for 21 hours, the reaction mixture was cooled,triethylamine (0.86 ml, 6.14 mmol) was added at room temperature and theresulting mixture was stirred for 80 minutes. The reaction mixture wasdiluted with dichloromethane:methanol [10:1 (v/v)] and washed withsaturated sodium bicarbonate solution and then the organic layer wasdried over anhydrous sodium, sulfate. The solvent was concentrated underreduced pressure and the residue obtained was purified by silica gelcolumn chromatography [n-hexane:ethyl acetate=9:1→7:3 (v/v)] to give1.46 g (89%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.39-1.63 (10H, m), 1.95-2.29 (3H, m),3.20-3.36 (1H, m), 3.68-3.86 (1H, m), 4.17-4.29 (1H, m), 4.43-4.58 (1H,m), 4.60-4.68 (1H, m), 8.74 (1H, s).

[Step 4]

(3R,6S)-6-(1,2,4-oxadiazol-3-yl)tetrahydro-2H-pyran-3-aminehydrochloride

The compound (1.46 g, 5.43 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 988 mg (88%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.75-1.88 (1H, m), 1.99-2.11 (1H, m),2.16-2.25 (1H, m), 2.26-2.35 (1H, m), 3.32-3.41 (1H, m), 3.58 (1H, dd,J=11.5, 9.6 Hz), 4.14-4.21 (1H, m), 4.76-4.81 (1H, m), 9.28 (1H, s).

Reference Example 27

[Step 1]

2,6-Anhydro-5-azido-1-O-[tert-butyl(dimethyl)silyl]-4,5-dideoxy-L-erythro-hex-3-ulose

A Dess-Martin reagent (876 mg, 2.00 mmol) was added to a dichloromethane(10 ml) solution of1,5-anhydro-2-azido-6-O-[tert-butyl(dimethyl)silyl]-2,3-dideoxy-D-ribo-hexitol(450 mg, 1.25 mmol) under ice cooling and the resulting mixture wasstirred for 75 minutes. Aqueous sodium thiosulfate solution was addedunder ice cooling, then the resulting mixture was subjected toextraction with ether and the organic layer was washed with brine. Theorganic layer was dried over anhydrous sodium sulfate, then the solventwas evaporated under reduced pressure and the residue was purified bysilica gel column chromatography [n-hexane:ethyl acetate=50:1→20:1(v/v)] to give 272 mg (76%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.02 (3H, s), 0.04 (3H, s), 0.85 (9H, s),2.55 (1H, dd, J=16.1, 6.4 Hz), 2.86 (1H, dd, J=16.1, 5.7 Hz), 3.58-3.67(1H, m), 3.87-4.00 (3H, m), 4.06-4.16 (1H, m), 4.31-4.39 (1H, m).

MS (ESI) m/z: 308 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-azido-6-O-[tert-butyl(dimethyl)silyl]-2,3-dideoxy-D-xylo-hexitol

Lithium tri-sec-butylborohydride/tetrahydrofuran solution (1.0 mol/l,0.83 ml, 0.83 mol) was added to a tetrahydrofuran (2.5 ml) solution ofthe compound (169 mg, 0.59 mmol) obtained in Step 1 above, at −78° C.and the resulting mixture was stirred at −78° C. for 45 minutes. 1Nhydrochloric acid was added, the resulting mixture was subjected toextraction with ethyl acetate and the organic layer was washed withbrine. The organic layer was dried over anhydrous sodium sulfate, thenthe solvent was evaporated under reduced pressure and the residue waspurified by silica gel column chromatography [n-hexane:ethylacetate=20:1→12:1 (v/v)] to give 101 mg (59%) of the title compound as acolorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.07 (3H, s), 0.08 (3H, s), 0.88 (9H, s),1.49-1.58 (1H, m), 2.28-2.36 (1H, m), 3.14-3.27 (2H, m), 3.43-3.48 (1H,m),3.85-3.96 (3H, m), 4.03-4.15 (2H, m).

MS (ESI) m/z: 288 (M+H)⁺.

[Step 3]

1,5-Anhydro-2-azido-6-O-[tert-butyl(dimethyl)silyl]-2,3-dideoxy-4-O-methyl-D-xylo-hexitol

The compound (160 mg, 0.56 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 23 to give the title compound.

[Step 4]

1,5-Anhydro-2-azido-2,3-dideoxy-4-O-methyl-D-xylo-hexitol

The compound (0.56 mmol) obtained in Step 3 above was used as a startingmaterial and treated in the same way as in Step 3 of Reference Example23 to give 62 mg (60%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.43-1.52 (1H, m), 2.10 (1H, dd, J=9.2, 2.8Hz), 2.47-2.56 (1H, m), 3.21-3.29 (1H, m), 3.40 (3H, s), 3.41-3.46 (1H,m), 3.51-3.55 (1H, m), 3.64-3.91 (3H, m), 4.09-4.17 (1H, m).

[Step 5]

2-Amino-1,5-anhydro-2,3-dideoxy-4-O-methyl-D-xylo-hexitol

The compound (62 mg, 0.33 mmol) obtained in Step 4 above was used as astarting material and treated in the same way as is Step 4 of ReferenceExample 14 to give 53 mg (100%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.19-1.30 (1H, m), 2.35-2.44 (1H, m),2.93-3.10 (2H, m), 3.28-3.32 (1H, m), 3.35 (3H, s), 3.45-3.51 (1H, m),3.56-3.67 (2H, m), 3.87-3.96 (1H, m).

MS (ESI) m/z: 162 (M+H)⁺.

Reference Example 28

2,6-Anhydro-3,4,5-trideoxy-5-(dibenzylamino)-L-erythro-hexonic acid

The same starting material (1.60 g, 4.70 mmol) as in Step 1 of ReferenceExample 5 was dissolved in methanol (30 ml), 1N sodium hydroxidesolution (10 ml) was gradually added under ice cooling and then theresulting mixture was stirred at room temperature for 3 hours. Dowex50W-X8 was added to the reaction mixture to adjust its pH to 5 to 6,insoluble matter was removed by filtration and then the filtrate wasconcentrated under reduced pressure to give 1.7 g (100%) of the titlecompound as a colorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.18-1.26 (1H, m), 1.36-1.48 (1H, m),1.79-1.97 (2H, m), 2.62 (1H, t, J=11.0 Hz), 3.18 (1H, t, J=10.4 Hz),3.40 (1H, d, J=11.5 Hz), 3.51-3.61 (4H, m), 3.90-3.99 (1H, m), 7.12-7.38(10H, m).

MS (ESI) m/z: 326 (M+H)⁺.

[Step 2]

(2S,5R)-5-(dibenzylamino)tetrahydro-2H-pyran-2-carboxamide

The compound (870 mg, 2.67 mmol) obtained in Step 1 above was dissolvedin N,N-dimethylformamide (30 ml), 1-hydroxybenzotriazole (361 mg, 2.67mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride(614 mg, 3.20 mmol) were added and the resulting mixture was stirred atroom temperature for 15 minutes. Ammonium chloride (285 mg, 5.44 mmol)and N,N-diisopropylethylamine (1.86 ml, 10.7 mmol) were added and theresulting mixture was stirred at room temperature for 8 hours. Thereaction mixture was diluted with ethyl acetate and the organic layerwas washed with saturated sodium bicarbonate solution and brine in thatorder and dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure to give 495 mg (57%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.35-1.45 (1H, m), 1.60-1.70 (1H, m),2.10-2.18 (1H, m), 2.21-2.28 (1H, m), 2.76 (1H, tt, J=11.4, 4.0 Hz),3.44 (1H, t, J=10.9 Hz), 3.67 (4H, q, J=14.2 Hz), 3.71-3.73 (1H, m),4.04 (1H, dq, J=11.0, 2.1 Hz), 5.35 (1H, s), 6.40 (1H, s), 7.21-7.36(10H, m).

MS (ESI) m/z: 325 (M+H)⁺.

[Step 3]

(2S,5R)-5-aminotetrahydro-2H-pyran-2-carboxamide

The compound (490 mg, 1.51 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 5 to give 215 mg (99%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.11-1.22 (1H, m), 1.25-1.35 (1H, m),1.83-1.91 (2H, m), 2.51-2.60 (1H, m), 2.90 (1H, t, J=10.5 Hz), 3.52 (1H,d, J=11.9 Hz), 3.78-3.84 (1H, m), 6.99 (1H, br s), 7.09 (1H, br s).

MS (ESI) m/z: 145 (M+H)⁺.

Reference Example 29

[Step 1]

Tert-butyl [4-(hydroxymethyl)-4-methoxycyclohexyl]carbamate (A)

Concentrated sulfuric acid (0.10 ml, 1.90 mmol) was added to a methanol(10 ml) solution of the same starting material (1.14 g, 5.02 mmol) as inStep 1 of Reference Example 17 and the resulting mixture was stirredovernight at room temperature. Potassium carbonate (1.34 g, 9.70 mmol)was added, followed by extraction with chloroform. The organic layer waswashed with water and brine and then dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure and theresidue obtained was purified by silica gel column chromatography (ethylacetate) to separately give 422 mg (34%) of the title compound and 239mg (18%) of the compound (B) as colorless amorphous solids.

¹H-NMR (500 MHz, CDCl₃) δ: 1.22-1.38 (3H, m), 1.44 (9H, s), 1.63 (3H, t,J=6.3 Hz), 1.80-1.83 (1H, m), 1.87-1.93 (2H, m), 3.19 (0.6H, s), 3.21(2.4H, s), 3.45 (0.4H, d, J=5.7 Hz), 3.55-3.61 (2.6H, m), 4.41-4.52 (1H,m).

[Step 2]

Tert-butyl[trans-4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-4-methoxycyclohexyl]carbamate(C) and tert-butyl[cis-4-({[tert-butyl(diphenyl)silyl]oxy}methyl)-4-methoxycyclohexyl]carbamate(D)

Tert-butyldiphenylchlorosilane (667 mg, 2.4 mmol) and imidazole (441 mg,6.5 mmol) were added to an N,N-dimethylformamide (4 ml) solution of thecompound (A) (413 mg, 1.59 mmol) obtained in Step 1 above and theresulting mixture was stirred overnight at room temperature. Thereaction mixture was diluted with ethyl acetate, washed with water andbrine and then dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [n-hexane:ethyl acetate=90:10 (v/v)]to separately give 513 mg of the title compound (C) (65%, highly polarcompound) and 123 mg of the title compound (D) (16%, low polar compound)as colorless amorphous solids.

Compound (C):

¹H-NMR (400 MHz, CDCl₃) δ: 1.08 (9H, s), 1.25-1.33 (2H, m), 1.45 (9H,s), 1.52-1.59 (2H, m), 1.63-1.70 (2H, m), 1.76-1.84 (2H, m), 3.23 (3H,s), 3.58 (2H, s), 3.61-3.67 (1H, m), 4.42-4.48 (1H, m), 7.37-7.47 (6H,m), 7.66-7.68 (4H, m).

Compound (D):

¹H-NMR (400 MHz, CDCl₃) δ: 1.05 (9H, s), 1.31-1.44 (13H, m), 1.77-1.85(4H, m), 3.18 (3H, s), 3.39 (1H, m), 3.49 (2H, s), 4.42 (1H, d, J=6.9Hz), 7.36-7.45 (6H, m), 7.64-7.66 (4H, m).

[Step 3]

Tert-butyl [trans-4-(hydroxymethyl)-4-methoxycyclohexyl]carbamate

The compound (C) (511 mg, 1.03 mmol) obtained in Step 2 above was usedas a starting material and treated in the same way as in Step 2 ofReference Example 1.7 to give 243 mg (91%) of the title compound as acolorless amorphous solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.31-1.38 (2H, m), 1.44 (9H, s), 1.63 (4H, t,J=6.3 Hz), 1.83 (1H, t, J=6.0 Hz), 1.87-1.93 (2H, m), 3.21 (3H, s),3.55-3.60 (3H, m), 4.47-4.51 (1H, m).

MS (FAB) m/z: 260 (M+H)⁺.

[Step 4]

(Trans-4-amino-1-methoxycyclohexyl)methanol hydrochloride

The compound (46 mg, 0.175 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a colorless solid.

[Step 5]

Tert-butyl [cis-4-(hydroxymethyl)-4-methoxycyclohexyl]carbamate

The compound (D) (127 mg, 0.254 mmol) obtained in Step 2 above was usedas a starting material and treated in the same way as in Step 2 ofReference Example 17 to give 59 mg (89%) of the title compound as acolorless amorphous solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.25 (2H, td, J=13.6, 3.6 Hz), 1.37 (2H, dq,J=3.4, 12.6 Hz), 1.44 (9H, s), 1.71 (1H, t, J=5.7 Hz), 1.80-1.83 (2H,m), 1.88-1.93 (2H, m), 3.19 (3H, s), 3.41-3.45 (3H, m), 4.43-4.46 (1H,m).

MS (FAB) m/z: 260 (M+H)⁺.

[Step 6]

(Cis-4-amino-1-methoxycyclohexyl)methanol

The compound (30 mg, 0.115 mmol) obtained in Step 5 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a colorless solid.

Reference Example 30

[Step 1]

2,6-Anhydro-5-[(tert-butoxycarbonyl)amino]-3,4,5-trideoxy-L-erythro-hexose

Dichloromethane (5 ml) and dimethyl sulfoxide (0.21 ml 2.85 mmol) weremixed under nitrogen atmosphere, a dichloromethane (5 ml) solution ofoxalyl chloride (0.21 ml, 2.50 mmol) was added dropwise at −78° C. andthe resulting mixture was stirred for 30 minutes. A dichloromethane (5ml) solution of the same starting material (440 mg, 1.90 mmol) as inStep 1 of Reference Example 2 was added dropwise at the same temperatureand the resulting mixture was stirred for 1 hour. Then a dichloromethane(4 ml) solution of N,N-diisopropylethylamine (1.65 ml, 9.50 mmol) wasadded dropwise and the resulting mixture was stirred at the sametemperature for 1hour, warmed to room temperature, and further stirredfor 1 hour. The reaction solvent was evaporated under reduced pressureand the residue was purified by silica gel column chromatography[n-hexane:ethyl acetate=1:1→1:2 (v/v)] to give 347 mg (80%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.36-1.44 (1H, m), 1.45 (9H, s), 1.53-1.63(1H, m), 1.94-2.01 (1H, m), 2.10-2.17 (1H, m), 3.15 (1H, t, J=10.5 Hz),3.59-3.67 (1H, m), 3.73 (1H, dd, J=11.0, 2.7 Hz), 4.17 (1H, dq, J=11.0,2.1 Hz), 4.38 (1H, br s), 9.65 (1H, s).

[Step 2]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,7-trideoxy-D-erythro-hepitol

The compound (2.80 g) obtained in Step 1 above was dissolved in diethylether (30 ml), methyl magnesium bromide/tetrahydrofuran solution (1.1mol/l, 54.0 ml, 59.4 mmol) was added dropwise at 0° C. under nitrogenatmosphere and then the resulting mixture was stirred at roomtemperature for 16 hours. Methanol (5 ml) was gradually added, followedby extraction with ethyl acetate. The organic layer was washed withaqueous ammonium chloride solution and brine in that order and driedover anhydrous magnesium sulfate. The solvent was evaporated underreduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=2:1→1:1 (v/v)] to give 1.07 g(73%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.14 (3H, d, J=6.4 Hz), 1.23-1.32 (1H, m),1.34-1.43 (1H, m), 1.44 (9H, s), 1.66-1.72 (1H, m), 2.08-2.14 (1H, m),2.64 (1H, br s), 2.99 (1H, t, J=10.8 Hz), 3.56 -3.64 (2H, m), 4.09-4.15(1H, m), 4.25 (1H, br s).

MS (ESI) m/z: 268 (M+H)⁺.

[Step 3]

2-Amino-1,5-anhydro-2,3,4,7-tetradeoxy-D-erythro-heptitol hydrochloride

The mixture (700 mg, 2.85 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 484 mg (93%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.06 (3H, d, J=6.4 Hz), 1.35-1.46 (1H, m),1.53-1.64 (1H, m), 1.66-1.73 (1H, m), 2.11-2.18 (1H, m), 2.99-3.14 (2H,m), 3.31 (1H, t, J=10.8 Hz), 3.55-3.63 (1H, m), 4.05-4.12 (1H, m).

MS (ESI) m/z: 146 (M+H)⁺.

Reference Example 31

[Step 1]

Tert-butyl [cis-4-hydroxy-4-(methoxymethyl)cyclohexyl]carbamate (A) andtert-butyl [trans-4-hydroxy-4-(methoxymethyl)cyclohexyl]carbamate (B)

Sodium methylate/methanol solution (28% w/w, 2.0 ml, 10.0 mmol) wasadded to a methanol (7 ml) solution of the same starting material (0.75g, 3.331 mmol) as in Step 1 of Reference Example 17 and the resultingmixture was stirred at 60° C. for 2 hours. Water was added, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue obtained was purified by silicagel column chromatography [n-hexane:ethyl acetate=1:1 (v/v)] to give 619mg of the title compound (A) (72%, low polar compound) as a colorlessamorphous solid. Also, 61 mg of the title compound (B) (7%, highly polarcompound) was obtained as a colorless amorphous solid.

Compound (A):

¹H-NMR (400 MHz, CDCl₃) δ: 1.35 (2H, td, J=13.3, 4.0 Hz), 1.44 (9H, s),1.47-1.57 (2H, m), 1.70-1.75 (2H, m), 1.79-1.83 (2H, m), 2.06 (1H, s),3.20 (2H, s), 3.38-3.43 (4H, m), 4.45-4.43 (1H, m).

MS (FAB) m/z: 260 (M+H)⁺.

Compound (B):

¹H-NMR DMSO-d₆) δ: CDCl₃) δ: 1.33-1.40 (2H, m), 1.44 (9H, s), 1.51-1.56(2H, m), 1.64-1.69 (2H, m), 1.91-1.96 (2H, m), 2.33 (1H, s), 3.31 (2H,s), 3.40 (3H, s), 3.61-3.64 (1H, m), 4.49-4.53 (1H, m).

MS (FAB) m/z: 260 (M+H)⁺.

[Step 2]

Cis-4-amino-1-(methoxymethyl)cyclohexanol hydrochloride

The compound (A) (80 mg, 0.31 mmol) obtained in Step 1 above was used asa starting material and treated in the same way as in Step 1 ofReference Example 2 to give the title compound as a colorless solid.

Reference Example 32

[Step 1]

1,5-Anhydro-2-azido-6-O[tert-butyl(dimethyl)silyl]-2,3-dideoxy-4-C-methyl-D-erythro-hexitol

Methylmagnesium bromide (1.06 mol/l, 0.47 ml, 0.50 mmol) was added to atetrahydrofuran (1.4 ml) solution of the compound (80 mg, 0.28 mmol)obtained in Step 1 of Reference Example 27 at −40° C. and the resultingmixture was gradually warmed to −10° C. 1N hydrochloric acid was addedand the resulting mixture was subjected to extraction with ethylacetate. The organic layer was washed with saturated sodium bicarbonatesolution and brine and dried over anhydrous sodium sulfate. The solventwas evaporated under reduced pressure and the residue was purified bysilica gel column chromatography [n-hexane:ethyl acetate=50:1→20:1(v/v)] to give 58 mg of a mixture of the title diastereomers (69%) as acolorless oil.

MS (ESI) m/z: 324 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-azido-2,3-dideoxy-4-C-methyl-D-erythro-hexitol

The mixture (58 mg, 0.19 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 23 to give 25 mg (70%) of the title compound as a colorless oil.

[Step 3]

2-Amino-1,5-anhydro-2,3-dideoxy-4-C-methyl-D-erythro-hexitol

The mixture (25 mg, 0.13 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 4 of ReferenceExample 14 to give 21 mg (100%) of the title compound as a colorlessoil.

MS (ESI) m/z: 162 (M+H)⁺.

Reference Example 33

[Step 1]

Tert-butyl {cis-4-hydroxy-4-[(methylthio)methyl]cyclohexyl}carbamate

A methanol (5 ml) solution of the same starting material (1.00 g, 4.41mmol) as in Step 1 of Reference Example 17 combined with sodiummethanethiolate (464 mg, 6.64 mmol) was stirred for 1 hour. The reactionmixture was diluted with ethyl acetate, washed with water, saturatedsodium bicarbonate solution, and brine in that order and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue obtained was purified by silica, gel columnchromatography [ethyl acetate:benzene=3:7 (v/v)] to give 766 mg (63%) ofthe title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.37-1.44 (11H, m), 1.49-1.57 (2H, m), 1.74(2H, dq, J=14.2, 3.1 Hz), 1.80-1.83 (2H, m), 2.15 (1H, s), 2.17 (3H, s),2.61 (2H, s), 3.37-3.44 (1H, m), 4.43-4.45 (1H, m).

MS (FAB) m/z: 276 (M+H)⁺.

[Step 2]

Tert-butyl {cis-4-hydroxy-4-[(methylsulfonyl)methyl]cyclohexyl}carbamate

M-chloroperbenzoic acid (25% hydrated, 538 mg, 2.34 mmol) was added to adichloromethane (5 ml) solution of the compound (2.76 mg, 1.00 mmol)obtained in Step 1 above under ice cooling and the resulting mixture wasstirred for 1 hour. The reaction mixture was diluted with ethyl acetate,washed with water, saturated sodium bicarbonate solution, and brine inthat order and then dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [ethyl acetate:n-hexane=7.3 (v/v)]to give 292 mg (95%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.44 (9H, s), 1.51-1.62 (4H, m), 1.80-1.86(2H, m), 2.03-2.10 (2H, m), 3.00 (3H, s), 3.19-3.21 (3H, m), 3.40-3.46(1H, m), 4.40-4.46 (1H, m).

MS (FAB) m/z: 308 (M+H)⁺.

[Step 3]

Cis-4-amino-1-[(methylsulfonyl)methyl]cyclohexanol hydrochloride

The compound (62 mg, 0.20 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a colorless solid.

Reference Example 34

[Step 1]

Tert-butyl [(3R,6S)-6-(ethylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (500 mg, 2.04 mmol) as in Step 1 of ReferenceExample 18 and ethylamine hydrochloride (250 mg, 3.06 mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 28 to give 123 mg (22%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.16 (3H, t, J=7.3 Hz), 1.32-1.54 (11H, m),2.09-2.15 (1H, m), 2.21-2.28 (1H, m), 3.04 (1H, t, J=10.7 Hz), 3.25-3.36(2H, m), 3.60 (1H, br s), 3.70 (1H, dd, J=11.6, 2.6 Hz), 4.12-4.18 (1H,m), 4.30 (1H, s), 6.50 (1H, br s).

MS (ESI) m/z: 295 (M+Na)⁺.

[Step 2]

(2S,5R)-5-amino-N-ethyltetrahydro-2H-pyran-2-carboxamide hydrochloride

The compound (120 mg, 0.44 mmol) obtained in Step 1 above was used andtreated in the same way as in Step 1 of Reference Example 2 to give 87mg (95%) of the title compound as a colorless amorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.98 (3H, t, J=7.2 Hz), 1.37-1.47 (1H, m),1.56 (1H, ddd, J=23.8, 12.2, 3.7 Hz), 1.96-2.08 (2H, m), 3.04-3.13 (3H,m), 3.54-3.59 (1H, m), 3.71 (1H, dd, J=11.2, 2.4 Hz), 4.02-4.07 (1H, m),7.69 (1H, t, J=5.5 Hz).

MS (ESI) m/z: 173 (M+H)⁺.

Reference Example 35

[Step 1]

Tert-butyl [(3R,6S)-6-vinyltetrahydro-2H-pyran-3-yl]carbamate

N-butyllithium/n-hexane solution (1.65 mol/l, 6.60 ml, 10.9 mmol) wasadded dropwise to a tetrahydrofuran (100 ml) suspension ofmethyltriphenylphosphonium bromide (3.90 g, 10.9 mmol) at −78° C. undernitrogen atmosphere and the resulting mixture was stirred for 15 minutesand then stirred at 0° C. for 45 minutes. After cooling to −78° C.again, a tetrahydrofuran (6 ml)/hexamethylphosphoric acid triamide (3ml) solution of the compound (1.00 g, 4.36 mmol) obtained in Step 1 ofReference Example 30 was added dropwise and the resulting mixture wasstirred at the same temperature for 30 minutes and then stirred at roomtemperature for 1 hour. Water (100 ml) was added, followed by extractionwith diethyl ether. The organic layer was washed with brine and driedover anhydrous magnesium sulfate. The solvent was evaporated underreduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=4:1 (v/v)] to give 553 mg (56%)of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.33 (1H, ddd, J=24.0, 12.4, 3.9 Hz), 1.44(9H, s), 1.47-1.56 (1H, m), 1.78 (1H, dq, J=13.6, 3.3 Hz), 2.06-2.14(1H, m), 3.06 (1H, t, J=10.5 Hz), 3.61 (1H, br s), 3.71-3.77 (1H, m),4.08-4.13 (1H, m), 4.28 (1H, br s), 5.12 (1H, dt, J=10.7, 1.3 Hz), 5.24(1H, dt, J=17.4, 1.6 Hz), 5.85 (1H, dq, J=17.4, 5.3 Hz).

MS (ESI) m/z: 228 (M+H)⁺.

[Step 2]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-D-erythro-heptitol

The compound (230 mg, 1.01 mmol) obtained in Step 1 above was dissolvedin a mixture of tert-butanol (5 ml), ethyl acetate (1.5 ml), and water(6 ml). Methanesulfonamide (115 mg, 1.2 mmol) and AD-mix-α (1.7 g) wereadded and the resulting mixture was stirred at room temperature for 16hours. Sodium bisulfite (2 g) was gradually added and the resultingmixture was further stirred for 15 minutes. After extraction with ethylacetate, the organic layer was washed with brine and dried overanhydrous magnesium sulfate. The solvent was evaporated under reducedpressure and the residue was purified by silica gel columnchromatography [chloroform:methanol=9:1 (v/v)] to give 206 mg (79%) ofthe title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.23-1.36 (1H, m), 1.44 (9H, s), 1.51-1.82(3H, m), 2.09-2.16 (1H, m), 2.22-2.29 (1H, m), 2.61 and 2.78 (total 1H,each d, J=5.0 and 3.7 Hz), 3.01 (1H, t, J=10.3 Hz), 3.30-3.35 (1H, m),3.51-3.56 (1H, m), 3.59-3.65 (1H, m), 3.69-3.75 (1H, m), 4.08-4.16 (1H,m), 4.27 (1H, br s).

MS (ESI) m/z: 284 (M+Na)⁺.

[Step 3]

2-Amino-1,5-anhydro-2,3,4-trideoxy-D-erythro-heptitol hydrochloride

The compound (200 mg, 0.77 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 166 mg (100%) of the title compound as a colorlessamorphous solid.

MS (ESI) m/z: 162 (M+H)⁺.

Reference Example 36

6-Chloro-3-[(5-chloropyridin-3-yl)methylene]-1,3-dihydro-2H-indol-2-one

5-Chloronicotinaldehyde (2.04 g, 14.4 mmol) was used as a startingmaterial and treated in the same way as in Reference Example 4 to give3.48 g (87%) of the title compound as a yellow solid.

MS (APCI) m/z: 291 (M+H)⁺.

Reference Example 37

[Step 1]

Tert-butyl[(3R,6S)-6-(isopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and isopropylamine (0.21 ml, 2.45 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 363 mg (78%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.16 (6H, d, J=6.4 Hz), 1.33 (1H, ddd,J=24.7, 12.4, 3.9 Hz), 1.43-1.54 (10H, m), 2.09-2.16 (1H, m), 2.21-2.27(1H, m), 3.03 (1H, t, J=10.5 Hz), 3.60 (1H, br s), 3.67 (1H, dd, J=11.4,2.7 Hz), 4.01-4.11 (1H, m), 4.12-4.17 (1H, m), 4.29 (1H, br s), 6.34(1H, d, J=7.3 Hz).

MS (ESI) m/z: 309 (M+Na)⁺.

[Step 2]

(2S,5R)-5-amino-N-isopropyltetrahydro-2H-pyran-2-carboxamidehydrochloride

The compound (350 mg, 1.22 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 or ReferenceExample 2 to give 198 mg (73%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.04 (6H, d, J=6.6 Hz), 1.42 (1H, ddd,J=24.4, 13.0, 3.6 Hz), 1.58 (1H, ddd, J=24.4, 12.3, 3.8 Hz), 1.93-1.99(1H, m), 2.06-2.11 (1H, m), 3.04-3.12 (1H, m), 3.31-3.33 (1H, m), 3.69(1H, dd, J=11.2, 2.4 Hz), 3.82-3.90 (1H, m), 4.09-4.12 (1H, m), 7.43(1H, d, J=8.1 Hz).

MS (ESI) m/z: 187 (M+H)⁺.

Reference Example 38

[Step 1]

Tert-butyl[(3R,6S)-6-(cyclopropylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and cyclopropylamine (0.21 ml, 2.45 mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 28 to give 231 mg (50%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 0.49-0.54 (2H, m), 0.74-0.80 (2H, m),1.27-1.38 (1H, m), 1.42-1.53 (10H, m), 2.08-2.14 (1H, m), 2.20-2.27 (1H,m), 2.68-2.74 (1H, m), 3.01 (1H, t, J=10.6 Hz), 3.57 (1H, br s), 3.68(1H, dd, J=11.5, 2.4 Hz), 4.09-4.14 (1H, m), 4.29 (1H, br s), 6.54 (1H,s).

MS (ESI) m/z: 307 (M+Na)⁺.

[Step 2]

(2S,5R)-5-amino-N-cyclopropyltetrahydro-2H-pyran-2-carboxamidehydrochloride

The compound (220 mg, 0.77 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 128 mg (75%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.43-0.47 (2H, m), 0.56-0.60 (2H, m),1.39-1.50 (1H, m), 1.57 (1H, ddd, J=23.6, 12.1, 3.4 Hz), 1.92-1.99 (1H,m), 2.03-2.11 (1H, m), 2.60-2.67 (1H, m), 3.02-3.12 (1H, m), 3.28-3.32(1H, m), 3.69 (1H, dd, J=11.0, 2.3 Hz), 4.05 (1H, dq, J=11.0, 2.3 Hz),7.72 (1H, d, J=4.6 Hz).

MS (ESI) m/z: 185 (M+H)⁺.

Reference Example 39

[Step 1]

Tert-butyl{(3R,6S)-6-[(methylsulfonyl)methyl]tetrahydro-2H-pyran-3-yl}carbamate

An N,N-dimethylformamide (5 ml) solution of the compound (621 mg, 2.01mmol) obtained in Step 1 of Reference Example 24 combined with sodiummethanethiolate (297 mg, 4.24 mmol) was stirred overnight at roomtemperature. The reaction mixture was diluted with ethyl acetate, washedwith water, 1N hydrochloric acid, saturated sodium bicarbonate solution,and brine in that order and then dried over anhydrous sodium sulfate.The solvent was evaporated under reduced pressure, the residue obtainedwas dissolved in dichloromethane (20 ml), m-chloroperbenzoic acid (25%hydrated, 1.9 g, 8.2 mmol) was added and the resulting mixture wasstirred for 1 hour. The reaction mixture was diluted with ethyl acetate,washed with water, saturated sodium bicarbonate solution, and brine inthat order and then dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [ethyl acetate:n-hexane=1:1 (v/v)]and subsequently purified by NH-silica gel column chromatography [ethylacetate:n-hexane=1:1 (v/v)] to give 505 mg (86%) of the title compoundas a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.30-1.56 (11H, m), 1.76 (1H, dq, J=13.4, 3.1Hz), 2.10-2.16 (1H, m), 2.92-2.99 (4H, m), 3.05 (1H, t, J=10.8 Hz), 3.23(1H, dd, J=15.1, 9.6 Hz), 3.57-3.64 (1H, m), 3.83-3.89 (1H, m),4.07-4.12 (1H, m), 4.23-4.29 (1H, m).

MS (FAB) m/z: 294 (M+H)⁺.

[Step 2]

(3R,6S)-6-[(methylsulfonyl)methyl]tetrahydro-2H-pyran-3-aminehydrochloride

The compound (61 mg, 0.21 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a colorless solid.

Reference Example 40

[Step 1]

Tert-butyl[(3R,6S)-6-(methylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and aqueous methylamine solution (40% w/w, 0.27 ml, 3.26mmol) were used as starting materials and treated in the same way as inStep 2 of Reference Example 28 to give 191 mg (45%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.32-1.55 (11H, m), 2.08-2.16 (1H, m),2.20-2.29 (1H, m), 2.82 (3H, d, J=5.1 Hz), 3.04 (1H, t, J=10.6 Hz),3.57-3.64 (1H, m), 3.72 (1H, dd, J=11.5, 2.4 Hz), 4.13-4.19 (1H, m),4.28 (1H, br s), 6.53 (1H, s).

MS (ESI) m/z: 259 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-methyltetrahydro-2H-pyran-2-carboxamide hydrochloride

The compound (190 mg, 0.74 mmol) obtained in Step 1 above was used as astarting material end treated in the same way as in Step 1 of ReferenceExample 2 to give 124 mg (86%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.36-1.47 (1H, m), 1.58 (1H, ddd, J=24.0,12.1, 3.7 Hz), 1.96-2.02 (1H, m), 2.04-2.10 (1H, m), 2.57 (3H, d, J=4.6Hz), 3.04-3.12 (1H, m), 3.35 (1H, t, J=10.3 Hz), 3.72 (1H, dd, J=11.2,2.5 Hz), 4.05-4.09 (1H, m), 7.67 (1H, d, J=4.6 Hz).

MS (ESI) m/z: 159 (M+H)⁺.

Reference Example 41

[Step 1]

Tert-butyl[(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and aqueous dimethylamine solution (50% w/w, 0.29 ml, 3.26mmol) were used as starting materials and treated in the same way as inStep 2 of Reference Example 28 to give 328mg (74%) of the title compoundas a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.41-1.42 (1H, m), 1.44 (9H, s), 1.83-2.00(2H, m), 2.16-2.22 (1H, m), 2.95 (3H, s), 3.07 (3H, s), 3.08-3.15 (1H,m), 3.66 (1H, br s), 4.04 (1H, dd, J=10.0, 3.2 Hz), 4.11 (1H, dd,J=10.7, 3.2 Hz), 4.40 (1H, br s).

MS (ESI) m/z: 273 (M+H)⁺.

[Step 2]

(2S,5R) -5-amino-N,N-dimethyltetrahydro-2H-pyran-2-carboxamidehydrochloride

The compound (320 mg, 1.17 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 289 mg (78%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.55-1.75 (3H, m), 2.07-2.13 (1H, m), 2.99(3H, s), 3.07-3.13 (1H, m), 3.15 (3H, s), 3.38 (1H, t, J=10.5 Hz),3.97-4.01 (1H, m), 4.13 (1H, dd, J=8.9, 3.4 Hz).

MS (ESI) m/z: 173 (M+H)⁺.

Reference Example 42

[Step 1]

Tert-butyl{(3R,6S)-6-[(2-hydroxyethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and 2-aminoethanol (0.15 ml, 2.45 mmol) were used as startingmaterials and created in the same way as in Step 2 of Reference Example28 to give 313 mg (67%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.33-1.41 (1H, m), 1.44 (9H, s), 1.48-1.57(1H, m), 2.10-2.18 (1H, m), 2.21-2.28 (1H, m), 2.78 (1H, br s), 3.05(1H, t, J=10.8 Hz), 3.38-3.51 (2H, m), 3.58-3.63 (1H, m), 3.70-3.77 (3H,m), 4.13-4.19 (1H, m), 4.33 (1H, br s), 6.97 (1H, br s).

MS (ESI) m/z: 289 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-(2-hydroxyethyl)tetrahydro-2H-pyran-2-carboxamidehydrochloride

The compound (310 mg, 1.07 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 310 mg (100%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.38-1.48 (1H, m), 1.54-1.64 (1H, m),1.97-2.04 (1H, m), 2.06-2.12 (1H, m), 3.06-3.17 (2H, m), 3.34-3.47 (4H,m), 3.71-3.79 (1H, m), 4.07-4.13 (1H, m), 7.56 (1H, t, J=5.7 Hz).

MS (ESI) m/z: 189 (M+H)⁺.

Reference Example 43

[Step 1]

2,6-anhydro-1,3,4-trideoxy-D-arabino-hept-3-enitol

Sodium methoxide/methanol solution (28% w/w, 0.40 ml, 2.1 mmol) wasadded to a methanol (15 ml) solution of5,7-di-O-acetyl-2,6-anhydro-1,3,4-trideoxy-D-arabino-hept-3-enitol(Synlett, 1996, 185; and Tetrahedron: Asymm., 2003, 14, 757) (1.56 g,6.83 mmol) and the resulting mixture was stirred at room temperature for3 hours. DOWEX 50WX8-200 was added to the reaction mixture to adjust itspH to 4 and then insoluble matter was removed by filtration. Thefiltrate was concentrated under reduced pressure to give the titlecompound.

[Step 2]

2,6-anhydro-7-O[tert-butyl(dimethyl)silyl]-1,3,4-trideoxy-D-arabino-hept-3-enitol

The compound (6.83 mmol) obtained in Step 1 above was used as a startingmaterial and treated in the same way as in Step 1 of Reference Example23 to give the title compound.

[Step 3]

2,6-anhydro-7-O-[tert-butyl(dimethyl)silyl]-1,3,4-trideoxy-5-O-(222-trichloroethanimidoyl)-D-arabino-hept-3-enitol

1,8-Diazabicyclo[5.4.0]undec-7-ene (1.00 ml, 6.83 mmol) was added to adichloromethane (22 ml) solution of the compound (6.83 mmol) obtained inStep 2 above combined with trichloroacetonitrile (0.82 ml, 8.20 mmol)under ice cooling and the resulting mixture was stirred at roomtemperature for 1 hour. The solvent in the reaction mixture wasevaporated under reduced pressure and the residue was dissolved inchloroform and added dropwise into n-hexane:ethyl acetate [4:1 v/v)]mixed solvent. The resulting insoluble matter was removed by filtrationthrough celite and the solvent in the filtrate was evaporated underreduced pressure. The residue obtained was purified by silica gel columnchromatography [n-hexane:ethyl acetate=99:1→10:1 (v/v)] to give 2.1 g(77%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.04 (6H, s), 0.87 (9H, s), 1.30 (3H, d,J=6.4 Hz), 3.74-3.91 (3H, m), 4.36-4.46 (1H, m), 5.25-5.30 (1H, m),5.86-5.93 (2H, m), 8.34 (1H, s).

[Step 4]

2,6-Anhydro-7-O-[tert-butyl(dimethyl)silyl]-1,3,4,5-tetradeoxy-3-[(trichloroacetyl)amino]-D-arabino-hept-4-enitol

Potassium carbonate (50 mg, 0.36 mmol) was added to an o-dichlorobenzene(11 ml) solution of the compound (2.13 g, 5.29 mmol) obtained in Step 3above and the resulting mixture was stirred under heating at 180° C. for4 hours. After cooling to room temperature, insoluble matter was removedby filtration through celite and then the solvent in the filtrate wasevaporated under reduced pressure to give the title compound.

[Step 5]

2,6-anhydro-3-[(tert-butoxycarbonyl)amino]-7-O-[tert-butyl(dimethyl)silyl]-1,3,4,5-tetradeoxy-D-arabino-hept-4-enitol

Potassium hydroxide (0.89 g) was added to a 2-propanol (9 ml) solutionof the compound (5.29 mmol) obtained in Step 4 above and the resultingmixture, was stirred for 28 hours. Insoluble matter was removed byfiltration through celite, the solvent was evaporated under reducedpressure and the residue obtained was dissolved in dichloromethane (9ml). Di-tert-butyl dicarbonate (1.38 g, 6.35 mmol) was added under icecooling and the resulting mixture was stirred at room temperature for 4hours. Water was added, the resulting mixture was subjected toextraction with chloroform and the organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=30:1→10:1 (v/v)] to give 1.3 g(71%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 0.04 (3H, s), 0.04 (3H, s), 0.87 (9H, s),1.15 (3H, d, J=6.0 Hz), 1.42 (9H, s), 3.62 (1H, dd, J=10.6, 5.50 Hz),3.72 (1H, dd, J=10.6, 6.4 Hz), 3.84-3.92 (1H, m), 3.96-4.04 (1H, m),4.13-4.20 (1H, m), 4.59 (1H, d, J=9.6 Hz), 5.83-5.89 (1H, m), 5.92-6.01(1H, m).

[Step 6]

2,6-Anhydro-3-[(tert-butoxycarbonyl)amino]-1,3,4,5-tetradeoxy-D-arabino-heptitol

The compound (960 mg, 2.68 mmol) obtained in Step 5 above was dissolvedin ethyl acetate (5 ml) and ethanol (5 ml), platinum (IV) oxide (18 mg,0.08 mmol) was added and the resulting mixture was stirred for 19 hoursunder hydrogen atmosphere. The catalyst was removed by filtrationthrough celite, then the solvent in the filtrate was evaporated underreduced pressure and the residue was purified by silica gel columnchromatography [n-hexane:ethyl acetate=9:1→2:3 (v/v)] to give 524 mg(79%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.17 (3H, d, J=6.9 Hz), 1.41-1.93 (14H, m),3.4503.83 (4H, m), 4.08-4.18 (1H, m), 4.54-4.66 (1H, m).

[Step 7]

3-Amino-2,6-anhydro-1,3,4,5-tetradeoxy-D-arabino-heptitol hydrochloride

The compound (524 mg, 2.14 mmol) obtained in Step 6above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 355 mg (92%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.24 (3H, d, J=6.9 Hz), 1.44-1.55 (1H, m),1.76-2.04 (3H, m), 3.27-3.34 (1H, m), 3.52 (1H, dd, J=11.5, 4.6 Hz),3.61-3.69 (1H, m), 3.75-3.84 (1H, m), 4.11-4.19 (1H, m).

Reference Example 44

[Step 1]

Tert-butyl[(3R,6S)-6-(azetidin-1-ylcarbonyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and azetidine hydrochloride (305 mg, 3.26mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 28 to give 244 mg (53%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.29-1.39 (1H, m), 1.44 (9H, s), 1.68-1.78(1H, m), 1.98-2.05 (1H, m), 2.08-2.16 (1H, m), 2.23-2.30 (2H, m), 3.02(1H, t, J=10.3 Hz), 3.56-3.66 (1H, m), 3.86 (1H, dd, J=11.2, 2.5 Hz),4.04 (2H, t, J=7.8 Hz), 4.10 (1H, dq, J=10.6, 2.1 Hz), 4.31 (2H, t,J=7.8 Hz), 4.33 (1H, br s).

MS (ESI) m/z: 285 (M+H)⁺.

[Step 2]

(3R,6S)-6-(azetidin-1-ylcarbonyl)tetrahydro-2H-pyran-3-aminehydrochloride

The compound obtained in Step 1 above was used as a starting materialand treated in the same way as in Step 1 of Reference Example 2 to give210 mg (100%) of the title compound as a colorless amorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.42-1.51 (1H, m), 1.55-1.61 (1H, m),1.78-1.85 (1H, m), 1.95-2.03 (1H, m), 2.14-2.22 (2H, m), 3.07-3.11 (1H,m), 3.59 (1H, t, J=6.7 Hz), 3.84 (2H, t, J=7.6 Hz), 3.95-4.01 (1H, m),4.04-4.10 (1H, m), 4.20 (2H, t, J=7.8 Hz).

MS (ESI) m/z: 185 (M+H)⁺.

Reference Example 45

[Step 1]

Tert-butyl{(3R,6S)-6-[(3-hydroxyazetidin-1-yl)carbonyl]tetrahydro-2H-pyran-3-yl}carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and 3-hydroxyazetidine hydrochloride (267 mg, 2.45 mmol) wereused as starting materials and treated in the same way as in Step 2 ofReference Example 28 to give 261 mg (53%) of the title compound as acolorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.33-1.42 (1H, m), 1.44 (9H, s), 1.64-1.76(1H, m), 2.01-2.07 (1H, m), 2.08-2.15 (1H, m), 2.37 (1H, d, J=5.6 Hz),3.01 (1H, td, J=10.5, 2.8 Hz), 3.60 (1H, br s), 3.82-3.91 (2H, m),4.06-4.17 (2H, m), 4.23-4.30 (1H, m), 4.35 (1H, br s), 4.51-4.57 (1H,m), 4.60-4.68 (1H, m).

MS (ESI) m/z: 301 (M+H)⁺.

[Step 2]

1-{[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]carbonyl}azetidin-3-olhydrochloride

The compound (310 mg, 1.03 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 249 mg (100%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.53-1.61 (2H, m), 1.78-1.83 (1H, m),2.04-2.07 (1H, m), 3.05-3.13 (1H, m), 3.30 (1H, dd, J=10.9, 6.0 Hz),3.57 (1H, dd, J=11.2, 3.7 Hz), 3.85-4.07 (4H, m), 4.34-4.46 (2H, m).

MS (ESI) m/z: 201 (M+H)⁺.

Reference Example 46

(3E/Z)-6-chloro-3-(3-chloro-2-fluorobenzylidene)-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one

6-Chloro-1,3-dihydro-2H-pyrrolo[3,2-c]pyridin-2-one (3.00 g, 17.8 mmol)was used as a starting material and treated in the same way as inReference Example 1 to give 3.94 g (72%) of the title compound as ayellow solid.

¹H-NMR (DMSO-d₆) δ: 6.98 (1H, s), 7.41 (1H, t, J=7.9 Hz), 7.70 (1H, s),7.78 (2H, q, J=7.0 Hz), 8.09 (1H, s), 11.38 (1H, br s).

MS (ESI) m/z: 309 (M+H)⁺.

Reference Example 47

[Step 1]

Tert-butyl[(3R,6S)-6-(tetrahydro-2H-pyran-4-ylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and tetrahydropyran-4-ylamine hydrochloride (270 mg, 1.96mmol) were used as starting materials and treated in the same way as inStep 2 of Reference Example 28 to give 355 mg (66%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.35 (1H, ddd, J=24.6, 12.3, 3.8 Hz), 1.44(9H, s), 1.45-1.56 (3H, m), 1.84-1.92 (2H, m), 2.10-2.16 (1H, m),2.22-2.27 (1H, m), 3.04 (1H, t, J=10.8 Hz), 3.48 (2H, td, J=11.7, 2.1Hz), 3.59-3.63 (1H, m), 3.70 (1H, dd, J=11.4, 2.3 Hz), 3.92-4.02 (3H,m), 4.13-4.19 (1H, m), 4.30-4.32 (1H, m), 6.45 (1H, d, J=7.8 Hz).

MS (ESI) m/z: 351 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-(tetrahydro-2H-pyran-4-yl)tetrahydro-2H-pyran-2-carboxamidehydrochloride

The compound (350 mg, 1.07 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 236 mg (83%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.40-1.64 (6H, m), 1.93-1.99 (1H, m),2.06-2.13 (1H, m), 3.04-3.12 (1H, m), 3.30 (2H, td, J=11.7, 2.3 Hz),3.37 (1H, t, J=9.4 Hz), 3.72 (1H, dd, J=11.2, 2.5 Hz), 3.74-3.82 (3H,m), 4.11 (1H, dq, J=10.5, 2.1 Hz), 7.63 (1H, d, J=7.8 Hz).

MS (ESI) m/z: 229 (M+H)⁺.

Reference Example 48

[Step 1]

Tert-butyl[(3R,6S)-6-(morpholin-4-ylcarbonyl)tetrahydro-2H-pyran-3-yl]carbamate

The same starting material (400 mg, 1.63 mmol) as in Step 1 of ReferenceExample 18 and morpholine (0.17 ml, 1.96 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 344 mg (67%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.37-1.43 (1H, m), 1.44 (9H, s), 1.87-1.99(2H, m), 2.15-2.22 (1H, m), 3.11 (1H, t, J=10.1 Hz), 3.50-3.74 (9H, m),4.01 (1H, dd, J=8.5, 3.9 Hz), 4.06-4.12 (1H, m), 4.41 (1H, s).

MS (ESI) m/z: 315 (M+H)⁺.

[Step 2]

(3R,6S)-6-(morpholin-4-ylcarbonyl)tetrahydro-2H-pyran-3-aminehydrochloride

The compound (340 mg, 1.08 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 283 mg (100%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.58-1.78 (3H, m), 2.08-2.13 (1H, m),3.06-3.13 (1H, m), 3.41-3.58 (9H, m), 3.99 (1H, dd, J=10.8, 2.5 Hz),4.15 (1H, dd, J=9.6, 3.2 Hz).

MS (ESI) m/z: 215 (M+H)⁺.

Reference Example 49

[Step 1]

Tert-butyl [(3R,6S)-6-(cyanomethyl)tetrahydro-2H-pyran-3-yl]carbamate

Potassium cyanide (741 mg, 11.4 mmol) was added to anN,N-dimethylformamide (10 ml) solution of the compound (678 mg, 2.19mmol) obtained in Step 1 of Reference Example 24 and the resultingmixture was stirred overnight at 100° C. The reaction mixture wasdiluted with ethyl acetate, washed with brine and then dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure and the residue obtained was purified by silica gel columnchromatography [ethyl acetate:chloroform=1:4 (v/v)] to give 392 mg (74%)of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.28-1.57 (11H, m), 1.87 (1H, dq, J=13.5, 3.1Hz), 2.13-2.16 (1H, m), 2.48-2.58 (2H, m), 3.04 (1H, t, J=10.9 Hz),3.50-3.56 (1H, m), 3.60-3.65 (1H, m), 4.09-4.12 (1H, m), 4.23-4.28 (1H,m).

MS (FAB) m/z: 241 (M+H)⁺.

[Step 2]

Tert-butyl[(3R,6S)-6-(2-amino-2-oxoethyl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (60 mg), 0.25 mmol) obtained in Step 1 above was added to amixture of sodium hydroxide (94 mg, 2.36 mmol), ethanol (5 ml), and 30%aqueous hydrogen peroxide solution (5 ml) and the resulting mixture wasstirred overnight at room temperature. The reaction mixture was dilutedwith ethyl acetate, washed with brine and then dried over anhydroussodium sulfate. The solvent was evaporated under reduced pressure andthe residue obtained was purified by silica gel column chromatography[methanol:chloroform=5:95 (v/v)] to give 9 mg (13%) of the titlecompound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.28-1.54 (11H, m), 1.73-1.76 (1H, m),2.08-2.10 (1H, m), 2.35-2.44 (2H, m), 3.04 (1H, t, J=10.9 Hz), 3.59-3.64(2H, m), 4.09-4.12 (1H, m), 4.32 (1H, d, J=8.0 Hz), 5.46 (1H, br s),6.30 (1H, br s).

MS (FAB) m/z: 259 (M+H)⁺.

[Step 3]

2-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]acetamide hydrochloride

The compound (39 mg, 0.15 mmol) obtained in Step 2 above was used andtreated in the same way as in Step 1 of Reference Example 2 to give thetitle compound as a colorless solid.

Reference Example 50

[Step 1]

Benzyl [trans-3-(hydrazinocarbonyl)cyclobutyl]carbamate

Hydrazine monohydrate (10 ml) was added to a methanol (50 ml) solutionof methyl trans-3-{[(benzyloxy)carbonyl]amino}cyclobutanecarboxylate(Neurochemical Research, 1980, 5, 393-400) (995 mg, 3.78 mmol) at roomtemperature and the resulting mixture was stirred for 24 hours. Theprecipitated solid was collected by filtration, washed with water andthen dried to give 760 mg (76%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 2.21-2.25 (2H, m), 2.61-2.64 (2H, m),2.81-2.87 (1H, m), 3.87 (2H, br s), 4.36 (1H, q, J=7.5 Hz), 4.83 (1H, brs), 5.09 (2H, s), 6.54 (1H, br s), 7.30-7.35 (5H, m).

MS (ESI) m/z: 265 (M+H)⁺.

[Step 2]

Benzyl [trans-3-(1,3,4-oxadiazol-2-yl)cyclobutyl]carbamate

The compound (760 mg, 2.89 mmol) obtained in Step 1 above was used as astarting material and treated in the same say as in Step 2 of ReferenceExample 3 to give 1.00 g (99%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 2.52-2.58 (2H, m), 2.76-2.79 (2H, m),3.67-3.72 (1H, m), 4.48-4.52 (1H, m), 5.10 (2H, s), 5.15 (1H, br s),7.30-7.41 (5H, m), 8.37 (1H, s).

MS (ESI) m/z: 274 (M+H)⁺.

[Step 3]

Trans-3-(1,3,4-oxadiazol-2-yl)cyclobutanamine

The compound (1.00 g, 3.66 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 331 mg (77%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CDCl₃) δ: 2.21-2.29 (2H, m), 2.67-2.74 (2H, m),3.67-3.71 (1H, m), 3.83-3.91 (1H, m), 8.35 (1H, s).

MS (ESI) m/z: 140 (M+H)⁺.

Reference Example 51

[Step 1]

Benzyl (trans-3-carbamoylcyclobutyl)carbamate

trans-3-{[(Benzyloxy)carbonyl]amino}cyclobutanecarboxylic acid (110 mg,0.44 mmol) was used as a starting material and treated in the same wayas in Step 1 of Reference Example 16 to give 47 mg (43%) of the titlecompound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 2.10-2.34 (2H, m), 2.59-2.71 (2H, m),2.90-3.01 (1H, m), 4.29-4.41 (1H, m), 4.95 (1H, br s), 5.09 (2H, s),5.30 (2H, br s), 7.29-7.40 (5H, m).

MS (ESI) m/z: 249 (M+H)⁺.

[Step 2]

Trans-3-aminocyclobutanecarboxamide

The compound (21 mg, 0.19 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 21 mg (97%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.96-2.09 (2H, m), 2.39-2.52 (2H, m),2.94-3.04 (1H, m), 3.54-3.69 (1H, m).

Reference Example 52

[Step 1]

Benzyl [trans-3-(dimethylcarbamoyl)cyclobutyl]carbamate

The same starting material as in Step 1 of Reference Example 51 andaqueous dimethylamine solution (50% w/w, 0.16 ml, 1.77 mmol) were usedas starting materials and treated in the same way as in Step 2 ofReference Example 28 to give 48 mg (39%) of the title compound as acolorless solid.

MS (ESI) m/z: 277 (M+H)⁺.

[Step 2]

Trans-3-amino-N,N-dimethylcyclobutanecarboxamide

The compound (48 mg, 0.17 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 26 mg (100%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 2.07-2.17 (2H, m), 2.45-2.56 (2H, m), 2.93(3H, s), 2.95 (3H, s), 3.33-3.42 (1H, m), 3.51-3.62 (1H, m).

MS (ESI) m/z: 143 (M+H)⁺.

Reference Example 53

[Step 1]

Benzyl [(3R,6S)-6-(diethylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (400 mg, 1.43 mmol) obtained in Step 3 of Reference Example18 and diethylamine (0.22 ml, 2.15 mmol) were used as starting materialsand treated in the same way as in Step 2 of Reference Example 28 to give514 mg (100%) of the title compound as a colorless amorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.12 (3H, t, J=7.1 Hz), 1.18 (3H, t, J=7.1Hz), 1.41-1.48 (1H, m), 1.80-1.87 (1H, m), 1.93-2.09 (1H, m), 2.18-2.23(1H, m), 3.13-3.20 (1H, m), 3.28-3.47 (4H, m), 3.71-3,.76 (1H, m), 4.02(1H, dd, J=8.9, 2.6 Hz), 4.12 (1H, dd, J=11.2, 3.2 Hz), 4.69-4.73 (1H,m), 5.06-5.12 (2H, m), 7.30-7.39 (5H, m).

MS (ESI) m/z: 335 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N,N-diethyltetrahydro-2H-pyran-2-carboxamide

The compound (480 mg, 1.43 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 282 mg (98%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 0.98 (3H, t, J=6.9 Hz), 1.10 (3H, t, J=6.9Hz), 1.50 (1H, ddd, J=23.5, 11.8, 4.7 Hz), 1.63-1.75 (2H, m), 2.01-2.08(1H, m), 2.92-3.00 (1H, m), 3.12-3.20 (1H, m), 3.23-3.39 (4H, m), 3.92(1H, dq, J=10.8, 2.1 Hz), 4.02 (1H, dd, J=9.6, 3.7 Hz).

MS (ESI) m/z: 201 (M+H)⁺.

Reference Example 54

[Step 1]

Benzyl [trans-3-(ethylcarbamoyl)cyclobutyl]carbamate

The same starting material as in Step 1 of Reference Example 51 andethylamine hydrochloride (79 mg, 0.96 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 35 mg (64%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.13 (3H, t, J=7.3 Hz), 2.04-2.30 (2H, m),2.57-2.67 (2H, m), 2.77-2.91 (1H, m), 3.25-3.35 (2H, m), 4.29-4.41 (1H,m), 4.91-5.15 (3H, m), 5.37 (1H, br s), 7.29-7.39 (5H, m).

MS (ESI) m/z: 277 (M+H)⁺.

[Step 2]

Trans-3-amino-N-ethylcyclobutanecarboxamide

The compound (84 mg, 0.30 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 43 mg (100%) of the title compound as a colorless oil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.10 (3H, t, J=7.1 Hz), 1.95-2.06 (2H, m),2.38-2.49 (2H, m), 2.87-2.99 (1H, m), 3.14-3.23 (2H, m), 3.57-3.68 (1H,m).

MS (ESI) m/z: 143 (M+H)⁺.

Reference Example 55

[Step 1]

Benzyl [trans-3-(hydroxymethyl)cyclobutyl]carbamate

Isobutyl chloroformate (0.14 ml, 1.04 mmol) and triethylamine (0.15 ml,1.04 mmol) were added in that order to a tetrahydrofuran (4 ml) solutionof the same starting material (260 mg, 1.04 mmol) as in Step 1 ofReference Example 51 under ice cooling, and the resulting mixture wasstirred at the same temperature for 10 minutes. Insoluble matter wasremoved by filtration through celite, methanol (1 ml) was added to thefiltrate and sodium borohydride (79 mg, 2.09 mmol) was added under icecooling, after stirring for 30 minutes, 1N hydrochloric acid was added.The solvent was evaporated under reduced pressure, the residue wassubjected to extraction with ethyl acetate and the organic layer waswashed with brine and then dried over anhydrous sodium sulfate. Thesolvent was evaporated under reduced pressure and the residue waspurified by silica gel column chromatography [n-hexane:ethyl acetate3:1→1:1 (v/v)] to give 111 mg (45%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.36 (1H, br s), 1.95-2.08 (2H, m), 2.15-2.27(2H, m), 2.32-2.47 (1H, m), 3.68 (2H, d, J=7.3 Hz), 4.17-4.33 (1H, m),4.93 (1H, br s), 5.08 (2H, s), 7.29-7.39 (5H, m).

MS (ESI) m/z: 236 (M+H)⁺.

[Step 2]

(Trans-3-aminocyclobutyl)methanol

The compound (34 mg, 0.14 mmol) obtained in Step 1 above was used as astarting material, and treated in the same way as in Step 3 of ReferenceExample 2 to give 11 mg (75%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.83-1.94 (2H, m), 2.04-2.15 (2H, m),2.26-2.39 (1H, m), 3.42-3.52 (1H, m), 3.55 (2H, d, J=7.3 Hz).

Reference Example 56

[Step 1]

Benzyl [trans-3-(tetrahydro-2H-pyran-4-ylcarbamoyl)cyclobutyl]carbamate

The same starting material as in Step 1 of Reference Example 51 and4-aminotetrahydropyran hydrochloride (99 mg, 0.72 mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 28 to give 104 mg (65%) of the title compound as a colorlesssolid.

¹H-NMR (DMSO-d₆) δ: 1.27-1.41 (2H, m), 1.61-1.71 (2H, m), 2.01-2.13 (2H,m), 2.22-2.31 (2H, m), 2.72-2.82 (1H, m), 3.28-3.35 (2H, m), 3.67-3.86(3H, m), 4.09-4.22 (1H, m), 4.99 (2H, s), 7.28-7.40 (5H, m), 7.58 (1H,d, J=8.3 Hz), 7.70 (1H, d, J=7.8 Hz).

MS (ESI) m/z: 333 (M+H)⁺.

[Step 2]

Trans-3-amino-N-(tetrahydro-2H-pyran-4-yl)cyclobutanecarboxamide

The compound (78 mg, 0.23 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 47 mg (100%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.41-1.56 (2H, m), 1.74-1.84 (2H, m),1.95-2.06 (2H, m), 2.38-2.48 (2H, m), 2.88-2.98 (1H, m), 3.41-3.51 (2H,m), 3.58-3.68 (1H, m), 3.80-3.97 (3H, m).

MS (ESI) m/z: 199 (M+H)⁺.

Reference Example 57

[Step 1]

Ethyl6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylate(racemate)

glycine ethyl ester hydrochloride (6.98 g, 50 mmol) and the compound(6.70 g, 50.0 mmol) obtained in Step 2 of Reference Example 21 weredissolved in tetrahydrofuran (210 ml) and N,N-dimethylformamide (210ml), triethylamine (7.6 ml, 54.5 mmol) and molecular sieves 4A (powder)(18.8 g) were added and the resulting mixture was stirred at 70° C. for1 hour.(3E/Z)-6-chloro-3-(3-chloro-2-fluorobenzylidene)-1,3-dihydro-2H-indol-2-one(WO2006/091646) (14.0 g, 45.4 mmol) was added to the reaction mixtureand the resulting mixture was stirred at 70° C. for 14 hours. Glycineethyl ester hydrochloride (1.58 g, 11.4 mmol) and the compound (1.52 g,11.4 mmol) obtained in Step 2 of Reference Example 21 were further addedto the reaction mixture and the resulting mixture was further stirred at70° C. for 18 hours. After cooling, insoluble matter was removed byfiltration through celite and the filtrate was concentrated underreduced pressure. Saturated sodium bicarbonate solution was added to theresidue, followed by extraction with ethyl acetate. The organic layerwas washed with water and brine and then dried over anhydrous magnesiumsulfate. The solvent was evaporated under reduced pressure and theresidue obtained was purified by silica gel column chromatography[n-hexane:ethyl acetate 9:1→1:1 (v/v)] to give 5.31 g (22%) of the titlecompound.

[Step 2]

Ethyl(3′R,4′S,5′R)-6″-chloro-4′-(3-chloro-2-fluorophenyl)-3,3-bis(fluoromethyl)-2″-oxo-1″,2″-dihydrodispiro[cyclobutane-1,2′-pyrrolidine-3′,3″-indole]-5′-carboxylate

The racemate (5.31 g, 10.1 mmol) obtained in Step 1 above wasfractionated and purified by chiral column liquid chromatography[fractionation conditions: CHIRALPAK IC, n-hexane:tetrahydrofuran=4:1(v/v)] to give 2.33 g (44%) of the title compound.

¹H-NMR (400 MHz, CDCl₃) δ: 1.19 (3H, t, J=7.1 Hz), 1.70 (1H, d, J=13.7Hz), 1.83-1.89 (1H, m), 2.20 (1H, d, J=12.8 Hz), 2.42 (1H, dd, J=12.8,2.7 Hz), 3.66-3.76 (1H, m), 3.77-3.96 (2H, m), 4.09-4.22 (2H, m), 4.45(1H, d, J=9.5 Hz), 4.48 (1H, d, J=9.5 Hz), 4.54-4.78 (2H, m), 6.81 (1H,d, J=1.8 Hz), 6.96 (1H, td, J=8.0, 1.2 Hz), 7.13 (1H, dd, J=8.0, 2.1Hz), 7.16-7.21 (1H, m), 7.36 (1H, br s), 7.40 (1H, dd, J=8.1, 2.0 Hz),7.44-7.48 (1H, m).

Reference Example 58

[Step 1]

Benzyl{(3R,6S)-6-[ethyl(methyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound (400 mg, 1.43 mmol) obtained in Step 3 of Reference Example18 and N-methylethanamine (0.19 ml, 2.15 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 466 mg (100%) of the title compound as a colorless amorphoussolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.11 and 1.18 (total 3H, each t, J=7.1 Hz),1.39-1.50 (1H, m), 1.82-1.90 (1H, m), 1.92-2.01 (1H, m), 2.16-2.25 (1H,m), 2.91 and 3.03 (total 3H, each s), 3.17 (1H, t, J=10.3 Hz), 3.33-3.49(2H, m), 3.71-3.78 (1H, m), 4.01-4.07 (2H, m), 4.10-4.15 (1H, m), 4.68(1H, d, J=6.9 Hz), 5.06-5.13 (2H, m), 7.31-7.38 (5H, m).

MS (ESI) m/z: 321 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-ethyl-N-methyltetrahydro-2H-pyran-2-carboxamide

The compound (450 mg, 1.40 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 240 mg (92%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.00-1.12 (3H, m), 1.49-1.55 (1H, m),1.68-1.75 (2H, m), 2.04-2.11 (1H, m), 2.76-2.83 (1H, m), 2.91-3.00 (1H,m), 3.19 (3H, s), 3.27 (1H, t, J=10.3 Hz), 3.31-3.38 (1H, m), 3.94 (1H,dd, J=11.0, 4.6 Hz), 4.06 (1H, t, J=6.4 Hz).

MS (ESI) m/z: 187 (M+H)⁺.

Reference Example 59

[Step 1]

Benzyl{(3R,6S)-6-[(2-fluoroethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound 400 mg, 1.43 mmol) obtained in Step 3 of Reference Example18 and 2-fluoroethanamine hydrochloride (214 mg, 2.15 mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 28 to give 310 mg (96%) at the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.32-1.45 (1H, m), 1.50-1.59 (1H, m),2.13-2.19 (1H, m), 2.26 (1H, dq, J=13.7, 3.2 Hz), 3.08 (1H, t, J=10.8Hz), 3.48-3.78 (4H, m), 4.18-4.23 (1H, m), 4.42-4.57 (3H, m), 5.06-5.14(2H, m), 6.89 (1H, br s), 7.31-7.39 (5H, m).

MS (ESI) m/z: 325 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-(2-fluoroethyl)tetrahydro-2H-pyran-2-carboxamide

The compound (300 mg, 0.92 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 140 mg (80%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.13-1.36 (2H, m), 1.86-1.93 (2H, m),2.53-2.61 (1H, m), 2.93 (1H, t, J=10.5 Hz), 3.30-3.44 (2H, m), 3.61 (1H,dd, J=11.2, 2.5 Hz), 3.84 (1H, dq, J=11.0, 2.1 Hz), 4.33-4.80 (2H, m),7.74 (1H, br s).

MS (ESI) m/z: 191 (M+H)⁺.

Reference Example 60

[Step 1]

Benzyl{(3R,6S)-6-[(2-methoxyethyl)(methyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound (400 mg, 1.43 mmol) obtained in Step 3 of Reference Example18 and (2-methoxyethyl) methylamine (191 mg, 2.15 mmol) were used asstarting materials and treated in the same way as in Step 2 of ReferenceExample 23 to give 442 mg (88%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.41-1.46 (1H, m), 1.82-1.99 (2H, m),2.17-2.23 (1H, m), 2.96 and 3.12 (total 3H, each s), 3.15-3.20 (1H, m),3.33 and 3.33 (total 3H, each s), 3.48-3.56 (3H, m), 3.70-3.78 (2H, m),4.04-4.17 (2H, m), 4.67 (1H, br s), 5.05-5.14 (2H, m), 7.30-7.39 (5H,m).

MS (ESI) m/z: 351 (M+H)⁺.

[Step 3]

(2S,5R)-5-amino-N-(2-methoxyethyl)-N-methyltetrahydro-2H-pyran-2-carboxamide

The compound (440 mg, 1.26 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 264 mg (97%) of the title compound as a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.53 1.73 (3H, m), 2.06-2.12 (1H, m), 2.80and 3.02 (total 3H, each s), 3.05-3.13 (1H, m), 3.21 and 3.25 (total 3H,each s), 3.35-3.41 (3H, m), 3.42-3.67 (2H, m), 3.95-4.01 (1H, m),4.11-4.17 (1H, m), 8.10 (2H, br s).

MS (ESI) m/z: 217 (M+H)⁺.

Reference Example 61

[Step 1]

Benzyl{(3R,6S)-6-[(2-methoxyethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound (600 mg, 2.15 mmol) obtained in Step 3 of Reference Example18 and 2-methoxyethylamine (0.28 ml, 3.23 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 359 mg (50%) of the title compound as a colorless solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.33-1.42 (1H, m), 1.50-1.57 (1H, m),2.12-2.17 (1H, m), 2.25 (1H, dq, J=13.6, 3.2 Hz), 3.07 (1H, t, J=10.6Hz), 3.37 (3H, s), 3.41-3.50 (4H, m), 3.68-3.72 (1H, m), 3.74 (1H, dd,J=11.5, 2.4 Hz), 4.17-4.22 (1H, m), 4.52 (1H, d, J=6.6 Hz), 5.06-5.14(2H, m), 6.84 (1H, br s), 7.31-7.39 (5H, m).

MS (ESI) m/z: 337 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N-(2-methoxyethyl)tetrahydro-2H-pyran-2-carboxamide

The compound (350 mg, 1.04 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 220 mg (100%) of the title compound as a colorlessoil.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.12-1.22 (1H, m), 1.24-1.34 (1H, m),1.85-1.92 (2H, m), 2.53-2.60 (1H, m), 2.61 (1H, t, J=10.5 Hz), 3.16-3.27(5H, m). 3.32 (2H, t, J=6.0 Hz), 3.58 (1H, dd, J=11.4, 2.3 Hz), 3.83(1H, ddd, J=11.0, 4.2, 1.8 Hz), 7.46 (1H, s).

MS (ESI) m/z: 203 (M+H)⁺.

Reference Example 62

[Step 1]

Benzyl[trans-4-({2-[(benzyloxy)acetyl]hydrazino}carbonyl)cyclohexyl]carbamate

The compound (507 mg, 1.74 mmol) obtained in Step 1 of Reference Example3 and benzyloxyacetic acid (0.28 ml, 1.92 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example28 to give 695 mg (91%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.08-1.21 (2H, m), 1.61-1.72 (2H, m),1.90-2.02 (2H, m), 2.06-2.21 (3H, m), 3.39-3.63 (1H, m), 4.10 (2H, s),4.50-4.70 (3H, m), 5.08 (2H, s), 7.29-7.42 (10H, m), 7.94-8.03 (1H, m),8.80-8.88 (1H, m).

[Step 2]

Benzyl(trans-4-{5-[(benzyloxy)methyl]-1,3,4-oxadiazol-2-yl}cyclohexyl)carbamate

Hexachloroethane (205 mg, 0.87 mmol), triethylamine (0.29 ml, 2.08mmol), and the compound (152 mg, 0.35mmol) obtained in Step 1 above wereadded to a dichloromethane (9 ml) solution of triphenylphosphine (273mg, 1.04 mmol) under ice cooling and the resulting mixture was stirredat room temperature for 24 hours. The reaction mixture was diluted Withdichloromethane:methanol [10:1 (v/v)], washed with 10% aqueous citricacid solution, and dried over anhydrous sodium sulfate. The solvent wasconcentrated under reduced pressure and the residue was purified bysilica gel column chromatography [n-hexane:ethyl acetate=2:1→1:1 (v/v)]to give 125 mg (86%) of the title compound as a colorless solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.20-1.33 (2H, m), 1.64-1.82 (2H, m),2.11-2.23 (4H, m), 2.78-2.88 (1H, m), 3.50-3.64 (1H, m), 4.62 (2H, s),4.67 (2H, s), 4.71-4.79 (1H, m), 5.09 (2H, s), 7.28-7.39 (10H, m).

MS (ESI) m/z: 422 (M+H)⁺.

[Step 3]

[5-(Trans-4-aminocyclohexyl)-1,3,4-oxadiazol-2-yl]methanol

The compound (125 mg, 0.30 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 52 mg (89%) of the title compound as a colorlesssolid.

¹H-NMR (500 MHz, CD₃OD) δ: 1.22-1.35 (2H, m), 1.58-1.69 (2H, m),1.97-2.04 (2H, m), 2.11-2.22 (2H, m), 2.64-2.72 (1H, m), 2.85-2.95 (1H,m), 4.71 (2H, s).

Reference Example 63

[Step 1]

Benzyl[trans-4-({2-[(2R)-2-(benzyloxy)propanoyl]hydrazino}carbonyl)cyclohexyl]carbamate

The compound (504 mg, 1.73 mmol) obtained in Step 1 of Reference Example3 and (R)-(+)-2-(benzyloxy)propionic acid (386 mg, 2.08 mmol) were usedas starting materials and treated in the same way as in Step 2 ofReference Example 28 to give 687 mg (88%) of the title compound as acolorless solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 1.28-1.39 (2H, m), 1.44 (3H, d, J=6.4 Hz),1.50-1.64 (2H, m), 1.87-1.96 (2H, m), 1.96-2.06 (2H, m), 2.21-2.32 (1H,m), 3.33-3.46 (1H, m), 4.12 (1H, q, J=6.4 Hz), 4.57 (1H, d, J=12.0 Hz),4.75 (1H, d, J=12.0 Hz), 5.15 (2H, s), 7.37 (1H, d, J=7.5 Hz), 7.41-7.57(10H, m), 9.86-9.90 (1H, m), 9.92-9.97 (1H, m).

[Step 2]

Benzyl(trans-4-{5-[(1R)-1-(benzyloxy)ethyl]-1,3,4-oxadiazol-2-yl}cyclohexyl)carbamate

The compound (687 mg, 1.52 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 62 to give 606 mg (92%) of the title compound as a colorlessoil.

¹H-NMR (500 MHz, CDCl₃) δ: 1.22-1.33 (2H, m), 1.61 (3H, d, J=6.9 Hz),1.65-1.78 (2H, m), 2.12-2.25 (4H, m), 2.78-2.88 (1H, m), 3.51-3.65 (1H,m), 4.51 (1H, d, J=11.5 Hz), 4.56 (1H, d, J=11.5 Hz), 4.59-4.69 (1H, m),4.80 (1H, q, J=6.7 Hz), 5.10 (2H, s), 7.23-7.43 (10H, m).

MS (ESI) m/z: 436 (M+H)⁺.

[Step 3]

(1R) -1-[5-(trans-4-aminocyclohexyl)-1,3,4-oxadiazol-2-yl]ethanol

The compound (606 mg, 1.39 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 288 mg (98%) of the title compound as a light brownoil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.21-1.36 (2H, m), 1.53-1.70 (5H, m),1.95-2.05 (2H, m), 2.11-2.22 (2H, m), 2.64-2.74 (1H, m), 2.84-2.96 (1H,m), 4.98 (1H, q, J=6.7 Hz).

Reference Example 64

[Step 1]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4-trideoxy-6-O-methyl-D-erythro-hexitol

The same starting material (500 mg, 2.16 mmol) as in Step 1 of ReferenceExample 2 was used and treated in the same way as in Step 2 of ReferenceExample 23 to give 433 mg (82%) of the title compound as a colorlesssolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.28 (1H, ddd, J=24.6, 12.5, 4.0 Hz),1.41-1.48 (10H, m), 1.65-1.73 (1H, m), 2.08-2.15 (1H, m), 3.02 (1H, t,J=10.8 Hz), 3.34-3.46 (6H, m), 3.60-3.65 (1H, m), 4.11 (1H, dd, J=11.2,3.4 Hz), 4.24 (1H, br s).

MS (ESI) m/z: 268 (M+Na)⁺.

[Step 2]

2-Amino-1,5-anhydro-2,3,4-trideoxy-6-O-methyl-D-erythro-hexitolhydrochloride

The compound (420 mg, 1.71 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 360 mg (100%) of the title compound ay a colorlessamorphous solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.24-1.35 (1H, m), 1.47-1.56 (1H, m),1.64-1.69 (1H, m), 2.01-2.07 (1H, m), 3.00-3.07 (1H, m), 3.22 (3H, s),3.24-3.31 (2H, m), 3.40-3.46 (2H, m), 3.97 (1H, dq, J=10.9, 2.2 Hz).

MS (ESI) m/z: 146 (M+H)⁺.

Reference Example 65

6-Chloro-3-[(2-chloropyrimidin-4-yl)methylene]-1,3-dihydro-2H-indol-2-one

2-Chloropyrimidine-4-carbaldehyde (3.05 g, 21.4 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 5.02 g (80%) of the title compound as a red solid.

¹H-NMR (500 MHz, DMSO-d₆) δ: 6.92 (1H, d, J=2.3 Hz), 7.10 (1H, dd,J=8.3, 2.0 Hz), 7.52 (1H, s), 8.00 (1H, d, J=5.2 Hz), 8.83 (1H, d, J=8.0Hz), 8.95 (1H, d, J=4.6 Hz), 10.94 (1H, s).

MS (EI) m/z: 291 (M+H)⁺.

Reference Example 66

(3E/Z)-6-chloro-3-(imidazo[1,2-a]pyridin-3-ylmethylene)-1,3-dihydro-2H-indol-2-one

Imidazo[1,2-a]pyridine-3-carbaldehyde (2.67 g, 18.3 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 2.44 g (45%) of the title compound as an orange solid.

MS (ESI) m/z: 295 (M+H)⁺.

Reference Example 67

[Step 1]

Tert-butyl[(3R,6S)-6-[2-(1H-benzotriazol-1-yloxy)-2-oxoethyl]tetrahydro-2H-pyran-3-yl]carbamate

Concentrated hydrochloric acid (40 ml) was added to the compound (1.99g, 8.28 mmol) obtained in Step 1 of Reference Example 49, concentratedsulfuric acid (20 ml) was added under ice cooling and then the resultingmixture was stirred at 100° C. for 2 hours. Ice (300 g) was added to thereaction mixture under ice cooling and then the resulting mixture wasrendered basic by gradual addition of sodium bicarbonate (84 g). Thereaction mixture was diluted with dioxane (400 ml), di-t-butyldicarbonate (11.5 g, 53.0 mmol) was added under ice cooling and then theresulting mixture was stirred at room temperature for 24 hours. Thereaction mixture was rendered acidic by addition of citric acid (53 g),followed by extraction with ethyl acetate. The organic layer was washedwith brine and then dried over anhydrous sodium sulfate. The solvent wasevaporated under reduced pressure, and the residue obtained wasdissolved in methylene chloride (20 ml). 1-Hydroxybenzotriazole (2.24 g,16.6 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimidehydrochloride (3.17 g, 16.5 mmol) were added and the resulting mixturewas stirred at room temperature for 24 hours. Brine was added to thereaction mixture, followed by extraction with ethyl acetate. The organiclayer was washed with saturated sodium bicarbonate solution and brine inthat order and then dried over anhydrous magnesium sulfate. The solventwas evaporated under reduced pressure, and the residue obtained waspurified by silica gel column chromatography [methanol:chloroform=5.95(v/v)] to give 2.27 g (73%) of the title compound as a solid.

MS (FAB) m/z: 377 (M+H)⁺.

[Step 2]

Tert-butyl{(3R,6S)-6-[2-(methylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}carbamate

Methylamine/tetrahydrofuran solution (2.0 mol/l, 1 ml) was added to atetrahydrofuran (5 ml) solution of the compound (378 mg, 1.00 mmol)obtained in Step 1 above and the resulting mixture was stirred at roomtemperature for 1 hour. The reaction mixture was diluted with ethylacetate, washed with water, saturated sodium bicarbonate solution, andbrine in that order and then dried over anhydrous sodium sulfate. Thesolvent was evaporated under reduced pressure and the residue obtainedwas purified by silica gel column chromatography [methanol:ethylacetate=5:95 (v/v)] to give 135 mg (49%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.27-1.35 (1H, m), 1.44-1.50 (10H, m),1.72-1.75 (1H, m), 2.06-2.10 (1H, m), 2.36 (2H, d, J=6.3 Hz), 2.80 (3H,d, J=5.2 Hz), 3.02 (1H, t, J=10.6 Hz), 3.58-3.63 (2H, m), 4.07-4.11 (1H,m), 4.28 (1H, br s), 6.22 (1H, br s).

MS (FAB) m/z: 273 (M+H)⁺.

[Step 3]

2-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]-N-methylacetamide

The compound (60 mg), 0.22 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a solid.

Reference Example 68

[Step 1]

Tert-butyl{(3R,6S)-6-[2-(dimethylmethylamino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}carbamate

The compound (385 mg, 1.00 mmol) obtained in Step 1 of Reference Example67 and aqueous dimethylamine solution (40 wt %, 0.25 ml, 2.00 mmol) wereused as starting materials and treated in the same way as in Step 2 ofReference Example 67 to give 168 mg (57%) of the title compound as asolid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.28-1.45 (11H, m), 1.85-1.88 (1H, m),2.06-2.09 (1H, m), 2.32 (1H, dd, J=15.2, 5.4 Hz), 2.66 (1H, dd, J=15.2,7.2 Hz), 2.95 (3H, s), 3.00-3.05 (4H, m), 3.59-3.62 (1H, m), 3.74-3.79(1H, m), 4.01-4.04 (1H, m), 4.32-4.30 (1H, m).

MS (FAB) m/z: 287 (M+H)⁺.

[Step 2]

2-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]-N,N-dimethylacetamide

The compound (69 mg, 0.24 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a solid.

Reference Example 69

[Step 1]

Benzyl [trans-3-(2-hydroxypropan-2-yl)cyclobutyl]carbamate

The same starting material (99 mg, 0.38 mmol) as in Step 1 of ReferenceExample 50 was used and treated in the same way as in Step 1 ofReference Example 5 to give 55 mg (55%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.16 (6H, s), 1.87-2.01 (2H, m), 2.27-2.41(4H, m), 4.06-4.18 (1H, m), 4.94 (1H, br s), 5.09 (2H, s), 7.30-7.39(5H, m).

MS (ESI) m/z: 264 (M+H)⁺.

[Step 2]

2-(Trans-3-aminocyclobutyl)propan-2-ol

The compound (55 mg, 0.21 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 24 mg (83%) of the title compound as an oil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.11 (6H, s), 1.76-1.86 (2H, m), 2.24-2.42(3H, m), 3.36-3.46 (1H, m).

Reference Example 70

[Step 1]

Tert-butyl {trans-4-[(2-formylhydrazino)carbonyl]cyclohexyl}carbamate

The same starting material (500 mg, 2.06 mmol) as in Step 1 of ReferenceExample 3 and formohydrazide (123 mg, 2.06 mmol) were used as startingmaterials and treated in the same was as in Step 4 of Reference Example18 to give 459 mg (78%) of the title compound as a solid.

MS (ESI) m/z: 286 (M+H)⁺.

[Step 2]

Tert-butyl [trans-4-(1,3,4-thiazol-2-yl)cyclohexyl]carbamate

A Lawesson's reagent (651 mg, 1.61 mmol) was added to a toluene (18 ml)suspension of the compound (459 mg, 1.61 mmol) obtained in Step 1 aboveat room temperature and the resulting mixture was heated to reflux for2.5 hours. After cooling, insoluble matter was removed by filtration andthe filtrate was concentrated under reduced pressure. The residueobtained was purified by medium pressure silica gel columnchromatography (hexane:ethyl acetate=3:1→1:1) to give 225 mg (49%) ofthe title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.26-1.37 (2H, m), 1.45 (9H, s), 1.64-1.75(2H, m), 2.11-2.31 (4H, m), 3.13-3.23 (1H, m), 3.44-3.61 (1H, m),4.40-4.57 (1H, m), 9.04 (1H, s).

[Step 3]

Trans-4-(1,3,4-thiazol-2-yl)cyclohexanamine hydrochloride

4N hydrochloric acid/1,4-dioxane (2.0 ml) and dichloromethane (0.5 ml)were added to the compound (51 mg, 0.18 mmol) obtained in Step 2 aboveat room temperature and the resulting mixture was stirred for 3 hours.The reaction mixture was concentrated under reduced pressure to give 46mg (99%) of the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.56-1.66 (2H, m), 1.72-1.83 (2H, m),2.15-2.22 (2H, m), 2.28-2.35 (2H, m), 3.18-3.34 (2H, m), 9.38 (1H, s).

Reference Example 71

[Step 1]

Benzyl[(3R,6S)-6-(5-methyl-1,3,4-oxazol-2-yl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (401 mg, 1.37 mmol) obtained in Step 4 of Reference Example13 and trimethyl orthoacetate (1.01 ml, 7.94 mmol) were used as startingmaterials and treated in the same way as in Step 2 of Reference Example3 to give 139 mg (30%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.48-1.63 (1H, m), 1.99-2.29 (3H, m), 2.54(3H, s), 3.24-3.36 (1H, m), 3.74-3.90 (1H, m), 4.12-4.23 (1H, m),4.55-4.69 (1H, m), 4.72-4.85 (1H, m), 5.02-5.20 (2H, m), 7.29-7.43 (5H,m).

[Step 2]

(3R,6S)-6-(5-methyl-1,3,4-oxazol-2-yl)tetrahydro-2H-pyran-3-amine

The compound (139 mg, 0.44 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 79 mg (99%) of the title compound as an oil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.40-1.50 (1H, m), 1.89-1.99 (1H, m),2.03-2.10 (1H, m), 2.10-2.18 (1H, m), 2.53 (3H, s), 2.78-2.86 (1H, m),3.18-3.26 (1H, m), 3.97-4.03 (1H, m), 4.59 (1H, dd, J=11.17, 2.58 Hz).

Reference Example 72

[Step 1]

Benzyl(trans-4-{[2-(methoxyacetyl)hydrazino]carbonyl}cyclohexylcarbamate

1-Hydroxybenzotriazole (231 mg, 1.71 mmol) and1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (394 mg,2.05 mmol) were added to an N,N-dimethylformamide (10 ml) suspension ofthe compound (499 mg, 1.71 mmol) obtained in Step 1 of Reference Example3 combined with methoxyacetic acid (0.16 ml, 2.05 mmol) and theresulting mixture was stirred at room temperature for 24 hours. Waterwas added to the reaction mixture and the precipitated solid wascollected by filtration and dried to give 553 mg (89%) of the titlecompound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.11-1.23 (2H, m), 1.34-1.47 (2H, m),1.70-1.79 (2H, m), 1.80-1.90 (2H, m), 2.05-2.15 (1H, m), 3.18-3.28 (1H,m), 3.31 (3H, s), 3.88 (2H, s), 5.00 (2H, s), 7.21 (1H, d, J=8.02 Hz),7.27-7.41 (5H, m), 9.61-9.74 (2H, m).

[Step 2]

Benzyl{trans-4-[5-(methoxymethyl)-1,3,4-oxazol-2-yl]cyclohexyl}carbamate

The compound (199 mg, 0.55 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 62 to give the title compound as a mixture withtriphenylphosphine oxide.

[Step 3]

Trans-4-[5-(methoxymethyl)-1,3,4-oxazol-2-yl]cyclohexanamine

10% Palladium carbon (200 mg) was added to a methanol (8 ml) solution ofthe mixture (399mg) obtained in Step 2 above and the resulting mixturewas stirred for 2 hours under hydrogen atmosphere. The catalyst wasremoved by filtration through celite and then the filtrate wasconcentrated under reduced pressure. The residue obtained was dissolvedin ethyl acetate, followed by extraction with 1N hydrochloric acid.Subsequently, the aqueous layer was rendered basic by addition of 1Nsodium hydroxide solution, followed by extraction withchloroform:methanol [5:1 (v/v)]. The organic layer was dried overanhydrous sodium sulfate. The solvent was evaporated under reducedpressure to give 78 mg (67%) of the title compound as an oil.

¹H-NMR (400 MHz, CD₃OD) δ: 1.22-1.36 (2H, m), 1.57-1.71 (2H, m),1.96-2.05 (2H, m), 2.12-2.21 (2H, m), 2.65-2.75 (1H, m), 2.85-2.96 (1H,m), 3.42 (3H, s), 4.62 (2H, s).

Reference Example 73

[Step 1]

Tert-butyl [(3R,6S)-6-(2-hydroxyethyl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (106 mg, 0.28 mmol) obtained in Step 1 of Reference Example67 was added to a tetrahydrofuran (5 ml) suspension of lithium aluminumhydride (103 mg, 270 mmol) under ice cooling and the resulting mixturewas stirred at room temperature for 24 hours. Water (0.1 ml) and 5Naqueous sodium hydroxide solution (0.1 ml) were added in that order tothe reaction mixture, water (0.1 ml) was further added and the resultingmixture was stirred for 1 hour. After removal by filtration throughcelite, the solvent was concentrated under reduced pressure. The residueobtained was purified by silica gel column chromatography [ethylacetate:n-hexane=10:0 v/v)] to give 15 mg (21%) of the title compound asa solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.24-1.33 (1H, m), 1.44-1.54 (10H, m),1.68-1.78 (3H, m), 2.07-2.09 (1H, m), 2.60 (1H, br s), 3.01 (1H, t,J=10.6 Hz), 3.43-3.48 (1H, m), 3.54-3.62 (1H, m), 3.73-3.79 (2H, m),4.06-4.09 (1H, m), 4.30 (1H, br s).

MS (FAB) m/z: 246 (M+H)⁺.

[Step 2]

2-[(2S,5R)-5-aminotetrahydro-2H-pyran-2-yl]ethanol

The compound (25 mg, 0.01 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a solid.

Reference Example 74

[Step 1]

Tert-butyl{(3R,6S)-6-[2-(2-formylhydrazino)-2-oxoethyl]tetrahydro-2H-pyran-3-yl}carbamate

Hydrazine monohydrate (0.06 ml, 1.2 mmol) was added to a tetrahydrofuran(5 ml) solution of the compound (397 mg, 1.10 mmol) obtained in Step 1of Reference Example 67 and the resulting mixture was stirred at roomtemperature for 2 hours. Formic acid (0.09 ml, 2.40 mmol) and1ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (461 mg, 2.40mmol) were added to the reaction mixture and the resulting mixture wasstirred at room temperature for 24 hours. Water was added to thereaction mixture, followed by extraction with chloroform:2-propanol [3:1(v/v)]. The organic layer was washed with saturated sodium bicarbonatesolution and brine in that order and dried over anhydrous sodiumsulfate. The solvent was concentrated under reduced pressure and theresidue obtained was purified by silica gel column chromatography[chloroform:methanol=90:10 v/v)] to give 118 mg (37%) of the titlecompound as a solid.

[Step 2]

¹H-NMR (500 MHz, DMSO-d₆) δ: 1.21-1.41 (11H, m), 1.69-1.72 (1H, m),1.81-1.84 (1H, m), 2.19-2.34 (2H, m), 2.92 (1H, t, J=10.8 Hz), 3.28-3.33(1H, m), 3.49-3.55 (1H, m), 3.74-3.71 (1H, m), 6.74 (1H, d, J=7.8 Hz),7.97 (1H, s), 9.93 (2H, s).

MS (FAB) m/z: 302 (M+H)⁺.

[Step 2]

Tert-butyl[(3R,6S)-6-(1,3,4-oxazol-2-ylmethyl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (114 mg, 0.38 mmol) obtained in Step 1 above was used as astarting material and treated in the same day as in Step 2 of ReferenceExample 62 to give 73 mg (68%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.27-1.37 (1H, m), 1.43-1.58 (10H, m),1.82-1.87 (1H, m), 2.10-2.15 (1H, m), 2.98-3.15 (3H, m), 3.61-3.61 (1H,m), 3.70-3.77 (1H, m), 4.03-4.08 (1H, m), 4.24-4.24 (1H, m), 8.35 (1H,s).

[Step 3]

(3R,6S)-6-(1,3,4-oxazol-2-ylmethyl)tetrahydro-2H-pyran-3-amine

The compound (73 mg, 0.26 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a solid.

Reference Example 75

[Step 1]

(6,6-Dimethoxyspiro[3.3]heptane-2,2-diyl)dimethanol

Diisopropyl 6,6-dimethoxyspiro[3.3]heptane-2,2-dicarboxylate (5.60 g,17.1 mmol) was used as a starting material and treated in the same wayas in Step 1 of Reference Example 73 to give 1.56 g (42%) of the titlecompound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.92 (4H, s), 2.21 (5H, s), 2.36 (2H, br s),3.12 (6H, s), 3.69 (4H, d, J=4.6 Hz).

[Step 2]

2,2-Bis[(benzyloxy)methyl]-6,6-dimethoxyspiro[3.3]heptane

Sodium hydride (755 mg, 17.3 mmol) was added to a dimethylformamide (40ml)/tetrahydrofuran (20 ml) solution of the compound (1.56 g, 7.20 mmol)obtained in Step 1 above, under ice cooling, the resulting mixture wasstirred at room temperature for 10 minutes, then benzyl bromide (2.06ml, 17.3 mmol) was added and the resulting mixture was stirred for 24hours. Saturated ammonium, chloride solution was added to the reactionmixture, followed by extraction with ethyl acetate. The organic layerwas washed with brine and then dried over anhydrous sodium sulfate. Thesolvent was evaporated under reduced pressure and the residue obtainedwas purified by silica gel column chromatography [n-hexane:ethylacetate=4:1 (v/v)] to give 2.25 g (79%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.96 (4H, s), 2.12 (4H, s), 3.10 (6H, s),3.43 (4H, s), 4.51 (4H, s), 7.26-7.32 (10H, m).

[Step 3]

6,6-Bis [(benzyloxy)methyl]spiro[3.3]heptan-2-one

The compound (2.25 g, 5.67 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 2 of ReferenceExample 21 to give 1.70 g (86%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 2.17 (4H, s), 3.01 (4H, s), 3.47 (4H, s),4.52 (4H, s), 7.27-7.36 (10H, m).

[Step 4]

N-Benzyl-6,6-bis[(benzyloxy)methyl]spiro[3.3]heptan-2-amine

Benzylamine (1.06 ml, 9.70 mmol) and acetic acid (0.56 ml, 9.70 mmol)were added to a dichloromethane (50 ml) solution of the compound (1.70g, 4.85 mmol) obtained in Step 3 above, the resulting mixture wasstirred for 10 minutes under ice cooling and then sodiumcyanoborohydride (610 mg, 9.70 mmol) was added to the reaction mixture.After stirring at room temperature for 24 hours, saturated sodiumbicarbonate solution was added to the reaction mixture, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous sodium sulfate. The solvent was evaporatedunder reduced pressure and the residue obtained was purified by silicagel column chromatography [chloroform:methanol=40:1 (v/v)] to give 1.27g (60%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.49 (2H, br s), 1.67-1.69 (2H, m), 1.85 (2H,s), 1.93 (2H, s), 2.23-2.28 (2H, m), 3.12-3.19 (1H, m), 3.42 (4H, s),3.65 (2H, s), 4.50 (4H, s), 7.21-7.38 (15H, m).

[Step 5]

(6-Aminospiro[3.3]heptane-2,2-diyl)dimethanol

20% Palladium hydroxide (254 mg) was added to an ethanol (30 ml)solution of the compound (1.27 g, 2.88 mmol) obtained in Step 4 aboveand the resulting mixture was stirred at room temperature for 3 daysunder hydrogen atmosphere. The catalyst was removed by filtrationthrough celite and then the filtrate was concentrated under reducedpressure to give 517 mg (99%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.62-1.86 (5H, m), 2.17-2.22 (2H, m),3.15-3.17 (6H, m), 4.58 (4H, br s)

Reference Example 76

[Step 1]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,6-tetradeoxy-6-[methylsulfonyl)amino]-D-erythro-hexitol

Triethylamine (0.12 ml, 0.88 mmol) and methanesulfonyl chloride (0.05ml, 0.67 mmol) were added to a dichloromethane (4 ml) solution of thecompound (101 mg, 0.44 mmol) obtained in Step 3 of Reference Example 24under ice cooling and the resulting mixture was stirred for 30 minutes,Water was added, followed by extraction with dichloromethane. Theorganic layer was washed with saturated ammonia chloride solution,saturated sodium bicarbonate solution, and brine in that order and thendried over anhydrous sodium sulfate. The solvent was evaporated underreduced pressure and the residue obtained was purified by silica gelcolumn chromatography [chloroform:methanol=95:5 (v/v)] to give 105 mg(77%) of the title compound as a solid.

¹H-NMR (500 MHz, CDCl₃) δ: 1.25-1.35 (1H, m), 1.44-1.51 (10H, m),1.66-1.72 (1H, m), 2.09-2.12 (1H, m), 2.97-3.06 (5H, m), 3.25-3.31 (1H,m), 3.37-3.43 (1H, m), 3.58 (1H, br s), 4.06-4.10 (1H, m), 4.25 (1H, brs), 4.67 (1H, br s).

MS (FAB) m/z: 309 (M+H)⁺.

[Step 2]

2-Amino-1,5-anhydro-2,3,4,6-tetradeoxy-6-[(methylsulfonyl)amino]-D-erythro-hexitol

The compound (101 mg, 0.33 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give the title compound as a solid.

Reference Example 77

[Step 1]

Benzyl [(3R,6S)-6-(dimethylcarbamoyl)tetrahydro-2H-pyran-3-yl]carbamate

The compound (200 mg, 0.72 mmol) obtained in Step 3 of Reference Example18 and dimethylamine hydrochloride (88 mg, 1.07 mmol) were used asstarting materials and treated in the same way as in Step 1 of ReferenceExample 72 to give 177 mg (81%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.43 (1H, m), 1.84-2.00 (2H, m), 2.19-2.21(1H, m), 2.95 (3H, s), 3.07 (3H, s), 3.15-3.18 (1H, m), 3.72-3.75 (1H,m), 4.06 (1H, dd, J=9.8, 2.4 Hz), 4.13 (1H, dd, J=11.0, 4.3 Hz),4.64-4.66 (1H, m), 5.09 (2H, br s), 7.30-7.40 (5H, m).

MS (ESI) m/z: 307 (M+H)⁺.

[Step 2]

(2S,5R)-5-amino-N,N-dimethyltetrahydro-2H-pyran-2-carboxamide

The compound (177 mg, 0.58 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 3 of ReferenceExample 2 to give 99 mg (99%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.22-1.35 (1H, m), 1.75-2.17 (5H, m), 2.93(1H, m), 2.95 (3H, s), 3.05 (3H, s), 3.07 (1H, m), 3.98-4.04 (2H, m).

MS (ESI) m/z: 173 (M+H)⁺

Reference Example 78

(3E/Z)-6-chloro-3-(3,5-dichlorobenzylidene)-1,3-dihydro-2H-indol-2-one

3,5-Dichlorobenzaldehyde (3.50 g, 20.0 mmol) was used as a startingmaterial and treated in the same way as in Reference Example 4 to give2.60 g (40%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 6.90 (1H, d, J=2.3 Hz), 6.95 (1H, dd,J=8.2, 1.8 Hz), 7.29 (1H, d, J=8.2 Hz), 7.59 (1H, s), 7.73 (3H, s),10.83 (1H, s).

Reference Example 79

[Step 1]

Tert-butyl{(3R,6S)-6-[methoxymethyl)carbamoyl]tetrahydro-2H-pyran-3-yl}carbamate

The same starting material (70.0 g, 0.29 mol) as in Step 1 of ReferenceExample 18 and N,O-dimethylhydroxylamine hydrochloride (34.0 g, 0.35mol) were used as starting materials and treated in the same way as inStep 2 of Example 12 to give 61.0 g (73%) of the title compound as asolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.44-1.50 (1H, m), 1.44 (9H, s), 1.77-1.93(2H, m), 2.14-2.22 (1H, m), 3.14-3.19 (1H, m), 3.21 (3H, s), 3.67-3.72(1H, m), 3.72 (3H, s), 4.20 (2H, dd, J=10.4, 3.6 Hz), 4.39 (1H, br s).

MS (ESI) m/z: 233 (M−55)⁺.

[Step 2]

Tert-butyl [(3R,6S)-6-acetyltetrahydro-2H-pyran-3-yl]carbamate

Methylmagnesium bromide-diethyl ether solution (3.0 mol/l, 176 ml, 0.53mol) was added dropwise to a tetrahydrofuran (600 ml) solution of thecompound (61.0 g, 0.21 mol) obtained in Step 1 above under ice coolingunder nitrogen atmosphere and then the resulting mixture was stirred atroom temperature for 3 hours. Water (200 ml) was added to the reactionmixture under ice cooling, the resulting mixture was stirred and thensaturated ammonium chloride solution (100 ml) was added, followed byextraction with ethyl acetate. The organic layer was washed with brineand then dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [n-hexane:ethyl acetate=2:1 (v/v)]to give 38 g (75%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.30-1.40 (1H, m), 1.44 (9H, s), 1.48-1.56(1H, m), 1.96-2.04 (1H, m), 2.11-2.18 (1H, m), 2.20 (3H, s), 3.06 (1H,t, J=10.6 Hz), 3.61-3.65 (1H, m), 3.69 (1H, dd, J=11.3, 2.7 Hz), 4.15(1H, ddd, J=10.6, 5.0, 2.0 Hz), 4.30 (1H, br s).

MS (ESI) m/z: 266 (M+Na)⁺.

[Step 3]

1,5-Anhydro-2-[(tert-butoxycarbonyl)amino]-2,3,4,7-tetradeoxy-D-ribo-heptitol

The compound (20.0 g, 82.0 mmol) obtained in Step 2 above was suspendedin 0.1 mol/l phosphate buffer solution (pH 6.4, 200 ml) and nicotinamideadenine dinucleotide (oxidized form) (133 mg, 0.20 mmol), ammoniumformate (1.26 g, 19.7 mmol), magnesium chloride (19 mg, 0.20 mmol), andisopropyl alcohol (10 ml) were added. Subsequently, 0.1 mol/l phosphatebuffer solution (pH 6.4, 10 ml) of CHIRALSCREEN-OH E039 kit (DaicelCorp.) (1.0 g) was added dropwise. the resulting mixture was stirred at30° C. for 16 hours. Dimethyl sulfoxide (8 ml), isopropyl alcohol (2ml), and 0.1 mol/l phosphate buffer solution (20 ml) were added to thereaction mixture, then formic acid was added to the reaction mixture toadjust its pH to 6.2 to 6.4 and the resulting mixture was stirred a 37°C. for 8 hours. After extraction with ethyl acetate, insoluble matterwas removed by filtration through celite, the filtrate was washed withbrine twice and then dried over anhydrous magnesium sulfate and thesolvent was evaporated under reduced pressure. The residue obtained waspurified by silica gel column chromatography [n-hexane:ethylacetate=2:1→1:1 (v/v)] to give 17.9 g (89%) of the title compound as asolid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.14 (3H, d, J=6.4 Hz), 1.26 (1H, ddd,J=24.7, 12.4, 4.1 Hz), 1.44 (9H, s), 1.50-1.60 (1H, m), 1.65-1.71 (1H,m), 2.00-2.04 (1H, m), 2.10-2.17 (1H, m), 3.02 (1H, t, J=10.8 Hz),3.14-3.19 (1H, m), 3.55-3.62 (1H, m), 3.80-3.87 (1H, m), 4.11 (1H, dq,J=10.6, 2.3 Hz), 4.21-4.26 (1H, m).

MS (ESI) m/z: 268 (M+Na)⁺.

[Step 4]

2-Amino-1,5-anhydro-2,3,4,7-tetradeoxy-D-ribo-heptitol hydrochloride

The compound (17.5 g, 71.0 mmol) obtained in Step 3 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 12.6 g (98%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.03 (3H, d, J=6.3 Hz), 1.21-1.33 (1H, m),1.44-1.55 (1H, m), 1.80-1.87 (1H, m), 2.04-2.11 (1H, m), 2.91-2.95 (1H,m), 2.96-3.03 (1H, m), 3.24 (1H, t, J=10.6 Hz), 3.40-3.45 (1H, m),3.97-4.02 (1H, m), 4.63 (1H, br s).

MS (ESI) m/z: 146 (M+H)⁺.

Reference Example 80

(3E/Z)-6-chloro-3-(3-chloro-2,4-difluorobenzylidene)-1,3-dihydro-2H-indol-2-one

3-Chloro-2,4-difluorobenzaldehyde (4.90 g, 44.9 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 8.03 g (56%) of the title compound as a solid.

MS (APCI) m/z: 326 (M+H)⁺.

Reference Example 81

(3E/Z)-6-chloro-3-(3-chlorobenzylidene)-1,3-dihydro-2H-indol-2-one

6-Chloro-1,3-dihydro-2H-indol-2-one (1.67 g, 10.0 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 760 mg (26%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 6.90 (1H, d, J=1.8 Hz), 6.94 (1H, dd,J=8.2, 2.3 Hz), 7.39 (1H, d, J=8.2 Hz), 7.55-7.56 (2H, m), 7.64 (1H, s),7.65-7.69 (1H, m), 7.74 (1H, s, 10.82 (1H, s).

Reference Example 82

(3E/Z)-6-chloro-3-(3-chloro-2,5-difluorobenzylidene)-1,3-dihydro-2H-indol-2-one

3-Chloro-2,5-difluorobenzaldehyde (6.00 g, 22.0 mmol) was used as astarting material and treated in the same way as in Reference Example 4to give 2.46 g (34%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 6.87-7.10 (2H, m), 7.14-9.17 (4H, m),10.89-10.96 (1H, m).

Reference Example 83

[Step 1]

Tert-butyl{1-[1H-benzotriazol-1-yl(imino)methyl]piperidin-4-yl}carbamate

A dichloromethane (50 ml) solution of tert-butyl piperidin-4-ylcarbamate(7.50 g, 37.9 mmol) was added dropwise to a dichloromethane (150 ml)solution of 1-(1H-benzotriazol-1-yl)-1-(2H-benzotriazol-2-yl)methanamine(J. Org. Chem. 2000, 65, 8080; and J. Org. Chem. 2003, 68, 4941) (10.0g, 37.9 mmol) and the resulting mixture was stirred at room temperaturefor 3 days. 10% Aqueous sodium carbonate solution was added to thereaction mixture, followed by extraction with dichloromethane. Theorganic layer was washed with brine and then dried over anhydrous sodiumsulfate. The solvent was evaporated under reduced pressure to give 10.6g (81%) of the title compound as an oil.

¹H-NMR (400 MHz, CDCl₃) δ: 1.45 (9H, s), 1.57-1.62 (2H, m), 2.04 (2H, d,J=11.4 Hz), 3.05-3.12 (2H, m), 3.71 (3H, d, J=13.3 Hz), 4.53 (1H, s),7.00 (1H, s), 7.46 (1H, t, J=8.2 Hz), 7.60 (1H, t, J=7.6 Hz), 7.71 (1H,s), 8.12 (1H, d, J=8.2 Hz).

[Step 2]

Tert-butyl [1-(1H-tetrazol-5-yl)piperidin-4-yl]carbamate

Sodium azide (2.00 g, 30.7 mmol) and acetic acid (1.70 ml, 30.7 mmol)were added to a chloroform (300 ml) solution of the compound (10.6 g,30.7 mmol) obtained in Step 1 above and the resulting mixture wasstirred at room temperature for 25 hours. Insoluble matter was removedby filtration and the filtrate was concentrated under reduced pressure.The residue obtained was purified by silica gel column chromatography[chloroform:methanol=30:1→10:1 (v/v)] to give 8.20 g (94%) of the titlecompound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 1.56-1.44 (11H, m), 1.96-1.92 (2H, m),3.21-3.14 (2H, m), 3.57 (1H, s), 3.84-3.81 (2H, m).

[Step 3]

1-(1H-tetrazol-5-yl)piperidin-4-amine dihydrochloride

The compound (8.20 g, 28.6 mmol) obtained in Step 2 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 6.90 g (92%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.57 (2H, ddd, J=24.2, 12.3, 4.0 Hz), 1.98(2H, d, J=10.1 Hz), 3.09 (2H, td, J=12.8, 2.0 Hz), 3.25 (1H, d, J=4.6Hz), 3.93 (2H, d, J=13.3 Hz), 8.30 (3H, s).

Reference Example 84

[Step 1]

Tert-butyl [(3R,6S)-6-carbamoyltetrahydro-2H-pyran-3-yl]carbamate

The same starting material (2.54 g, 10.3 mmol) as in Step 1 of ReferenceExample 18 and ammonium chloride (1.07 g, 20.0 mmol) were used asstarting materials and treated in the same way as in Step 2 of Example12 to give 1.83 g (75%) of the title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.35 (1H, ddd, J=24.7, 12.7, 3.9 Hz), 1.44(9H, s), 1.53-1.63 (1H, m), 2.11-2.18 (1H, m), 2.23 (1H, dq, J=13.6, 3.3Hz), 3.06 (1H, t, J=10.7 Hz), 3.58-3.67 (1H, m), 3.74 (1H, dd, J=11.5,2.4 Hz), 4.14-4.20 (1H, m), 4.29 (1H, br s), 5.37 (1H, br s), 6.47 (1H,br s).

MS (ESI) m/z: 267 (M+Na)⁺.

[Step 2]

(2S,5R)-5-aminotetrahydro-2H-pyran-2-carboxamide hydrochloride

The compound (1.82 g, 7.45 mmol) obtained in Step 1 above was used as astarting material and treated in the same way as in Step 1 of ReferenceExample 2 to give 1.31 g (97%) of the title compound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.39-1.48 (1H, m), 1.57 (1H, ddd, J=23.8,12.5, 3.9 Hz), 1.95-2.01 (1H, m), 2.04-2.11 (1H, m), 3.07-3.09 (1H, m),3.31-3.36 (1H, m), 3.67 (1H, dd, J=11.1, 2.6 Hz), 4.03-4.08 (1H, m),7.12 (2H, s), 7.20 (2H, s).

MS (ESI) m/z: 145 (M+H)⁺.

Reference Example 85

[Step 1]

Methyl2,6-anhydro-3,4,5-trideoxy-5-(dibenzylamino)-5-methyl-L-glycero-hexonate(A) and methyl2,6-anhydro-3,4,5-trideoxy-5-(dibenzylamino)-2-methyl-L-glycero-hexonate(B)

Lithium bis(trimethylsilyl)amide/tetrahydrofuran solution (1.0 mol/l, 37ml, 37.0 mmol) was added dropwise to a tetrahydrofuran (70 ml) solutionof the same starting material (6.20 g, 18.0 mmol) as in Step 1 ofReference Example 5 combined with hexamethylphosphoric acid triamide(6.40 ml, 36.0 mmol) at −78° C. under nitrogen atmosphere and then theresulting mixture was stirred at room temperature for 1 hour. Aftercooling to −78° C. again, methyl iodide (5.6 ml, 90.0 mmol) was addeddropwise and the resulting mixture was stirred at room temperature for16 hours. The reaction mixture was diluted with ethyl acetate and theorganic layer was washed with saturated ammonium chloride solution andbrine and dried over anhydrous magnesium sulfate. The solvent wasevaporated under reduced pressure and the residue obtained was purifiedby silica gel column chromatography [n-hexane:ethyl acetate=93:7 (v/v)]to give a mixture of the compounds A and B. The mixture obtained wasfractionated and purified by chiral column liquid chromatography[fractionation conditions: CHIRALCEL OD-H, n-hexane:ethanol=90:10 (v/v)]to give 1.10 g (17%) of the title compound A as an oil. The residue wasfractionated and purified by chiral column liquid chromatography[fractionation conditions: CHIRALPAK IC, n-hexane:ethanol=90:10 (v/v)]to give 299 mg (5%) of the title compound B as an oil.

Compound A:

¹H-NMR (400 MHz, CDCl₃) δ: 1.32 (3H, s), 1.36-1.55 (2H, m), 1.88-1.94(1H, m), 2.36 (1H, dt, J=13.1, 3.2 Hz), 2.75-2.82 (1H, m), 3.56 (1H, t,J=11.3 Hz), 3.58 (2H, d, J=14.0 Hz), 3.65 (2H, d, J=14.0 Hz), 3.76 (3H,s), 3.87 (1H, dq, J=11.4, 2.2 Hz), 7.19-7.36 (10H, m).

MS (ESI) m/z: 354 (M+H)⁺.

Compound B:

¹H-NMR (400 MHz, CDCl₃) δ: 1.45 (3H, s), 1.76-1.92 (4H, m), 2.76-2.83(1H, m), 3.67 (2h, d, J=14.0 Hz), 3.73 (3H, s), 3.73-3.78 (3H, m), 3.86(1H, dd, J=11.8, 5.0 Hz), 7.19-7.23 (2H, m), 7.26-7.35 (8H, m).

MS (ESI) m/z: 354 (M+H)⁺.

[Step 2]

Methyl 5-amino-2,6-anhydro-3,4,5-trideoxy-5-methyl-L-glycero-hexonatehydrochloride (C)

4N hydrochloric acid/dioxane solution (2 ml) and 10% palladium carbon(200 mg) were added to a methanol (20 ml) solution of the compound A(1.10 g, 3.11 mmol) obtained in Step 1 above and the resulting mixturewas stirred at room temperature for 16 hours under hydrogen atmosphere.20% Palladium hydroxide carbon (200 mg) was further added to thereaction mixture and the resulting mixture was stirred at roomtemperature for 48 hours under hydrogen atmosphere. The catalyst wasremoved by filtration through celite and then the filtrate wasconcentrated under reduced pressure to give 703 mg (100%) of the titlecompound as a solid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.27 (3H, s), 1.39-1.54 (2H, m), 1.93-2.00(1H, m), 2.17-2.23 (1H, m), 3.04-3.12 (1H, m), 3.41 (1H, t, J=11.1 Hz),3.69 (3H, s), 3.83-3.89 (1H, m), 8.17 (2H, br s).

MS (ESI) m/z: 174 (M+H)⁺.

[Step 3]

Methyl2,6-anhydro-3,4,5-trideoxy-5-(dibenzylamino)-2-methyl-L-glycero-hexonate(D)

20% Palladium hydroxide carbon (200 mg) was added to a methanol (6 mol)solution of the compound B (295 mg, 0.83 mmol) obtained in Step 1 aboveand the resulting mixture was stirred at room temperature for 5 hoursunder hydrogen atmosphere. The catalyst was removed by filtrationthrough celite and then the filtrate was concentrated under reducedpressure to give 119 mg (83%) of the title compound as an oil.

¹H-NMR (400 MHz, DMSO-d₆) δ: 1.29 (3H, s), 1.55-1.66 (2H, m), 1.73-1.80(1H, m), 1.84-1.90 (1H, m), 2.84-2.87 (1H, m), 3.46-3.50 (1H, m), 3.60(1H, dd, J=12.4, 2.7 Hz), 3.65 (3H, s).

MS (ESI) m/z: 174 (M+H)⁺.

Reference Example 86

(3E/Z)-6-chloro-3-[(2-chloro-3-fluoropyridin-4-yl)methylene]-1,3-dihydro-2H-pyrrolo[3,2-c]pyrrolidin-2-one

6-Chloro-1,3-dihydro-2H-pyrrolo[3,2-c]pyrrolidin-2-one (7.00 g, 41.5mmol) and 2-chloro-3-fluoroisonicotinaldehyde monohydrate (7.37 g, 4.15mmol) were used as starting materials and treated in the same way as inReference Example 1 to give 5.17 g (4:%) of the title compound as asolid.

¹H-NMR (400 MHz, DMSO-d₆) δ: 7.00 (1H, s), 7.62 (1H, s), 7.84 (1H, t,J=4.8 Hz), 8.10 (1H, s), 8.42 (1H, d, J=4.6 Hz), 11.47 (1H, br s).

MS (ESI) m/z: 310 (M+H)⁺.

Reference Example 87

[Step 1]

6″-Chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[3,2-c]pyridine]-1′,2″(1″H)-dione

Triethylamine (0.50 ml, 3.56 mmol) and molecular sieves 4A (powder)(1.34 g) were added to a toluene (30 ml) solution of glycine tert-butylester (467 mg, 3.56 mmol) and 4,4-dimethylcyclohexanone (449 mg, 3.56mmol) and the resulting mixture was stirred at 70° C. for 1.5 hours. Thecompound (1.00 g, 3.23 mmol) obtained in Reference Example 86 was addedto the reaction mixture and the resulting mixture was stirred at 70° C.for 3 hours. Glycine tert-butyl ester (106 mg, 0.81 mmol) and4,4-dimethylcyclohexanone (102 mg, 0.81 mmol) were further added to thereaction mixture and the resulting mixture was stirred at 80° C. for 24hours. After cooling, insoluble matter was removed by filtration throughcelite and the filtrate was concentrated under reduced pressure. Theresidue obtained was purified by silica gel column chromatography[n-hexane:ethyl acetate=100:0→0:100 (v/v)] to give 613 mg (35%) of thetitle mixture as a solid.

MS (ESI) m/z: 549 (M+H)⁺.

[Step 2]

(3′S,4′R,7′S,8′S,8a′R)-6″-chloro-8′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-3′,4′-diphenyl-3′,4′,8′,8a′-tetrahydro-1′H-dispiro[cyclohexane-1,6′-pyrrolo[2,1-c][1,4]oxazine-7′,3″-pyrrolo[3,2-c]pyridine]-1′,2″(1″H)-dione

The mixture of isomers (480 mg) obtained in Step 1 above wasfractionated and purified by chiral column liquid chromatography[fractionation conditions: CHIRALPAK IA,n-hexane:tetrahydrofuran:ethanol=85:15:5 (v/v)] to give 187 mg (39%) ofthe title compound as a solid.

¹H-NMR (400 MHz, CDCl₃) δ: 1.19 (3H, t, J=7.1 Hz), 1.70 (1H, d, J=13.7Hz), 1.87 (1H, d, J=13.7 Hz), 2.20 (1H, d, J=12.8 Hz), 2.42 (1H, dd,J=12.8, 2.7 Hz), 3.70 (1H, s), 3.81 (1H, q, J=9.2 Hz), 3.93 (1H, q,J=9.2 Hz), 4.09-4.22 (2H, m), 4.47 (2H, s), 4.54-4.78 (2H, m), 6.81 (1H,d, J=1.8 Hz), 6.96 (1H, td, J=8.0, 1.2 Hz), 7.13 (1H, dd, J=8.0, 2.1Hz), 7.16-7.21 (1H, m), 7.38-7.42 (2H, m), 7.44-7.48 (1H, m).

MS (ESI) m/z: 549 (M+H)⁺.

[Step 3]

6″-Chloro-4′-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2″-oxo-1″,2″-dihydrodispiro[cyclohexane-1,2′-pyrrolidine-3′,3″-pyrrolo[3,2-c]pyridine]-5′-carboxylicacid hydrochloride

Concentrated hydrochloric acid (1.12 ml, 13.7 mmol) Was added to thecompound (150 mg, 0.27 mmol) obtained in Step 2 above under ice coolingand the resulting mixture was stirred at room temperature tor 1 hour.The reaction mixture was concentrated under reduced pressure to give 137mg (9.4%) or the title compound as a solid.

¹H-NMR (400 MHz, CD₃OD) δ: 0.79 (3H, s), 1.04 (3H, s), 1.39-1.66 (4H,m), 1.87-2.12 (3H, m), 2.50 (1H, dd, J=14.2, 3.2 Hz), 5.16 (1H, d,J=10.1 Hz), 5.47 (1H, d, J=10.5 Hz), 6.95 (1H, s), 7.67 (1H, t, J=5.0Hz), 8.24 (1H, d, J=5.0 Hz), 8.57 (1H, d, J=1.8 Hz). MS (ESI) m/z: 493(M+H)⁺.

[Preparation Examples]

(Preparation Example 1) Powder

5 G of the compound of Example 1, 895 g of lactose, and 100 g of cornstarch can be mixed using a blender to give powders.

(Preparation Example 2) Granule

5 G of the compound of Example 5, 895 g of lactose, and 100 g oflow-substituted hydroxypropylcellulose are mixed, then 300 g of 10%aqueous hydroxypropylcellulose solution is added and the resultingmixture is kneaded. This product can foe granulated using an extrusiongranulator and dried to give granules.

(Preparation Example 3) Tablet

5 G of the compound of Example 12, 90 g of lactose, 34 g of corn starch,20 g of crystalline cellulose, and 1 g of magnesium stearate can bemixed using a blender and then compressed in a tableting machine to givetablets.

[Test Examples]

(Test Example 1 Mdm2/p53 Binding Assay)

A protein dilution containing 6.25 nM each of His-p53 (fusion protein ofa p53 partial protein having p53 amino acids at positions 1 to 132, witha histidine protein) and GST-Mdm2 (fusion protein of an Mdm2 partialprotein having Mdm2 amino acids at positions 25 to 108 with leucineresidue 33 substituted by glutamic acid, with glutathione transferase)proteins was prepared using a protein buffer solution (20 mM HEPES pH7.4, 150 mM NaCl, 0.1% BSA). This protein dilution was added in anamount of 8 μl/well to a 384-well plate (384-well low volume NBC,Corning Inc., catalog No: 3676).

Next, a test compound was diluted with DMSO to produce a protein buffersolution containing 10% dilution, and this buffer solution was added inan amount of 4 μl/well to the plate.

Subsequently, a solution containing an XL665-labeled anti-His antibody(HTRF monoclonal anti-6HIS antibody labeled with XL665 (catalog No:61HISXLB), Schering/Cisbio Bioassays) and a europium (Eu)-labeledanti-GST antibody (HTRF monoclonal anti-GST antibody labeled witheuropium cryptate, Schering/Cisbio Bioassays, catalog No: 61GSTKLB) atconcentrations of 2.5 μg/ml and 0.325 μg/ml, respectively, was preparedusing an antibody diluting buffer solution (20 mM HEPES pH 7.4, 150 mMNaCl, 0.1% BSA, 0.5 M KF). These dilutions were added in an amount of 8μl/well (total reaction solution volume: 20 μl/well). Then the plate wasincubated at 25° C. for 1 hour.

Time-resolved fluorescence at 620 and 665 nm was measured at anexcitation wavelength of 320 nm using a plate reader (ARVOsx,PerkinElmer Co., Ltd. or PHERAstar, BMG LABTECH). Ratio (R) wascalculated using the measured values (RFU 620 nm and RFU 665 nm)according to the following formula:

R=(RFU 665 nm-BI-C×RFU 620 nm)/RFU 620 nm

BI: measured value at 665 nm of reaction solution (only each buffersolution) nonsupplemented with each protein, the compound, and theantibodies

C (correction factor)=(A−BI)/D

A and D: each measured value at 665 nm and 620 nm of reaction solutionsupplemented with only Eu-labeled anti-GST antibody solution

The R value calculated from one well supplemented with His-p53,GST-Mdm2, the test compound, and each antibody was defined as R(sample). The R value calculated from the well supplemented withHis-p53, GST-Mdm2, and each antibody but without the test compound wasdefined as R (control). The R value calculated from the wellsupplemented with GST-Mdm2, the test compound, and each antibody butwithout His-p53 was defined as R (background). T/C was calculated fromthe formula shown below. An IC₅₀ value for Mdm2/p53 binding wascalculated by sigmoid fitting. The results are shown in Table 1.

T/C=(R (sample)−R (background))/(R (control)−R(background))

The IC₅₀ value of the compound of each Example was as follows:

0.001≦IC₅₀ (μM)<0.05: Example No. 3, 6, 7, 8, 9, 11, 12, 13, 16, 20, 21,23, 25, 27, 28, 29, 30, 33, 34, 36, 38, 40, 41, 42, 44, 46, 48, 49, 53,55, 56, 57, 65, 67, 68, 69, 70, 71, 72, 75, 76, 77, 78, 81, 82, 83, 85,86, 87, 89, 90, 92, 97, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108,109, 110, 111, 113, 114, 115, 116, 117, 118, 119, 120, 122, 124, 125,126, 127, 128, 129, 130, 134, 136, 139, 141, 142, 144, 146, 148, 150,151, 152, 153, 156, 158, 167, 172, 174, 176, 178, 179, 180, 181, 182,185, 186, 187, 188, 189, 191, 192, 193.

0.05≦IC₅₀ (μM)<0.1: Example No. 1, 2, 5, 10, 15, 17, 18, 19, 22, 24, 26,31, 32, 35, 37, 39, 45, 47, 50, 51, 52, 54, 58, 59, 60, 61, 62, 63, 64,66, 73, 74, 79, 80, 84, 88, 91, 93, 94, 95, 96, 98, 112, 121, 123, 131,132, 133, 137, 138, 140, 143, 145, 147, 149, 154, 155, 157, 159, 160,161, 162, 163, 165, 166, 169, 170, 171, 173, 175, 177, 193, 184, 190.

0.1≦IC₅₀ (μM)<0.5: Example No. 4, 14, 43, 135, 164, 168.

(Test Example 2 Cell Growth Inhibition Assay)

A cell growth inhibition assay was conducted using a human lungcancer-derived cell line NCI-H460 having wild-type p53.

NCI-H460 cells were suspended in a medium (RPMI1640 medium containing10% fetal bovine serum) and the suspension was added in an amount of 500cells/150 μl/well to a 96-well plate. A test compound was dissolved inDMSO and this solution was diluted with medium to prepare a samplesolution (DMSO concentration: 1% or lower). On the next day, mediumnonsupplemented with the test compound, or the sample solution, wasadded in an amount of 50 μl/well. Cells were then cultured at 37° C. for3 days in a 5% CO₂ atmosphere.

An MTT assay was conducted immediately after the nonsupplemented mediumor the sample solution was added. Another MTT assay was conducted afterculturing the cells for 3 days. The MTT assays were conducted as shownbelow.

A 5 mg/ml MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide, Sigma-Aldrich Co., M-2128) solution was prepared using aphosphate buffer solution (Dulbecco's Phosphate-buffered Saline). ThisMTT solution was added in an amount of 20 μl/well. Then the plate wascultured at 37° C. for 4 hours in a 5% CO₂ atmosphere. The plate wascentrifuged at 1200 rpm for 5 minutes and then the culture supernatantwas removed by aspiration using a dispenser. DMSO was added in an amountof 150 μl/well to dissolve generated formazan. The plate was stirredusing a plate mixer for uniform color development from each well. Theabsorbance of each well was measured at OD 540 nm and at a reference OD(660 ml) using a plate reader (SpectraMax PLUS384, Molecular Devices,CA, USA).

The OD value measured on the day of adding the sample solution wasdefined as S. The OD value measured three days after addition of thesample solution was defined as T. The OD value measured three days afteraddition of the DMSO dilution was defined as C. T/C (%) was determinedat each concentration according to the formula shown below in order toprepare a dose response curve, from which 50% growth inhibitionconcentration (GI₅₀ value) was calculated.

T/C (%)=(T−S)/(C−S)×100

The GI₅₀ values of the compounds of Examples subjected to this test wereas follows:

GI₅₀ (μM)<0.1: Example No. 20, 31, 35, 70, 99, 100, 110, 113, 116, 156,160, 182.

0.1≦GI₅₀ (μM)<0.5: Example No. 1, 3, 13, 16, 17, 18, 23, 24, 32, 34, 38,51, 57, 67, 69, 77, 88, 90, 93, 94, 96, 97, 107, 109, 111, 112, 115,117, 154, 161, 162, 183, 184, 185, 188, 191.

0.5≦GI₅₀ (μM)<1.0: Example No. 3, 7, 11, 14, 25, 26, 40, 47, 53, 54,108, 114.

1.0≦GI₅₀ (μM)<5.0: Example No. 2, 4, 5, 6, 28, 29, 30, 164, 179, 180,186.

5.0<GI₅₀ (μM): Example No. 174

(Test Example 3 Anti-Tumor Activity Test)

A human osteosarcoma cell line SJSA-1 or SJSA-1-RE (cells in which a p53reporter gene is incorporated into SJSA-1) is subcutaneouslytransplanted into nude mice (BALB/C-nu/nu SLC, male, Japan SLC, Inc.).At the point in time when the tumor size reaches approximately 100 to200 mm³, the mice are divided into groups (6 mice/group). A testcompound is suspended in 0.5% methylcellulose solution and orallyadministered twice a day (bid) at a dose of 50 mg/kg, once a day (qd) ata dose of 50 mg/kg, or once a day (qd) at a dose of 25 mg/kg for 4consecutive days. After a 2-day drug holiday, the mice are dissected,the tumors are excised and then their weights are measured.

The anti-tumor effect (IR (%)) is calculated according to the followingformula:

IR (%)=[1−(average tumor weight of compound−administered group/averagetumor weight of untreated control group)]×100.

Test Example 4 Metabolic Stability Test)

100 μl of 100 mM phosphate buffer solution (pH 7.4) containing 3 μM testcompound was added to 100 μl of reaction solution containing 100 mMphosphate buffer solution (pH 7.4), 30 mM glucose 6-phosphate, 10 mMMgCl₂.6H₂O, 3 units/ml glucose 6-phosphate 1-dehydrogenase, and 0.3 to1.5 mg/ml human liver microsomes and the mixture was incubated at 37° C.for 20 minutes. Then 70 μl of 100 mM phosphate buffer solution (pH 7.4)containing 3 mM NADP+ was added and the mixture was further incubated at37° C. for 30 minutes to conduct a microsomal metabolism test. Thecompound was quantified by the internal standard method using aquadrapole mass spectrometer connected to a high performance liquidchromatography apparatus. The metabolic stability (residual percentageof compound: MS %) was determined according to the following formula:

MS (human) (%)=(peak area ratio of test compound after addition of NADP+and incubation for 30 minutes)/(peak area ratio of test compound beforeaddition of NADP+)×100.

(peak area ratio: peak area of test compound divided by that of internalstandard substance)

Of the compounds of the Examples subjected to this test, the followingcompounds exhibited an MS % of 30 or more:

70≦MS %≦100: Example No. 1, 2, 3, 4, 6, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 20, 23, 24, 25, 23, 30, 31, 34, 36, 38, 39, 40, 41, 43, 45,46, 51, 53, 54, 56, 57, 60, 63, 64, 65, 67, 69, 70, 76, 77, 73, 84, 65,37, 88, 90, 91, 92, 93, 94, 95, 98, 103, 106, 107, 108, 109, 110, 122,123, 124, 124, 125, 126, 149, 151, 156, 157, 156, 159, 163, 164, 165.

50≦MS %<70: Example No. 5, 32, 35, 37, 47, 48, 55, 59, 63, 71, 99, 128,155.

30≦MS %<50: Example No. 7, 19, 26, 52, 62, 66, 100, 101, 127, 153.

What is claimed is:
 1. A compound represented by general formula (1) ora salt thereof:

wherein ring A represents a spiro-linked 4- or 6-membered saturatedhydrocarbon ring optionally substituted with one or more substituentsselected from Group 1, or a spiro-linked 6-membered saturatedheterocyclic ring optionally substituted with one or more substituentsselected from Group 1; ring B represents a benzene ring optionallysubstituted with one or more substituents selected from Group 2, apyridine ring optionally substituted with one or more substituentsselected from Group 2, or a pyrimidine ring optionally substituted withone or more substituents selected from Group 2; R¹ represents an arylgroup optionally substituted with one or more substituents selected fromGroup 3, a heteroaryl group optionally substituted with one or moresubstituents selected from Group 3, a C₃-C₆ cycloalkyl group optionallysubstituted with one or more substituents selected from Group 3, or aC₃-C₆ cycloalkenyl group optionally substituted with one or moresubstituents selected from Group 3; R² represents a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom; and R³ represents a grouprepresented by the following general formula (3) or (4):

wherein in formula (3), the broken line in the ring structure indicatesthat the bond may be a double bond, R⁶ represents a C₁-C₆ alkyl groupoptionally substituted with one or more substituents selected from Group4, a carbamoyl group optionally substituted with one or moresubstituents selected from Group 5, a 5- or 6-memberednitrogen-containing heteroaryl group optionally substituted with an oxogroup or one or more C₁-C₆ alkyl groups optionally substituted with anoxo group or one hydroxy group, a hydroxy group, or —NR′R″, wherein R′and R″ each independently represent a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group optionally substituted with oneor more substituents selected from a C₁-C₆ alkyl group and a hydroxygroup, R⁷ represents a C₁-C₆ alkyl group optionally substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or R⁶ and R⁷ maytogether form a spiro-linked 4- to 6-membered hydrocarbon ring or aspiro-linked 4- to 6-membered nitrogen-containing heterocyclic ring, R⁸is absent or represents one or more substituents selected from a hydroxygroup, a C₁-C₆ alkyl group, and a C₁-C₆ alkoxy group, and Z representsCH₂; and in formula (4), R⁹ represents a C₁-C₆ alkyl group optionallysubstituted with one or more substituents selected from Group 4, acarbamoyl group optionally substituted with one or more substituentsselected from Group 5, a 5- or 6-membered nitrogen-containing heteroarylgroup optionally substituted with an oxo group or one or more C₁-C₆alkyl groups optionally substituted with an oxo group or one hydroxygroup, a hydroxy group, or —NR′R″, wherein R′ and R″ each independentlyrepresent a C₁-C₆ alkyl group optionally substituted with one to threehalogen atoms, an oxo group, or one to three hydroxy groups, a C₃-C₄cycloalkyl group optionally substituted with one to three halogen atomsor one to three hydroxy groups, or a hydrogen atom, or R′ and R″together with the nitrogen atom to which R′ and R″ are bonded maytogether form a 4- to 7-membered nitrogen-containing heterocyclic groupoptionally substituted with one or more substituents selected from aC₁-C₆ alkyl group and a hydroxy group, R¹⁰ represents a C₁-C₆ alkylgroup optionally substituted with one hydroxy group, a hydroxy group, ora hydrogen atom, or R⁹ and R¹⁰ may together form a spiro-linked 4- to6-membered hydrocarbon ring or a spiro-linked 4- to 6-memberednitrogen-containing heterocyclic ring, and R¹¹ represents one or moresubstituents selected from a hydroxy group, a C₁-C₆ alkyl group, and aC₁-C₆ alkoxy group, wherein Group 1 represents a halogen atom, a C₁-C₆alkyl group optionally substituted with one to three halogen atoms, aC₁-C₆ alkoxy group, or a cyano group, Group 2 represents a halogen atom,a C₁-C₆ alkyl group optionally substituted with one to three halogenatoms, a C₃-C₄ cycloalkyl group optionally substituted with one to threehalogen atoms, a vinyl group, an ethinyl group, a cyano group, or aC₁-C₆ alkoxy group, Group 3 represents a halogen atom, a C₁-C₆ alkylgroup optionally substituted with one to three halogen atoms or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, a vinylgroup, an ethinyl group, a cyano group, —OR, —NR′R″, —COOR′, or —CONHR′,wherein R′ and R″ each independently represent a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, a C₃-C₄ cycloalkyl group optionally substituted with oneto three halogen atoms or one to three hydroxy groups, or a hydrogenatom, or R′ and R″ together with the nitrogen atom to which R′ and R″are bonded may together form a 4- to 7-membered nitrogen-containingheterocyclic group optionally substituted with one or more substituentsselected from a C₁-C₆ alkyl group and a hydroxy group, Group 4represents a halogen atom, a hydroxy group, a carbamoyl group, amorpholino group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylsulfonyl group, or—NR′R″, wherein R′ and R″ each independently represent a C₁-C₆ alkylgroup optionally substituted with one to three halogen atoms, one tothree hydroxy groups, or an oxo group, a C₃-C₄ cycloalkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom, or R′ and R″ together with thenitrogen atom to which R′ and R″ are bonded may together form a 4- to7-membered nitrogen-containing heterocyclic group optionally substitutedwith one or more substituents selected from a C₁-C₆ alkyl group and ahydroxy group, and Group 5 represents a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, one to three hydroxygroups, or a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₁-C₆alkoxygroup, or a tetrahydropyranyl group.
 2. A compound according to claim 1represented by general formula (5) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 1; R¹² and R¹³ represent a group selected from ahalogen atom, a C₁-C₆ alkyl group optionally substituted with one tothree halogen atoms, and a cyano group; R¹⁴ is absent or represents oneor more substituents selected from a halogen atom, a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms, and a cyanogroup; and R¹⁵ is absent or represents one or more substituents selectedfrom Group 3, wherein Group 3 has the same meaning as Group 3 inclaim
 1. 3. A compound according to claim 1 represented by generalformula (6) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 1 ; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and cyano group.
 4. A compound according to claim 1 representedby general formula (7) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 1; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and a cyano group.
 5. A compound according to claim 1 representedby general formula (8) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 1; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and a cyano group.
 6. A method of inhibiting Mdm2 comprisingadministering a compound according to claim 1 or a salt thereof to asubject in need thereof.
 7. A method of inhibiting Mdm2 ubiquitin ligasecomprising administering a compound according to claim 1 or a saltthereof to a subject in need thereof.
 8. A method of inhibiting p53-Mdm2binding comprising administering a compound according to claim 1 or asalt thereof to a subject in need thereof.
 9. A method of inhibitingsuppression of p53 transcription activity comprising administering acompound according to claim 1 or a salt thereof to a subject in needthereof.
 10. A method of inhibiting p53 degradation comprisingadministering a compound according to claim 1 or a salt thereof to asubject in need thereof.
 11. A compound represented by general formula(1) or a salt thereof:

wherein ring A represents a spiro-linked 4- or 6-membered saturatedhydrocarbon ring optionally substituted with one or more substituentsselected from Group 1, or a spiro-linked 6-membered saturatedheterocyclic ring optionally substituted with one or more substituentsselected from Group 1; ring B represents a benzene ring optionallysubstituted with one or more substituents selected from Group 2, apyridine ring optionally substituted with one or more substituentsselected from Group 2, or a pyrimidine ring optionally substituted withone or more substituents selected from Group 2; R¹ represents an arylgroup optionally substituted with one or more substituents selected fromGroup 3, a heteroaryl group optionally substituted with one or moresubstituents selected from Group 3, a C₃-C₆ cycloalkyl group optionallysubstituted with one or more substituents selected from Group 3, or aC₃-C₆ cycloalkenyl group optionally substituted with one or moresubstituents selected from Group 3; R² represents a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom; and R³ represents a grouprepresented by the following general formula (3) or (4):

wherein in formula (3), the broken line in the ring structure indicatesthat the bond may be a double bond, R⁶ represents a C₁-C₆ alkyl groupoptionally substituted with one or more substituents selected from Group4, a carbamoyl group optionally substituted with one or moresubstituents selected from Group 5, a 5- or 6-memberednitrogen-containing heteroaryl group optionally substituted with an oxogroup or one or more C₁-C₆ alkyl groups optionally substituted with anoxo group or one hydroxy group, a hydroxy group, or —NR′R″, wherein R′and R″ each independently represent a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group optionally substituted with oneor more substituents selected from a C₁-C₆ alkyl group and a hydroxygroup, R⁷ represents a C₁-C₆ alkyl group optionally substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or R⁶ and R⁷ maytogether form a spiro-linked 4- to 6-membered hydrocarbon ring or aspiro-linked 4- to 6-membered nitrogen-containing heterocyclic ring, R⁸is absent or represents one or more substituents selected from a hydroxygroup, a C₁-C₆ alkyl group, and a C-C₆ alkoxy group, and Z representsCH₂ or O; and in formula (4), R⁹ represents a C₁-C₆ alkyl groupoptionally substituted with one or more substituents selected from Group4, a carbamoyl group optionally substituted with one or moresubstituents selected from Group 5, a 5- or 6-memberednitrogen-containing heteroaryl group optionally substituted with an oxogroup or one or more C₁-C₆ alkyl groups optionally substituted with anoxo group or one hydroxy group, a hydroxy group, or —NR′R″, wherein R′and R″ each independently represent a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group optionally substituted with oneor more substituents selected from a C₁-C₆ alkyl group and a hydroxygroup, R¹⁰ represents a C₁-C₆ alkyl group optionally substituted withone hydroxy group, a hydroxy group, or a hydrogen atom, or R⁹ and R¹⁰may together form a spiro-linked 4- to 6-membered hydrocarbon ring or aspiro-linked 4- to 6-membered nitrogen-containing heterocyclic ring, andR¹¹ represents one or more substituents selected from a hydroxy group, aC₁-C₆ alkyl group, and a C₁-C₆ alkoxy group, wherein Group 1 representsa halogen atom, a C₁-C₆ alkyl group optionally substituted with one tothree halogen atoms, a C₁-C₆ alkoxy group, or a cyano group, Group 2represents a halogen atom, a C₁-C₆ alkyl group optionally substitutedwith one to three halogen atoms, a C₃-C₄ cycloalkyl group optionallysubstituted with one to three halogen atoms, a vinyl group, an ethinylgroup, a cyano group, or a C₁-C₆ alkoxy group, Group 3 represents ahalogen atom, a C₁-C₆ alkyl group optionally substituted with one tothree halogen atoms or one to three hydroxy groups, a C₃-C₄ cycloalkylgroup optionally substituted with one to three halogen atoms or one tothree hydroxy groups, a vinyl group, an ethinyl group, a cyano group,—OR′, —NR′R″, —COOR′, or —CONHR′, wherein R′ and R″ each independentlyrepresent a C₁-C₆ alkyl group optionally substituted with one to threehalogen atoms or one to three hydroxy groups, a C₃-C₄ cycloalkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom, or R′ and R″ together with thenitrogen atom to which R′ and R″ are bonded may together form a 4- to7-membered nitrogen-containing heterocyclic group optionally substitutedwith one or more substituents selected from a C₁-C₆ alkyl group and ahydroxy group, Group 4 represents a halogen atom, a hydroxy group, acarbamoyl group, a morpholino group, a C₁-C₆ alkoxy group, a C₁-C₆alkylsulfonyl group, or —NR′R″, wherein R′ and R″ each independentlyrepresent a C₁-C₆ alkyl group optionally substituted with one to threehalogen atoms, one to three hydroxy groups, or an oxo group, a C₃-C₄cycloalkyl group optionally substituted with one to three halogen atomsor one to three hydroxy groups, or a hydrogen atom, or R′ and R″together with the nitrogen atom to which R′ and R″ are bonded maytogether form a 4- to 7-membered nitrogen-containing heterocyclic groupoptionally substituted with one or more substituents selected from aC₁-C₆ alkyl group and a hydroxy group, and Group 5 represents a C₁-C₆alkyl group optionally substituted with one to three halogen atoms, oneto three hydroxy groups, or a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkylgroup, a C₁-C₆ alkoxy group, or a tetrahydropyranyl group.
 12. Acompound according to claim 11 represented by general formula (5) or asalt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 11; R¹² and R¹³ represent a group selected from ahalogen atom, a C₁-C₆ alkyl group optionally substituted with one tothree halogen atoms, and a cyano group; R¹⁴ is absent or represents oneor more substituents selected from a halogen atom, a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms, and a cyanogroup; and R¹⁵ is absent or represents one or more substituents selectedfrom Group 3, wherein Group 3 has the same meaning as Group 3 in claim11.
 13. A compound according to claim 11 represented by general formula(6) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 11; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and cyano group.
 14. A compound according to claim 11 representedby general formula (7) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and Rrespectively, in claim 11; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and a cyano group.
 15. A compound according to claim 11represented by general formula (8) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 11; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆alkyl group optionally substituted with one to three halogen atoms,and a cyano group.
 16. A method of inhibiting Mdm2 comprisingadministering a compound according to claim 11 or a salt thereof to asubject in need thereof.
 17. A method of inhibiting Mdm2 ubiquitinligase comprising administering a compound according to claim 11 or asalt thereof to a subject in need thereof.
 18. A method of inhibitingp53-Mdm2 binding comprising administering a compound according to claim11 or a salt thereof to a subject in need thereof.
 19. A method ofinhibiting suppression of p53 transcription activity comprisingadministering a compound according to claim 11 or a salt thereof to asubject in need thereof.
 20. A method of inhibiting p53 degradationcomprising administering a compound according to claim 11 or a saltthereof to a subject in need thereof.
 21. A compound represented bygeneral formula (1) or a salt thereof:

wherein ring A represents a spiro-linked 4- or 6-membered saturatedhydrocarbon ring optionally substituted with one or more substituentsselected from Group 1, or a spiro-linked 6-membered saturatedheterocyclic ring optionally substituted with one or more substituentsselected from Group 1; ring B represents a benzene ring optionallysubstituted with one or more substituents selected from Group 2, apyridine ring optionally substituted with one or more substituentsselected from Group 2, or a pyrimidine ring optionally substituted withone or more substituents selected from Group 2; R¹ represents an arylgroup optionally substituted with one or more substituents selected fromGroup 3, a heteroaryl group optionally substituted with one or moresubstituents selected from Group 3, a C₃-C₆ cycloalkyl group optionallysubstituted with one or more substituents selected from Group 3, or aC₃-C₆ cycloalkenyl group optionally substituted with one or moresubstituents selected from Group 3; R² represents a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom; and R³ represents a grouprepresented by the following general formula (3) or (4):

wherein in formula (3), the broken line in the ring structure indicatesthat the bond may be a double bond, R⁶ represents a C₁-C₆ alkyl groupoptionally substituted with one or more substituents selected from Group4, a carbamoyl group optionally substituted with one or moresubstituents selected from Group 5, a 5- or 6-memberednitrogen-containing heteroaryl group optionally substituted with an oxogroup or one or more C₁-C₆ alkyl groups optionally substituted with anoxo group or one hydroxy group, a hydroxy group, or —NR′R″, wherein R′and R″ each independently represent a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, an oxo group, or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, or ahydrogen atom, or R′ and R″ together with the nitrogen atom to which R′and R″ are bonded may together form a 4- to 7-memberednitrogen-containing heterocyclic group optionally substituted with oneor more substituents selected from a C₁-C₆ alkyl group and a hydroxygroup, R⁷ represents a C₁-C₆ alkyl group optionally substituted with onehydroxy group, a hydroxy group, or a hydrogen atom, or R⁶ and R⁷ maytogether form a spiro-linked 4- to 6-membered hydrocarbon ring or aspiro-linked 4- to 6-membered nitrogen-containing heterocyclic ring, R⁸is absent or represents one or more substituents selected from a hydroxygroup, a C₁-C₆ alkyl group, and a C₁-C₆ alkoxy group, and Z representsO; and in formula (4), R⁹ represents a C₁-C₆ alkyl group optionallysubstituted with one or more substituents selected from Group 4, acarbamoyl group optionally substituted with one or more substituentsselected from Group 5, a 5- or 6-membered nitrogen-containing heteroarylgroup optionally substituted with an oxo group or one or more C₁-C₆alkyl groups optionally substituted with an oxo group or one hydroxygroup, a hydroxy group, or —NR′R″, wherein R′ and R″ each independentlyrepresent a C₁-C₆ alkyl group optionally substituted with one to threehalogen atoms, an oxo group, or one to three hydroxy groups, a C₃-C₄cycloalkyl group optionally substituted with one to three halogen atomsor one to three hydroxy groups, or a hydrogen atom, or R′ and R″together with the nitrogen atom to which R′ and R″ are bonded maytogether form a 4- to 7-membered nitrogen-containing heterocyclic groupoptionally substituted with one or more substituents selected from aC₁-C₆ alkyl group and a hydroxy group, R¹⁰ represents a C₁-C₆ alkylgroup optionally substituted with one hydroxy group, a hydroxy group, ora hydrogen atom, or R⁹ and R¹⁰ may together form a spiro-linked 4- to6-membered hydrocarbon ring or a spiro-linked 4- to 6-memberednitrogen-containing heterocyclic ring, and R¹¹ represents one or moresubstituents selected from a hydroxy group, a C₁-C₆ alkyl group, and aC₁-C₆ alkoxy group, wherein Group 1 represents a halogen atom, a C₁-C₆alkyl group optionally substituted with one to three halogen atoms, aC₁-C₆ alkoxy group, or a cyano group, Group 2 represents a halogen atom,a C₁-C₆ alkyl group optionally substituted with one to three halogenatoms, a C₃-C₄ cycloalkyl group optionally substituted with one to threehalogen atoms, a vinyl group, an ethinyl group, a cyano group, or aC₁-C₆ alkoxy group, Group 3 represents a halogen atom, a C₁-C₆ alkylgroup optionally substituted with one to three halogen atoms or one tothree hydroxy groups, a C₃-C₄ cycloalkyl group optionally substitutedwith one to three halogen atoms or one to three hydroxy groups, a vinylgroup, an ethinyl group, a cyano group, —OR, —NR′R″, —COOR′, or —CONHR′,wherein R′ and R″ each independently represent a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, a C₃-C₄ cycloalkyl group optionally substituted with oneto three halogen atoms or one to three hydroxy groups, or a hydrogenatom, or R′ and R″ together with the nitrogen atom to which R′ and R″are bonded may together form a 4- to 7-membered nitrogen-containingheterocyclic group optionally substituted with one or more substituentsselected from a C₁-C₆ alkyl group and a hydroxy group, Group 4represents a halogen atom, a hydroxy group, a carbamoyl group, amorpholino group, a C₁-C₆ alkoxy group, a C₁-C₆ alkylsulfonyl group, or—NR′R″, wherein R′ and R″ each independently represent a C₁-C₆ alkylgroup optionally substituted with one to three halogen atoms, one tothree hydroxy groups, or an oxo group, a C₃-C₄ cycloalkyl groupoptionally substituted with one to three halogen atoms or one to threehydroxy groups, or a hydrogen atom, or R′ and R″ together with thenitrogen atom to which R′ and R″ are bonded may together form a 4- to7-membered nitrogen-containing heterocyclic group optionally substitutedwith one or more substituents selected from a C₁-C₆ alkyl group and ahydroxy group, and Group 5 represents a C₁-C₆ alkyl group optionallysubstituted with one to three halogen atoms, one to three hydroxygroups, or a C₁-C₆ alkoxy group, a C₃-C₆ cycloalkyl group, a C₁-C₆alkoxy group, or a tetrahydropyranyl group.
 22. A compound according toclaim 21 represented by general formula (5) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 21; R¹² and R¹³ represent a group selected from ahalogen atom, a C₁-C₆ alkyl group optionally substituted with one tothree halogen atoms, and a cyano group; R¹⁴ is absent or represents oneor more substituents selected from a halogen atom, a C₁-C₆ alkyl groupoptionally substituted with one to three halogen atoms, and a cyanogroup; and R¹⁵ is absent or represents one or more substituents selectedfrom Group 3, wherein Group 3 has the same meaning as Group 3 in claim21.
 23. A compound according to claim 21 represented by general formula(6) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 21; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and cyano group.
 24. A compound according to claim 21 representedby general formula (7) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 21; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆ alkyl group optionally substituted with one to three halogenatoms, and a cyano group.
 25. A compound according to claim 21represented by general formula (8) or a salt thereof:

wherein ring A, R², and R³ have the same meanings as ring A, R², and R³,respectively, in claim 21; R¹², R¹³, and R¹⁶ represent a group selectedfrom a halogen atom, a C₁-C₆ alkyl group optionally substituted with oneto three halogen atoms, and a cyano group; and R¹⁴ is absent orrepresents one or more substituents selected from a halogen atom, aC₁-C₆alkyl group optionally substituted with one to three halogen atoms,and a cyano group.
 26. A method of inhibiting Mdm2 comprisingadministering a compound according to claim 21 or a salt thereof to asubject in need thereof.
 27. A method of inhibiting Mdm2 ubiquitinligase comprising administering a compound according to claim 21 or asalt thereof to a subject in need thereof.
 28. A method of inhibitingp53-Mdm2 binding comprising administering a compound according to claim21 or a salt thereof to a subject in need thereof.
 29. A method ofinhibiting suppression of p53 transcription activity comprisingadministering a compound according to claim 21 or a salt thereof to asubject in need thereof.
 30. A method of inhibiting p53 degradationcomprising administering a compound according to claim 21 or a saltthereof to a subject in need thereof.